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Mental retardation (MR) is a handicap with severe implications not only for those 
that suffer from this disability, but also for their families, society and the welfare 
systems which support them.  A large proportion of these individuals are afflicted 
with the X-linked form of the condition.   To date a total of 87 genes have been 
implicated in the pathogenesis of X-linked mental retardation (XLMR).  A number of 
these XLMR genes (~22%) are known or putative transcriptional regulators, which 
control gene regulation via various epigenetic mechanisms. Integral to the 
functioning of these epigenetic mechanisms is DNA methylation, occurring at CpG 
islands located in gene promoters where methylation is associated with gene 
silencing.  In this study it was hypothesised that alterations to the DNA methylation 
profile were a molecular feature of MR in patients positive for mutations in putative 
‘epigenetic’ XLMR genes.  
 
In order to test this hypothesis it was first necessary to identify patients with disease-
causing XLMR mutations.  Given the complex genetic landscape of MR, several 
molecular approaches were employed in order to achieve this objective.  Analysis of 
genomic copy number in a MR patient cohort using microarray technologies revealed 
three disease-causing mutations.  These included a 17p11.2Del in an isolated case of 
MR which results in the Smith Magenis syndrome in this patient. Also, a de novo 
Xq25Dup was detected in an isolated male MR case.  Finally, a large X-
chromosomal deletion (Xp26.3-27.3Del) was identified in a familial case of XLMR; 
this aberration exhibits low penetrance in the family.  X-chromosomal linkage 
analysis in four XLMR families defined a critical interval in two of these families.  A 
disease-causing mutation in the ATRX gene was subsequently identified by positional 
candidate gene screening in one family.  In the second family with a defined disease-
associated chromosomal interval, no mutations were identified by positional 
candidate screening of known XLMR genes in the region.  This result suggested that 
this family may harbour a mutation in a novel XLMR candidate gene.  Finally, 
functional candidate gene screening in two commonly mutated XLMR genes (ARX 
and KDM5C) led to the identification of two disease-causing mutations in the ARX 












7_8insTAC) in KDM5C.  The outcomes of the mutation screening phase of this 
dissertation have resulted in the addition of two diagnostic tests (ARX and ATRX) to 
the repertoire of tests offered to patients with MR in South Africa.  Also, the 
diagnostic protocol for copy number analysis using microarrays is now in the 
development stage. 
 
The ATRX mutation positive family identified in this study was shown to exhibit 
altered DNA methylation at ATF7IP2 by whole-genome DNA methylation profiling.  
This methylation profiling entailed methylation dependant immunoprecipitation 
(MeDIP) and subsequent hybridisation to a whole-genome CpG island and promoter 
array using DNA from four affected and three unaffected males. The methylation 
fold changes generated for each individual were used to identify differentially 
methylated regions (DMRs) between patient and control samples using a novel 
statistical approach.  From these analyses, the ATF7IP2 promoter region exhibited 
significant hypermethylation in the ATRX mutation positive individuals.  This gene, 
ATF7IP2, has been shown to interact at a protein level with MBD1; known to play a 
role in the formation of silent chromatin complexes, much like ATRX.  The nature of 
this interaction and its putative ramifications was hypothesised. 
 
The findings presented in this dissertation therefore suggested that transcriptional 
regulator XLMR genes may affect the DNA methylation profiles of mutation 
positive MR patients in a limited manner, at least for ATRX patients.  Thus, the 
findings of this study, as well as the methodology presented, has provided a novel 
research strategy which can be employed in order to elucidate the role of this critical 














CHAPTER 1  
LITERATURE REVIEW 
 
Mental retardation (MR) is estimated to have a prevalence of 1-3% in the developed 
world, making it a common congenital disorder (Leonard and Wen. 2002).  Patients 
afflicted with MR have a decreased ability to adapt their behaviour to the changing 
environment, rendering them dependent on constant support from families and/or 
social workers, as well as the country’s welfare systems.  Furthermore, patients often 
require specialist medical treatment owing to the high comorbidity rate of MR with 
additional clinical features/disorders.  The characteristics and implications of this 
handicap make MR an important medical and socio-economic-impacting disorder. 
 
In developing countries, there tends to be an increased incidence of MR, with factors 
such as malnutrition, cultural deprivation and poor healthcare hypothesised to 
contribute to this increase (Durkin. 2002).  This enhanced MR incidence further 
impacts on the already underfunded and overstretched welfare and public health 
systems, particularly in developing countries such as South Africa. 
 
MR is one of the most common reasons for referral to paediatric, neurological or 
genetic clinics.  Despite this, MR often cannot be ascribed to a specific genetic or 
environmental cause, therefore limiting the prognosis and monitoring of a patient’s 
condition, as well as accurate genetic counselling of the family.   
 
Finally, the medical and socio-economic impact of the condition is exascerbated by 
the lack of treatment for almost all forms of MR.  This lack of available treatments 
reflects our limited understanding of MR pathogenesis and highlights the importance 
of MR research aimed at characterising patients’ deficits in cognitive development 














1.1 MENTAL RETARDATION 
MR is a complex and clinically heterogeneous condition which lacks an entirely 
comprehensive description.  The most commonly used definition is as described by 
the American Psychiatric Association, which reads: ‘This disorder is characterised by 
significantly subaverage intellectual functioning (an intelligence quotient (IQ) of 
approximately 70 or below) with onset before 18 years and concurrent deficits or 
impairments in adaptive functioning ( American Psychiatric Association. Task Force 
on DSM-IV. 1994).  Moreover, MR can be characterised according to the degree of 
severity of the condition, as measured by the IQ score (Table 1.1).  MR can be 
further classified according to clinical presentation into two groups: syndromic MR 
in which the cognitive deficits present in combination with additional clinical 
features and non-syndromic features in which MR is the only clinical feature (Mulley 
et al. 1992). 
   
Table 1.1 Classes of MR as defined by IQ score (American Psychiatric Association. 
Task Force on DSM-IV. 1994).  
Class of MR IQ level range 
Mild 50-55 to ~70 
Moderate 35-40 to 50-55 
Severe 20-25 to 35-40 
Profound Below 20-25 
 
In developed countries the prevalence of mild MR is estimated to be 1-3%, while 
more severe forms (IQ<50) occur in only 0.3-0.5% of the population, as reviewed 
previously (Stevenson, Schwartz and Schroer. 2000).  In South Africa, studies 
focused on estimating the prevalence of the disorder are limited.  However, a study 
by Christianson and colleagues (2002) showed an MR prevalence of 3.6% in a rural 
community, suggesting local estimates may reflect those in the international 














The causes of MR are diverse and can be attributed to a myriad of both genetic and 
environmental factors.  The most common pathogenic environmental factors include 
perinatal asphyxia, neonatal or postnatal central nervous system (CNS) infection and 
intrauterine exposure to toxins (including alcohol exposure) (Vasconcelos. 2004).  In 
South Africa and particularly the Western Cape, foetal alcohol syndrome (FAS) is 
one of the leading contributors to the burden of MR, with a prevalence of up to 67.2 - 
89.2 cases per 1000 children (May et al. 2007, Urban et al. 2008).  
 
It has been estimated that 60-75% of severe MR cases and 38-55% of mild cases can 
be attributed to a specific cause (Inlow and Restifo. 2004).  Of these diagnoses it is 
estimated that genetic causes account for approximately 25-50% of severe MR 
(McLaren and Bryson. 1987).  In comparison, mild MR can be attributed to a genetic 
cause in a much smaller percentage (5-17%) of cases (Aicardi. 1998, King, Rotter 
and Motulsky. 2002).   
 
The exact contribution of genetics to the pathogenesis of MR remains unknown, 
difficult to estimate, and exhibits inter-study variability. However, it remains evident 
that there is a strong hereditary component to the pathogenesis of MR, thus 
exemplifying the necessity for genetic MR research in order to enhance clinical 
management of the disorder.  With this in mind, this study embraced a two tiered 
approach.  Firstly, in order to address the lack of molecular MR diagnoses, 
particularly in a developing country such as South Africa, a variety of molecular 
techniques were employed in order to identify underlying disease-causing alterations 
in a group of South African patients.  The results of these investigations would guide 
the expansion of the repertoire of MR diagnostic tests offered to South African MR 
patients. Secondly, in order to contribute to the understanding of MR pathogenesis, 
the downstream effects of disease-causing alterations on epigenetic mechanisms was 
assessed.  More specifically, potential alterations to the DNA methylation profile in 














1.2 GENETIC ETIOLOGY OF MR 
The genetic causes of MR are diverse and can be roughly distinguished into three 
primary groups. The first comprises copy number changes (chromosomal 
aneuploidies and gross/minor chromosomal aberrations) which generally exert their 
pathogenic effects by altered gene dosage.  The second group encompasses the 
imprinting disorders which manifest due to disruptions at loci controlled by 
monoallelic gene expression.  Lastly, the third group consists of monogenic disorders 
arising from mutations in single genes leading to anomalous protein function (Chelly 
et al. 2006). 
 
In general, gene dosage effects and imprinting disorders are associated with the 
syndromic form of MR, while non-syndromic forms of the disorder occur primarily 
in monogenic forms of MR.  However, this over-simplification is increasingly being 
challenged with the identification of patients with small copy number variations 
(CNVs) having a non-syndromic clinical presentation (Lugtenberg et al. 2006).  In 
addition, a number of monogenic disorders, specifically X-linked MR (XLMR), are 
associated with a clinical presentation reflecting both forms of the disorder, even in 
patients with the same mutations (Chiurazzi, Tabolacci and Neri. 2004).   
 
1.2.1 CHROMOSOMAL ABERRATIONS 
Chromosomal aneuploidies are the largest of the genomic abnormalities and are 
generally the result of errors during meiosis (Table 1.2).  Chromosomal monosomy is 
rare, with the karyotype 46 XO (Turner syndrome), the only monosomy compatible 
with life.  Patients with Turner syndrome often present with learning disabilities 
particularly in spatial reasoning and mathematics.  However, chromosomal trisomies 
are more commonly seen in pregnancies that proceed to term and include Edwards 
syndrome (trisomy 18) and Patua syndrome (trisomy 13).  However, individuals born 
with these disorders generally do not survive beyond 18 months of age owing to the 
severity of these congenital abnormalities.  Finally, Down syndrome (trisomy 21) is 
the only chromosomal aneuploidy in which patients survive till adulthood.  Down 
syndrome has a prevalence of 1 in 800 live births making it one of the most common 













Besides whole chromosomal aneuplodies, it has also been established that partial 
chromosomal copy number changes or translocations can cause MR (Table 1.2).  
Traditionally these chromosomal aberrations have been detected using conventional 
cytogenetic techniques such as G-banded karyotyping.  However, this technique has 
a limited resolution of 5-10Mb and therefore allows chromosomal aberration 
detection in only 3-5% of patients with MR (Stankiewicz and Beaudet. 2007).   
 
Molecular cytogenetic techniques such as FISH (fluorescent in situ hybridisation) 
and molecular methods including MLPA (multiplex ligation-dependant probe 
amplification) have been developed with the aim of increasing the ability to detect 
smaller copy number changes.  These techniques have been successfully developed 
to investigate genomic regions harbouring known microdeletion syndromes (Table 
1.2).  In addition, these molecular techniques can be adapted to target subtelomeric 
regions which are prone to re-arrangement and account for 5-6% of all MR (Flint and 
Knight. 2003). 
 
With the advent of microarray technologies and the application of these platforms to 
detect chromosomal changes, the ability to detect even smaller copy number changes 
has become a reality.  These smaller copy number changes are termed ‘Copy 
Number Variations (CNVs)’ and are defined as: DNA segments greater than 1 kb in 
length that are present in fewer or more copies than expected in the genome that have 
not arisen from the insertion or deletion of transposable elements (Zahir and 
Friedman. 2007).  Numerous international studies have employed array technology 
in order to identify MR-causing CNVs.  These studies report a variable pick-up rate 
of between 4-24% (Aston et al. 2008, de Vries et al. 2005, Fan et al. 2007, Friedman 
et al. 2006, Menten et al. 2006, Rosenberg et al. 2005, Rosenberg et al. 2006, 
Schoumans et al. 2005, Shaw-Smith et al. 2004, Slater et al. 2005, Tyson et al. 2005, 
Vissers et al. 2003).  The variability observed between detection rates is owing to 
differential clinical inclusion and exclusion criteria, as well as the microarray design 
employed.  The highest pick-up rates were observed when high resolution tiling 
arrays were used and MR patient cohorts consisted of patients in whom additional 
dysmorphic and clinical features were present (Rosenberg et al. 2006, Shaw-Smith et 
al. 2004).  The role of CNVs in the pathogenesis of MR is discussed in further detail 













Table 1.2 Examples of chromosomal copy number changes and the molecular and 















Cri de Chat syndrome (5p) 
 
4p, 9q 












Williams syndrome  
Rubenstein Taybi syndrome 
Smith Magenis syndrome 
DiGeorge syndrome 
 
22q11 deletion syndrome 









Several new microdeletion/duplication 
syndromes detected using array technologies e.g. 
15q24 microdeletion syndrome (Sharp et al. 
2007) 




1.2.2 IMPRINTING DISORDERS 
Genomic imprinting involves monoallelic expression of genes at certain genomic 
loci in a parent-of-origin dependent manner.  This monoallelic expression is achieved 
through the imprinting control region (ICR) which establishes DNA methylation 
patterns in a parent-of-origin manner.  Of the approximately 60 imprinted loci known 
to date (catalogued at http://www.geneimprint.com) a large proportion of these genes 
are expressed in the brain in both a spatial and temporal fashion (Wilkinson, Davies 














Perhaps the most well-known of these neurodevelopmentally-associated imprinted 
loci is located at 15q11.2-q13 (Figure 1.1).  Paternally derived deletions at this locus 
cause Prader-Willi syndrome (PWS) occurring with a frequency of 1 in 20000 births. 
PWS is characterised by MR, failure to thrive in infancy, hyperphagia and obesity in 
childhood and behavioural problems (Goldstone. 2004). Conversely, maternally 
derived deletions within this region result in Angelman syndrome (AS), occurring 
with a frequency of 1 in 15000 births and characterised by MR, speech impairment 




Figure 1.1 The 15q11.2-q13 imprinted locus associated with Prader-Willi/Angelman syndrome 
(PWS/AS).  This locus contains two imprinting control regions (ICR) which drive the parentally-
determined monoallelic expression of genes in the region (as indicated by the black arrows).  This 
allele-specific expression as determined by the ICRs is maintained by DNA methylation and 
additional histone modifications.  Paternally derived deletions in the region lead to PWS, as gene 
expression cannot occur from the imprinted maternal locus, conversely AS occurs due to deletions of 
the maternally derived allele (adapted from Bienvenu et al. 2006) 
 
 
While these two disorders are defined by distinct phenotypes, both exhibit MR as a 
defining feature, thus illustrating the importance of these imprinted loci in neuronal 
development.  Furthermore, a second imprinted locus (8q24) has recently been 
implicated in MR, with mutations in the maternally-expressed KCNK9 leading to 
Birk Barel MR dysmorphism syndrome (Barel et al. 2008).  To date, 15q11.2-q13 
and 8q24 are the only imprinted loci to be associated with MR, however, given the 
proportion of imprinted genes expressed in the brain, imprinted loci are attractive 













1.2.3 MONOGENIC DISORDERS  
The number of monogenic causes of MR are biased towards the X-linked form of the 
disorder with over 80 XLMR genes identified to date (Chiurazzi et al. 2008).  By 
comparison, the exact number of autosomal MR genes is difficult to quantify given 
the clinical and genetic heterogeneity of the disorder.  In 2004 an extensive literature 
review and text mining approach using (amongst other resources) the online 
mendelian inheritance in man (OMIM) database at NCBI estimated that the number 
of MR genes stands at 282 (including XLMR genes) (Inlow and Restifo. 2004).  The 
original dataset used for this study was obtained from OMIM using the search phrase 
‘mental retardation’ which returned a total of 1010 entries (Inlow and Restifo. 2004).  
By comparison, in 2009 (December) a search for the same phrase in OMIM returned 
a total of 1626 ‘hits’ clearly illustrating the increasing number of MR genes (and 
CNVs).  This figure is most likely due to recent technological advances in 
microarray applications for CNV detection, homozygosity mapping and diagnostics 
as well as improvements in high-throughput DNA sequencing techniques.  These 
technologies allow a more rapid and in-depth approach to molecular MR diagnoses. 
Furthermore, these additional OMIM entries reflect an increased number of entries 
for a single MR locus, due to differential clinical diagnosis.  These observations 
furthermore illustrate the extent of both the clinical and genetic heterogeneity of MR. 
 
While the exact number of MR genes remains unknown, there are a number of well 
known autosomal MR monogenic genes.  Mutations in these genes primarily exhibit 
an autosomal dominant (AD) inheritance pattern and include a variety of syndromes 
such as: Rubenstein-Taybi syndrome (CBP mutations), DiGeorge and 
velocardiofacial syndrome (TBX1 mutations, as well as larger chromosomal 
deletions) and Smith-Magenis syndrome (mutations in RA1, but also loci-specific 
deletions) (Petrij et al. 1995, Slager et al. 2003, Yagi et al. 2003).  These ADMR 
genes (and others) have principally been identified through positional candidate gene 
mutation screening at either translocation breakpoints or at common microdeletion 
loci where patients have tested negative by conventional deletion screening.  
However, the rare occurrence of patients with these types of mutations has hindered 
the identification of additional AD genes as has the common de novo nature of 












Until recently the vast majority of autosomal recessive mental retardation (ARMR) 
genes remained elusive.  However, with the advent of DNA microarray technologies 
it has now become possible to conduct whole-genome homozygosity mapping in 
consanguineous families. Recently, using this approach, several ARMR genes have 
been identified, they include: PRSS12, CRBN, CC2DIA, GRIK2 and TUSC3, 
TRAPPC9, FA2H (Basel-Vanagaite et al. 2006, Higgins et al. 2004, Mir et al. 2009, 
Molinari et al. 2002, Motazacker et al. 2007, Dick et al. 2010).  It is anticipated that 
the application of this technique will lead to the identification of a substantial 
proportion of ARMR genes.   
 
1.2.3.1 X-Linked Mental Retardation (XLMR) 
It has been known for over 30 years that MR is more prevalent in males than 
females. This preponderance is attributed, in part, to mutations in X chromosomal 
genes (X-linked Mental Retardation – XLMR) which are estimated to account for 
10-15% of all MR (Ropers and Hamel. 2005).  To date there have been over 80 
XLMR genes implicated in MR, a figure disproportionally higher than autosomal 
monogenic causes.  This preponderance of XLMR genes led to the hypothesis that 
genes involved in cognitive development cluster on the X chromosome, possibly due 
to positive sexual selection (Zechner et al. 2001).  Opponents to this theory suggested 
that the increased number of XLMR genes was merely due to an ascertainment bias 
owing to the relative ease with which X-linked traits can be mapped in hemizygous 
males as well as the fortuitous availability of large pedigrees.  However, support for 
this hypothesis was outlined by Inlow and Restifo (2004) where these authors 
concluded that there is a 1.9 fold overrepresentation of MR genes on the X 
chromosome and that this observation was not due to ascertainment bias (Inlow and 
Restifo. 2004).  This empirical evidence suggests that those genes involved in 
cognitive development and functions are overrepresented on the X chromosome. 
 
XLMR phenotypes 
As aforementioned, MR can be categorised into two clinically distinct groups, those 
that manifest with additional clinical phenotypes (syndromic) and those that present 
with MR only (non-syndromic).  With specific reference to XLMR these groups are 












syndromic mental retardation (MRXS or S-XLMR) (Chiurazzi, Tabolacci and Neri. 
2004, Kleefstra and Hamel. 2005).  Furthermore, the MRXS class can be further sub-
divided into two groups (Chiurazzi et al. 2008): 
1. Syndromes: characterised by multiple congenital anomalies (MCA) 
2. Neuromuscular disorders: characterised by muscular or neurological 
abnormalities (epilepsy, seizures, dystonia, spasticity, muscle weakness etc). 
To date 215 conditions have been described, comprising 98 syndromes, 51 
neuromuscular phenotypes and 66 MRX conditions (Chiurazzi et al. 2008). 
 
XLMR genes 
Of the 215 XLMR conditions described previously, 97 have been mapped to 
definitive loci and 82 genes have been cloned (Chiurazzi et al. 2008). Furthermore, 
over the past year, five additional XLMR genes (CASK, SYP, ZNF711, SIZN1, IAP) 
have been reported, bringing the total to 87 X-linked genes involved in the 
pathogenesis of MR (Figure 1.2) (Cho et al. 2008, Molinari et al. 2008, Tarpey et al. 
2009).   
 
These genes have been identified using a number of strategic molecular approaches.  
Firstly, a large collaborative study conducted at the Sanger Institute, Cambridge, UK 
resulted in the identification of the XLMR genes CASK, SYP and ZNF711 (as well as 
six others included in the review by (Chiurazzi et al. 2008) by re-sequencing of 718 
Vega-annotated X-chromosomal genes (at a coverage of 75%) in 208 XLMR family 
probands (Tarpey et al. 2009).  Secondly, a functional candidate gene approach was 
used to identify two novel XLMR genes.  The first, SIZN1 (ZCCHC12), was selected 
for mutation screening in a group of XLMR patients based on its localisation to the X 
chromosome, basal forebrain cholinergic neuronal expression and SIZN1 function 
(Cho et al. 2008).  The second novel gene, IAP (MAGT1), is a paralogue of the 
recently identified autosomal recessive non-syndromic mental retardation gene 
TUSC3 and was therefore selected for mutation screening in a XLMR cohort 
(Molinari et al. 2008).  Taken together, these studies illustrate the importance of 















Figure 1.2 Ideogram of the X chromosome depicting the chromosomal location of all 87 known 
XLMR genes. (Adapted from Chiurazzi et al. 2008). 
 
Despite the considerable number of XLMR genes that have been identified, the 
majority of XLMR cases cannot be attributed to a molecular cause.  A review of 
approximately 600 XLMR families which comprise the EuroMRX consortium 
showed that the underlying etiology was known in only 42% of XLMR families 
(with at least one obligate female carrier) and 17% of brother-pairs (2-5 sibs) (de 
Brouwer et al. 2007).  Even the recent X-chromosomal re-sequencing project, which 
led to the identification of nine novel XLMR genes has not vastly improved these 
numbers (Tarpey et al. 2009).  In this study, the 208 patients investigated by Tarpey 
and colleagues (2009) were mutation-negative for cytogenetic abnormalities as well 
as for unambiguous disease-causing mutations in the known XLMR genes.  The nine 
genes identified in this study account for 25% of families investigated collectively 













Of the known XLMR genes, there is a variable mutation frequency that is gene 
specific.  By far the most common form of XLMR is the fragile X syndrome (FXS), 
caused by a CGG repeat expansion in the promoter of the fragile X mental 
retardation protein gene (FMR1) and accounting for 15-25% of XLMR (Kleefstra 
and Hamel. 2005).  Mutations in the Aristaless related homeobox (ARX) gene are the 
second biggest contributor to XLMR.  ARX mutations account for up to 9.5% of 
XLMR in patients that are negative for the FXS repeat mutation (Poirier et al. 2006).  
The etiology of the remaining patients can be attributed to mutations in a number of 
XLMR associated genes, each accounting for a small proportion of the total 
incidence. These include; MECP2, SLC6A8, JARID1C, IL1RAPL1, PAK3, DLG3 and 
FTSJ1 (Table 1.3) (de Brouwer et al. 2007).   
 
Table 1.3 Mutation frequencies of XLMR genes in the EuroMRX families (adapted 
from de Brouwer et al. 2007) 










1.  ARX Aristaless related homeobox *300382 7.5 1.5 
2.  MECP2 Methyl CpG binding protein 2 *300045 6.2 0 
3.  OPHN1 Oligophrenin 1 *300127 4.8 4.6 
4.  PQBP1 Polyglutamine binding protein 1 +300463 4.5 0 
5.  KDM5C 
(JARID1C) 
Lysine (K)- specific demethylase 
5C *314690 4.2 4.3 
6.  ACSL4 acyl-CoA synthetase long-chain 
family member 4 *300157 3.1 1.7 
7.  FTSJ1 FtsJ homolog 1 *300499 2.5 1.2 
8.  SLC6A8 
solute carrier family 6 
(neurotransmitter transporter, 
creatine), member 8 
*300036 1.8 1.8 
9.  IL1RAPL1 interleukin 1 receptor accessory protein-like 1 *300206 1.5 1.7 
10.  PHF8  PHD finger protein 8 *300560 1.3 0 
 
The high proportion of XLMR families whose phenotype has not been defined by a 
molecular cause highlights the importance of the application of novel techniques to 
identify XLMR genes or disease-mechanisms.  High-throughput DNA sequencing 
technologies such as those described by Tarpey et al. (2009) will certainly play a role 
in future identification of XLMR genes in large XLMR cohorts.  Furthermore, the 












disease-causing regulatory variants (e.g. in promoter/enhancer/silencer regions).  
While this methodology is likely to enhance the number of disease-causing DNA 
sequence variants, it is hypothesised that a significant proportion of XLMR will be 
attributed to, as yet, unknown disease-mechanisms.  Candidate alternative pathogenic 
mechanisms could include X-chromosomal DNA methylation aberrations.  
Therefore, it is essential that the existing DNA methylation technologies are adapted 
to identify aberrant DNA methylation in XLMR patients.  Finally, it has been 
hypothesised that the male excess of MR may be attributed to X-linked ‘risk factors’, 
genetic variations which predispose to, rather than cause MR (Mandel and Chelly. 
2004).  This multifactorial hypothesis has been expanded to include variations which 
may occur on the autosomes and/or include CNVs which constitute a ‘general MR 
predisposition’ in males (Raymond and Tarpey. 2006).  While an attractive 
hypothesis, to date, no ‘risk factors’ of MR have been identified to support this 
polygenic model. 
 
Molecular pathology of XLMR genes 
The 87 known XLMR genes are involved in a host of cellular processes and have a 
wide variety of functions within these processes (Figure 1.3).  Not surprisingly, those 
genes which play a role in signal transduction account for a substantial proportion of 
XLMR (18%) as do proteins found in the cell’s ‘membrane component’ (16%) which 
participate in cell-signalling.  Together, these biological processes are vital for 
neuronal cell-cell communications which contribute to synaptic plasticity and correct 
neuronal development.  However, the largest number of XLMR genes are either 
known or postulated to play a role in transcription regulation (22%).  Transcription 
regulation is a complex process which is epigenetically controlled so as to induce a 
chromatin state which is either open (active gene transcription) or closed (gene 














Figure 1.3 Pie chart illustrating the diverse protein functions of the 87 known XLMR genes. (Adapted 
from Chiurazzi et al. 2008).  
1.3 THE EPIGENETIC BASIS OF DISEASE 
Epigenetics is defined as mitotically and meiotically heritable changes in gene 
regulation which are not dependant on the primary DNA code (Levenson and Sweatt. 
2005).  The epigenetic mechanisms which govern gene regulation consist primarily 
of two components: DNA methylation and histone modifications, which act in a co-
ordinated fashion with non-coding RNA (ncRNAs) and chromatin remodelling 
complexes.  These mechanisms function together to create a dynamic chromatin 
structure which controls gene expression in a tissue specific and developmentally 
regulated manner.  In addition, epigenetic responses can be articulated in the 
presence of both stochastic and environmental cues further lending to the flexibility 
of this regulatory mechanism. 
 
The role of epigenetics in disease is a rapidly expanding concept with a number of 
diseases resulting from aberrant epigenetic mechanisms (Table 1.4).  To date, the 
best characterised is the role of aberrant DNA methylation in the development of 
numerous cancers, as reviewed elsewhere by (Sharma, Kelly and Jones. 2010).  
However, aberrant epigenetic mechanisms are also involved in a variety of disorders 










































Table 1.4 Disorders associated with aberrant epigenetic mechanisms 
 
Disorder Manifestations Etiology 
Angelman syndrome MR 
Imprinting deregulation of UBE3A at 
15q11-13 (maternal) (Bienvenu and 
Chelly. 2006) 
Prader-Willi syndrome MR 
Imprinting deregulation of genes at 
15q11-13 (paternal) (Bienvenu and 
Chelly. 2006) 
ATR-X syndrome MR 
ATRX mutations hypomethylation 
of specific repeat and satellite 
sequences (Gibbons et al. 2000) 
Coffin-Lowry syndrome MR  
RSK2 mutations  histone 
phosphorylation (Harum, Alemi and 
Johnston. 2001) 
Rett syndrome MR 
MECP2 mutations  recruits 
repressive and activating complexes to 
methylated DNA (Chahrour and 
Zoghbi. 2007, Yasui et al. 2007) 
Rubinstein-Taybi 
syndrome MR 
CBP mutations  histone acetylation 








DNMT3B mutations DNA 
hypomethylation (Ehrlich et al. 2008) 
BWS (Beckwith-
Wiedemann syndrome) 
Organ overgrowth Imprinting deregulation of genes at 
11p15.5 (Maher and Reik. 2000) 
Leukaemia Disturbed 
haematopoiesis 
Chromosomal translocations involving 
histones acetyl transferases (HATs) 
and histone methyltransferases 
(HMTs) (Claus and Lubbert. 2003) 
Various cancers 
Microsatellite instability De novo methylation of MLH1(Kane 
et al. 1997) 
Uncontrolled 
proliferation 
De novo methylation of various gene 
promoters (Jones and Baylin. 2002) 
Disruption of SWI-SNF 
chromatin remodelling 
complex  
SNF5, BRG1, BRM mutations 





Loss of imprinting (Chao and 













1.3.1 CHROMATIN STRUCTURE 
The human genome comprises of approximately three billion base pairs. These 
nucleotides, which when extended in linear form would be 2m in length, need to be 
tightly compacted within the cell which has a diameter of only 10µm.  This excessive 
DNA packaging into the cell is achieved through the formation of chromatin. By 
definition, chromatin is the state in which DNA is packaged within the cell and 
comprises DNA as well as associated proteins and RNA.   
 
The most basic unit of chromatin is the nucleosome (Figure 1.4).  Each nucleosome 
is linked to the next by a short fragment (10-100bp) of linker DNA completing a 
10nm fibre representing a ‘beads on a string’ structure.  Furthermore, the histone 
protein, H1, anchors the two turns of DNA around the nucleosome and adjacent H1 
histones associate with one another to make up the 30nm solenoid structure.  
Additional hierarchical packaging of the DNA results ultimately in the chromosomal 
structure visible at metaphase (Figure 1.5) (Alberts. 2008). 
 
Figure 1.4 Structure of the nucleosome. The nucleosome consists of 147bp of DNA wrapped around 
the histone protein octomer which consists of two molecules of each of the four core histones (H2A, 
H2B, H3 and H4) is anchored by the histone H1.  The amino acid residues within the histone tails are 
amenable to modifications which alter the tertiary chromatin structure upon which transcription is 
















Figure 1.5 The hierarchical process of packaging DNA into the cell (Alberts et al. 2008). 
 
 
Euchromatic regions are generally regions of DNA associated with an open 
chromatin formation and are actively transcribed.  Conversely, heterochromatin 
comprises tightly packaged DNA in a ‘closed’ chromatin structure and encompasses 
regions that are not being transcribed.  This dynamic nature of chromatin is achieved 
by epigenetic modifications which constitute the ‘epigenome’ and consists primarily 
of two mechanisms: histone modifications and DNA methylation. 
 
1.3.2 THE EPIGENETIC MECHANSIMS 
1.3.2.1 Histone modifications 
The four core histones which make up the nucleosome are generally globular in 
shape but are also characterised by N-terminal ‘tails’.  The amino acid residues that 
constitute these histone tails protrude beyond the nucleosomal structure and are 












generally basic nature of the nucleosome and hence affect the ability of the structure 
to bind negatively charged DNA thus inducing either a ‘closed’ or ‘open’ 
conformation.  In addition, these diverse histone modifications act as epigenetic 
marks which signal downstream protein-protein interactions which further maintain 
the appropriate chromatin state. 
 
The complexity of histone modifications is illustrated by the following features: 
 The 60 different amino acid residues within the histone tails are each 
amenable to various covalent modifications. (Kouzarides. 2007) (Table 1.5).  
Given the octomeric composition of the nucleosome this equates to a total of 
at least 480 residues amenable to post-translational modifications per single 
nucleosome.  The most commonly targeted residues are lysine and arginine, 
with less well-studied modifiable residues including serine, threonine, 
glutamic acid and proline. 
 The array of histone modifications which can occur, of which histone 
acetylation, methylation and phosphorylation are the best categorised.  Less 
well known modifications include ubiquitylation, sumoylation, ADP 
ribosylation, deimination and proline isomerisation.   
 The variable nature of Lysine methylation which can occur in either mono-, 
di- or tri-methyl forms and arginine methylation can include mono- and di- 
(both asymmetric and symmetric) methylation. 
 The recruitment of a wide-range of non-histone proteins by these histone 
modifications concomitantly signals for the ordered recruitment of additional 
gene-regulatory epigenetic complexes (as reviewed in Kouzarides. 2007).  
These enzyme complexes include the ATPase dependant remodelers, the 
silencing polycomb group proteins (PcG) and the activating trithorax group 


















Table 1.5 Some examples of well known histone modifications and their effect on 
the chromatin state (adapted from Kouzarides. 2007). 
Chromatin 
modification Enzymes involved 
Example of modifiable 















(Lysine residues) (HMTs) 












Phosphorylation e.g. RSK2  H3S10 activation 
Ubiquitylation 
e.g. Bmi/Ring1A protein found 
in the polycomb complex  H2AK119 repression 
K= Lysine, S= Serine 
 
1.3.2.2 DNA methylation 
DNA methylation is the only known covalent modification of DNA in humans and is 
the result of the addition of a methyl group to the 5th position of the cytosine 
pyrimidine ring located at CpG dinucleotides (Wu and Santi. 1985).  These CpG 
dinucleotides are underrepresented in the genome and methylation occurs at up to 
70% of these sites (Cooper and Krawczak. 1989).  The remainder are generally 
unmethylated and are organised in clusters known as CpG islands which encompass 
gene promoters (Bird. 1986).   
 
DNA methylation is catalysed by enzymes known as DNA methyltransferases 
(DNMTs), details of which appear in Table 1.6.  DNA methylation was long 
believed to be a stable epigenetic mark; however, the observation of demethylation 
during development suggests that a DNA demethylation enzyme/s may also exist.  
This is a subject of much debate with the alternative proposal that DNA 
demethylation may be a passive event occurring during DNA replication (Costello 
and Plass. 2001).  However, rapid DNA demethylation has been observed in long 
term memory formation (Miller and Sweatt. 2007).  Also more recently, a 
transcriptionally active gene (TFF1) that undergoes promoter DNA methylation and 












et al. 2008, Metivier et al. 2008).  Finally, the Vitamin D biosynthesis gene CYP27B1 
undergoes active DNA de/methylation in the presence of parathyroid hormone (PTH) 
and vitamin D3 respectively (Kim et al. 2009).  Collectively, this evidence suggests 
that DNA demethylation may, in part, be responsible for temporal and spatial gene 
expression.  
 




Maintenance of the parental DNA methylation pattern during DNA 
replication(Razin and Szyf. 1984) 
Forms a repressive complexes including HDACs (Robertson et al. 
2000) 
DNMT3A 
De novo DNA methylation capabilities  
Establish methylation patterns during development  
Able to target unmethylated CpG islands (Okano et al. 1999). 
DNMT3B 
De novo DNA methylation capabilities  
Establish methylation patterns during development  
Able to target unmethylated CpG islands (Okano et al. 1999). 
DNMT3L 
Lacks catalytic enzyme activity, but could act as a DNMT3A/B co-
factor in the recruitment of HDAC (Deplus et al. 2002).  Essential 
for genomic imprinting during germ cell development (Bourc'his et 
al. 2001). 
DNMT2 Lacks catalytic activity, function unclear, able to methylate a tRNA 
(Goll et al. 2006, Okano, Xie and Li. 1998) 
 
 
DNA methylation has a number of diverse functions: 
 Transcriptional silencing: A well-established attribute of cytosine 
methylation is transcriptional silencing (Razin and Riggs. 1980), achieved by 
two mechanisms.  Firstly, cytosine methylation can prevent the DNA binding 
of transcription factors to regulatory regions, hence inhibiting recruitment of 
transcription-inducing complexes (Watt and Molloy. 1988).  Secondly, the 
recruitment of methylated DNA binding domain (MBD) proteins to 
methylated CpG islands leads to the recruitment of co-repressors and histone 
modifying enzymes which reinforce the inactive chromatin state at target 
genes (Boyes and Bird. 1991, Fujita et al. 1999, Hendrich and Bird. 1998, 












 X-inactivation: in females the active X chromosome is relatively 
hypomethylated at promoter regions and hypermethylated at intragenic 
regions (Hellman and Chess. 2007).  
 Genomic imprinting: variable DNA methylation of paternal and maternal 
promoter regions controls monoallelic expression at target loci.   
 Genome stability: is enforced by the hypermethylated DNA state as 
illustrated by the pathogenesis of the ICF syndrome.  This disorder results 
from DNMT3B mutations which predispose the resultant hypomethylated 
centromeric regions to chromosomal translocations (Ehrlich. 2003).  
 Suppression of transposable elements: LINEs, SINEs and intracisternal A 
particle (IAP) elements have the potential to transpose throughout the 
genome and hence disrupt genomic integrity.  These elements are subject to 
DNA methylation in order to prevent expression and subsequent mobilisation 
(Rollins et al. 2006). 
 Embryological development: DNA methylation plays a critical role during 
this phase of human development, particularly during implantation when de 
novo demethylation is succeeded by establishment of DNA methylation 
patterning (Kafri et al. 1992, Monk, Boubelik and Lehnert. 1987).  
 
1.3.2.3 Interplay between DNA methylation and histone modifications 
DNA methylation and histone modifications both have regulatory roles in the 
mediation of the chromatin state.  However, these mechanisms are not independent 
and correct maintenance of a particular expression state is dependent on a functional 
interaction/relationship between these two epigenetic mechanisms.  There has been 
much debate about the nature and direction of this relationship.  Given the evidence 
for both histone modifications and DNA methylation acting as the primary epigenetic 
mark, it is likely that a bi-directional model will be adopted. 
 
There are instances where DNA methylation acts as the primary epigenetic mark.  
For instance, DNA methylation acts as a marker for the recruitment of MBD 
proteins.  These MBD proteins recruit additional chromatin repressive complexes 
including HDACs and members of the polycomb repressive complexes.  There are 












transcription regulation complexes involving MeCP2.  MeCP2 a MBD protein, has 
numerous regulatory functions which include transcription repression e.g. at the 
BDNF promoter (Martinowich et al. 2003).  This repression acts by binding to 
methylated DNA at promoter regions and recruiting members of a repressive 
complex including SIN3A (transcriptional co-repressor), BRM and ATRX 
(SWI/SNF- related-chromatin-remodelling proteins) and HDACs (Bienvenu and 
Chelly. 2006, Nan et al. 2007). 
 
Conversely, histone modifications may act as a marker for DNA methylation.  This 
was elegantly illustrated by Mutskov et al. (2004) where transgenes integrated into 
chicken embryos were silenced by epigenetic mechanisms.  This transgene silencing 
by promoter DNA methylation was preceded by histone acetylation and H3K4 
demethylation, suggesting that, in this instance, DNA methylation is not the primary 
epigenetic mark (Mutskov and Felsenfeld. 2004).  Also, a recent genome-wide 
promoter analysis of the epigenetic changes between embryonic stem cells (ESCs), 
neuronal progenitor cells and terminally differentiated pyramidal neurons found that 
genes which were destined to become inactive in the committed state were inactive 
prior to DNA methylation in 62% of cases.  This suggests that the inactive state is 
conferred by an additional epigenetic mark, possibly H3K4 demethylation and 
H3K27 methylation (Mohn et al. 2008).   
 
These examples illustrate just some of the incidences of a bidirectional relationship 
between DNA methylation and histone modifications and further reinforce the notion 






















1.3.3 EPIGENETICS IN NEUROGENESIS, NEURONAL DEVELOPMENT 
AND FUNCTIONING 
 
There is ample evidence for the role of epigenetic mechanisms controlling both 
neurogenesis as well as neuronal development and functioning.  Neurogenesis is, at 
least in part, controlled by the protein, restriction element 1 (RE1) silencing 
transcription factor (REST).  In non-neuronal tissues, REST binds to DNA at short 
consensus sequences known as RE1 (or neuron-restrictive silencing element (NRSE) 
and promotes protein-protein interaction with DNMTs, HDACs, MBDs, transcription 
factors, chromatin remodelers and co-regulators (coREST).  The formation of this 
REST-associated protein complex enforces a repressive epigenetic state which 
includes marks such as: DNA methylation, H3K9 methylation and H3K4 
demethylation at the target DNA region (Ballas and Mandel. 2005).  In this way 
neuronal gene expression is restricted to the nervous system.  Conversely, in stem 
cells as well as neuronal progenitor cells, the REST complex bound at the RE1 motif 
of neuronal promoters is generally associated with active chromatin modification 
marks.  Rapid dissociation of REST from the RE1 site during neurogenesis is 
achieved through REST degradation or ncRNA-mediated activation, hence allowing 
neuronal gene expression (Ballas and Mandel. 2005, Kuwabara et al. 2004). 
 
It has also been hypothesised that epigenetic mechanisms play a role in learning and 
memory.  In order to develop long-term memories there is accumulating evidence 
that neuronal functioning makes use of epigenetic mechanisms in a manner similar to 
cell state commitment during development (Figure 1.6) (Levenson and Sweatt. 2005, 
Levenson et al. 2006, Miller, Campbell and Sweatt. 2008, Swank and Sweatt. 2001).  
Again, these epigenetic changes include both changes in DNA methylation and 
histone modifications as well as interaction between the two.  For example, it was 
demonstrated that acetylation of histone H3 occurs in rat hippocampal regions 
subsequent to contextual fear conditional training (Levenson et al. 2004).  In 
addition, DNMT inhibition prevented this memory-associated H3 acetylation, thus 
illustrating the necessity for interplay between these two epigenetic mechanisms for 













Figure 1.6 Epigenetic mechanisms in learning and memory.  In response to a particular external 
stimulus, epigenetic changes such as DNA methylation and histone modifications lead to a change in 
gene expression.  This modified expression ultimately leads to altered neuronal and synaptic function 
which forms the basis of learning as well as memory formation and consolidation (adapted from 
Levenson and Sweat, 2005) 
 
 
1.3.1 PATHOGENEIC ROLE OF EPIGENETICS IN XLMR 
 
Perhaps the best example of the role of epigenetics in neuronal development and 
functioning is the observation of cognitive defects in patients with mutations in 
XLMR genes that play a role in transcriptional regulation.  Of the 87 known XLMR 
genes, 22% are either known or hypothesised to play a role in transcriptional 



















Table 1.7 XLMR genes involved in transcription regulation with putative/proven 
epigenetic effects (adapted from Chiurazzi et al. 2008) 
 Gene Function 
1.  ARX Transcription repressor and activator (Seufert, 
Prescott and El-Hodiri. 2005) 
2.  ATRX Chromatin remodeler 
3.  BCOR Chromatin remodeler 
4.  BRWD3 Chromatin remodeler (Field et al. 2007) 
5.  CDKL5 Kinase, involved in MeCP2 phosphorylation 
6.  JARID1C Histone H3K4 demethylation (Iwase et al. 2007) 
7.  MECP2 MBD protein, transcription repression and 
activation (Chahrour and Zoghbi. 2007) 
8.  MED12 RNA Polymerase II transcription mediator, 
transcription co-activator 
9.  PHF6 Transcription regulation 
10.  PHF8 Transcription regulation 
11.  PQBP1 Transcription regulation 
12.  RPS6KA3 Kinase 
13.  RPS6KA6 Kinase 
14.  SIZN1 Transcription regulation (Cho et al. 2008) 
15.  SOX3 Transcription regulation 
16.  ZNF41 Transcription regulation: DNA binding protein 
17.  ZNF674 Transcription regulation: DNA binding protein 
18.  ZNF711 Transcription regulation: DNA binding protein 
19.  ZNF81 Transcription regulation: DNA binding protein 
 
The most well-studied of these ‘epigenetic’ XLMR genes is MECP2, mutated in 
patients with NS-XLMR, Rett syndrome (atypical and typical) and an Angelman 
syndrome-like phenotype (Couvert et al. 2001, Villard et al. 2000, Watson et al. 
2001).  MeCP2 is a MBD protein originally thought to act as a transcriptional 
repressor by binding methylated DNA and recruiting chromatin repression 
complexes (Chahrour and Zoghbi. 2007).  While this transcription repressor activity 
of MeCP2 has been reported e.g. at the BDNF gene (Chen et al. 2003), MeCP2 also 
acts as a transcription activator.  In mouse hippocampal cells MeCP2 acts as an 
activator at 85% of investigated gene promoters by association with the protein 
cAMP responsive element binding protein 1 (CREB1) at the promoter start site of 
active genes (Chahrour et al. 2008).  Finally, patients with MECP2 mutations have 












postnatal neuronal function (LaSalle et al. 2001).  Collectively, these results suggest 
that aberrant expression of MeCP2 has effects on expression of downstream target 
genes ultimately leading to the neurological defects in patients with MeCP2 
mutations.   
 
While less well-studied, evidence suggests that the additional XLMR ‘epigenetic’ 
genes may lead to neurological defects due to aberrant gene expression of target 
genes and that this aberrant expression is a downstream effect of alteration to 
epigenetic mechanisms.   The focus of this study was therefore to investigate DNA 
methylation profiles in XLMR ‘epigenetic’ gene mutation positive individuals.  The 
outcomes of these experiments contribute to the understanding of the role of DNA 
methylation in XLMR pathogenesis.  However, in addition, the development of this 
whole-genome DNA methylation approach presents an alternative strategy for the 
identification of novel MR candidate genes. 
 
1.4 AIMS AND OBJECTIVES 
Aim: To establish whether an alteration to the DNA methylation profile is a 
molecular feature of MR in patients positive for mutations in putative ‘epigenetic’ 
XLMR genes. 
 
This aim was achieved by fulfilment of the following objectives (Figure 1.7): 
Part A: Identifying the primary DNA mutation by: 
 Whole-genome CNV analysis, which included: 
 CNV analysis in a clinically stratified cohort using whole-genome 
SNP arrays 
 Putative CNV validation from the SNP array using genomic qPCR 
(quantitative PCR) 
 Assessing the association between the detected CNV and MR, using a 
















 Linkage analysis and positional candidate gene screening, which involved:  
 Whole X chromosome microsatellite genotyping for linkage analysis 
in suitable XLMR families 
 Positional candidate gene screening within the linked critical intervals 
to identify DNA sequence alterations using Sanger DNA sequencing 
 Assessing the association between detected DNA sequence alterations 
and XLMR using a variety of techniques including: bioinformatic 
interrogation, literature review, mRNA investigation, familial co-
segregation and background population screening. 
 Functional candidate genes analysis which included: 
 Screening of functional candidate genes for DNA sequence alterations 
in clinically stratified cohorts using Denaturing high performance 
liquid chromatography (dHPLC) and Sanger DNA sequencing, 
 Assessment of the association between detected DNA sequence 
alterations and XLMR using a variety of techniques as described 
above. 
 
Part B: Identifying whole-genome DNA methylation aberrations by: 
 Investigating the genome-wide DNA methylation patterns in XLMR gene 
mutation positive individuals using MeDIP (methylation dependant immuno-
precipitation) –Chip  
 Validating putative differentially methylated regions (DMRs) by bisulphite 
Sanger DNA sequencing 
 Semi-quantification of DNA methylation ratios at DMRs using PCR cloning 










































IDENTIFICATION OF DISEASE-CAUSING 
MUTATIONS IN SOUTH AFRICAN XLMR 
PATIENTS 
 
In order to investigate the central hypothesis of this dissertation, that alteration to the 
DNA methylation profile is a molecular feature of MR in patients positive for 
mutations in putative ‘epigenetic’ XLMR genes, it was first necessary to identify 
patients with mutations in these XLMR genes.  Given the complex genetic landscape 
of XLMR disease-causing alterations, a multifaceted approach was required in order 
to define the molecular etiology of XLMR.  This approach was a vital first step in 
identifying suitable XLMR mutation positive patients in whom this hypothesis could 
be tested. 
 
Part A of this dissertation details the various molecular techniques and strategic 
approaches employed in order to ascertain the underlying molecular etiology in this 
cohort of South African XLMR patients.  These techniques include copy number 
analysis using SNP arrays to identify disease-causing CNVs across the genome 
(Chapter 2).  Also, X-chromosomal linkage analysis (Chapter 3) and subsequent 
positional candidate gene screening (Chapter 4) was conducted.  Finally, functional 
candidate XLMR genes were selected for investigation in stratified cohorts based on 
mutation frequencies previously reported by the international community (Chapter 
5).  Those patients shown to be positive for mutations in XLMR genes were 
subsequently prioiritised for investigation of whole-genome DNA methylation 














CHAPTER 2  
WHOLE-GENOME COPY NUMBER VARIATION 















Alterations of chromosomal copy number have long-been established as a major 
contributor to MR.  Traditionally, cytogenetic techniques such as G-banded 
karyotyping have been used to identify large chromosomal abnormalities in 3-5% of 
MR patients (Stankiewicz and Beaudet. 2007).  However, due to the limited 
resolution of this technique (5-10Mb), a substantial proportion of aberrations go 
undetected.  Higher-resolution technologies were thus developed to address this 
limitation. These technologies included molecular cytogenetic techniques such as 
FISH and molecular techniques including MLPA.  These target-specific technologies 
have been successfully utilised for the detection of common 
microdeletion/duplication syndromes and subtelomeric rearrangements in 5-6% of 
MR cases (Flint and Knight. 2003).  However, to date, the most promising 
technological advancement has been the adaption of microarrays to detect CNVs at 
an even greater resolution, with detection rates of up to 24% in MR patients (Aston 
et al. 2008). 
 
2.1.1 MICROARRAY TECHNOLOGIES 
Early application of microarrays for CNV detection using bacterial artificial 
chromosome (BAC) arrays was to assess copy number in solid tumour cancer cells 
(Kononen et al. 1998).  Subsequently, this technology has been applied in a wider 
diagnostic setting, particularly in the molecular diagnosis of MR.  Recent technical 
developments within this field have led to the replacement of BAC probes with 
synthesised oligonucleotides.  These oligonucleotide arrays have a higher resolution, 
greater flexibility and are less time-consuming to manufacture.  There are two 
primary applications of oligonucleotide microarrays for CNV detection which differ 
primarily on the reference genome source used to calculate copy number: 
  Two-fluorophore hybridisation: entails competitive hybridisation of 
differentially fluorescently-labelled test and reference samples to the array 
platform (generally arrays comprised of random 50-80mer probes specific to 
the regions of interest are used).  Subsequently, allelic copy number is 












 One- fluorophore hybridisation: a single fluorescently-labelled test sample 
is hybridised to the array platform (generally arrays comprised of SNP-
specific probes are used).  Subsequently, the intensity ratios between a test 
and reference sample are compared in silico to calculate allelic copy number.   
 
The second method has the advantage of producing both genotype and copy number 
data, also, it negates the need for the use of reference DNA for every sample tested 
(for a more detailed review see Friedman et al. 2006, Zahir and Friedman. 2007).  
 
2.1.2 CNV DETECTION RATES IN MR STUDIES USING MICROARRAYS 
CNV detection using both two-fluorophore, and one-fluorophore microarray 
hybridisation yield variable detection rates of 5-24% (Table 2.1).  These pick-up 
rates were dependent on both the resolution of the array platform as well as the 
clinical inclusion criteria (Table 2.1).  Analyses of these various studies indicate that 
the highest diagnostic yields were obtained in those studies which employed high-
resolution whole-genome microarrays.  Also, higher pick-up rates were demonstrated 
in cohorts consisting of patients presenting with MR in conjunction with 
dysmorphism and/or additional features, or MCA.   
 
Detection rates were furthermore largely dependent on the microarray design, more 
specifically, whether a ‘tiling’ or ‘targeted’ array was used.  There has been much 
debate in recent literature regarding the use of ‘targeted’ versus ‘tiling’ microarrays 
to detect disease-causing CNVs in MR cohorts (Bejjani and Shaffer. 2006, Veltman 
and de Vries. 2006, Veltman and de Vries. 2007).  ‘Targeted’ arrays are designed to 
detect disease-causing aberrations in subtelomeric/ pericentromeric regions as well as 
chromosomal intervals commonly implicated in microdeletion/duplication 
syndromes.  The major advantage of these arrays is the exclusion of detecting 
variants with unknown significance as interpretation of the disease-association of 












Table 2.1 Details of previous studies that employed microarrays to detect genomic copy number changes in MR patient cohorts.  
 






(Vissers et al. 2003) 3569 BAC clone whole-genome tiling array  MR with dysmorphism 20 2 10 
(Shaw-Smith et al. 
2004) 3500 clone BAC whole-genome tiling array 
MR with dysmorphism 
and/or additional features 50 7 14 
(de Vries et al. 2005) 32447 BAC clone whole-genome tiling array  MR  100 10 10 
(Schoumans et al. 2005) 2600 BAC clone whole-genome tiling array  MR with dysmorphism 41 4 10 
(Tyson et al. 2005) Spectral genomics 3Mb and 1Mb BAC arrays MR with dysmorphism 22 3 14 
(Ballif et al. 2006) 831 or 969 BAC clone targeted array  Diverse DD- MR 3600 182 5 
(Friedman et al. 2006) Affymetrix 100K oligonucleotide array MR 100 11 11 
(Krepischi-Santos et al. 
2006) 3500 clone BAC whole-genome tiling array 
Syndromic MR or 
additional features 95 16 17 
(Menten et al. 2006) 3431 clone BAC whole-genome tiling array MCA and/or MR 140 19 14 
(Miyake et al. 2006) 2173 clone BAC whole-genome tiling array Idiopathic MR  30 5 17 
(Rosenberg et al. 2006) 3500 clone BAC whole-genome tiling array MR with dysmorphism 81 13 16 
(Shaffer et al. 2006) 831 BAC clone targeted array  Diverse DD- MR 1500 84 6 
(Sharp et al. 2006) 2007 BAC clone array encompassing 130 LCR regions MR and/or dysmorphism or MCA 290 16 6 
(Engels et al. 2007) 6K BAC array and 8K BAC array 
MR with dysmorphism 
and/or additional features 
or MCA 








(Fan et al. 2007) 
434 BAC clone targeted array (Constitutional Chip – 
Spectral genomics) 
Whole-genome oligonucleotide array (Agilent) with 30-
35kb resolution 
MR-DD with two or more 
dysmorphic features 
100 









































(Shaffer et al. 2007) 589 BAC clone targeted array Idiopathic MR  8789 604 7 
(Shen et al. 2007) >10 000 60-mer Agilent oligonucleotide targeted array (to known MR regions)  
DD-MD with dysmorphism 
or MCA 211 25 12 
(Wagenstaller et al. 
2007) 
 
100K Affymetrix oligonucleotide array MR with/out dysmorphism 67 11 16 
(Aston et al. 2008) 
Spectral genomics/ PerkinElmer oligonucleotide 
Constitutional Chip (targeted array)  






















(Koolen et al. 2008) 32447 BAC clone whole-genome tiling array  MR 386 35 9 
(Nowakowska et al. 
2008) 853 BAC clone targeted array  
MR with additional 
features 91 19 12 
(Friedman et al. 2009) 500K Affymetrix oligonucleotide array MR with dysmorphism 100 16 16 
(Jaillard et al. 2009) Agilent 44K oligonucleotide arrays MCA and/or MR 132 19 14 
(McMullan et al. 2009) 500K Affymetrix oligonucleotide array Unexplained MR  120 18 15 











In contrast to ‘targeted’ arrays, whole genome ‘tiling’ arrays present an unbiased 
approach to CNV detection, with both benign and disease-causing variants being 
identified.  In general, explication of the pathogenic nature of a CNV is twofold.  
Firstly, the presence of the CNV in databases such as the database of genomic 
variation (DGV) or in the literature (also catalogued in the UCSC Genome Browser 
as ‘structural variation tracks’) would suggest the CNV is benign.  Secondly, parental 
DNA samples are assessed to determine whether the CNV arose de novo or was 
inherited from an unaffected parent.  However, this exclusion rationale also has its 
caveats in that it assumes that a particular CNV is fully penetrant.  Also, the extent of 
CNV polymorphism is at present, unknown, concomitantly a number of benign 
variants have yet to be characterised and catalogued in the aforementioned databases.   
 
Despite the caveats associated with CNV interpretation, a whole-genome ‘tiling’ 
approach has been shown to have a higher diagnostic yield as compared to ‘targeted’ 
arrays (Table 2.1).  In a recent study of over 1000 MR patients using array-
technologies, Aston and colleagues (2008) demonstrated that the detection rate of 
‘targeted’ and ‘tiling’ arrays was 9% and 24% respectively (Aston et al. 2008).  
Similarly, a comparative study of 100 MR patients identified disease-causing 
variants in 5% of patients using a targeted array, compared to a 15% pick-up rate 
using whole-genome tiling arrays (Fan et al. 2007).  The higher detection rate in 
whole-genome studies can be ascribed to two main attributes; firstly a number of 
disease-causing CNVs arise de novo.  These de novo mutations are generally not 
located in CNV hotspots and are thus not due to non-allelic homologous 
recombintation (NAHR) which tends to occur at low copy repeat (LCR) regions.  
Therefore, while these events tend to be rare, the occurrence of de novo disease-
causing CNVs are relatively common, given the large size of the human genome.  
Secondly, the number of known microdeletion/duplication syndromes is, at present, 
under-represented. This is evident in the number of microdeletion/duplication 
syndromes that have been identified in recent years as a result of CNV analyses 
using microarrays.  These novel microdeletion/ duplications include: 17q21.31 
(OMIM #610443) (Koolen et al. 2008), 15q24 (Sharp et al. 2007), 14q11.2 (Zahir et 















Given the high diagnostic yield of disease-causing CNVs in MR cohorts using 
microarray technologies, South African XLMR patients were selected from the 
Divisional DNA bank for copy number investigations.  This genome-wide CNV 
analysis had a dual objective.  Firstly, to assess the feasibility of incorporation of 
microarray CNV technologies into the diagnostic testing protocol offered to South 
African MR patients and their families.  Secondly, in view of the central aim of this 
dissertation, to investigate DNA methylation profiles in XLMR mutation positive 
individuals, the presence of MR-causing CNVs in this cohort was investigated in an 
effort to identify individuals suitable for further epigenomic studies. 
 
2.2 METHODS 
Patient DNA samples selected for molecular investigations in this study, form part of 
the Division of Human Genetics, University of Cape Town (UCT) DNA bank.  
These probands were all referred by various clinicians to the Division for molecular 
testing for the fragile X syndrome (FXS). At the commencement of this dissertation 
DNA samples from approximately 450 families with MR had been catalogued and 
stored.   In addition, patient/guardian permission was obtained for both the diagnostic 
testing of FXS as well as for further research (Appendix 2A) (subject to approval by 
the UCT Faculty of Health Sciences Ethics committee).  All research was also 
approved by the aforementioned Ethics committee (REC 466/2005) 
 
From the total of 450 MR families within the UCT DNA bank, 148 demonstrated an 
X-Linked inheritance pattern.  Of these XLMR families, 35 (23%) tested positive for 
the CGG repeat expansion at the 5’ UTR of the FMR1 gene.  Therefore, the 
molecular etiology of the remaining 77% of XLMR families or 90% of all patients in 















2.2.1 PATIENT COHORT SELECTION 
In total, 30 patients were selected for whole genome CNV investigations (Appendix 
2B) based on the following inclusion criteria: 
 MR and at least one additional clinical feature, dysmorphism or MCA. 
 Negative for the FMR1 expansion mutation  
 Normal karyotype using standard G-banded cytogenetic analysis.   
In this section of the dissertation, the study cohort comprised of both XLMR 
probands as well as isolated cases of MR due to the whole-genome nature of the 
CNV analysis (at the time of this study’s commencement single chromosome (e.g. 
X-chromosome) oligonucleotide arrays were not yet available). 
 
2.2.2 WHOLE-GENOME CNV ANALYSIS  
A medium resolution (250K) whole genome array was utilised for CNV detection in 
this patient cohort.  Given the lack of resources available at UCT, these studies were 
conducted together with Drs Hans van Bokhoven, Arjan de Brouwer and colleagues 
in the Department of Human Genetics, Radboud University Medical Centre, 
Nijmegen, The Netherlands.   
 
2.2.2.1 Array preparation, labelling and hybridisation 
Whole-genomic DNA was isolated from leukocytes of all 30 patients and 
subsequently analysed using the 250K Nsp Array [Affymetrix] as per manufacturer’s 
instructions outlined in the GeneChip® Mapping 500K Assay Manual [Affymetrix].  
Briefly, whole-genomic DNA from each patient was fragmented using the restriction 
enzyme (RE) NspI.  Subsequently, the fragmented DNA was subject to whole-
genome amplification using adapters ligated to the NspI cleavage sites.  All samples 
were denatured, fluorescently end-labelled and hybridised to the array platform by 
incubation in a GeneChip® Hybridisation Oven 640 [Affymetrix].  Thereafter, all 
arrays were washed and stained in a GeneChip® Fluidics Station 450 [Affymetrix] 












2.2.2.2 Array data analysis 
The GeneChip® Operating Software (GCOS) [Affymetrix] was used to generate and 
acquire the raw data from each array.  Raw data was analysed using the GeneChip® 
Genotyping Analysis Software (GTYPE) [Affymetrix] and genotype calls generated.  
In turn, these genotyping calls were used to determine copy number across the 
genome using the programme copy number analysis for genechip (CNAG) Version 
2.0 as per software instructions (CNAG User Manual Version 2.0) (Yamamoto et al. 
2007).  A pool of ten female and ten male reference samples were used to determine 
copy number.  From this pool, the CNAG software automatically selected the sex-
matched reference (R) sample/s with the lowest standard deviation (optimally <0.2) 
as compared to the test (patient) (T) sample.  The fluorescent signal intensity values 
from the selected reference sample/s were then used to calculate the Log2 
transformed test over reference (T/R) value.  These T/R values were visualised using 
the ’chromosome view’ in CNAG as well as in chromosome-specific Microsoft 
Office Excel V.2007 [Microsoft] files so as to identify regions beyond the set 
thresholds of >0.3 and <-0.3 for duplications and deletions respectively. 
 
2.2.2.3 Interpretation of CNVs 
In order to limit the follow-up molecular investigations to those CNVs which were 
most likely associated with MR, variants were excluded according the criteria 
detailed below.  
 Previously identified in normal controls: the CNV was excluded if it was 
previously reported in either the DGV at http://projects.tcag.ca/variation/ or 
in the ‘structural variation tracks’ at the UCSC Genome Browser 
http://genome.ucsc.edu/ (these tracks are compiled from the literature and 
encompass a variety of whole-genome CNV population-based studies) 
 Inheritance pattern: if the family history was indicative of a particular MR 
inheritance pattern that the CNV did not adhere to, that CNV was excluded 
from further analysis (e.g. an autosomal CNV in a XLMR family) 
 No known genes: If the CNV was predicted to encompass no known genes, it 












2.2.3. CNV VALIDATION BY QUANTITATIVE REAL-TIME PCR 
Subsequent to candidate CNV prioritisation, validation of all putative disease-
causing CNVs was conducted using genomic quantitative real-time PCR (qPCR).  
For each putative CNV, five sets of primers were designed, three of which were 
located within the chromosomal region, while the remaining two flanked the region 
of interest (Appendix 2C).  Furthermore, in patients Fx444.1 and XMR8.1 the 
breakpoints of the CNVs, Xq26.3-27.3Del and Xq25Dup respectively, were also 
determined using qPCR (Appendix 2C)  
 
A qPCR mix was prepared consisting of: 8µM of forward and reverse primer, 5ng of 
genomic DNA, 1× iQ SYBRGreen Supermix [Biorad] and distilled water to a final 
volume of 25µl.  The qPCR profile consisted of an initial denaturation step at 95°C 
for 3 minutes (min), followed by 40 amplification cycles at 95°C for 15 seonds (s) 
and 60°C for 30s.  This was followed by incubation at 95°C for 1min and 65°C for 
an additional minute.  Finally 60, ten second 0.5°C increment steps were performed 
(from a start point of 65°C) in order to create a dissociation (or ‘melt’) curve.  All 
qPCR reactions were performed on a 7500 Fast Real-Time PCR system [Applied 
Biosystems].  DNA samples were amplified in triplicate for each primer pair of the 
qPCR reaction. 
 
The 2–ΔΔCt method was used to calculate fold differences (between calibrator and test 
sample) as described previously (Livak and Schmittgen. 2001).  Amplicons from 
three reference genes, CFTR, MTC8 and STXBP5, were used for quantification 
normalisation.  Validation experiments demonstrated that the qPCR efficiency of 
amplicons from the reference genes and the target loci (chromosomal regions 
encompassing putative CNVs) was 100%, i.e. the amount of PCR product is doubled 
in every cycle.  DNA from a normal female was used as the calibrator sample and the 
Cq (quantification cycle, or crossing point) value was adjusted for male samples 
when performing qPCR on X-chromosomal regions.  The fold differences derived 
from the 2–ΔΔCt method for each of the three reference genes (CFTR, MTC8 and 
STXBP5) was averaged for each target primer pair and plotted on a line graph using 
Microsoft Office Excel V. 2007 [(Microsoft].  Also, where possible, the presence of 












2.2.4 MOLECULAR FOLLOW-UP INVESTIGATIONS IN FAMILY FX444 
2.2.4.1 X chromosome microsatellite marker genotyping in the family trio 
In order to show X-chromosomal haplotype segregation in family Fx444, thirteen 
microsatellite markers distributed between 5-10Mb across the entire X chromosome 
were genotyped in all three family members (Fx444.1/2/3).   
 
The microsatellite marker PCR amplification consisted of two rounds of PCR, firstly 
the microsatellite repeats were amplified with M13-labelled target-specific primers.  
Secondly, the PCR products were pooled and labelled with fluorescent tags (Hex, 
Ned, Fam, Rox) using primers specific for the M13 sequence.  Also, the reverse 
primer contained a ‘PIG’ tail, used to reduce the stutter associated with microsatellite 
marker PCR products (Brownstein, Carpten and Smith. 1996).  The PCRs were 
performed in a total volume of 25µl which consisted of 1× Taq buffer [Invitrogen], 
75mM MgCl2 [Invitrogen], 3µM dNTPs [Bioline] and 1.5U Taq [Invitrogen].  The 
two rounds of PCR differed in terms of both the template and primer used: 
 PCR 1: 1µM forward/reverse M13-labelled microsatellite marker specific 
primers and 100ng of patient DNA  (Appendix 2D) 
 PCR2: 2µl of first-round PCR product was used as the template for 
amplification using 2µM fluorescently labelled M13 specific forward primer 
and 1µM PIG-tailed M13 specific reverse primer.  
 
A touchdown PCR profile was used which consisted of: an initial denaturation at 
95°C for 5min followed by 10 cycles of 95°C for 15s, primer annealing using a 
‘touchdown’ protocol (0.5°C decrements per cycle) from 58°C to 54°C for 15s, 
followed by elongation at 72°C for 30s.  Hereafter, 20/10 (PCR1/2) cycles of 95°C 
for 15s, 54°C for 15s, followed by elongation at 72°C for 30s and a final elongation 
step of 72°C for 10min were performed.  PCR reactions were performed on an 
Applied Biosystems GeneAmp® PCR system. 
 
Microsatellite marker PCR products were combined with the GeneScan™ 500 LIZ® 
size standard [Applied Biosystems] and subject to capillary electrophoresis on an 
ABI Prism® 3100 Genetic Analyser [Applied Biosystems] in accordance with 












V3.0 [Applied Biosystems] software and haplotypes generated with the Cyrillic 
Software V2.0 [Cherwell Scientific]. 
 
2.2.4.2 X-inactivation investigations in unaffected carrier mother (Fx444.2) 
The X-inactivation ratio in an unaffected carrier female (Fx444.2) was established 
using an X-inactivation assay.  In order to conduct this assay, the methylation status 
of a CpG island located within the variable number of tandem repeats (VNTR) 
region of the MAOA gene was analysed as described previously (with modifications) 
(Hendriks et al. 1992, Plenge et al. 1999) 
 
Methylation sensitive DNA digestion with HhaI 
The cleavage activity of HhaI is blocked by methylation of cytosine nucleotides at 
CpG dinucleotides, which is a hallmark of X-inactivation.  Therefore, DNA (1µg) 
from the unaffected mother (Fx444.2) as well as the sons (Fx444.1/3) was digested 
with the methylation sensitive enzyme, HhaI, as per manufacturer’s instructions 
[Fermentas].  Simultaneously all DNA samples from family Fx444 were ‘mock-
digested’ i.e. digestion reagents and incubation times were identical except for the 
lack of enzyme addition to the ‘mock-digestion’ samples.   
 
PCR of MAOA VNTR region 
The VNTR region of MAOA was subsequently amplified by PCR in all familial DNA 
samples (digested and mock-digested) (the heterozygosity of individual Fx444.2 at 
this locus was tested prior to HhaI digestion).  The PCR was performed in a 25µl 
reaction consisting of: 10µM of forward (5' FAM-acagcctgaccgtggagaag 3') and 
reverse (5' gaacggacgctccattcgga 3') primers, 5µM dNTPs [Bioline], 100ng of DNA, 
1× Go Taq buffer [Promega] and 1U Go Taq DNA polymerase [Promega].  The PCR 
profile consisted of an initial denaturation step at 95ºC for 5 min, followed by 30 
cycles at 95ºC for 30s, 58ºC for 30s, and 72ºC for 30s.  A final elongation at 72ºC for 
5 min completed the PCR amplification. PCR was conducted on a Px2 thermal cycler 















Genotyping of the MAOA VNTR locus 
The size of the MAOA VNTR PCR products was assessed by capillary 
electrophoresis conducted on an ABI Prism® 3100 Genetic Analyser [Applied 
Biosystems] in accordance with manufacturer’s protocols.  Software analysis was 
conducted using GeneScan™ V3.7 [Applied Biosystems].  Peak heights of 
fluorescence intensity from the GeneScan™ V3.7 software output were used to 
calculate allele-inactivation ratios. 
 
Calculation of X-chromosome inactivation ratios. 
In order to ensure success of the HhaI methylation-sensitive digestion, complete 
degradation of the male MAOA VNTR PCR product was first confirmed (this active 
X-chromosome is unmethylated and therefore not protected from HhaI digestion).  
Subsequently, the equation below (Equation 1) was used to calculate a corrected ratio 
(CR) for the two female alleles (adapted from Boudewijns, van Dongen and 
Langerak. 2007).  The smaller of the two MAOA VNTR alleles was designated with 
the letter S and the larger allele, L.  Bias towards either of the two alleles owing to 
PCR amplification bias was negated by division of the HhaI digested sample ratio 
(S1/L1) by the ratio of the mock-digested sample (S2/L2).  From this CR, the 
percentage of inactivated X-chromosomes in the sample cell population for 











CR =  S1 (Hha1 digested)    S2 (Hha1 un-digested) 














2.3.1 CNV DETECTION USING 250K SNP ARRAY 
Whole-genome copy-number analysis of 30 MR patients with a syndromic clinical 
presentation revealed a total of 92 CNVs (Appendix 2E).  Of these CNVs, 64 were 
found in either the DGV or in the ‘structural variation tracks’ archived in the UCSC 
Genome Browser (Appendix 2E and Figure 2.1).  These 64 CNVs therefore 
constitute known copy number polymorphisms (CNPs) and are most likely not 
associated with the disorder in these MR patients.  
 
The remaining 28 CNVs had not been previously described in any of the structural 
variation databases, suggesting they constitute either novel CNPs, or rare variants 
which could contribute to MR pathogenesis.  Of these 28 variations, ten autosomal 
CNVs were excluded from further investigation as they were detected in X-linked 
families and are thus unlikely to be the direct disease-causing mutation.  Also, five 
CNVs were excluded as they were located in chromosomal regions which, at present, 
contain no known genes.  Ultimately, in total, validation experiments by genomic 




Figure 2.1 An example of a commonly detected CNP.  This UCSC Genome Browser exert shows a 
frequent centromeric 14q11.2 CNP which encompasses several genes involved in olfactory system 
functioning (ORN4, ORK2, ORK5, ORK1).  Deletions are illustrate in red (e.g. the ‘Locke’ track), 
duplications in green (e.g. the ‘Sebat’ track) and undetermined copy number changes are illustrated in 
grey (‘Redon’ track).  Both deletions and duplications at this locus were observed in the South African 


















Table 2.2 The thirteen CNVs detected by microarray analysis selected for validation 








2.3.2 VALIDATION OF CNVS BY GENOMIC qPCR 
Of the 13 CNVs subject to validation, six were shown to be false positives: 
1. The 0.4Mb 14q32.12Dup in individual Fx233 (Figure 2.2)  
2. The 0.7Mb Xp11.22Dup in individual Fx277 
3&4.  The 1.4Mb Xp22.11Dup and the 1.7Mb Xp11.3Dup in individual Fx 512 
5&6.  The 0.1Mb Xq25Del identified in individuals Fx517 and XMR14 
 
The remaining seven novel CNVs were confirmed using qPCR (Table 2.3). Of these, 
two CNVS were causative of the MR phenotype (in individuals Fx343.1 and 
XMR8.1).  Firstly, the 17p11.2Del was identified in individual Fx343.1, this deletion 
overlaps with the Smith-Magenis microdeletion syndrome.  Secondly, a de novo 
Xq25Dup was detected in individual XMR8.1.  The remaining five CNVs are of 
indeterminate disease-causing nature.  The segregation pattern of the 6q24.3Dup and 
4p16.3Del identified in individuals Fx151.1 and XMR12.1 could not be determined 
due to a lack of family DNA material.  Finally, the Xq26.3- 27.3Del in family Fx444 
has an unknown effect on MR etiology.  
 PATIENT CHANGE SIZE (Mb) 
1.  FX151 6q24.3Dup 1.2 
2.  FX233 14q32.12Dup 0.4 
3.  FX277 Xp11.22Dup 0.7 
4.  FX343 17p11.2Del 3.0 
5.  FX444 Xq26.3-27.1Del 2.1 
6.  FX444 Xq27.2-27.3Del 1.9 
7.  FX444 Xq27.3Del 1.5 
8.  FX512 Xp22.11Dup 1.4 
9.  FX512 Xp11.3Dup 1.7 
10.  FX517 Xq25Del 0.1 
11.  XMR14 Xq25Del 0.1 
12.  XMR8 Xq25Dup 0.8 














Figure 2.2 An example of a false positive CNV detected by SNP array analysis: a 14q32.12Dup identified in patient Fx233.1.  (a) The Log2 ratios of the raw data (upper red 
track) and the normalised data (lower blue track) for each microarray SNP on chromosome 14.  Below this data the ideogram is depicted along with the distribution of the 
SNPS, which appear in green.  The 14q32.12Dup reflected positive Log2 ratios and is illustrated by the red arrows. (b) By qPCR this CNV was shown to be a false positive 
in both affected males (Fx233.1/2), as reflected in the allele copy number of two across the region (i.e. for the external primers designed in BTBD7 and RPS6KA5 and internal 













Table 2.3 Details of the seven novel CNVs detected by the 250K array and confirmed by genomic qPCR  
 





1.  FX151 6q24.3Dup 1.2 XLMR sib-pair 
Only DNA from 
mother available – 












    3,4,5. FX444 Xq26.3- 27.3Del* ~9 XLMR 
Both mother and 
unaffected brother 
carry the deletion 
Numerous see 
figure 5.5 undetermined 2.5  
6.  XMR8 Xq25Dup 0.8 Isolated male  
Mother not carrier 







7.  XMR12 4p16.3Del 1.6 Isolated female Familial DNA not available 
At least 
ADRAC2C 




Deletion lies at the 
distal end of the 
WHS# locus. 
An abnormality on 







* Whole-genome CNV analysis suggested three distinct deletions spanning the Xq26.3-27.3 chromosomal region; however, genomic qPCR investigations in this 














Figure 2.3 The 6q24.3Dup identified in MR patient, Fx151.1 (a) An exert from UCSC illustrating the genes encompassed by the 6q24.3Dup (b) The Log2 ratios of the raw 
data (upper red track) and the normalised data (lower blue track) for each microarray SNP on chromosome 6.  Below this data the ideogram is depicted along with the 
distribution of the SNPS, which appear in green.  The 6q24.3Dup reflected positive Log2 ratios and is illustrated by the red arrows. (c) By qPCR, it was concluded that this 
CNV includes the chromosomal region encompassing EPM2A, SHPRH1 and GRM1 as indicated by the copy number of three in patient Fx151.1 as compared to the normal 
autosomal copy number (two) at the flanking primer sets (UTRN, STXBP5).  By comparison, the individuals mother (Fx151.2) does not appear to be a carrier of this CNV, 














Figure 2.4 The 17p11.2 Del in patient, Fx343.3 causing Smith-Magenis Syndrome. (a) The Log2 ratios of the raw data (upper red track) and the normalised data (lower blue 
track) for each microarray SNP on chromosome 17.  Below this data the ideogram is depicted along with the distribution of the SNPS, which appear in green.   The 
17p11.2Del reflected  negative Log2 ratios and is illustrated by the red arrows. (b) By qPCR, it was demonstrated that this CNV encompasses the genes, FLCN4, SMCR7 and 













Figure 2.5 The Xq26.3-27.3Del in patient Fx444.1 (a) An exert from UCSC illustrating the genes and known CNVs encompassed by the Xq26.3-27.3Del (b) The Log2 ratios 
of the raw data (red track) and the normalised data (blue track) for each microarray SNP on chromosome X.  Below this data the ideogram is depicted along with the 
distribution of the SNPS, which appear in green.  The Xq26.3-27.3Del reflected negative Log2 ratios (red arrows). (c) By qPCR this CNV was shown to span the 
chromosomal region encompassing the F9 to SLITRK2 genes as indicated by the copy number of zero (male patient Fx444.1) as compared to the normal male X-












Individual Fx444.1 presented with profound MR and a multitude of additional 
clinical features including: Haemophilia B, growth retardation, Lennox Gestualt 
epilepsy syndrome, short broad feet and hands with clinodactyly, undescended testes, 
hypotonia and no speech or ambulation.  In total the deletion spans approximately 
9Mb and encompasses 21 known genes and eight predicted genes or open reading 
frames (ORFs) (Figure 2.5a).  Not surprisingly, the F9 gene, mutations in which 
cause Haemophilia B, was deleted in affected individual Fx444.1 who presented with 
this clinical feature.   
 
The family history of Fx444 was particularly interesting (Figure 2.6a), with the 
proband’s maternal male cousin presenting with a very similar phenotype (severe 
MR, seizures, haemophilia B, growth retardation, deceased in pre-teen years).  In 
contrast, the proband’s half-brother (Fx444.3) and maternal grandfather presented 
only with Haemophilia B (the half-brother also has learning disabilities, the cognitive 
function of the maternal grandfather was not known).  DNA samples were only 
available for the proband’s mother (Fx444.2) and half-brother (Fx444.3).  
Intriguingly, by qPCR it was established that not only was the proband’s mother a 
carrier for this mutation but also that his half-brother inherited the same 9Mb 
Xq26.3-27.3Del (Figure 2.6b).   
 
A repeated qPCR experiment on fresh DNA samples from all family members 
yielded the same inheritance pattern of the deletion for the half-brothers.  In addition, 
the deletion breakpoints were defined by qPCR to a proximal chromosomal region of 
~900kb and a distal ~500kb region.  These findings revealed identical Xq26.3-














Figure 2.6 The segregation of the Xq26.3-27.3Del in family Fx444. (a) The pedigree of family 
Fx444. (b) the qPCR profiles demonstrated that the breakpoints of the deletion lie between FGF13 
and F9 (centromeric break point) and in the gene poor region between genes SLITRK2 and FMR1 
(telomeric break point).  Also, the qPCR results demonstrated that the half-brothers (Fx444.1/3) carry 





















Figure 2.7 The Xq25Dup in patient XMR8.1 (a) An exert from UCSC illustrating the genes and known CNVs encompassed by the Xq25Dup (b) The Log2 ratios of the raw 
data (upper red track) and the normalised data (lower blue track) for each microarray SNP on chromosome X.  Below this data the ideogram is depicted along with the 
distribution of the SNPS, which appear in green.  The Xq25Dup reflected positive Log2 ratios and is illustrated by the red arrows. (c) By qPCR, the breakpoints of this CNV 
were mapped to GRIA3 intron 11 centromerically and telomerically to lie between SH2DIA4 and ODZ1.  The copy number from the qPCR lies between two and three for all 
‘duplicated probes’, it was difficult to determine whether this alteration was a duplication or triplication, however, based on the Log2 ratios the former was more likely.  The 













Figure 2.8 The 4p16.3Del in patient XMR12 lies distal to the Wolf-Hirschhorn microdeletion syndrome chromosomal region (a) The Log2 ratios of the raw data (red track) 
and the normalised data (blue track) for each microarray SNP on chromosome X.  Below this data the ideogram is depicted along with the distribution of the SNPS, which 
appear in green.  The 4p16.3Del reflects negative Log2 ratios (red arrows). (b) By qPCR this CNV was shown to include ADRAC2 as indicated by the copy number of 













Figure 2.9 An exert from the UCSC Genome Browser illustrating the 4p16.3Del detected in patient XMR12.  The region was characterised by a large number of segmental 
duplications (see ‘Duplications of >1000 bases of non-repeat masked sequence’ track) and a high frequency of repetitive sequence (see ‘Repeat Masker’ track).  These two 












2.3.3 MOLECULAR FOLLOW-UP INVESTIGATIONS IN FAMILY FX444 
2.3.3.1 X chromosome microsatellite marker genotyping in the family trio 
In order to further validate that the Xq26.3-27.3Del segregated in the family as 
suggested by the qPCR results, whole X-chromosome allele segregation analysis was 
performed using microsatellite markers.  This haplotype analysis demonstrated that 
both the individual with severe syndromic MR (Fx444.1) and his mildly affected 
half-brother (Fx444.3) inherited the same maternal X chromosome in the 
chromosomal region encompassing the deletion (Figure 2.10).   
 
 
Figure 2.10 The X-chromosomal haplotype segregation in family Fx444.  The allele segregation 
analysis conducted in this family demonstrated that the half-brothers (Fx444.1/3) have inherited the 
same maternal X chromosome (red bar) in the region of the Xq26.1-27.3 Del (which falls between 
markers DXS1212 and DXS1193, hence the deletion of marker DXS1192).  In fact, the only 
difference in X-chromosomal genetic material between the half-brothers is owing to a recombination 
between markers DXS1202 (~26.2Mb) and DXS8090 (~36.7Mb).  This haplotype analysis further 












2.3.3.2 X-inactivation analysis in unaffected female Fx444.2 
In order to ascertain the X-inactivation pattern in the half-brothers’ mother 
(Fx444.2), X-inactivation analysis was performed at the MAOA VNTR locus.  From 
these analyses it was established that the X-inactivation ratio was 45:55 (Figure 
2.11).  This X-inactivation ratio suggests random X-inactivation in the unaffected 
female (Fx444.2) with no bias toward preferential inactivation of the X-chromosome 
with the Xq26.3-27.3Del (i.e. the 318bp MAOA VNTR allele)  
 
 
Figure 2.11The X-inactivation pattern in the unaffected mother (Fx444.2) of the half-brothers 
Fx444.1 and Fx444.3.  (a) The electropherogram generated by size-based electrophoresis illustrating 
the MAOA VNTR allele in affected individual Fx444.1.  Both half-brothers carried the 318bp allele 
(blue) at this locus. The 500bp Rox size standard [Applied Biosytems] is illustrated in red (b) The 
electropherogram illustrating the intensity of the two MOAO VNTR alleles (318bp and 348bp) (blue) 
prior to digestion of the unaffected mother’s DNA sample with the methylation-specific enzyme HhaI.  
There was evidence in this electropherogram of preferential amplification of the larger (348bp) allele 
(blue) as compared to the smaller (318bp) allele (blue).  (c) The electropherogram illustrating the 
intensity of the two MOAO VNTR alleles (318bp and 348bp) (blue) after digestion of the unaffected 
mother’s DNA sample with the methylation-specific enzyme HhaI.  Once the allele-specific PCR 
amplification bias was accounted for it was concluded that the X-inactivation ratio was 45:55, 















2.4 DISCUSSION  
The whole-genome copy number analysis of 30 MR patients with MR and 
dysmorphism and/or additional clinical features using a 250K SNP array revealed a 
total of 92 CNVs.  Of these 92 CNVs, 79 variants (86%) were excluded from follow-
up investigations. A total of 64 (69%) CNVs encompassed known CNPs.  Also, the 
chromosomal location of 10 CNVs (11%) did not concur with familial inheritance 
pattern and therefore are most likely not the disease-causing mutation.  Finally, five 
CNVs (6%) were predicted to span chromosomal regions harbouring no known 
genes. While putative effects of these CNVs on the regulatory regions of 
neighbouring genes cannot be excluded, these variants were not further investigated 
in this particular study.  The exclusion of 89% of the CNVs detected illustrates the 
structural variability of the genome as described previously (Alkan et al. 2009, 
Conrad et al. 2009, Redon et al. 2006, Sharp, Cheng and Eichler. 2006).  Also, the 
vast majority of CNVs detected in this study were excluded, thus illustrating that the 
adopted exclusion criteria, while not optimal, were still effective in interpreting the 
pathogenic nature of CNVs. 
 
The remaining 13 CNVs (14%) withstood the initial exclusion criteria and were 
therefore subject to validation by genomic qPCR.  Of these, six (46%) variants were 
shown to be false positives.  This result illustrates two important points; firstly the 
importance of verifying all CNVs detected by microarrays using a second 
quantitative technique.  Secondly, the statistical modelling used to predict copy 
number was evidently sub-optimal.  In this study CNAG was used to predict copy 
number from the genotype calls generated by the Affymetrix GTYPE software.  The 
CNAG software calculates log2 ratios from the genotype call data of both the test 
and reference sample/s and subsequently uses a hidden markov model (HMM) to 
generate allele calls.  This program has certain weaknesses best illustrated by the 
following examples. Firstly, all false positives generated the expected allele calls of 
three or one (the designated values for duplications and deletions respectively) using 
the HMM.   Secondly, all false positive changes showed the deletion of at least four 
consecutive SNPs, or the duplication of six consecutive SNPs, as recommended 












thresholds, both in terms of number and intensity, of duplication/deletion calls was 
insufficiently stringent.  However, the converse was also shown to be true as the 
HMM failed to predict allelic loss for the 17p11.2Del identified in individual 
Fx343.1.  This deletion was only detected by manual Excel visualisation of the Log2 
ratios and verified by qPCR.  These data clearly illustrate that the algorithms used to 
calculate copy number are not optimal.  It should be noted that other platforms which 
use two-flurophore hybridisation methods (where test and reference sample are 
competitively hybridised to and array as oppose to the in silico analysis adopted 
here) suffer from similar sensitivity problems. It was concluded that the CNAG 
algorithm is useful in automatically identifying potential CNVs, however, validation 
by a second technique is recommended, as is manual assessment of data. 
 
The remaining seven CNVs were shown to constitute ‘real’ copy number changes, 
i.e. identified by the SNP array and verified using qPCR.  These seven CNVs 
included a duplication of indeterminate disease-association (6q24.3Dup) in family 
Fx151.1, as well as one known disease-causing alteration (17p11.2Del) in individual 
Fx343.1. Most interestingly, a novel 9Mb X-linked deletion (detected as three 
separate deletions on the SNP array) (Xq26.3-27.3Del) was detected in a severely 
affected MR patient as well as his ‘unaffected’ brother, suggesting this variant 
exhibits low penetrance.  Also, a novel de novo disease-causing mutation (Xq25Dup) 
in XMR8 was detected.  Finally, a 4p16.3Del that falls within a known microdeletion 
syndrome chromosomal region (Wolf-Hirschhorn syndrome) was identified in 
individual XMR12.1, this patient was also shown to carry a chromosome 6p 
abnormality by G-banded karyotype.  The disease-causing nature of these alterations 
in this patient are unknown at this stage.  
 
The approximately 1.2Mb 6q24.3 duplication identified in patient Fx151.1 was not 
inherited from the unaffected mother (Fx151.2).  Further attempts to assess the 
segregation of this variant in the family were thwarted by the inability to contact 
additional family members (affected male sib and unaffected father).  Therefore, 
given this lack of additional familial DNA material, the pathogenic nature of this 
variant remains to be established.  However, it was interesting to note that the 
duplicated chromosomal region encompasses EPM2A and GRM1, which could pose 












in patients with a progressive epilepsy syndrome, myoclonic epilepsy of Lafora 
(OMIM #254780). While the patients in family Fx151 do not present with epilepsy, 
given the role of EPM2A in cognitive function, this gene presents an interesting 
pathogenic MR candidate gene.  Also, the duplicated gene, GRM1 functions as a 
glutamate receptor, these receptors are involved in glutamatergic neurotransmission.  
There are numerous examples of defects in the glutamatergic neurotransmission 
system causing cognitive defects.  For instance, mutations in GRIA3 (also a 
glutamate receptor) have been shown to cause XLMR (Wu et al. 2007).  Also, 
excessive stimulation of mGluR5 (metabotropic glutamate receptor 5) was 
demonstrated to be an important pathogenic mechanism underlying the MR etiology 
in Fragile X syndrome patients (Antar et al. 2004).  Finally, CNVs encompassing 
genes that comprise the glutamate receptor complex are enriched in patients with MR 
(Poot et al. 2009).   Collectively, this evidence suggests that dosage effects of 
EPM2A and GRM1 may contribute to the disease aetiology in family Fx151.1, 
however, no conclusions can be reached until the segregation of this CNV in the 
family has been established. 
 
The 3Mb, 17p11.2Del detected in patient Fx343.1 falls within the pericentromeric 
chromosomal region in which heterozygous deletions cause Smith Magenis 
syndrome.  This syndrome is characterised by MR, a typical facial dysmorphism, 
behavioural problems, cardiac and genitourinary abnormalities (OMIM #189920).  
Individual Fx343.1 presented with a syndromic form of MR including hyperphagia, 
behavioural problems, micropenis and a high pain tolerance. Therefore, the clinical 
presentation of this patient overlapped with the some of the features of Smith-
Magenis syndrome.  This prompted, a detailed retrospective review of this patient’s 
medical records (which were not available prior to this study) which showed that a 
diagnosis of Smith-Magenis syndrome was previously made on the basis of a 
positive FISH result at 17p11.2.    Therefore, it was concluded that this 3Mb 
17p11.2del was the MR-causing mutation in Fx343.1 and that this deletion was most 















Individual Fx444.1 was found to carry an approximately 9Mb X chromosomal 
deletion (Xq26.3-27.3Del) encompassing 21 known genes (Table 2.4).  This deletion 
was transmitted from the carrier mother (Fx444.2) to both her sons (who have 
different fathers), Fx444.1 and Fx444.3 as confirmed by both qPCR and haplotype 
analysis.  Interestingly, despite the half-brothers carrying the same 9Mb deletion, 
their phenotypic expression was highly variable.  The severely affected proband 
(Fx444.1) presents with profound MR, Haemophilia B, growth retardation, Lennox 
Gestualt epilepsy syndrome, short and broad feet and hands with clinodactyly, 
undescended testes, hypotonia and an absence of speech or ambulation.  Conversely, 
the proband’s half-brother (Fx444.3) presents with haemophilia B and learning 
disabilities with no additional clinical features.  
 
Equally surprising was the fact that the chromosomal region in which the 9Mb 
Xq26.3-27.3Del lies was not a gene-poor interval and encompasses a total of 21 
known genes and eight uncharacterised transcripts.  Male X-chromosomal 
hemizygosity renders the Xq26.3-27.3Del males in this family null for the proteins 
encoded by the 21 known genes in this region.  Thus the haemophilia B phenotype of 
the half-brothers can be accounted for by the deletion of F9 which encodes blood 
clotting factor IV.   
 
Similar large Xq deletions are reported in the literature in patients with syndromic 
MR (Parvari et al. 1999, Rousseau et al. 1991).  However, in contrast to the deletion 
described here, all reported deletions encompass either the known MR genes, FMR1 
(distal to this deletion) or PHF6 (proximal to this deletion).  The deletion of these 
two genes was reported to cause the MR phenotype in these XqDel patients.  
Conversely, given that the Xq26.3-27.3Del mutation described here does not 
encompass these MR genes, it was difficult to draw parallels between the phenotype 












Table 2.4 The genes encompassed within the Xq26.3-27.1Del chromosomal region identified in Family Fx444 
Gene Associated disorder Function 
1.  F9 Haemophilia B (OMIM #306900) Factor IV clotting factor 
2.  MCF2 Loss of the proteins N-terminal owing to recombination gives the mutated protein oncogeneic potential GDP-GTP exchange factor that modulates GTPase activity of Rho family 
3.  ATP11C 
None known 
(another ATPase family member (ATP6AP2) has been 
previously implicated in XLMR)  (Ramser et al. 2005) 
ATPase, Class VI, type 11C 
4.  SOX3 XLMR with growth hormone deficiency (Laumonnier et al. 2002) 
Transcription factor involved in embryological development and determination of 
cell fate 
5.  CDR1 target molecule of autoantibodies in patients with paraneoplastic cerebellar degeneration 
Cerebellar degeneration-related protein 1 
 
6.  LDOC Putative tumour suppressor gene Putative regulator of the transcriptional response mediated by nuclear factor kappa B (NF-KappaB) 
7.  SPANX 
None known 
 
The SPANX genes are a group of sperm associated proteins which encode 
differentially-expressed testes-specific proteins that localise to various sub-cellular 
compartments. 
8.  SPANXA1 
9.  SPANXC 
10.  SPANXE 
11.  SPANXF1 
12.  SPANXN1 
13.  SPANXN2 
14.  SPANXN3 
15.  SPANXN4 
16.  MAGEC1 
tumour-specific antigens, putative cancer immunotherapy 
targets 
Members of the melanoma antigen gene (MAGE) family.  They are tumour-specific 
antigens that are recognised by autologous cytolytic T lymphocytes. 
Not expressed in normal tissue except the testis and various tumours 
17.  MAGEC2 
18.  MAGEC3 
19.  UBE2NL 
None known, 
However, an X-chromosomal UBE family member, UBE2A has 
been implicated in XLMR (Nascimento et al. 2006) 
Ubiquitin-conjugating enzyme 
20.  SLITRK2 None known, however, other family members have been 
associated with various disorders: 
SLITRK1: Gilles De La Tourette syndrome (GTS)  
Members of the SLITRK family are integral membrane proteins, also the proteins’ C-
terminal shows homology with neurotrophin receptors.  These genes are expressed 












Interestingly, the SOX3 gene was also encompassed in the Xq26.3-27.3Del.  SOX3 
mutations have been shown to cause MR. (Laumonnier et al. 2002).   Furthermore, 
ATP11C and UBE2NL both belong to protein families previously implicated in MR 
(ATP6AP2 and UBE3A/UBE2A respectively).  Finally, SLITRK2 and SLITRK4 are 
neuronal transmembrane proteins that control neurite outgrowth (Aruga and 
Mikoshiba. 2003, Aruga, Yokota and Mikoshiba. 2003).  SLITRK protein family 
members are thought to play a role in the disease-mechanisms of associated 
neurological disorders including Gilles de la Tourette Syndrome (SLITRK1, OMIM 
#137580) and psychiatric disorders (SLITRK2) (Smith et al. 2009).  Collectively, the 
function of at least some of these 21 deleted genes would appear to account for the 
MR phenotype in family Fx444.  However, given the half-brothers’ phenotypic 
variability the pathogenic role of this deletion was not immediately clear.  There are  
two potential hypotheses for this variability.  First, that the Xq26.3-27.3Del is not the 
disease-causing mutation in this family and that the MR etiology is owing to another 
mutation/s.  Alternatively, the Xq26.3-27.3Del is the disease-causing mutation in this 
family, but exhibits low penetrance.   
 
The first hypothesis assumes the phenotypic variability observed in the family was 
owing to an alternative mutation.  At this point it was useful to examine the pedigree 
of family Fx444 (Figure 2.6a).  Given the haemophilia B phenotype in the half-
brothers’ maternal grandfather, it was assumed that the Xq26.3-27.3Del was 
originally inherited from this individual through the maternal line (Fx444.2).  
Similarly, it was assumed (but cannot be proven) that the half-brothers’ maternal 
cousin inherited the deletion from the maternal grandfather by transmission through 
his mother.  The proposed unidentified mutation could be inherited in either an X-
linked or autosomal fashion, although the pedigree supports an X-linked mode of 
inheritance. Given the lack of syndromic clinical presentation in the maternal 
grandfather it was assumed that a second X-linked mutation could not have been 
inherited from him.  Alternatively a second X-linked mutation could have been 
inherited from the maternal grandmother.  A recombination between the maternal 
and paternal chromosomes in Fx444.2 and her sister could lead to both the 
unidentified X-linked mutation and the Xq26.3-27.3Del being present on the same 
allele.  This inheritance pattern would account for the syndromic MR presentation 












However, if this were the case it would be expected that the female carriers (Fx444.3 
and her sister) would present with at least a mild MR phenotype, yet this clinical 
feature is not present in these individuals, suggesting an X-linked inheritance of a 
second mutation unlikely.  Second to this, the X-inactivation pattern in the half-
brothers mother (Fx444.2) was shown to be random (45:55) by X-inactivation 
studies at the MAOA VNTR locus.  Given that up to 50% of XLMR carrier females 
exhibit skewed X-inactivation (i.e. >>80:20) (Plenge et al. 2002), the random X-
inactivation pattern observed in this individual may suggest that the carrier females 
do not carry a second XLMR mutation.  An autosomal mutation is also unlikely 
given the strong X-linked inheritance pattern in the family and that the severely 
affected maternal cousins share only 6.25% genetic material. 
 
Low penetrance of Xq26.3-27.3Del can also account for the Fx444 familial 
phenotypic variability since mouse models of the XLMR gene SOX3 exhibit a 
similar phenotypic variability. One third of Sox3 male knockout mice were 
phenotypically normal, while the remaining two thirds exhibited a spectrum of 
abnormalities including craniofacial defects, poor growth and general weakness, the 
most severely affected mice did not survive to the weaning stage (Figure 5.12) 




Figure 2.12 A pair of Sox3 null littermates at 2 weeks illustrating the degree of phenotypic 
variability.  Here the phenotypic variability is clearly evident in the level of growth retardation as well 















In human studies, a SOX3 polyalanine expansion mutation has been reported to cause 
XLMR with growth hormone deficiency (Laumonnier et al. 2002).  In addition, a 
detailed MRI study revealed that SOX3 mutations resulted in infundibular hypoplasia 
and hypopituatism in all patients assessed (leading to growth hormone deficiency) 
but MR was not a consistent feature (Woods et al. 2005).  Finally, duplications of the 
gene have been reported in patients with X-linked hypopituitarism and variable 
levels of MR (Solomon et al. 2004).  These investigations all illustrate the variable 
level of MR associated with SOX3 mutations and reflect the phenotypic variability 
observed in this family.  It would therefore be interesting to compare the half-
brothers pituitary function at a biochemical level (e.g. luteinizing hormone (LH) and 
follicle-stimulating hormone (FSH) and thyroid stimulating hormone (TSH) levels) 
to elucidate any potential differences between the males on a sub-clinical level.  
However, owing to difficulties contacting family Fx444.1 these investigations have 
not been possible at present. 
 
These aforementioned studies and observations may explain the observed phenotype 
of a single SOX3 deletion.  However, it must still be noted that the Xq26.3-27.3Del 
encompasses an additional 20 genes (F9 leads to the haemophilic phenotype).  Of 
these genes, nine (SPANX, SPANXA1, SPANXC, SPANXE1, SPANXF, SPANXN1, 
SPANXN2, SPANXN3, SPANXN4) form part of the sperm associated protein family.  
This family of proteins encode differentially-expressed testes-specific proteins that 
localise to various sub-cellular compartments and thus are unlikely to contribute to 
the disease-etiology in the family (Zendman et al. 2003).  Similarly, three genes 
belong to the melanoma antigen gene (MAGE) family which encode tumour specific 
antigens and are not predicted to play a role in the phenotype of family Fx444.  The 
remaining genes MCF2, CDR1 and LDOC can also be potentially excluded from 
playing a role in the syndromic MR pathogenesis given the putative role of these 
genes at various stages of cancer progression.   
 
The remaining deleted genes ATP11C, UBE2NL, SLITRK2, SLITRK4 could be 
hypothesised to contribute to the familial MR etiology.  ATP11C and UBE2NL both 
belong to protein families which have been implicated in MR (Nascimento et al. 
2006, Ramser et al. 2005).  Similarly, the SLITRK protein family have been shown to 












disorders (Aruga and Mikoshiba. 2003, Aruga, Yokota and Mikoshiba. 2003, Smith 
et al. 2009).  However, all four of these genes form part of protein families whose 
members may have overlapping functions.  This redundant function may account for 
the lack of a severe syndromic MR phenotype in some Fx444 family members.  
Ultimately the  Xq26.3-27.3Del phenotype may be modified by genetic variants in 
not only the protein families to which ATP11C, UBE2NL, SLITRK2/4 and SOX3 
belong, but also by genetic and epigenetic variation acting on the biological systems 
implicated in the pathogenesis of syndromic MR in this family. 
 
In conclusion, we hypothesise that the Xq26.3-27.3Del is most likely the disease-
causing mutation in family Fx444.1, although a second mutation cannot be excluded.  
This hypothesis was supported by the phenotypic variability observed in Sox3 knock-
out mice, as well as the variability of clinical presentation (particularly with respect 
to MR) in patients with SOX3 mutations (Rizzoti et al. 2004, Solomon et al. 2004, 
Woods et al. 2005). Furthermore, inter and intra-familial variability for CNVs has 
been reported before, with individuals carrying a 15q13 dup/del (van Bon et al. 2009) 
and 16p11.2Del (Bijlsma et al. 2009) presenting with variable phenotypes.  However, 
this is the first report of extreme intra-familial variability in hemizygous males for an 
X-linked deletion.   
 
In an isolated case of MR, patient XMR8 was found to carry a de novo 0.8Mb 
Xq25Dup which encompassed four known genes: GRIA3, STAG2, THOC2 and 
XIAP.  The duplication breakpoints were determined to lie within GRIA3 intron 12 
(proximal end) and in the intragenic region between genes STAG2 and ODZ1 
(proximal end).   
 
Similar Xq25 duplications have been reported in two patients with MR, the dosage-
sensitive gene within the duplicated region was concluded to be GRIA3 (Bonnet et al. 
2009, Chiyonobu et al. 2007) (Table 2.5).  Mutations which affect GRIA3 (including 
missense mutations, gene deletions) function have been previously reported in 
patients with mild-moderate NS-XLMR (Wu et al. 2007).  Similarly, the previously 
described Xq25Dups resulted in reduced levels of GRIA3 in one patient (Chiyonobu 
et al. 2007), and aberrant GRIA3 transcripts in the second patient (Bonnet et al. 












transcript. However, in contrast the Xq25Dup in XMR8 identified in this study, 
involved duplication of the last four exons of this transcript.  Therefore, essentially it 
was predicted that this patient may still have one functional copy of the GRIA3 
transcript.  Unfortunately, mRNA could not be obtained from this patient to confirm 
the presence of normal levels of the compleete GRIA3 transcript.  Thus it could not 
be ruled out that the duplication affects the GRIA3 transcript in a manner similar to 
the previously described duplications. 
 
Table 2.5 Clinical and molecular features of patients carrying Xq25Dup 




first 6 exons) 




minor facial dysmorphism (hypertelorism, 









first 11 exons) 
 
Female (mother): language/learning 
disabilities and facial hypotonia 
Male sibs presenting with:  
severe MR 
 language delay 
 minor facial dysmorphism  
behavioural problems 












Male patient presenting with: 
severe MR 
skeletal (skull) abnormalities 
minor brain malformations 
distinct facial dysmorphism 
genitourinary and motor abnormalities  
behavioural problems 




These results suggest that additional genetic factors contribute to the syndromic MR 
etiology in patient XMR8, possibly through the altered gene dosage of THOC2, 
STAG2 and XIAP encompassed by the duplication (Table 2.5).  While none of these 
genes have been previously implicated in XLMR, STAG2 is a good candidate for a 
contributor to the MR phenotype in this individual given its putative function as a 
chromatin remodeler.  Duplications in other chromatin remodelers such as ATRX and 












previously reported in syndromic cases of severe MR. (Lugtenberg et al. 2009, 
Thienpont et al. 2007, Van Esch et al. 2005).  Also, by comparison to the clinical 
picture of these previously reported patients, patient XMR8 has a far more severe 
presentation suggesting a role for THOC2 in the pathogenesis of the syndromic MR 
in the patient described in this study.  These results suggest that THOC2 may be a 
candidate MR gene, or at least play a role in embryological development.  
 
Table 2.6 The predicted function of the genes encompassed by the Xq25Dup 
identified in sporadic syndromic MR patient XMR8 





Glutamate receptor: AMPA-sensitive excitatory 






Component of the cohesion complex required for sister 
chromatid pairing after DNA replication (ATRX has been 





THO2 forms part of the TREX (transcription/export) 
complex which associates with RNA polymerase II 









Member of a protein family involved in the inhibition of 
apoptosis through binding of TRAF1/2 (tumour necrosis 
factor receptor-associated factor) 
*XLP: XLP is a rare immunodeficiency characterized by extreme susceptibility to infection with Epstein-Barr 
virus (EBV). Symptoms include severe or fatal mononucleosis, acquired hypogammaglobulinemia, pancytopenia 
and malignant lymphoma 
 
Bonnet and colleagues (2009) suggest that the second duplication (encompassing 
XIAP and STAG2) identified in their study does not contribute to the disease etiology 
due to the CNV’s overlap with a known CNP (Bonnet et al. 2009).  However, basing 
this hypothesis on the presence of a CNP should carry a note of caution.  The known 
CNPs in the region include a CNV of unknown direction (i.e. loss/gain) which is 
particularly unreliable (Redon et al. 2006). The second identified CNP is a small 
deletion within STAG2 (McCarroll et al. 2006).  In contrast to the duplications 
described here, this deletion may have different pathogenic mechanisms to the 
duplications described in these patients (Figure 2.7). Lastly, as these CNPs were 
archived within the DGV database, the gender of the individuals in whom these 
variants were detected is unknown which may further influence the pathogenic effect 













Finally, the observation of three different but overlapping duplications in this Xq25 
region suggests that this interval may be predisposed to structural rearrangements 
and may constitute a novel ‘duplication hotspot’.  To this end, Chiyonobu and 
colleagues assessed 23 male MR patients for the presence of the Xq25 duplication 
they described but found no further rearrangements (Chiyonobu et al. 2007).  
However, the small size of this cohort was a limiting factor and a larger-scale 
investigation in additional severely affected males with a similar phenotype to those 
described here will give a better indication as to the likelihood of the existence of a 
duplication hotspot.   
 
Patient XMR12, presented with MR, microcephaly, minor facial dysmorphism, 
seizures and classic lissencephaly.  Upon whole-genome SNP-array analysis an 
approximately 1.6Mb deletion was detected in the 4p16.3 subtelomeric region.  
Heterozygous deletions in this region are known to cause Wolf-Hirschhorn syndrome 
(WHS) (OMIM: #194190), a syndromic form of MR.  WHS is characterised by MR, 
seizures, congenital heart defects, genital/renal anomalies and a distinctive facial 
dysmorphism which includes: microcephaly, hypertelorism, prominent glabella, 
broad and/or beaked nose, short philtrum, micrognathia, downturned corners of the 
mouth, dysplastic ears and preauricular tags (Zollino et al. 2008).  The clinical 
presentation of patient XMR12 shows some overlap with the features of WHS, 
including: MR, seizures, microcephaly and some minor facial dysmorphism (broad 
forehead, brachycephaly, hypertelorism and a broad nasal root and tip), but does not 
include lissencephaly.  However, it should be noted that while this deletion does lie 
within the chromosomal interval deleted in WHS patients, it does not overlap with 
the WHS critical region (WHSCR) common to all patients described to date (Zollino 
et al. 2008).  Secondly, the genomic architecture of this subtelomeric region makes it 
prone to structural variation and several CNPs have been described in the DGV in 
this region.  However, none of these CNPs overlap completely with the variant 
described here and none of them overlap the ADRAC2 gene.   
 
It should also be noted that prior karyotype analysis showed an abnormal banding 
pattern on chromosome 6p, the disease-causing nature of this change could not be 
determined as the parents were unavailable for testing.  Further molecular analysis by 












6p. The 4p16.3Del was the only other potentially disease-causing CNV detected.  
These results suggest that patient XMR12 may carry a 4:6 translocation (with the 
resultant small 4p16.3 deletion occurring at the translocation breakpoint) which may 
be associated with the disorder.  FISH analysis using probes from either chromosome 
four and/or six should be performed to confirm this hypothesis.    
 
Ideally the patient’s parents need to be tested for both the abnormality on 6p and the 
deletion at 4p16.3 in order to elucidate the disease-causing nature of these variations.  
Until these analyses are done, no conclusions can be drawn as to the disease-
association of the 4p16.3Del or the 6p chromosomal abnormality, nor can the parents 
be offered any valuable recurrence risk estimates. 
 
In conclusion it has been illustrated that the application of the 250K Affymetrix SNP 
array for copy number analysis efficient in the detection of MR-causing CNVs. The 
exclusion criteria adopted here are, in the majority of cases (86%), effective in 
excluding benign CNVs from further analysis.  However, the importance of using a 
second technique to verify variants detected by whole-genome array investigations 
has also been highlighted.  The detection of a 9Mb X chromosomal deletion 
(Xq26.3-27.3Del) which exhibits low penetrance raises important questions for the 
genetic counselling approaches in families with known and putative disease-causing 
mutations.  In this study we detected three disease-causing CNVs (17p11.2Del, 
Xq25Dup and Xq26.3-27.3Del) in the 30 MR patients assessed thus demonstrating a 
detection rate of 10%.  This finding highlights the significant contribution that CNVs 
make to the MR etiology in patients with unexplained MR and emphasises the 
importance of implementing this technology in the MR diagnostic setting in South 
Africa.  Moreover, the disease-causing mutations identified in these CNV analyses 




































Linkage analysis has long been established as one of the most important tools in the 
identification of disease genes.  In the late 1980s linkage analysis used in conjunction 
with information from chromosomal rearrangements led to the identification of 
disease genes for, amongst others, chronic granulomatous disease and Duchenne 
muscular dystrophy.  Subsequently, using only linkage analysis and the positional 
candidate gene approach the gene responsible for cystic fibrosis was identified.  
Since then there has been a flurry of genes discovered by linkage analysis with over 
40 genes indentified preceding 1995 and hundreds more subsequently (Collins. 
1995). Today, this positional candidate approach is still used for the mapping of rare, 
autosomal recessive and complex disorders with progress being aided by the 
development of high-throughput whole-genome technologies as well as the wealth of 
genetic information generated by the human genome project. 
 
The use of X-chromosomal linkage analysis and subsequent positional candidate 
gene selection to identify disease-causing mutations in four South African XLMR 
families was one of the primary strategies adopted in this study.  The rationale for the 
use of this well-established technique includes both technical and practical 
motivations.  Firstly, discovery of a fair proportion of the 87 XLMR genes identified 
to date was due to the successful implementation of linkage analysis in multiple 
XLMR families (Chiurazzi et al. 2008).  This is due to the more easily identifiable X-
linked inheritance pattern in MR families as well as the relative ease with which 
molecular techniques can be applied to the male hemizygous X-chromosomal state.  
Secondly, given the clinical and genetic heterogeneity associated with the disorder it 
is a tedious and difficult task to select an XLMR candidate gene based on a familial 
phenotype.  Performing linkage analysis on only a single chromosome allows the 
definition of a critical interval within a family and can significantly reduce the 
number of genes which need to be investigated.  For these reasons, those families 
which showed clear X-linked inheritance and were of sufficient size, were selected 














3.2.1 FAMILY SELECTION 
XLMR families with unexplained MR were selected for inclusion in this linkage 
analysis study for definition of a critical disease-associated chromosomal region.  
Family selection was based on the following inclusion criteria: 
 A Clear X-linked recessive inheritance pattern 
 Families negative for the FXS CGG repeat expansion mutation 
 Families of sufficient size to conduct meaningful linkage analysis, i.e. a 
minimum of a mother and two affected sons. 
 
Originally only two families were selected for linkage analysis, families XMR2 and 
Fx56.  Family XMR2 consisted of over 50 relatives spanning four generations while 
Fx56 consisted of seven family members from three generations.  Subsequently, an 
additional two smaller families (Fx36 and Fx67) were included in the study in an 
attempt to refine the critical interval in families XMR2 and Fx56.  The smaller 
families, Fx36 and Fx67, consisted of carrier mothers as well as two and three 
affected brothers respectively (all pedigrees in Appendix 3A). 
 
The clinical presentation of patients was not part of the inclusion criteria for the 
selection of families for linkage analysis.  Nevertheless, affected XMR2 family 
members presented with a syndromic form of XLMR while patients in families Fx56, 
Fx67 and Fx36 manifested with NS-XLMR.  A more detailed clinical review of 
patient phenotypes was conducted once a critical disease-associated chromosomal 
interval was defined and in order to prioritise positional candidate genes which were 
















3.2.2 MICROSATELLITE MARKER ANALYSIS 
3.2.2.1 Whole X chromosomal screen 
A previous study in this laboratory excluded the chromosomal region encompassing 
the ARX gene as being associated with MR in families XMR2 and Fx56 (Honours 
(Med) dissertation by G.Carvill, 2005).  Consequently the chromosomal region 
surrounding ARX (Xptel – Xp21.2) was not included in linkage analysis in these 
families.  Thirteen microsatellite markers spanning the remainder of the X 
chromosome (Xp21.2- Xqtel) were selected from the ABI® Prism Linkage Mapping 
Set V2 Panel 28 [Applied Biosystems] (Appendix 3B).  These microsatellite markers 
were spaced at between 2 and 12Mb intervals (except for the 24Mb centromeric 
interval) so as to allow for a comprehensive screen of the X chromosome.  The 
selected microsatellite markers were amplified from DNA of 12 and four family 
members of XMR2 and Fx56 respectively.   Also, in family Fx67, total of 13 X-
chromosomal microsatellite markers (Appendix 3B) were retrospectively genotyped 
in the four individuals comprising this family. 
 
PCR amplification was performed according to manufacturer’s instructions on an 
Applied Biosystems GeneAmp® PCR system 9700 thermal cycler and products were 
visualised with ethidium bromide (EtBr) on a 1% agarose gel with a 100bp molecular 
weight (MW) marker [Fermentas] (Appendix 3C) in order to establish PCR success.  
Genotyping of microsatellite markers was achieved on an ABI Prism® 3100 Genetic 
Analyser [Applied Biosystems] in accordance with manufacturer’s protocols and 
analysed using the GeneMapper™ V3.0 [Applied Biosystems] software. 
 
3.2.2.2 Fine mapping markers 
Once a chromosomal region indicative of an association with the disorder was 
established in XMR2, an additional ten microsatellite markers within the applicable 
interval (between DXS993 and DXS986) were selected in order to refine this critical 
region (Appendix 3B).  Furthermore, four family members were recruited to this 
study and genotyped, in order to refine this disease-associated interval.  The 10 













Fine mapping at the same critical interval (between DXS993 and DXS986) was also 
conducted in family FX56 using six of the aforementioned microsatellite markers 
(Appendix 3B).  Finally, in families Fx36 and Fx67, these six fine mapping 
microsatellite markers, as well as the microsatellite markers within the disease-
associated interval (DXS993, DXS991, DXS986) were genotyped in these families 
in an attempt to refine the critical interval in families XMR2 and Fx56. 
 
Retrospectively, an additional eight fine-mapping microsatellite markers (between 
DXS987 and DXS993 and at a second region between DXS990 and DXS1106) were 
genotyped in family Fx67 in an attempt to refine the chromosomal regions 
suggestive of disease-association in this family (Appendix 3B). 
 
All microsatellite markers were selected using the uniSTS database (NCBI) 
(http://www.ncbi.nlm.nih.gov/).  Selected markers were either commercially 
available (Research Genetics) or alternatively, synthesised using a Beckman Oligo 
1000M DNA synthesizer and labelled with a 5’ fluorescent tag [synthesised by P. 
Ma, UCT].  A range of PCR protocols were used to amplify the selected 
microsatellite markers (Appendix 3D) on a Px2 thermal cycler [Thermo Electron 
Corporation].  Gel electrophoresis and genotyping analysis was performed as above. 
 
3.2.3 TWO-POINT LINKAGE ANALYSIS 
Two-point linkage analyses were performed for each microsatellite marker using the 
MLINK programme from the LINKAGE software package (Version 5.1.).  Full 
penetrance of the XLMR gene was assumed and the frequency of the disease allele 
was set at 0.0001, otherwise all analyses were conducted as previously described 


















The results of the two-point linkage analyses for the 13 microsatellite markers used 
in the initial whole X chromosomal genotyping performed on DNA samples from 12 
individuals comprising family XMR2 is shown in Table 3.1. These preliminary 
findings suggested linkage to the chromosomal region encompassing microsatellite 
marker DXS991 with a maximum LOD score of 2.83 (θ = zero) at DXS991 (Table 
3.1).  This chromosomal region (Xp11.4-Xq21.1 ) spanned an approximately 38Mb 
chromosomal region between (but excluding) microsatellite markers DXS993 and 
DXS986 
 
Table 3.1 Two-point LOD scores for microsatellite markers from initial X-
chromosomal screen in Family XMR2* 
*maximum LOD score for 12 individuals (grandmother’s genotype inferred) in this family was 2.83 
Linked microsatellite markers appear in bold 
 
 
Haplotypes were constructed from the genotyping data of the 13 microsatellite 
markers used in this initial whole X-chromosomal screen (Figure 3.1). 
MARKER LOD SCORES AT APPLICABLE θ VALUES 
 0  0.1 0.2  0.3 0.4 0.5 
DXS1214 -∞ -0.53 -0.01 0.13 0.11 0 
DXS1068 -∞ -0.53 -0.01 0.13 0.11 0 
DXS993 -∞ 0.62 0.58 0.39 0.15 0 
DXS991 2.83 2.34  1.79 1.19 0.56 0 
DXS986 -∞ -2.29 -1.18 -0.6 -0.23 0 
DXS990 -∞ 1.38 1.20 0.86 0.46 0 
DXS1106 -∞ 0.43 0.60 0.50 0.28 0 
DXS8055 uninformative 
DXS1001 -∞ -0.53 -0.01 0.13 0.11 0 
DXS1047 -∞ -0.53 -0.01 0.13 0.11 0 
DXS1047 -∞ -0.53 -0.01 0.13 0.11  0 
DXS1227 -∞ -0.78 -0.21 -0.02 0.03 0 
DXS8043 -∞ -0.07 0.12 0.15 0.11 0 












Figure 3.1 The three generation pedigree of 12 individuals comprising family XMR2 showing 
individual haplotypes from the initial whole X chromosomal analysis.  The maternal grandmother’s 
genotype was inferred as designated by the allele occurring in brackets e.g. (1).  Haplotypes are 
represented by solid coloured bars, with the disease-associated haplotype represented in red.  The red 
rectangle encompasses the region of positive linkage at microsatellite marker DXS991 with a 
maximum LOD score of 2.83. It should also be noted that there was a significant degree of non-
paternity in this family, with each of the five sisters (and the sixth in Figure 3.2) having a different 
father.  As the XLMR in this family was due to an X-chromosomal mutation, which segregates 













Prior to fine mapping of the 38Mb disease-associated interval, an additional three 
family members were recruited for linkage analysis in this family 
(XMR2.8/29/30/31).  The results of the two-point linkage analyses using the ten fine-
mapping microsatellite markers in these 16 family members of XMR2 is given in 
Table 3.2.  The critical interval was refined to a 10Mb region between (but not 
including) microsatellite markers DXS8111 and DXS986 (Xq13.1-q21.1) with a 
maximum LOD score of 3.08 (θ = zero) across the region (i.e. DXS8052-DXS56).   
 
Table 3.2 Two-point LOD scores in family XMR2 for fine mapping microsatellite 
markers  
*maximum LOD score for 13 individuals (grandmother’s genotype inferred) in this family was 3.08 
Linked microsatellite markers with the highest LOD score appear in bold 
 
Haplotypes for these 16 individuals were generated from the genotypes of the ten 
microsatellite markers, the haplotype regions encompassing the critical interval are 
shown in Figure 3.2.  Interestingly, the unaffected individual, XMR2.31, inherited 
the same haplotype as the affected relatives until a recombination event between 
microsatellite markers DXS8111 and DXS8052 (Figure 3.2).  This recombination 
ultimately resulted in the reduction of the linked interval to the 10Mb chromosomal 
region at Xq13.1-q21.1 (between microsatellite markers DXS8111 and DXS986). 
 
No additional family members were available for genotyping analysis making it 
impossible to further refine this 10Mb critical interval, therefore this region was 
interrogated for positional candidate genes (Chapter 4). 
MARKER LOD SCORES AT APPLICABLE θ VALUES 
 0  0.1 0.2  0.3 0.4 0.5 
DXS6810 -∞ 0.32 0.42 0.36 0.22 0 
G10578 -∞ 0.99 0.89 0.63 0.29 0 
DXS1199 1.03 0.87 0.69 0.49 0.27 0 
DXS1190 1.33 1.14 0.92 0.67 0.37 0 
DXS6785 2.36 1.95 1.49 0.99 0.46 0 
DXS8111 -∞ 1.84 1.55 1.09 0.54 0 
DXS8052 3.08 2.50 1.89 1.24 0.58 0 
DXS559 3.08 2.50 1.89 1.24 0.58 0 
DXS441 3.08 2.52 1.92 1.27 0.61 0 















Figure 3.2 The four generation pedigree of selected individuals comprising family XMR2 showing fine-mapping of the critical interval.  The maternal 
grandmother’s genotype was inferred as designated by the allele in brackets e.g. (1).  Haplotypes are represented by solid coloured bars, the disease-associated 
haplotype is represented in red.  The red rectangle encompasses the region of positive disease-association between microsatellite markers DXS8111 and DXS986 
with a LOD score of 3.08.  It should also be noted that there was a significant degree of non-paternity in this family, with each of the six sisters having a different 












The whole X-chromosomal linkage analysis in 13 microsatellite markers in family 
Fx56 led to the identification of a disease-associated chromosomal region that 
overlapped with family XMR2.  Fine mapping of an additional six microsatellite 
markers within this region in family Fx56 ultimately led to the identification of a 
disease-associated interval between (but not including) microsatellite markers 
DXS1068 and DXS8055.  The maximum LOD score of 0.60 (θ=zero) was achieved 
for the chromosomal interval encompassing markers DXS993-DXS986 (Table 3.3).  
Although this LOD score was not statistically significant, this chromosomal region 
could not be excluded due to the co-segregation of alleles for markers DXS1068-
DXS8055 (and DXS1227) in affected individuals in this three generational pedigree.   
 
Table 3.3 Two-point LOD scores in family Fx56 for X-chromosomal microsatellite markers 
*maximum LOD score for 4 individuals in this family was 0.60 
Linked microsatellite markers with the highest LOD score appear in bold 
 
Haplotypes were constructed from the genotypes of the 19 X-chromosomal 
microsatellite markers (initial whole-X screen and fine mapping markers) in family 
Fx56 (Figure 3.3).  Unfortunately, no further family members were available for 
genotyping analysis and thus the disease-associated interval could not be reduced in 
this family, nor the LOD score increased.  The disease-associated chromosomal 
region (Xp11.4-Xq21.1) spanned approximately 76Mb and contains roughly 397 
genes (based on March 2006 assembly) of which 33 have been implicated in XLMR.   
MARKER LOD SCORES AT APPLICABLE θ VALUES 
 0  0.1 0.2  0.3 0.4 0.5 
DXS1214 -∞ -0.70 -0.40 -0.22 -0.10 0 
DXS1068 -∞ -0.48 -0.26 -0.16 -0.08 0 
DXS993 0.60 0.47 0.34 0.21 0.1 0 
DXS6810 uninformative 
G10578 0.60 0.47 0.34 0.21 0.1 0 
DXS1199 0.60 0.47 0.34 0.21 0.1 0 
DXS991 0.60 0.47 0.34 0.21 0.1 0 
DXS1190 0.60 0.47 0.34 0.21 0.1 0 
DXS6785 0.60 0.47 0.34 0.21 0.1 0 
DXS559 uninformative 
DXS986 0.60 0.47 0.34 0.21 0.1 0 
DXS990 0.30 0.26 0.20 0.15 0.08 0 
DXS1106 0.30 0.21 0.13 0.06 0.02 0 
DXS8055 -∞ -0.19 0.01 0.07 0.06 0 
DXS1001 -∞ -0.44 -0.19 -0.08 0.02 0 
DXS1047 -∞ -0.19 0.01 0.07 0.06 0 
DXS1227 0.30 0.26 0.20 0.15 0.08 0 
DXS8043 -∞ -0.19 0.01 0.07 0.06 0 














Figure 3.4 The three generation pedigree of Fx56, showing haplotype analysis from the genotyping of 
19 X-chromosomal microsatellite markers.  Haplotypes are represented by solid coloured bars, with 
the disease-associated haplotype represented in red.  The disease-associated region was defined by the 
recombination between markers DXS1068 and DXS993 in individual FX56.4 on the Xp arm and 












Genotyping analysis using nine microsatellite markers spanning Xp11.4-Xq21.1 was 
originally conducted in the smaller families, Fx36 and Fx67, in order to refine the 
critical interval originally identified in families XMR2 and Fx56.  The combined data 
(from all four families) was assessed in an attempt to refine the critical interval in 
families XMR2 and Fx56.  Haplotype analysis in family Fx36 showed allele co-
segregation across the entire investigated chromosomal interval, Xp11.4-Xq21.1 
(Figure 3.4).  Conversely, in family Fx67 the region Xp11.4-Xq21.1 was shown not 
to segregate with the disorder (Figure 3.5).  Taken together, these results were not 
successful in refining the critical interval in families XMR2 and Fx56. 
 
 
Figure 3.4 The two generation pedigree of selected individuals illustrating the allele segregation in 
family Fx36 for the nine microsatellite markers genotyped in the Xp11.4-Xq21.1 region.  Haplotypes 
are represented by solid coloured bars, with the disease-associated haplotype represented in red.  In 
this study the two both affected brothers (Fx36.3 and 36.4) were shown to have inherited the same 
haplotype for this particular chromosomal region; therefore this interval (Xp11.4-Xq21.1) may 


















Figure 3.5 The two generation pedigree of selected individuals illustrating the allele segregation in 
family Fx67 for the nine microsatellite markers in the Xp11.4-Xq21.1 region.  Haplotypes are 
represented by solid coloured bars.  In this study two of the affected brothers (Fx67.2/3) inherited the 
same haplotype (red) for this particular chromosomal region.  However, in contrast, affected 
individual Fx67.4 has inherited a different haplotype (green), therefore, this allele segregation analysis 
demonstrated that this chromosomal region was unlikely to harbour the disease-causing mutation. 
 
No indication of disease-association in family Fx67 was evident at the nine 
microsatellite markers spanning Xp11.4-Xq21.1.  However, genotyping of an 
additional ten X-chromosomal microsatellite markers in family Fx67 demonstrated 
that only a single marker, DXS1068, segregated with the disorder in the three 
affected brothers.  A significant LOD score cannot be generated due to the small size 
of the family (the maximum LOD score for this family is 0.40 (θ=zero)). However, 
co-segregation of DXS1068 with the disorder suggested this region was associated 
with MR in Fx67.  Therefore, subsequent genotyping of seven microsatellite markers 
flanking marker DXS1068, demonstrated that a total of five microsatellite markers 
segregated with the disorder in this family (though genotyping of one of these 
markers, DXS1214, was uninformative in this family) (Figure 3.6).  This putatively 
disease-associated region spanned the interval between (but not including) markers 
DXS9896 and DXS990.  This chromosomal interval spans approximately 12Mb and 
is relatively gene poor; therefore, this region was further assessed for positional 













It should also be noted that while DXS1068 was the only microsatellite marker 
which segregated with the disorder in this family, there was an additional 
chromosomal interval which could not be excluded due to a recombination between 
markers DXS990 and DXS1106.  An additional marker (DXS6789) within this 
region was genotyped and led to the identification of another putative disease-
associated region between but not including DXS990 and DXS6789 (Figure 3.6).  
This region could not be further refined, however, this chromosomal interval 
contains no known genes and was therefore not investigated further. 
 
 
Figure 3.6 The two generation pedigree of selected individuals illustrating the allele segregation in 
family Fx67 for the 18 microsatellite markers spanning the remainder of the X chromosome 
(excluding Xp11.4-Xq21.1).  Haplotypes are represented by solid coloured bars, the ‘affected’ allele is 
represented in red whereas the normal allele is represented in green.  In this study, five microsatellite 
markers were shown to segregate with the disorder (red rectangle) in family Fx67.  These results 













To date, linkage analysis has been successfully applied in the identification of a large 
proportion of the 87 known XLMR genes (Chiurazzi et al. 2008).  In this study, the 
linkage analysis technique was employed in order to identify a disease-associated X-
chromosomal interval in four South African XLMR families, with a view towards 
positional candidate gene selection and subsequent mutation detection. 
 
In the largest of the investigated families, XMR2, initial whole X-chromosomal 
microsatellite analysis in 12 individuals led to the identification of a 38Mb region 
with a maximum LOD score of 2.83 (θ=zero), at marker DXS991.  This LOD score 
was statistically significant (i.e. LOD score <2, for the X-chromosome), and was thus 
indicative of disease-association of this locus in family XMR2.  Therefore, fine 
mapping in this region was conducted including four additional family members 
(total of 16 individuals) in order to refine the disease-associated interval.  A 
recombination event in a newly-recruited family member (XMR2.31) reduced the 
interval to a chromosomal region spanning approximately 10Mb with a maximum 
LOD score of 3.08 (θ=zero) across the linked interval (i.e. DXS8052-DXS56).  The 
increase in LOD score reflects the inclusion of additional family members in the 
analysis, as well as the recombination in individual XMR2.13.  This statistic was the 
maximum LOD score that could be achieved for a family of this size.    The fine 
mapping in family Fx67 reduced the critical interval to a 10Mb chromosomal region 
(Xq13.1-q21.1), flanked by (but not including) the microsatellite markers DXS8111 
and DXS986.  Given that the LOD score of 3.08 (θ=zero) was also statistically 
significant, it was highly probable that this chromosomal region harboured the 
disease-causing mutation in this family.  The selected positional candidate genes 
within this disease-associated interval are discussed in further detail in Chapter 4. 
 
In family Fx56, the initial whole X-chromosomal screen identified a disease-
associated interval (Xp11.4-Xq21.1) between (but excluding) the microsatellite 
markers DXS1068 and DXS8055.  The LOD score for this chromosomal region in 
family Fx56 was 0.60 (θ = zero), achieved for the chromosomal interval 
encompassing markers DXS993-DXS986.  This statistic was also the maximum 











was not statistically significant, this was a reflection of the small family size rather 
than any genetic factor.  Unfortunately, additional Fx56 family members could not 
be recruited and therefore further fine mapping of the disease-‘associated’ X-
chromosomal interval could not be conducted.  This disease-associated chromosomal 
interval spans approximately 76Mb, encompassing roughly 397 genes of which 33 
have been previously implicated in the pathogenesis of XLMR.  Of these 33 XLMR 
genes, 11 (PAK3, ACSL4, NLGN3, DLG3, ARHGEF9, JARID1C, FTSJ1, ZNF81, 
ZNF41, ZNF674, EFHC2) have been shown to be mutated in patients with NS-
XLMR.  Given the non-syndromic clinical presentation of affected individuals in 
family Fx56, it was difficult to prioritise NS-XLMR genes for mutation detection 
analysis in the absence of additional clinical features.  For these reasons it was 
deemed neither financially nor technically viable at this point to conduct positional 
candidate gene analysis in this particular XLMR family. 
 
The X-chromosomal allele segregation analysis in families Fx36 and Fx67 was 
originally conducted in an attempt to refine the linkage interval identified in families 
XMR2 and Fx56 (i.e. Xp11.4-Xq21.1) using combined data.  Haplotype analysis 
across the Xp11.4-Xq21.1 interval in family Fx36 showed this entire chromosomal 
region segregated with the disorder in this family.  Given that all nine microsatellite 
markers (DXS993-DXS986) segregated with the disorder in this family, this 
information was not informative with respect to refining the critical interval in 
families Fx56 and XMR2.  Conversely, in family Fx67, haplotype analysis in the 
same region (Xp11.4-Xq21.1) showed no disease-association with this chromosomal 
region.  Due to the lack of recombination events in families Fx36 and Fx67 within 
Xp11.4-Xq21.1, haplotype analysis of this region was ultimately ineffective in 
narrowing the linkage interval in families XMR2 and Fx56.  
 
One could question the validity of using information from multiple families to refine 
a critical region for gene identification in XLMR families.  While this is common 
practice for clinically homogenous disorders it is particularly difficult to apply to 
XLMR given the high degree of genetic and clinical heterogeneity.  This is 
especially true in this case where these XLMR families have a diverse and variable 
clinical presentation and are unlikely to have the same underlying pathogenic 












XLMR genes (e.g. ARX, SLC6A8, MECP2, OPHN1, ATRX) are implicated in the 
pathogenesis of both syndromic and non-syndromic forms of the disorder (Chiurazzi, 
Tabolacci and Neri. 2004). 
 
Family Fx67 was not linked to the aforementioned Xp11.4-Xq21.1 chromosomal 
region investigated in this study using nine microsatellite markers.  Further 
genotyping and haplotype analysis of microsatellite markers spanning the remainder 
of the X chromosome showed the marker DXS1068 segregated with the disorder in 
this family.  Despite the fact that a statistically significant LOD score could not be 
obtained for due to the small family size (the maximum LOD score for this family is 
0.40 (θ=zero), allele segregation analysis demonstrated that a total of five 
microsatellite markers segregated with the disorder (DXS1214-DXS8042).  This 
12Mb interval  (Xp21.1-Xp11.4) is relatively gene poor with 27 known genes (based 
on human genome assembly 36, March 2006), of which only two have been 
previously implicated in XLMR.  These two XLMR genes, ATP6AP2 and TM4SF2 
have been shown to be mutated in NS-XLMR making them good positional 
candidate genes given the non-syndromic presentation of MR in family Fx67.  
Therefore, these two XLMR genes were assessed for DNA sequence variations as 
described in Chapter 4. 
 
One of the major caveats in these linkage analyses was the limited number of family 
members available for genotyping analysis.  The only family of sufficient size to 
produce a statistically significant LOD score, was family XMR2 which included 
genotype information from 16 individuals.  For the remaining families the LOD 
scores were all below one, resulting in a less than 10 times greater chance that the 
observed linkage is real as opposed to occurring randomly.  Genotyping analysis in 
an increased number of individuals would have a directly proportional effect on the 
LOD score.  However, all three families with low LOD scores, FX56/36/67, could 
not be contacted or visited and therefore additional family members could not be 
recruited.  In future studies it would be recommended that frequent contact is 














As previously mentioned, linkage analysis is a well established technique, it could be 
argued that its use here is outdated and novel high-throughput methods would be 
better suited for XLMR gene identification.  It is true that the application of high-
throughput sequencing and microarray technologies holds much promise for the 
diagnosis of MR.  The speed with which many different genes can be analysed is a 
huge advantage particularly in the case of XLMR where diagnosis is complicated by 
high degrees of clinical and genetic heterogeneity.  This is particularly true in NS-
XLMR cases where a lack of additional clinical features makes the selection of one 
or several candidate genes from a host of NS-XLMR genes virtually impossible.   
 
Recently, the advantages of these technologies have been illustrated in an 
investigation of 208 XLMR families by high-throughput Sanger sequencing which 
led to the discovery of nine novel of disease-associated genes (Tarpey et al. 2009).  
While several of the South African XLMR families described in this dissertation 
were included in this study, the cost of these technologies is prohibitive for 
diagnostic applications in a developing country such as South Africa.  It is envisaged 
that as the costs of these technologies are reduced in the future, it will become 
possible to conduct mutation detection in all XLMR genes in patients as a routine 
diagnostic test, both in South Africa and the larger international community. 
 
Nevertheless, this ideal diagnostic situation will not be a reality for a number of years 
and alternative forms of molecular diagnoses of MR need to be expanded in the 
South African setting.  While linkage analysis cannot always lead to the 
identification of a disease-causing mutation, it can give an indication of the 
chromosomal region most likely associated with the disease phenotype in a particular 
XLMR family.  The haplotype analyses described in this study could be used for 
carrier testing for individuals in family XMR2 in the absence of a known familial 
disease-causing mutation.  This information is vital in better genetic management 
and counselling for families with a history of XLMR. 
 
In conclusion, two independent critical intervals were identified in families Fx67 and 
XMR2 and positional candidate genes could be selected.  Here it has been 
demonstrated that the linkage analysis technique is still a valuable way to eliminate 












CHAPTER 4  

















Subsequent to the definition of a critical chromosomal interval by linkage analysis, 
positional candidate gene selection is necessary to identify the molecular basis of the 
underlying familial MR etiology.  In this study, positional candidate genes were 
selected from the linked chromosomal interval in family XMR2 and the disease-
associated region in Fx67.  These preliminary linkage analyses significantly reduced 
the number of XLMR-candidate genes in each family from the 87 known XLMR 
genes.  Positional candidate genes were not selected in families Fx56 and Fx36 as the 
disease-associated chromosomal intervals in these families spanned large regions and 
did not sufficiently reduce the number of XLMR-candidate genes. 
 
4.1.1 POSITIONAL CANDIDATE GENE SELECTION: FAMILY XMR2 
Linkage analysis in family XMR2 identified a 10Mb critical interval located at 
Xq13.1-q21.1 with a maximum LOD score of 3.08 (θ=zero) across the region (i.e. 
DXS8052-DXS56) (Chapter 3).  This critical interval spanned the chromosomal 
region flanked by markers DXS8111 and DXS986.  The linked region encompassed 
~70 genes, nine of which (DLG3, MED12, NLNGN3, SLC16A2, KIAA2022, ATRX, 
ATP7A, IAP and PGK1) have been previously associated with XLMR.  These nine 
XLMR genes were prioritised for successive mutation screening in affected 
individuals of family XMR2.   
 
A number of the XLMR genes in the Xq13.1-q21.1 chromosomal interval are 
associated with clinical features which did not overlap considerably with the 
phenotype of affected individuals in family XMR2.  On this basis, a number of 
candidate XLMR genes were not deemed a high priority for mutation screening, 
including: DLG3 (NS-XLMR) (OMIM +300189), MED12 (FG syndrome) (OMIM 
*300188), NLNGN3 (X-linked Asperger syndrome) (OMIM *300336), ATP7A (X-
linked Menkes disease) (OMIM *300011) and PGK1 (phosphoglycerate kinase-1 
deficiency) (OMIM *311800).  Also, mutations in SLC16A2 are known to cause 
Allan-Herndon-Dudley syndrome (AHDS) (OMIM *300095).  While AHDS features 
showed some phenotypic overlap with the clinical presentation of XMR2 affected 
males, all AHDS patients exhibit elevated serum T3 (Triiodothyronine) levels 












normal levels of this thyroid hormone upon biochemical investigation, therefore 
SLC16A2 was excluded as a candidate gene for MR in this family.    
 
Mutation detection in KIAA2022 also did not take precedence, as the exact role of 
KIAA2022 in the pathogenesis of XLMR has not been fully established.  To date, 
only a single KIAA2022 mutation has been described in two MR patients with an X-
inversion (which also disrupts another gene, P2RY8) (Cantagrel et al. 2004, 
Cantagrel et al. 2004).  Finally, mutations in IAP were only identified in 2008 after 
the conclusion of the positional candidate gene mutation screening in family XMR2; 
IAP was therefore never considered a candidate in this family (Molinari et al. 2008).   
 
The only remaining XLMR candidate gene in the linked region was ATRX (OMIM 
*300032), mutations in which are associated with a syndromic form of XLMR.  
Upon thorough review of the phenotype of the affected individuals in family XMR2, 
there was an adequate degree of clinical overlap with known ATR-X patients to 
select ATRX as the first candidate gene for mutation detection in this family. 
 
4.1.1.1 Positional candidate gene: ATRX 
Phenotypes associated with ATRX mutations 
Mutations in ATRX were first identified in X-Linked alpha thalassaemia mental 
retardation (ATR-X) syndrome.  This syndrome is characterised by severe mental 
retardation, alpha thalassaemia, facial dysmorphism and urogenital abnormalities 
(Weatherall et al. 1981).  However, the clinical spectrum associated with ATRX has 
since been expanded to include the following allelic conditions: 
 Carpenter-Waziri syndrome (Abidi et al. 1999) 
 Juberg-Marsidi syndrome (Villard et al. 1996)  
 NS-XLMR without alpha thalassaemia and/or epilepsy  (Guerrini et al. 2000, 
Villard et al. 1996, Wieland et al. 2005, Yntema et al. 2002) 
 XLMR with spastic paraplegia (Lossi et al. 1999) 
 Holmes-Gang syndrome (Stevenson et al. 2000) 
 Smith-Fineman-Myers syndrome (Villard et al. 2000) 












This wide range of clinical conditions caused by ATRX mutations complicates a 
clinical diagnosis.  However, the prevalence of particular clinical features in ATRX 
mutation positive patients, as provided by Gibbons (2006) may serve as a guide for 
conducting ATRX screening.  These features include: profound MR (95% cases), 
characteristic facial features (<90% cases), genetic abnormalities (80% cases), alpha 
thalassaemia (90% cases), skeletal abnormalities (90% cases), microcephaly (75% 
cases), short stature (65% cases), seizures (30% cases), cardiac defects (20% cases) 
and renal/urinary abnormalities (15% cases) (Gibbons. 2006). 
 
ATRX: The gene and its protein 
Mutations in ATRX (also known as XNP or XH2) and the resulting S-XLMR 
phenotype were first identified in 1995 (Gibbons et al. 1995).  The gene, located at 
Xq13 spans approximately 300kb of genomic DNA and contains 36 exons (Picketts 
et al. 1996). 
 
The ATRX gene encodes for a number of alternately spliced mRNA transcripts.  
There are at least two larger ~10.5kb transcripts which are variable at the 5’end and 
give rise to 265kDa and 280kDa proteins (Picketts et al. 1996).   An additional 
shorter transcript (~7kb) has also been described, this isoform retains intron 11, 
resulting in a truncated protein (Garrick et al. 2004).  ATRX is expressed in multiple 
foetal and adult tissues including brain, lung, kidney, liver as well as adult 
lymphocytes (Villard et al. 1997).   
 
The ATRX protein is a member of the mating type switching/sucrose non-fermenting 
(SWI/SNF) family of chromatin associated proteins.  There are two principle 
domains that comprise the structure of ATRX, the N-terminus ATRX-DNMT3-
DNMT3L (ADD) domain and the C-terminal helicase domain (Figure 4.1) (Aapola 
et al. 2000).  The ADD domain is comprised of three regions: a GATA-like zinc 
finger, a PHD (plant homeodomain) –like zinc finger and a C-terminal α-helix 
domain (Argentaro et al. 2007).   Collectively these motifs may act as DNA or 
chromatin binding sites (directly or indirectly).  This hypothesis is supported by 












 The domain has high sequence and structural similarity to the de novo 
DNA methyltransferases (DNMT3A/3B/L) which possess DNA binding 
abilities (Xie et al. 1999)  
 PHD zinc fingers are predicted to tether proteins either directly or 
indirectly to chromatin (Bienz. 2006).   
 The structure of the GATA-like zinc finger has DNA binding potential 
(Argentaro et al. 2007).   
 
These investigations and observations would suggest a DNA and protein-protein 
interacting function for ATRX but to date the nature of this relationship remains 
elusive. 
 
Figure 4.1 A schematic representation of the domains of the ATRX protein (not to scale).  (adapted 
from Tang 2006, *ADD domain details from Argentaro et al. 2007, #interacting protein domain details 
from Park et el. 2004, %details from Nan et al. 2007. 
 
At the C-terminus lies the helicase domain which belongs to the SNF2 (SWI/SNF) 
family of chromatin associated proteins (Picketts et al. 1996).  Members of the SNF2 
protein family are generally involved in transcription and cell cycle regulation as 
well as mitotic chromosome segregation (Carlson and Laurent. 1994).  The ATRX 
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chromatin state by altering mononucleosome disruption patterns as well as inducing 
triple-helix DNA displacement (Xue et al. 2003). 
 
A number of additional motifs are present in ATRX, including a nuclear localisation 
signal (NLS) and a SNF2 conserved motif.  Finally, two separate stretches of 
glutamic acid (E) and glutamine residues (Q) are present in ATRX, these regions are 
both thought to play a role in protein-protein interactions (Park et al. 2004, Picketts 
et al. 1996).   
 
ATRX has also been shown to interact with a number of proteins, including: 
Enhancer of zeste homolog 2 (EZH2) (Cardoso et al. 1998), heterochromatic protein 
(HP1) (Berube et al. 2002, McDowell et al. 1999), MeCP2 (Nan et al. 2007) and the 
transcription/apoptosis co-factor, death-domain associated protein (DAXX) (Ishov, 
Vladimirova and Maul. 2004) (Figure 4.1).  In summary, the ATRX structural 
domains and interacting protein partners suggest a role for this protein as a chromatin 
remodeler.   
 
In addition to functioning as a chromatin remodeler, ATRX may have a dual role, 
also participating in cell-cycle regulation.  This hypothesis is supported by several 
lines of empirical evidence, including: 
 ATRX is phosphorylated at metaphase and localises to the cytoplasm and 
decondensed chromatin (Berube, Smeenk and Picketts. 2000) 
 ATRX is required for chromosome alignment and meiotic spindle 
organisation in mouse oocytes (De La Fuente et al. 2004) 
 ATRX plays a role in sister chromatid cohesion and chromosome congression 
during metaphase of mitosis (Ritchie et al. 2008).   
 
 
ATRX mutations associated with XLMR 
To date 113 mutations in ATRX have been reported as being causative of XLMR (see 
supplementary material in Gibbons et al. 2008 for full listing).  Generally ATRX 
mutations occur in one of two mutation ‘hotspots’.  The ADD domain, encoded by 
exons 7, 8 and the first 300bp of 9, constitutes the first hotspot.  Mutations in this 












second hotspot falls within the helicase domain (encoded by exons 18-29), with 
mutations in this region contributing to 41% of all reported mutations.  However, 
33% of ATRX mutations occur in exons 18-20 and 26-29, which encode for a portion 
of the helicase domain.  Therefore, collectively mutations in the ADD and part of the 
helicase domain (exons 18-20 and 26-29) account for 76% of all mutations (Badens 
et al. 2006). The screening of these regions is therefore a cost effective and logical 
approach to ATRX mutation screening. 
 
The vast majority of ATRX mutations are not recurrent and are detected only in 
single families, with minimal exceptions.   These exceptions include the two 
common ATRX mutations, firstly the 536A>G identified in nine families and 
secondly the 736C>T described in 35 families (Gibbons et al. 2008). 
 
The common 736C>T mutation provides an excellent example of the intra and 
interfamilial clinical variability between ATRX patients.  To date, 35 individuals have 
been identified with this mutation, but the percentage of HbH inclusions (the 
diagnostic test for alpha thalassaemia) ranges from 0-14% (Gibbons and Higgs 
2000).  This observation suggests that other factors, which may act either directly or 
indirectly with ATRX modify the expression of α-globin, thus accounting for this 
phenotypic variability. 
 
The range of clinical features resulting from ATRX mutations are associated with 
mutations dispersed across the gene, suggesting similar pathophysiological 
mechanisms for mutations within either of the two domains.  This complicates 
attempts to draw genotype-phenotype correlations with some exceptions.  Firstly, it 
has been observed that mutations which lead to loss of the C-terminal of ATRX are 
associated with more severe urogenital abnormalities (micropenis and ambiguous 
genitalia) (Gibbons et al. 2008).  Secondly, in a focused study of helicase domain 
mutations, Baden and colleagues (2006) noted that individuals with mutations 
affecting this domain had a milder phenotype compared to those patients with ADD 
domain mutations.  This milder phenotype manifests as delayed psychomotor 












The pathophysiological basis of ATRX mutations 
The structure of ATRX (particularly the presence of the ADD and helicase domain) 
and the protein’s interaction with DAXX, EZH2, MeCP2 and HP1, as well as the 
protein’s localisation to heterochromatic regions, strongly supports the hypothesis 
that ATRX is a chromatin remodeler (as described in Section 4.1.1.1).  However, the 
exact mechanisms by which the deregulation of this physiological process leads to 
the observed MR phenotype is poorly understood with studies to date giving limited 
insight. 
 
The hypothesis that the epigenetic state is deregulated in ATRX mutation positive 
patients  is supported by changes in the methylation profiles of rDNA genes located 
within acrocentric chromosomes as well as at Y-specific and subtelomeric repeats 
(Gibbons et al. 2000).  In addition, mutations in the C-terminal of the protein have 
been shown to attenuate the ability of the protein to localise to promyelocytic 
leukemia nuclear bodies (PML-NBs).  These nuclear bodies include the PML protein 
in complex with up to 70 other proteins.  The PML-NBs are involved in a wide 
variety of cellular processes one of which includes transcription regulation (Zhong, 
Salomoni and Pandolfi. 2000).  It has been speculated that the reduced localisation of 
ATRX to the PML-NBs in mutation positive individuals could affect chromatin 
remodelling and thus transcription repression during neuronal development (Berube 
et al. 2008)  
 
Full null-Atrx mice exhibit embryonic lethality; however, a conditional Atrx-
knockout in the forebrain of mice led to hypocellularity in the neocortex and 
hippocampus as well as reduced forebrain size.  These anatomical abnormalities are 
due to increased neuronal apoptosis leading the authors to conclude that Atrx is an 
essential constituent of neuronal development and cell survival (Berube et al. 2005).   
In addition, the overexpression of ATRX in transgenic mice led to a high incidence of 
embryonic death, neural tube defects and growth retardation.  Those mice that did 
survive to term exhibited seizures, abnormal behaviour, craniofacial abnormalities 
and prenatal death.  These studies showed that ATRX dosage is important for 













In support of the dual role for ATRX in transcription and cell-cycle regulation, 
siRNA ATRX knockdown in HeLa cells resulted in aberrant sister chromatid 
cohesion and chromosome co-segregation at metaphase (Ritchie et al. 2008).  This 
observation was not due to the mislocalisation of HP1, nor were characteristic 
histone modifications altered, suggesting that ATRX ablation affects mitosis by some 
other mechanism (Ritchie et al. 2008).  In addition, the conditional forebrain of Atrx-
knockout mice exhibited defects in mitosis in the neuroprogenitor cells of the 
embryonic forebrain (Berube et al. 2005).  These results may explain the abnormal 
brain development and reduced cortical size associated with ATRX loss. 
 
4.1.2 POSITIONAL CANDIDATE GENE SELECTION: FAMILY FX67 
Linkage analysis in family Fx67 led to the identification of an 12Mb disease-
associated chromosomal region between markers DXS9896 and DXS993 (Xp21.1-
Xp11.4) (Chapter 3).  This relatively gene-poor region encompasses 27 known genes 
(based on human genome assembly 36, March 2006) of which only two have been 
previously associated with the pathogenesis of XLMR.  These XLMR genes, 
ATP6AP2 and TSPAN7 are both associated with mild-moderate non-syndromic MR 
and are therefore good candidates for mutation detection in NS-XLMR family FX67. 
 
4.1.2.1 Positional candidate gene: ATP6AP2 
Phenotypes associated with ATP6AP2 mutations 
To date one XLMR family has been described with a mutation in ATPase, H+ 
transporting, lysosomal accessory protein 2 (ATP6AP2) (OMIM *300556).  Hedera 
et al. (2002) first described a family of seven affected males presenting with mild to 
moderate MR and epilepsy (designated XMRE).  A marked degree of intra-familial 
variation was also reported, with variable presentation of behavioural problems 

















ATP6AP2: The gene and its protein 
ATP6AP2 was previously mapped to Xp11.4 by genomic sequence analysis (Demirci 
et al. 2001).  The gene consists of nine exons and spans a chromosomal region of 
approximately 50kb.  ATP6AP2 encodes for a 2.4kb mRNA transcript which is 
highly expressed in the heart, brain and placenta with intermediate expression in the 
liver, pancreas and kidney and limited expression in the skeletal muscle and lung 
(Nguyen et al. 2002). 
 
Upon translation, the ATP6AP2 mRNA encodes for the renin receptor.  The renin-
angiotensin system (RAS) is responsible for the maintenance of blood pressure and 
water-electrolyte balance.  Before the identification of the renin receptor it was 
hypothesised that the primary function of renin was the cleavage of angiotensinogen 
to angiotensin I (AngI).  After a second cleavage stage the active form, angiotensin II 
(AngII) is produced which exerts its physiological effects on blood-pressure and 
fluid balance.  However, recent studies have shown that the RAS system is involved 
in additional physiological systems including, and of particular interest here, the 
CNS where it is responsible for cell proliferation and death, maintenance of neuro-
endocrine systems and cognitive properties (McKinley et al. 2003).  Some neuronal 
cell types, particularly astrocytes also express ATP6AP2 with concomitant 
production of the renin receptor.  Upon activation by renin binding, this membrane-
bound receptor was shown to have a fourfold increase in AngII production (Nguyen 
et al. 2002).  In addition this binding led to activation of the mitogen-activated 
protein (MAP) kinases, ERK1/2, which have been shown to play a role in memory 
consolidation and long term potentiation (Adams and Sweatt. 2002, Bozon et al. 
2003, Nguyen et al. 2002). 
 
ATP6AP2 mutations associated with XLMR 
To date, a single family has been reported with an ATP6AP2 mutation.  In this family 
a c.321C>T, p.D107D was identified by linkage analysis and subsequent positional 
candidate gene sequencing.  This silent mutation disrupts a putative exonic splice 
enhancer (ESE) site and leads to partial exclusion of exon 4 in 50% of an affected 
individual’s mRNA.  This partial exonic exclusion results in a frameshift and 













The pathophysiological basis of ATP6AP2 mutations 
By functional analysis, Ramser et al. (2005) showed that the c.321C>T mutation and 
the resultant mutant receptor was still able to bind renin and induce catalytic activity 
to AngI in a way that was comparable to the wild type receptor.  However, binding 
of renin to the mutant receptor resulted in a modest but reproducible reduction in 
ERK1/2 signalling.  It was therefore hypothesised that the XMRE phenotype in this 
family results from reduced ERK1/2 signalling and concomitant impairment in 
memory consolidation and long-term potentiation (Ramser et al. 2005). 
 
4.1.2.2 Positional candidate gene: TSPAN7 
Phenotypes associated with TSPAN7 mutations 
The second XLMR candidate gene in family Fx67 was tetraspanin 7 (TSPAN7, alias 
TM4SF2) (OMIM *300096).  Mutations in TSPAN7 have been identified in four 
families, including a X:2 female translocation patient who exhibited mild MR and 
minor autistic features (Zemni et al. 2000).  The additional TSPAN7 mutation 
positive families all presented with mild to moderate non-syndromic XLMR (Abidi 
et al. 2002, Zemni et al. 2000). 
 
TSPAN7: The gene and its protein 
TSPAN7, located at Xp11.4, spans approximately 20kb of genomic DNA and 
consists of seven exons.  The gene is highly expressed in the hippocampus and 
cerebral cortex (Zemni et al. 2000).  
 
The TSPAN7 gene encodes for a member of the transmembrane 4 superfamily, also 
known as the tetraspanin family of proteins.  Members of this protein family are 
generally cell-surface proteins that control signal transduction of cellular processes 
such as morphology, invasion, motility, signalling and fusion (Hemler. 2005).  In 
addition, members of this family have been shown to interact with beta-1 integrins, 
through this interaction it is possible that TSPAN7 controls neurite outgrowth by 













TSPAN7 mutations associated with XLMR 
The first TSPAN7 mutation was identified in an isolated female MR patient, this 
individual exhibited loss of gene expression due to an X:2 translocation (Zemni et al. 
2000).  Subsequent to the identification of this XLMR gene, analysis of probands 
from 33 XLMR families led to the identification of two additional disease-causing 
mutations (Zemni et al. 2000).  Finally, Abidi et al. (2002) reported a 2bp deletion 
(564delGT) which led to a frameshift and premature truncation of the protein at 
amino acid 192 (Abidi et al. 2002). 
 
The pathophysiological basis of TSPAN7 mutations 
Little is known about the pathogenic mechanisms that are induced by TSPAN7 
mutations.  All mutations lie in the larger of two extracellular loops responsible for 
protein-protein interactions, but little is known of the protein substrates or disease 
mechanism (Abidi et al. 2002, Hemler. 2005, Zemni et al. 2000).  Given the neuronal 
localisation of TSPAN7, as well as its putative interaction with beta-1 integrins, it 
has been hypothesised that TSPAN7 mutations lead to reduced regulation of the actin 
cytoskeleton with concomitant effects on neurite development and outgrowth (Zemni 
et al. 2000). 
 
4.2 METHODS 
4.2.1 MUTATION DETECTION IN ATRX: FAMILY XMR2  
4.2.1.1 Clinical presentation of patients in family XMR2 
The seven affected males in family XMR2 presented with a syndromic form of 
XLMR with a broad spectrum of clinical features (Table 4.1).  Three of the seven 
affected individuals in family XMR2 are deceased; two succumbed to accidental 
deaths and a third died at the age of 38 years from pneumonia following recurrent 
chest infections and unexplained weight loss. The surviving men have an age range 















Table 4.1 The clinical presentation of the seven affected males in family XMR2 
Clinical presentation # of affected individuals with feature (%) 








Narrow bi-frontal diameter 
Hypertelorism 
Prognathism (more pronounced in puberty) 
Carp-shaped mouth 
Small, posteriorly-rotated ears  
Widows peak 



















Aggressive and disruptive behaviour 
Epilepsy (onset after puberty) 
Hypotonia (in infancy) 
Short stature (below 3rd centile) 
Gastro-oesophageal reflux 









The clinical presentation of affected individuals was characterised by intrafamilial 
variation, particularly with respect to patients’ neurocognitive abilities (Table 4.1).  
For example, only one affected male was able to speak in short sentences as 
compared to the remainder of the patients who could only speak short words or had 
no speech at all.  Interestingly, this individual was also the only affected member of 
this family to have a normal head circumference.  Similarly, there was a large age 
range (3.5–7.5 years) within which affected individuals learnt to walk.  
 
Detailed neuroimaging investigations have not been performed in the affected 
individuals of this family.  Only one patient underwent an MRI scan which showed 
features of cerebral atrophy and periventricular leucomalacia but his premature birth 
was likely to have contributed to the findings.  It should also be noted that no genital 
abnormalities were detected in this family.  Finally, only a single affected individual 
in this family (XMR2.5) underwent biochemical evaluation for HbH inclusions, this 












4.2.1.2 mRNA isolation and cDNA synthesis 
Mutation detection analyses were performed in the ATRX mutation ‘hotspots’ i.e. 
exons 7-9 (hotspot 1 in the ADD domain), exons 18-20 (hotspot 2 in the helicase 
domain) and exons 26-29 (hotspot3 in the helicase domain).  In order to exclude 
investigation of intronic DNA regions, mRNA and subsequently synthesised cDNA, 
was used for this mutation screening.  MRNA was isolated from an affected 
individual (XMR2.5) using the PAXgene™ Blood RNA System [PreAnalytix] 
according to manufacturer’s instructions.  Subsequently, complete cDNA synthesis 
was performed using the iScript™ cDNA Synthesis Kit [Bio-Rad] as per 
manufacturer’s instructions. 
 
4.2.1.3 cDNA PCR amplification of ATRX hotspots 
PCR primers were designed in order to amplify the three mutation ‘hotspots’ of 
ATRX (GenBank accession no. NM_000489.2) from the synthesised cDNA 
(Appendix 4A).  PCR amplifications were performed in a 25µl reaction containing 
400ng of patient’s cDNA, 10µM of each forward and reverse primer, 2.5µM dNTP’s 
[Bioline], 1× Go Taq buffer [Promega] and 1U Go Taq polymerase [Promega].  The 
PCR profile consisted of an initial denaturation step at 95ºC for 5 min, followed by 
30 cycles at 95ºC for 1min, 57 ºC for 1min, and 72ºC for 1min.  A final elongation at 
72ºC for 5 min completed the PCR amplification. PCR was conducted on a Px2 
thermal cycler [Thermo Electron Corporation].  PCR products were visualised by 
EtBr staining subsequent to electrophoresis on a 3% agarose gel alongside a 100bp 
molecular weight marker [Fermentas]. 
 
4.2.1.4 ATRX genomic DNA PCR amplification  
In order to elucidate the genomic DNA context of a cDNA mutation corresponding 
to exon 26, PCR primers were designed to flank the 5’ intronic region of exon 26 
(intron 25).  This primer set consisted of the forward primer: 5’ ttctgggatagtctctgtcc 
3’ and reverse primer: 5’ ccaatttcctctgccattcg 3’.  PCR was performed as above 
(Section 4.2.1.3) with the exception of the use of 100ng of patients’ genomic DNA as 
opposed to cDNA.  The PCR profile consisted of an initial denaturation step at 95ºC 












final elongation at 72ºC for 5 min completed the PCR amplification. PCR was 
conducted on a Px2 thermal cycler [Thermo Electron Corporation].  PCR products 
were subject to the same electrophoresis protocol as above (Section 4.2.1.3). 
 
4.2.1.5 DNA sequencing analysis of DNA amplicons 
Sanger DNA sequencing was performed in order to identify the putative underlying 
DNA mRNA/DNA sequence variations.  The total volume of DNA products 
generated from amplification of the cDNA mutation ‘hotspots’ and the exon 26 
genomic DNA region were electrophoresed on a 1% agarose gel and the bands 
excised.  Purification of the fragments was achieved using the Qiagen™ Extraction 
Kit according to the standard manufacturer’s protocol.   
 
The direct DNA sequencing reaction was performed in a 10µl final reaction-volume 
containing 500ng of purified DNA template, 10µM of either forward/ reverse primer, 
2µl Big Dye terminator mix [Applied Biosystems] and 1× Big Dye terminator 
sequencing buffer [Applied Biosystems].  The sequencing profile entailed an initial 
denaturation at 94ºC for 5 minutes followed by 25 cycles of 94ºC for 20s, 50ºC for 
10s and 60ºC for 4min.  The Applied Biosystems GeneAmp® DNA system 9700 
thermal cycler was used for this amplification. 
 
Purification of DNA sequencing products was performed using ethanol precipitation. 
All DNA sequencing products were electrophoresed on the ABI Prism® 3100 
Genetic Analyser and analysed using the Sequence Analysis version 3.7 Software 
[Applied Biosystems].  BioEdit Sequence Alignment Editor 
(http://www.mbio.ncsu.edu/BioEdit/bioedit.html) was used to align the resultant 














4.2.2 MUTATION DETECTION IN TSPAN7 AND ATP6AP2: FAMILY FX67  
4.2.2.1 Clinical information of family FX67 
Family FX67 consisted of three affected brothers who presented with NX-XLMR.  
The only additional clinical feature was epilepsy, present in all three affected males. 
 
4.2.2.2 PCR amplification of ATP6AP2 and TSPAN7 exons 
PCR primers were designed for the nine ATP6AP2 exons (GenBank NM_005765.2) 
and the seven protein-coding TSPAN7 exons (GenBank NM_004615.2) (Appendix 
4A).  PCR amplification for all exons of ATP6AP2 and TSPAN7 were performed as 
described in Section 4.2.1.4 with the following exceptions: 
 The primer annealing temperature for ATP6AP2 exons 1, 2, 3, 5-9 was 56ºC. 
 The primer annealing temperature for exons 3 and 8 of ATP6AP2 and exons 
2-7 of TSPAN7 was 60ºC 
 The primer annealing temperature of TSPAN7 exon 1 was 64ºC and Failsafe 
buffer J [Epicentre Technologies] replaced the 2.5µM dNTP’s [Bioline] and 
1× Go Taq buffer [Promega]. 
 
4.2.2.3 DNA sequencing of ATP6AP2 and TSPAN7 exons 
DNA sequencing was performed as before using ATP6AP2 and TSPAN7 specific 
primers (Section 4.2.1.5). 
 
4.2.2.4 X-inactivation analysis of unaffected mother Fx67.1 
Up to 50% of XLMR carrier females exhibit skewed X-inactivation (i.e. >>80:20) 
(Plenge et al. 2002).  Therefore, the presence of skewed X-inactivation in the 
unaffected mother (Fx67.1) of family Fx67 would be highly indicative of the 
disorder in this family indeed being attributed to an X-linked mutation.  
Consequently, in order to better estimate the possibility of the condition being X-
linked in this trio of brothers, an X-inactivation assay was performed before 
screening novel XLMR candidate genes.  To assess the X-inactivation pattern of 
individual Fx67.1, the methylation status of a CpG island located within the variable 
number of tandem repeats (VNTR) region of the MAOA gene was analysed as 













4.3.1 MUTATION DETECTION IN ATRX: FAMILY XMR2  
4.3.1.1 cDNA sequencing analysis of ATRX mutation hotspots 
DNA sequencing analysis of the first mutation hotspot (exon7-first 300bp of exon 9) 
as well as the second (exons 18-20) showed no alteration in the cDNA sequence of 
the affected individual (XMR2.5).  However, the PCR product corresponding to the 
third mutation hot spot (exons 26-29) showed a reduction in size as compared to the 
control sample when analysed by agarose gel electrophoresis (Figure 4.2).  
Sequencing analysis confirmed a 66bp deletion in the cDNA of the affected 
individual (Figure 4.3).  This cDNA deletion correlates to the first 66bp of exon 26 
and was designated r.5957_6022del.  The deletion of these 66 nucleotides results in a 
loss of 22 amino acids, p.1987_2008del as well as an alteration of the preceding 
amino acid, p.1986S>N. 
 
4.3.1.2 Genomic DNA sequencing analysis of r.5957_6022del. 
In order to characterise the genomic DNA context of the r.5957_6022del, DNA 
sequencing of the intron/exon boundaries of exon 26 was performed.  This analysis 
revealed a 24bp deletion (as compared to the 66bp mRNA deletion) within exon 26 
and was designated c.5987_6011del (Figure 4.3).  These findings show that the 
genomic deletion causes aberrant splicing of exon 26, leading to the exclusion of the 
5’ end of the exon (Figure 4.3).  The c.5987_6011del segregated with MR as it was 


































Figure 4.2 Results of cDNA PCR amplification for the two ATRX helicase domain ‘hotspots’. PCR 
products were separated by gel electrophoresis (2% agarose gel) and visualised with EtBr. Lane 1 
shows the 100bp molecular weight marker (GeneRuler™ 100bp DNA Ladder Plus [Fermentas]). The 
second and third lanes show the results of PCR amplification for the first helicase domain hotspot.  A 
band of the correct size (626bp) was obtained for both the control (Lane 2) and the patient (XMR2.5) 
samples (Lane 3).  The intensity of the band is lower in the patient sample (XMR2.5), most likely 
indicative of reduced levels of ATRX mRNA transcript.  The final two lanes represent the second 
helicase domain mutation hotspot demonstrating the control PCR  product of 687bp (Lane 4) and the 
621bp PCR product in XMR2.5 (Lane 5) demonstrating the 66bp deletion (r.5957_6022del) in this 
XLMR patient.  Once again, the intensity of the band (XMR2.5 - Lane 5) illustrates a reduced 






















Figure 4.3 The mRNA mutation (r.5956_6022del) and corresponding genomic DNA deletion 
(c.5987_6011del) in patient XMR2.5. (a) Sequencing of genomic DNA of ATRX exon 26 showing the 
sequence flanking the 24bp deletion (c.5987_6011del), red arrow indicates nucleotides flanking the 
deletion site. (b) Sequencing of cDNA of the DNA encoding for the second chromatin remodelling 
domain showing the 66bp deletion (r.5956_6022del), red arrow indicates nucleotides flanking the 
deletion site. (c) location of the 24bp genomic deletion (c.5987_6011del) in exon 26 spanning base 
pairs 31-55, also illustrating the retention of the donor/acceptor splice sites. (d) The resultant 66bp 
cDNA deletion (r.5956_6022del), spanning the first 66bp of exon 26 due to an aberrant splicing 














Figure 4.4 Co-segregation of the 24bp genomic DNA deletion (c.5987_6011del) with MR in family 
XMR2 (a) Pedigree of ATRX mutation positive family. (b)  Agarose gel (3%) electrophoresis 
(visualised with EtBr) subsequent to PCR amplification of the intron/exon boundary of exon 26. The 
first lane shows the 100bp molecular weight marker (GeneRuler™ 100bp DNA Ladder Plus 
[Fermentas]).  Subsequent lanes show the deletion segregating in the family with amplicon sizes of 
335bp (normal allele) and 311bp (mutant allele - c.5987_6011del), all lane numbers correspond to 
numbering system of the Fx444 family pedigree in (a). 
 
 
4.3.1.3 Analysis of ESE consensus sites within the c.5987_6011del  
The c.5987_6011del identified in family XMR2, resulted in aberrant exon 26 
splicing (exclusion of the first 66 bp of exon 26).  Given that the c.5987_6011del did 
not disrupt the acceptor/donor sites of exon 26, this alternate splicing was due to a 
disruption of an alternative consensus splicing motif.  Therefore, the integrity of 
exonic splice enhancer (ESE) sites was assessed using the programme ESE finder 
(http://rulai.cshl.edu/cgi-bin/tools/ESE/).  This in silico prediction tool demonstrated 
that the c.5987_6011del led to the disruption of a Srp40 and SC35 consensus 
sequence (Figure 4.5).  It was probable that the disruption of one or both of these 














Figure 4.5 The distribution of the highest-scoring consensus sequence locations for each of the five 
ESE sites in the wild type as well as the ATRX c.5987_6011del in family XMR2, as predicted by the 
ESEFinder tool.  The illustrations above show the distribution of the predicted ESE binding sites, 
according to exon 26 DNA sequence (y-axis), as well as the probability scores of each of these sites 
(x-axis).  The results of this in silico predictive tool, suggested that the c.5987_6011del disrupts a 















4.3.2 MUTATION DETECTION IN ATP6AP2 AND TSPAN7: FAMILY FX67 
POSITIONAL CANDIDATE GENES ANALYSIS.  
4.3.2.1 Genomic DNA sequencing analysis of ATP6AP2 
No DNA sequence variations were detected in any of the nine ATP6AP2 exons 
evaluated by genomic DNA sequencing. 
 
4.3.2.2 Genomic DNA sequencing analysis of TSPAN7 
No DNA sequence variations were detected in exons 2-7 of the TSPAN7 gene by 
genomic DNA sequencing.  However, two variants were detected in the 5’UTR in all 
affected individuals (Fx67.2/3/4).  The first was a transition, designated c.-125G>A 
and the second a 3bp deletion designated c.-28_30delCCG.   
 
The c.-125G>A transition was described in the Ensembl database (Ensembl release 
52, December 2008) as a SNP, but there was no report in dbSNP (NCBI).  The 
Ensembl record (ENSSNP3520788) shows no population or linkage disequilibrium 
data.  Individual genotypes are available from Craig Venter’s sequenced genome, 
this individual has the A variant.  Given the normal cognitive function in this 
individual it was concluded that the c.-125G>A variant does not contribute to the 
disease aetiology in this family. 
 
The 3bp deletion (c.-28_30delCCG) was present in dbSNP (NCBI), accession 
number: rs3833408.  There was no population, linkage disequilibrium or individual 
data available for the variant and it has not been validated by independent methods or 
multiple submissions.  At date of submission of this dissertation this variant has no 
















4.3.2.3 X-inactivation analysis in unaffected female Fx67.1 
In order to ascertain the X-inactivation pattern in the affected boys’ (Fx67.2/3/4) 
mother (Fx67.1), X-inactivation analysis was performed at the MAOA VNTR locus.  
From these analyses it was established that the X-inactivation ratio was 72:28 
(Figure 4.6).  The allele (and therefore X-chromosome) which was preferentially 
inactivated in Fx67.1 (318bp MAOA VNTR allele) was the same allele which was 
transmitted to all three affected boys.  These results indicate that there was mild 
preferential inactivation of the ‘affected’ X chromosome (assuming X-linked 
inheritance of MR). 
 
 
Figure 4.6 The X-inactivation pattern in the unaffected mother (Fx67.1) of the three male-sibs 
presenting with NS-XLMR in family Fx67 (i.e. Fx67.2/3/4).  (a) The electropherogram generated by 
size-based capillary electrophoresis illustrating the MAOA VNTR allele in affected individual Fx67.2.  
All affected brothers carry the 318bp allele (blue) at this locus. The 500bp Rox size standard [Applied 
Biosytems] is illustrated in red (b) The electropherogram illustrating the intensity of the two MAOA 
VNTR alleles (318bp and 348bp) (blue) prior to digestion of the unaffected mother’s DNA sample 
with the methylation-specific enzyme HhaI.  There waa evidence in this electropherogram of 
preferential amplification of the smaller (318bp) allele (blue) as compared to the larger (348bp) allele 
(blue).  (c) The electropherogram illustrating the intensity of the two MAOA VNTR alleles (318bp and 
348bp) (blue) after digestion of the unaffected mother’s DNA sample with the methylation-specific 
enzyme HhaI.  Once the allele-specific PCR amplification bias was accounted for it was concluded 













Mutation detection in positional candidate genes subsequent to linkage analysis is an 
important step in identifying the underlying molecular defect in a family with a 
genetic disorder.  In this study, linkage analysis identified a 10Mb and 11Mb 
minimal critical interval in XLMR families XMR2 and FX67 respectively (Chapter 
3).  Positional candidate genes were selected from these critical intervals and 
mutation detection was performed, in order to ultimately identify mutation positive 
patients applicable for epigenetic profile analyses. 
 
The critical chromosomal interval in family XMR2 idenitied in this study 
encompassed approximately 70 genes, including nine known XLMR genes (DLG3, 
MED12, NLNGN3, SLC16A2, KIAA2022, ATRX, ATP7A, IAP and PGK1).  
Subsequent to a thorough clinical review of affected individuals in family XMR2, the 
overall familial clinical picture was more suggestive of ATRX being associated with 
XLMR in this family.  Therefore, ATRX was selected as our primary candidate gene 
and mutation detection via direct sequencing of the ATRX mutation hotspots was 
performed.  These investigations identified a novel splicing mutation, 
c.5987_6011del in the ATRX helicase domain. 
 
The 24bp genomic deletion, c.5987_6011del results in a larger, 66bp deletion in the 
mRNA transcript (r.5957_6022del).  Interestingly, this mRNA mutation has been 
described previously in two independent reports (Gibbons and Higgs. 2000, Gibbons 
et al. 2008).  However, the underlying genomic mutation in these reports was 
different to the deletion described here (c.5987_6011del).  The two previously 
reported mutations include an intronic c.5957-2A>G splicing variant and a nonsense 
mutation, c.6003G>A, which was predicted to give rise to premature truncation 
(p.W2001X) (Gibbons and Higgs. 2000, Gibbons et al. 2008).  Given that these three 
different genomic DNA mutations (c.5987_6011del, c.5957-2A>G, c.6003G>A) 
result in the same larger mRNA deletion, it was likely that these genomic mutations 
induce the same aberrant splicing event, ultimately resulting in partial exonic 
exclusion.  The ensuing aberrantly-spliced transcript encodes a protein with 22 
amino acids absent from the helicase domain.  Despite the predicted deleterious 












phenotypic rescue as an ATRX null allele is expected to be lethal (Garrick et al. 
2006).  These three genomic mutations could all encode for a truncated ATRX 
protein.  Firstly, the c.6003G>A mutation encode for a p.W2001X truncating 
mutation.  Secondly, the c.5957-2A>G, was predicted to lead to non-recognition of 
the AG acceptor site, thus putatively leading to whole exon 26 skipping (or cryptic 
activation of a downstream acceptor site).  This reading frame alteration could result 
in a frameshift, ultimately leading to premature ATRX truncation.  Lastly, the 
c.5987_6011del identified in this study, was predicted to give rise to a frameshift 
mutation which would also lead to premature truncation 56 amino acids downstream 
(p.1987fsX56).  Therefore, we hypothesise that the observed aberrant splicing was 
due to interruption of a common exonic ESE site (in the cases of c.5987_6011del and 
c.6003G>A) and alternative recognition of a donor site (c.5957-2A>G) resulting in 
the activation of a downstream cryptic ESE site. 
 
ESE sites are regions of conserved exonic sequence which are believed to act as 
binding sites for Ser/Arg (SR) rich proteins.  These SR proteins are responsible for 
exon definition through protein-protein interaction with other components of the 
splicesome, essential for correct pre-mRNA splicing (Figure 4.7) (Cartegni, Chew 




Figure 4.7 A theoretical model for exonic splicing through the formation of the splicesome.  SR 
proteins bind to the ESE consensus sequence through its RNA-recognition motifs (RRM).  Through 
its Arg/Ser rich (RS) domain the SR protein also interacts with U2AF (35 subunit) and U1 snRNP 
(70K subunit) which bind to the acceptor AG and donor GU sites respectively.  These components 
then either directly or indirectly recruit the remainder of the splicesome complex (from Cartegni, 
















The programme ESE finder (http://rulai.cshl.edu/cgi-bin/tools/ESE/) uses weighted 
matrix values and consensus sequences for each of the four SR proteins (SF2/ASF, 
SC35, SRp40, SRp55) to computationally predict functional ESE sites (Cartegni et 
al. 2003).  The use of this prediction tool showed that the c.5987_6011del and 
c.6003G>A mutations lead to the interruption of a common predicted SRp40 
consensus sequence located at nucleotides 42-48 of ATRX exon 26 (Figure 4.8).  This 
interruption could lead to the activation of a downstream cryptic SRp40 site located 
at exon 26 nucleotides 91-98 (numbered according to the wildtype transcript).  To 
further support this hypothesis there is evidence suggesting that the SR rich proteins 
which bind at ESE sites interact with the U2 auxiliary factor 35 (U2AF35) which 
binds at the AG acceptor site (Figure 4.8) (Cartegni, Chew and Krainer. 2002).  The 
mutation at c.5957-2A>G could lead to the recognition of a cryptic AG acceptor site 
(located 38bp upstream of the cryptic SRp40 site) (Figure 4.8).  Assumption of this 
model would provide a plausible explanation of the common mRNA mutation 
despite independent genomic DNA mutations.  
 
 
Figure 4.8 Illustration of the putative alternative splicing mechanism by which the three genomic 
mutations give rise to the same 66bp mRNA deletion (r.5957_6022del).  First, illustrated in blue is the 
wildtype SRp40 consensus ESE binding site within ATRX exon 26.  The consensus sequence at this 
site is disrupted by the c.6003G>A mutation, becoming AGACTGA (hence not recognised by 
SRp40), and the site is deleted completely by the c.5987_6011del mutation.  These mutations could 
lead to the activation of the downstream cryptic SRp40 site (illustrated in red).  Under normal 
conditions the AG acceptor site is recognised by U2AF35 which in turn interacts with SRp40 to form 
part of the splicesome.  However, the c.5957-2A>G abolishes this site leading to the cryptic 
recognition of the AG site and subsequent interaction with the downstream SRp40 ESE.  In this way 
all three mutations are hypothesised to make use of the downstream SRp40 site to induce mutation 
skipping and subsequent phenotypic rescue. 
 
It should, however, be noted that this proposed model presents merely a theoretical 
explanation, in order to test this hypothesis an in vitro splicing assay could be 
performed.  This would entail the cloning of cDNA PCR products from all three 












assessment of the resultant mRNA transcripts.  Double knock-out mutants in both the 
wildtype and cryptic SRp40 sites would further elucidate the validity of this 
theoretical hypothesis. 
 
Previously Wada and colleagues (2006) demonstrated that the disruption of an ESE 
site by a single base pair change (c.370G>T) results in the exclusion of several exons 
in ATRX (Wada et al. 2006).  While this missense mutation (p.G124C) was located 
outside the ADD domains, it lies in a highly conserved region of 36 amino acids 
(Park et al. 2004). Therefore, it was likely that the region encompassed by this 
mutation undergoes the same splicing-induced phenotypic rescue as described above.   
Finally, it has been previously suggested that phenotypic rescue mechanisms such as 
those described here are present in all truncating mutations upstream of the helicase 
domain (Gibbons et al. 2008). 
 
The clinical presentation of affected individuals in family XMR2 was characterised 
by intrafamilial variability especially with respect to the patients’ neurocognitive 
abilities.  It would be interesting to conduct quantitative mRNA investigations in the 
surviving affected males in order to investigate the degree of phenotypic rescue as 
compared to the severity of MR and additional clinical features.  Unfortunately, at 
this stage, collection of fresh blood samples for RNA analyses in all surviving 
patients has not been feasible; therefore, it has not been possible to perform these 
investigations.   
 
The mutant mRNA transcript (r.5956_6022del), when translated, results in an ATRX 
protein lacking 22 amino acids (p.1987_2008del) and an altered amino acid distal to 
the deletion (p.1986S>N).  This mutation resides in the functionally significant C-
terminal helicase domain of the ATRX protein and deletes a number of highly 
conserved residues (Park et al. 2004).  It has been shown that mutations in the 
helicase domain affect the ATPase activity of the ATRX protein.  A study by Tang 
and colleagues (2004) demonstrated reduced activity in recombinant ATRX carrying 
missense mutations involving non-conserved amino acids in the helicase domain.  
This led the authors to hypothesis that the deletion of highly conserved domains in 
this region would be lethal as the ATPase ‘dead’ mutant completely abolished 












described here involves the deletion of a highly conserved region and would seem to 
contradict this statement.  However, this mutation was not located in the catalytic 
sites and could therefore only impair ATPase activity rather than completely abolish 
function.  Therefore, the findings of this study suggest that the pathogenic effect of 
amino acid changes in the helicase domain is dependent on the location as well as the 
conservation of the amino acid in question. 
 
This study has identified a novel c.5987_6011del as the mutation underlying a 
syndromic form of XLMR in a South African family.  The clinical presentation of 
affected individuals includes severe MR, microcephaly and hypotonic facial features, 
but excluded α-thalassaemia.  While 90% of individuals with ATRX mutations 
present with α-thalassaemia, studies suggest that the absence of this haematological 
feature should not be an exclusion factor in the decision to conduct ATRX mutation 
screening (Villard et al. 1999).  Villard and colleagues (1999) propose that the most 
valuable diagnostic criteria for screening of the ATRX hotspots are MR, 
microcephaly and hypotonic facial features (Villard et al. 1999).  In addition, the 
large percentage of α-thalassaemia in ATRX mutation positive patients may be a 
reflection of selection bias towards patients exhibiting α-thalassaemia. Therefore, 
unbiased mutation screening in affected individuals presenting with only clinical 
features outlined by Villard and colleagues, may result in a reduction in the 
percentage of ATRX mutation positive patients presenting with alpha thalassaemia.  
Certainly, the results of this study would support this screening strategy.  Screening 
of larger clinically stratified cohorts will lend an indication to the feasibility of 
including ATRX mutation ‘hotspot’ testing in the diagnostic protocols for MR 
patients, particularly in a developing country such as South Africa. 
 
The critical chromosomal interval identified in family FX67 spanned an 11Mb 
chromosomal region (Xp21.1-Xp11.4), which encompassed 27 genes, two of which 
are known XLMR genes, ATP6AP2 and TSPAN7.  Mutation detection in both of 
these positional candidate genes revealed no disease-causing mutations.  Two SNPs 
were identified in exon 1 of the TSPAN7 gene; these alterations are most likely not 
associated with the disease-phenotype in this XLMR family owing to their 













In addition to the two known XLMR genes, the XLMR-associated chromosomal 
interval in family Fx67 encompasses an additional 25 genes.  Prior to selection of 
novel XLMR-candidate genes from these 25 genes, X-inactivation analysis was 
conducted.  It has been shown that up to 50% of XLMR carriers show skewed X-
chromosome inactivation, with preferential activation of the ‘normal’ allele (Plenge 
et al. 2002).  Skewed X-inactivation in the carrier mother (Fx67.2) of this family 
would support the strategy to select and screen novel candidate MR genes in this 
region.  However, X-inactivation analysis in this female showed an X-inactivation 
ratio of 72:28, towards selective inactivation of the ‘disease-associated’ allele.  It has 
been demonstrated that this mild degree of skewing is present in female control 
subjects (Plenge et al. 2002).  Plenge and colleagues (2002) demonstrated that X-
inactivation ratios in excess of 70:30 were present in 30 female control subjects as 
compared to 63 XLMR carrier females (Plenge et al. 2002).  This makes XLMR 
carrier females approximately twice as likely to have skewed X-inactivation as 
compared to the background population.  Therefore, the 72:28 X-inactivation ratio 
was suggestive of the disorder being X-linked in family Fx67.  However, given the 
genetic heterogeneity and diverse functions in which XLMR gene products 
participate it was exceptionally difficult to prioritise XLMR-candidate genes.  
Finally, the LOD score in this family was 0.60 (θ=zero), a figure which was not 
statistically significant, but merely suggestive of linkage to this region given the co-
segregation of alleles in the affected males.  Taken together, it was decided that it 
was not feasible to screen novel XLMR-candidate genes in the region at this time.  It 
is envisaged that as next generation DNA sequencing technologies become more 
affordable, screening of candidate-XLMR genes in this region will be possible. 
 
In conclusion the positional candidate gene approach in this study has led to the 
identification of an ATRX disease-causing mutation in family XMR2.  Also, with the 
establishment of the ATRX ‘hotspot’ mutation detection protocol, testing can now be 
offered in the diagnostic setting through the NHLS (National Health Laboratory 
Services) for clinically suitable MR patients.  The enhancement of the repertoire of 
diagnostic protocols offered to MR patients will lead to better genetic management 
and counselling for those families afflicted with MR.  Finally, given the proposed 
role of ATRX as a chromatin remodeler as well as the family size, XMR2 provided 













CHAPTER 5  


















The 21st century has seen a rapid expansion in the molecular tools and technologies 
available to molecular geneticists, concomitantly there has been an explosion in the 
number of genetic disorders which can now be attributed to a molecular cause.    
XLMR disorders have been no exception, in the last 5 years 42 genes have been 
found to cause XLMR, a figure comparable to the 45 XLMR genes identified since 
the first XLMR gene, FMR1, was identified in 1991 (i.e. 1991-2004) (Chiurazzi, 
Tabolacci and Neri. 2004, Chiurazzi et al. 2008, Verkerk et al. 1991).  Along with 
enhancing the gene discovery process, these technological advancements have also 
assisted XLMR gene screening in large cohorts of clinically relevant patients.  Such 
studies have enabled researchers to estimate the mutation frequencies of most of the 
87 known XLMR genes, with certain genes being more frequently mutated than 
others (Chiurazzi et al. 2008, de Brouwer et al. 2007).   
 
FMR1 was the first gene to be associated with XLMR; in 1991 it was shown that a 
FMR1 5’UTR CGG expansion was the molecular cause of the FXS (Verkerk et al. 
1991).  Since then, the FXS has been established as the most common type of XLMR 
accounting for 15-25% of all XLMR (Kleefstra and Hamel. 2005).  As described 
previously, of the approximately 450 families referred to the Division of Human 
Genetics, UCT for FXS testing only 23% of patients have been shown to be positive 
for the FMR1 5’UTR expansion mutation.   
 
The second most commonly implicated XLMR gene is the Aristaless Related 
Homeobox (ARX) gene, with reported mutation frequencies of between 6.6 and 9.5% 
(de Brouwer et al. 2007, Mandel and Chelly. 2004, Poirier et al. 2004).  ARX 
mutations account for a diverse range of phenotypes, including non-syndromic MR.  
Given this relatively high mutation frequency and the clinical heterogeneity 
associated with ARX mutations, molecular ARX investigations were conducted in all 
XLMR families as well as all sporadic MR males who’s DNA was available in the 















Internationally, the remaining explained XLMR cases are accounted for by smaller 
mutation frequencies in a number of genes, including (most commonly): MECP2, 
OPHN1, PQBP1 and KDM5C (JARID1C) (de Brouwer et al. 2007).  Of these genes, 
MECP2 duplications were investigated in the UCT MR DNA bank in a separate 
study.  OPHN1 and PQBP1 are associated with very specific syndromic forms of 
MR which were not common in this group of South African patients and were 
therefore not investigated at this stage (Bergmann et al. 2003, Martinez-Garay et al. 
2007).  Finally, within the MR families of the EuroMRX consortium DNA bank, 
KDM5C was shown to account for the disorder in 4.2% and 4.3% of XLMR families 
and sib-pairs respectively (de Brouwer et al. 2007).  KDM5C mutations have been 
identified in patients with a subset of clinical features which were also prevalent in 
the UCT DNA bank (Abidi et al. 2008, Adegbola et al. 2008, Jensen et al. 2005, 
Santos et al. 2006).  Therefore, KDM5C was selected as a functional candidate gene 
in this study for investigation in a clinically stratified XLMR cohort. 
 
In this study, two of the most frequently mutated XLMR genes (ARX and KDM5C) 
were investigated in a cohort of South African XLMR patients selected from the 
UCT DNA bank.  The purposes of these investigations were two-fold.  Firstly, 
determining the ‘common’ XLMR gene mutation frequencies in South African 
patients provides guidance for the feasibility and practicality of expanding the 
repertoire of XLMR diagnostic tests.  Secondly, in those patients in whom putative 
‘epigenetic’ XLMR gene mutations are identified, DNA methylation profiles can be 
investigated in order to test the central hypothesis of this dissertation (i.e. whether an 
alteration to the DNA methylation profile is a molecular feature of MR in patients 
positive for mutations in putative ‘epigenetic’ XLMR genes.). 
 
5.1.1 FUNCTIONAL CANDIDATE GENE: ARX 
5.1.1.1 Phenotypes associated with ARX mutations 
The identification of MR-causing mutations in the ARX gene were first described in 
2002 in patients with both MRX and MRXS (Stromme et al. 2002b).  Subsequent 
studies in numerous cohorts have led to the identification of ARX mutations in 












 Non-syndromic MR with/without epilepsy (Bienvenu et al. 2002, Gronskov 
et al. 2004, Laperuta et al. 2007, Partington et al. 2004, Poirier et al. 2005, 
Poirier et al. 2006, Rujirabanjerd et al. 2007, Stepp et al. 2005, Stromme et al. 
2002b, Troester, Trachtenberg and Narayanan. 2007) 
 Numerous MR syndromes of which epilepsy is a core feature.  These include: 
West syndrome or X-linked infantile spasms syndrome (ISSX) (OMIM 
#308350), early infantile epileptic encephalopathy-1 (EIEE1), Ohtahara 
syndrome (OMIM #308350), X-linked myoclonic epilepsy with generalized 
spasticity and intellectual disability (XLMESID) (OMIM #300432), as well 
as ISSX with severe dyskinetic quadriparesis (Guerrini et al. 2007, Kato et al. 
2003, Kato et al. 2007, Scheffer et al. 2002, Stromme et al. 2002a, Stromme 
et al. 2002b, Wohlrab et al. 2005) 
 Partington syndrome (OMIM #309510) (Frints et al. 2002, Gronskov et al. 
2004, Stromme et al. 2002b, Turner et al. 2002) 
 X-Linked lissencephaly with ambiguous genitalia (XLAG) (OMIM #309215)  
(Bhat et al. 2005, Kato et al. 2004, Kitamura et al. 2002, Uyanik et al. 2003) 
 Gross brain malformations including agenesis of the corpus callosum (ACC) 
with abnormal genitalia (Proud syndrome) (OMIM #300004), 
hydraencephaly, transsphenoidal encephalocele and hypopituitarism (Kato et 
al. 2004, Van Esch et al. 2004). 
 
5.1.1.2 ARX: The gene and its protein 
The ARX gene (OMIM *300382) was identified by Stromme et al. (2002) using 
transcription mapping in a candidate region originally refined by linkage analysis to 
Xp22 (Stromme et al. 2002b). The ARX gene spans a chromosomal region of 12.5kb 
and consists of five exons.  The GC content of this gene is high, reaching 78% in 
exon 2.  Other features include GCG and GCC repetitive regions in exons 2 and 4 
respectively.  The ARX coding DNA sequence is highly conserved amongst various 













The ARX gene is flanked at both 3’and 5’ends by stretches of highly conserved 
nucleotide sequences.  These conserved regions are known as ultraconserved 
elements (UCEs) defined as DNA segments longer than 200bp that are 100% 
conserved between orthologous sequences in other species (human, rat, mouse).  
There are 11 UCEs that flank ARX and it has been postulated that these elements act 
as ARX transcription enhancers (Bejerano et al. 2004).  More recently it has been 
shown that one of these 11 UCE elements (uc.467), does indeed act as an ARX 
enhancer (Colasante et al. 2008).  Collectively this evidence suggests that these 11 
UCEs are good candidates for mutation detection in patients with XLMR.  However, 
it should be noted that deletion of one of these UCEs was shown to lead to no 
recognizable phenotype in knock-out mice (Ahituv et. al. 2007), suggesting that the 
role of UCEs may be more complex than previously anticipated. 
 
The ARX gene transcribes a range of isoforms (Table 5.1).  Recently it has been 
suggested that the discrepancy in transcript sizes is not due to alternative splicing, 
but rather due to alternate polyadenylation site usage, thus resulting in variable 
3’UTR lengths (Gecz, Cloosterman and Partington. 2006).  Notwithstanding this size 
discrepancy, it has been established that expression levels in foetal brain tissue are 
far higher than the adult counterpart, suggesting an involvement in neuronal 
maturation and development (Ohira et al. 2002, Poirier et al. 2004). 
 
Table 5.1 Localisation and size of mRNA transcript of the ARX gene 
 Size of isoforms of the ARX mRNA transcript (kb) 

























The ARX protein has an open reading frame of 1686bp and consists of 562 amino 
acids.  ARX is a member of the Aristaless-related subset of the paired (Prd) class of 
homeodomain proteins (Ohira et al. 2002, Stromme et al. 2002b).   This family of 
transcription factors are known to play a role in cerebral development and patterning 












regulator with both repressive and activating roles (Fullenkamp and El-Hodiri. 2008, 
McKenzie et al. 2007, Seufert, Prescott and El-Hodiri. 2005). 
 
 ARX consists of a number of functional domains (Figure 5.1): 
 The octapeptide motif: located at the N-terminus, is a DNA binding site 
and is known as the Goosecoid Engrailed Homology (GEH) or eh1 within 
the Engrailed (En) homeoprotein (Poirier et al. 2004).  This DNA binding 
domain acts as a transcription repressor through interaction with the 
Groucho/transducin enhancer of split (TLE) family of co-repressors 
(Fullenkamp and El-Hodiri. 2008, McKenzie et al. 2007) 
 Three nuclear localisation signals (NLSs): located throughout the ARX 
protein (Gecz, Cloosterman and Partington. 2006) 
 The homeodomain: a DNA binding domain which has been shown to 
repress expression of at least one gene to date (Pax4) by binding at the 
promoter sequence. (Collombat et al. 2005).  Also it has been shown that 
IPO13, a mediator of nuclear import, interacts with the ARX homeodomain 
(Shoubridge et al. 2007) 
 Four polyalanine tracts: these elements are common components of 
transcription factors (Lavoie et al. 2003).  Expansions of these polyalanine 
tracts in other transcription factors (e.g. SOX3, HOXD13, FOXL2, ARX) are 
associated with a range of genetic disorders (Albrecht and Mundlos. 2005).  
While the function of these alanine tracts remain largely elusive it has been 
suggested that they may act as spacer elements which maintain the protein 
tertiary structure integrity, and/or facilitate protein-protein interactions 
and/or DNA binding (as reviewed in (Amiel et al. 2004)). 
 The other repression domain (ORD): the second transcription repression 
domain (Fullenkamp and El-Hodiri. 2008, McKenzie et al. 2007).  This 
domain is Groucho-independent and the repression activity has been shown 
to be enhanced by C-Terminal Binding Protein 1 (CtBP1) binding 
(Fullenkamp and El-Hodiri. 2008) 
 The Aristaless domain: was shown to act as a transcriptional activator 














Figure 5.1 A schematic representation of the domains of the ARX protein (Gecz, Cloosterman and 
Partington. 2006).*as reported in Fullenkamp and El-Hodiri. 2008.aa=amino acid 
 
5.1.1.3 X mutations associated with XLMR 
To date 34 ARX mutations have been identified in 88 families (Appendix 5A).  There 
appears to be a strong genotype-phenotype correlation between the severity of 
mutations and the corresponding clinical manifestations.  This allows mutations to be 
categorised into two groups, delineated according to the presence or absence of 
malformation features (clinical details in Appendix 5A): 
 Severe mutations are those resulting in a loss of function of the protein.  
These include mutations leading to protein truncation or non-conservative 
missense mutations in the homeodomain or Aristaless domain (Figure 5.2).  
Severe mutations are associated with malformation phenotypes including 
XLAG and gross malformations of the brain. 
 Less severe (mild) mutations are those that have less impact on the functional 
deficit of the protein.  These include conservative mutations in the 
homeodomain, mutations outside the homeodomain and Aristaless domain, 
C-terminal truncations encompassing the Aristaless domain, as well as 
expansions of the polyalanine tracts (Figure 5.2).  Mild mutations are 
associated with NS-XLMR as well syndromic manifestations including West 
syndrome, Partington Syndrome and XLMESID. 
Octapeptide (aa 27-34) 
Nuclear localisation signal (aa 82-89, 325-332, 379-386) 
Homeodomain (aa 328-387) 
Aristaless Domain (aa 527-542) 
Acidic domain (aa 224-255) 
Other repression domain (ORD) (aa 398-448)* 













While there is evidently a clear genotype–phenotype correlation for ARX mutations, 
there is one exception described to date.  Van Esch and colleagues (2004) identified 
an individual with severe brain malformations (Transsphenoidal encephalocele and 
hypopituitarism) who carries the normally ‘mild’ ARX mutation, c.428_451dup24 
(Van Esch et al. 2004).   
 
It is also interesting to note that all expansion mutations in the first polyalanine tract 
(c.304ins(GCG)7 and c.298_330dupGCGGCA(GCG)9) are associated with MR 
syndromes of which epilepsy is a core feature e.g. ISSX, EIEE and West syndrome 
(Appendix 5A).  Several smaller expansions of this tract have also been reported in 
patients with NS-XLMR with absence of seizures (c.304ins(GCG)1, c.304ins(GCG)2 
and c.304ins(GCG)3) (Bienvenu et al. 2002, Gronskov et al. 2004).  These findings 
led to the suggestion that the longer the expansion the more severe the clinical 
presentation and the earlier the onset of the disorder.  However, the c.304ins(GCG)1 
expansion was identified in a normal male control DNA sample and also did not 
segregate with the disorder in one family (Gronskov et al. 2004).  The 
c.304ins(GCG)1 mutation is therefore not a disease-causing mutation.  To date, the 
larger polyalanine expansions have not been identified in normal controls, suggesting 
a threshold effect for the number of alanines tolerated. 
 
Expansions of the first polyalanine tract account for 14 out of the 88 (16%) known 
ARX mutations.  However, the most common ARX mutation is the expansion from 12 
to 20 alanine residues in the second polyalanine tract (c.428_451dup24), accounting 
for 40/88 of cases (45%).  This duplication exhibits both inter- and intra- familial 
clinical heterogeneity and has been detected in a number of clinical presentations 













Figure 5.2 Schematic representation of known mutations in the ARX gene.  Malformation phenotypes include XLAG as well as other gross malformations of the brain.  Mild 
mutations are those responsible for non-malformation phenotypes including MRX, Partington Syndrome, West syndrome and XMESID 
p.Y27X 























16 to 23 alanines (c.304(GCG)7) 

















12 to 20 alanines 
(c.428_451dup24) 
12 to 21 alanines 
c.430_456dup 



















5.1.1.4 The pathophysiological basis of ARX mutations 
Several lines of evidence support the role of ARX as a bi-functional transcription 
repressor and activator (Fullenkamp and El-Hodiri. 2008, McKenzie et al. 2007, 
Seufert, Prescott and El-Hodiri. 2005).  In support of this function, ARX mutant 
constructs (corresponding to those seen in XLMR patients) in the two repressive 
domains (the octapeptide and the ORD) exhibited reduced repressive activity 
(Fullenkamp and El-Hodiri. 2008, McKenzie et al. 2007).  In contrast, ARX mutants 
encompassing the Aristaless domain showed up to a 14 fold increase in reporter 
activity, supporting the hypothesis that this domain acts as a transcription activator 
(McKenzie et al. 2007).  These results show that ARX mutations which occur within 
these transcriptional regulatory elements disrupt the bi-functional regulator role of 
ARX, resulting ultimately in the MR phenotype. 
 
A significant percentage (61%) of ARX mutations can be attributed to expansion of 
either one of the first two polyalanine tracts.  The expansion of polyalanine tracts in 
other proteins (particularly transcription factors) beyond a certain threshold leads to 
protein misfolding, aggregation and degradation, ultimately resulting in cell death.  
The pathological consequences of this protein aggregation is thought to be the 
molecular mechanism underlying a number of genetic disorders (as reviewed in 
Albrecht and Mundlos. 2005).  There are however, conflicting reports as to whether 
the polyalanine expansions in ARX result in protein aggregation.  The first 
investigation for polyalanine nuclear inclusions found that expansions in the first 
polyalanine tract (c.304ins(GCG)7) did not lead to intranuclear inclusions (Poirier et 
al. 2004).  However, subsequently, two groups demonstrated that c.304ins(GCG)7 
forms aggregates in the cytoplasm (Gecz, Cloosterman and Partington. 2006, 
Shoubridge et al. 2007) while another reported intranuclear inclusions (Nasrallah, 
Minarcik and Golden. 2004).  Concerning the expansion of the second polyalanine 
tract (c.428_451dup), two conflicting studies have been published by the same group 
with the first reporting polynuclear inclusions (Gecz, Cloosterman and Partington. 
2006) and the second showing no aggregation in either the nucleus or cytoplasm 
(Shoubridge et al. 2007).  This discrepancy could be attributed to the different 












the role of protein aggregation as a disease mechanism in patients with ARX 
polyalanine expansions remains inconclusive at this stage. 
 
In studies involving Arx mutant mice Kitamura et al. (2002) showed that Arx plays a 
critical role in the development of the forebrain.  These Arx mutants showed aberrant 
GABAergic interneuronal differentiation and impaired migration from the ganglionic 
eminence to the developing cortex (Kitamura et al. 2002, Kitamura et al. 2009).  
Subsequent studies in additional mutant/ knock-out Arx mice and xArx frogs 
morpholinos have corroborated the critical role of ARX in the development of the 
human forebrain, particularly in GABAergic and cholinergic neuronal migration and 
basal ganglia differentiation (Colombo et al. 2004, Colombo et al. 2007, Seufert, 
Prescott and El-Hodiri. 2005).   
 
Furthermore, transcriptome analysis from Arx mutant mice by Fulp et al. (2008) 
demonstrated dysregulation of 84 genes in the absence of Arx.  Interestingly, this 
dysregulated data set was enriched for genes involved in biological processes 
involving neuronal migration, neurogenesis, transcription regulation and axonal 
guidance.  Also, a number of the human orthologues of the identified Arx 
transcription targets have been associated with neurological disorders such as 
epilepsy, autism and MR.  This study further emphasises the role of Arx in neuronal 
development and provides interesting candidate genes for mutation screening in 
patients with MR (Fulp et al. 2008).   
 
5.1.2 FUNCTIONAL CANDIDATE GENE: KDM5C (JARID1C) 
5.1.2.1 Phenotypes associated with KDM5C mutations 
In keeping with the diverse clinical spectrum of mutations in XLMR genes, the 
phenotypes associated with KDM5C mutations are broad, encompassing both MRX 
and MRXS.  The severity of MR associated with KDM5C mutations ranges from 
mild to severe and includes the manifestation of a number of additional clinical 
features (Table 5.2).  From the six studies published to date there appears to be a 
preponderance of certain clinical features in KDM5C  mutation positive patients, 












spasticity (35%), aggressive behaviour (30%), epilepsy/seizures (30%) and hand 
abnormalities (30%) (Abidi et al. 2008, Adegbola et al. 2008, Jensen et al. 2005, 
Rujirabanjerd et al. 2009, Santos et al. 2006, Tzschach et al. 2006). 
 
Table 5.2 A summary of the clinical features described in the 20 KDM5C  mutation 
positive families reported to date (Abidi et al. 2008, Adegbola et al. 2008, Jensen et 
al. 2005, Rujirabanjerd et al. 2009, Santos et al. 2006, Tzschach et al. 2006). 
 
Clinical feature Familial incidence (%) 
MR 20/20 (100) 
Speech impairment 9/20 (45) 
Short stature 8/20 (40) 
Hyperrreflexia/ spasticity  7/20 (35) 
Aggression 6/20 (30) 
Epilepsy/ seizures 6/20 (30) 
Hand abnormalities (Broad hand/tapering fingers, Camptodactly 
and clinodactyly, Large fingers/proximal thumb, brachydactyly) 
6/20 (30) 
Strabismus 4/20 (20) 
Microcephaly 4/20 (20) 
Prominent ears 3/20 (15) 
Small testes 2/20 (10) 
High narrow plate 2/20 (10) 
Cafe au Lait spot/ abnormal skin pigmentation 2/20 (10) 
Macrocephaly 1/20 (5) 
Facial hypotonia 1/20 (5) 
Overfriendly/anxious 1/20 (5) 
Autism spectrum disorder 1/20 (5) 
Club feet 1/20 (5) 
High prominent nasal bridge 1/20 (5) 














5.1.2.2 KDM5C: The gene and its protein 
The association of  lysine (K)-specific demethylase 5C (KDM5C) (alias SMCX, 
JARID1C) with XLMR was first identified in 2005 by systematic mutation screening 
of 47 candidate genes in XLMR families with overlapping Xp11 linkage intervals 
(Jensen et al. 2005).  Located at Xp11.22, KDM5C consists of 26 exons and spans a 
length of 34kb.   
 
Investigations pertaining to the X-inactivation status of KDM5C in females have 
produced conflicting results.  Several studies have shown KDM5C escapes X–
inactivation in both mouse and the human genomes (Agulnik et al. 1994, Carrel and 
Willard. 2005, Li and Carrel. 2008, Murakami et al. 2009).  However, another study 
showed partial X-inactivation at different developmental stages and in certain adult 
tissues (Sheardown et al. 1996).  Finally, females who are carriers of disease-causing 
KDM5C mutations exhibit a skewed X-inactivation pattern suggesting the gene is 
subject to X-inactivation (Abidi et al. 2008). 
 
KDM5C encodes for a transcript of ~6kb and is expressed in a variety of tissues.  
Expression was highest in the brain and skeletal muscle, with moderate expression in 
the lung and minimal expression in the pancreas, heart and liver (Jensen et al. 2005). 
 
The KDM5C transcript consists of an open reading frame of 4680bp and translates 
into a 1560 amino acid protein.  KDM5C forms part of the JARID1 (Jumonji (Jmj) 
AT-rich interactive domain) family.  This protein has high homology to three other 
JARID1 protein family members, JARID1A/B/D with 51%, 47% and 85% amino 
acid conservation respectively (Jensen et al. 2005).   
 
KDM5C is a transcription regulator and chromatin remodeler and has recently been 
shown to act as a histone demethylase responsible for the demethylation of 
di/trimethylated- histone H3 lysine 4 (H3K4me2 and H3K4me3) (Iwase et al. 2007, 
Tahiliani et al. 2007).  The protein consists of a number of functional domains 












1. The JmjN domain: common to a subset of the JmjC protein family and 
maintains the structural integrity of the protein, particularly the JmjC domain, 
and hence promotes optimal catalytic activity of KDM5C (Chen et al. 2006) 
2. The AT-rich domain-interacting domain (ARID): the function of this 
domain within KDM5C is largely unknown.  However, ARID has been 
shown to bind DNA in a sequence-specific and non-sequence-specific 
manner suggesting a role for KDM5C in DNA binding (Kortschak, Tucker 
and Saint. 2000) 
3. Two Plant Homeodomain (PHD) zinc fingers: (designated PHD1 and 
PHD2).  PHD1 motif tethers KDM5C to tri-methylated histone H3 lysine 9 
(H3K9me3) (Iwase et al. 2007).  The function of the C-terminal PHD2 
remains elusive 
4.  The JmjC domain: catalyses the demethylation of H3K4me3 and H3K4me2 
(Iwase et al. 2007) 
5. The C5HC2 zinc finger: the function of this domain remains unclear but 
















JmjN (aa 13-59) 
Arid/Bright (aa 76-184) 
PHD Zinc Finger (aa 326-374 and 1187-1250) 
 JmjC (aa 501-617) 












KDM5C is a histone demethylase responsible for demethylation of H3K4me3 and 
H3K4me2 through the catalytic activity of the JmjC domain.  This demethylase 
activity is directed by the binding of the PHD1 domain to H3K9me3 (Iwase et al. 
2007).  Trimethylation of H3K4 and H3K9 have opposite effects on transcription 
regulation, with H3K4me3/me2 being associated with gene activation and H3K9me3 
with a repressive state.  Therefore, KDM5C facilitates the cross-talk which occurs 
between different histone residues in order to co-ordinate a particular expressive state 
where protein binding to H3K9me3 (repressive) leads to demethylation of H3K4me3 
to H3K4me2 and H3K4me1, hence inducing a repressive chromatin state (Figure 5.4).   
 
 
Figure 5.4 The histone H3K4 demthylase activity of KDM5C.  By binding of the KDM5C PHD 
domain to the repressive H3K9me3 epigenetic mark the JmjC domain catalyses the demethylation of 
H3K4me3 and H3K4me2 to further induce a repressive chromatin state and prevent target gene 
expression. 
 
To further support the role of KDM5C as a chromatin remodeler, chromatin 
immunoprecipitation (ChIP) experiments from nuclear extracts show that the protein 
exists in complex with numerous other chromatin modifiers, including RE-1 
Transcription Factor (REST) (Tahiliani et al. 2007).  REST is responsible for the 
repression of neuronal genes in non-neuronal cell types.  Using ChIP assays it was 
shown that KDM5C and REST were both present at RE-1 target sites, providing 
further evidence that these two proteins interact to control the expression of neuronal 













5.1.2.3 KDM5C mutations associated with XLMR 
To date 20 families comprising a total of 44 affected males and four carrier females 
with mild intellectual disability have been reported with mutations in KDM5C 
(Appendix 5B) (Figure 5.5) (Abidi et al. 2008, Adegbola et al. 2008, Jensen et al. 
2005, Rujirabanjerd et al. 2009, Santos et al. 2006).  Of the 282 families screened for 
KDM5C mutations in the European XLMR consortium, a total of 13 families carry 
mutations in KDM5C (de Brouwer et al. 2007, Rujirabanjerd et al. 2009).   This 
equates to a frequency of 4.6% in this population group, resulting in KDM5C being 
quoted as one of the genes more commonly implicated in XLMR.   
 
Mutations in KDM5C do not appear to present with a clear genotype-phenotype 
correlation.  All truncating mutants identified to date result in severe MR.  However, 
missense mutations in the functional domains result in both severe and mild MR.  
The majority of mutations cluster between amino acids 332 and 766 encompassing 
the three functional domains, PHD1, JmjC and C5HC2 (which correlates to exons 4-
16).  Fourteen of the 20 (70%) mutations identified to date cluster in this region.  
Future investigations in larger cohorts will determine whether this region constitutes 




Figure 5.5 Schematic of disease-associated mutations in KDM5C.  The functional domains are 
represented as in Figure 5.4.  Colour of text indicates the severity of MR: red – severe, green – 














5.1.2.4 The pathophysiological basis of KDM5C mutations 
KDM5C is a histone demethylase responsible for the demethylation of H3K4me3 and 
H3K4me2 and exists in a protein-complex (including REST) that represses neuronal 
gene expression in non-neuronal tissues (Iwase et al. 2007, Tahiliani et al. 2007).  
Iwase et al. generated four mutant KDM5C recombinant proteins which represented 
four known XLMR-causing mutations (Asp87Gly, Asp402Tyr, Glu698Lys and 
Tyr751Cys).  H3K4 demethylase activity was impaired in these mutants in a manner 
that seemed to be directly proportional to the severity of MR (Tahiliani et al. 2007).  
These results suggest that the pathogenesis of XLMR in KDM5C mutation positive 
patients is due to ectopic neuronal gene regulation. 
 
Animal models for Kdm5c mutants have been generated in order to better understand 
the pathophysiological effects of gene mutations.  Kdm5c knockdown in the 
zebrafish resulted in neurodevelopmental defects including aberrant brain patterning 
and autonomous neuronal cell death (Iwase et al. 2007).  In rats, conditional KDM5C 
knockdown (restricted to the primary granules) did not result in neuronal cell death, 
but rather a significant decrease in dendritic length (Iwase et al. 2007).  This 
dendritic morphological abnormality is also commonly seen in patients with XLMR 
(Ropers and Hamel. 2005).  These studies show that KDM5C plays a critical role in 
neuronal development and that mutations in this gene lead to MR, possibly through 



















5.2.1 FUNCTIONAL CANDIDATE GENE: ARX  
5.2.1.1 ARX mutation detection cohort selection 
Owing to the clinical heterogeneity associated with ARX mutations as well as their 
purported high frequency, clinical presentation of patients (besides MR) was not a 
criterion for ARX mutation detection selection.  Instead cohorts were stratified 
according to the MR inheritance pattern which in turn determined the adopted ARX 
screening protocol.  The first two cohorts consisted of 77 affected males from 
families showing a clear or putative X-Linked inheritance pattern and 36 affected 
males that formed part of a sib-pair.  These cohorts were subject to mutation 
detection across the entire ARX coding region (Appendix 5C).  A third cohort of 183 
patient samples, each representing isolated cases of MR, was screened for the 
common ARX polyalanine expansions (c.428_451dup c.304ins(GCG)7) (Appendix 
5C).  All patients were previously shown to be mutation negative for the FMR1 
5’UTR CGG expansion resulting in Fragile X syndrome.  
 
5.2.1.2 PCR amplification of the five ARX exons 
Six sets of PCR primers were used to amplify the five ARX exons (exon 2 consisted 
of two overlapping fragments due to the exon’s large size) (Appendix 5D).  
Significant difficulty was experienced in ARX exon amplification (particularly exon 
2) owing to the gene’s high GC content.  For these reasons PCR amplification of 
each exon required different PCR reagents and amplification profiles (Appendix 5E). 
 
5.2.1.3 dHPLC analysis of the five ARX exons 
dHPLC analysis was conducted as per manufacturer’s instructions [Transgenomic®].  
Optimal chromatographic methods were designed using WAVEMAKER™ software 
[Transgenomic®].  The selected method temperatures for each individual exon were 
as follows: exon 1: 62.4ºC and 65.4ºC, exon 2a: 69ºC, 68.2ºC and 71.6ºC, exon 2b: 
65.4ºC and 66.6ºC, exon 3: 62ºC and 63.4ºC, exon 4: 63.5ºC, 66.9ºC and 68.1ºC and 













Patient-amplified DNA (test) PCR samples were mixed in a 1:1 ratio with a wild 
type sample, denatured at 95ºC for 5 minutes on a Hybaid touchdown thermal cycler 
and allowed to re-anneal on the block overnight.  A total volume of 5-7µl of the re-
annealed heterogeneous solution was injected onto the column.  Analysis of dHPLC 
profiles was conducted using WAVEMAKER™ software [Transgenomic®].   
 
5.2.1.4. DNA sequencing of ARX dHPLC variants 
All samples exhibiting deviant dHPLC profiles were subject to Sanger DNA 
sequencing in order to elucidate the underlying DNA sequence variation.  DNA 
sequencing of the sample exhibiting a deviant profile in ARX exon 3 was performed 
as described previously (Section 4.2.1.4).  However, DNA sequencing of variants 
with altered dHPLC profiles in exon 2A required extensive optimisation and 
adjustments to the sequencing protocol.  Ultimately the optimised DNA sequencing 
reaction consisted of:  40µM of a nested reverse primer (sequence supplied by Prof J. 
Gecz, 5'-ctcggtgccggtgccaccac-3) or 40µM of the aforementioned forward primer, 
500ng of purified PCR product, 1× Big Dye terminator sequencing buffer [Applied 
Biosystems], 8µl Big Dye terminator mix [Applied Biosystems] and 10% glycerol 
[Merck].  Sequencing reactions were cycled through an initial denaturation at 98ºC 
(10min), followed by 25 cycles of denaturation at 98ºC for 1min, primer annealing at 
55ºC for 1min and elongation at 72ºC for 2min, on a GeneAmp® PCR system 9700 
thermal cycler [Applied Biosystems].  
 
5.2.1.5 c.428_451dup and c.304ins(GCG)7 PCR-based screen 
The same PCR amplification protocol as that of exon 2a was used for amplification 
of the c.428_451dup and c.304ins(GCG)7 mutations with the following exceptions: 
 0.1 units of GoTaq polymerase [Promega] was used instead of ELT  
 The forward primer: 5’gctcccctaagagcaggagg 3’ (so as to amplify a smaller 
fragment which was easier to separate by gel electrophoresis) was used 
 
PCR products were analysed on a 0.8% agarose gel and visualised with EtBr. A 
c.428_451dup mutation negative and positive control samples were used, these 












available for the c.304ins(GCG)7 mutation, but the expected product size of 498bp 
was expected to be distinguishable from the wildtype (477bp product), although not 
from the c.428_451dup (501bp product). 
 
5.2.2 FUNCTIONAL CANDIDATE GENE: KDM5C  
5.2.2.1 KDM5C mutation detection cohort selection 
A cohort of 25 patients (Appendix 5C) was selected for the KDM5C mutation screen, 
the criteria by which these individuals were selected is given below:  
 A Clear X-linked recessive inheritance of mental handicap 
 Negative for the Fragile X syndrome expansion mutation 
 Negative for mutations in the ARX gene 
 A clinical presentation indicative of KDM5C mutations (Table 5.2). 
 
5.2.2.2 PCR amplification of the 26 KDM5C exons 
Primers were designed in order to amplify all 26 exons, as well as the intron-exon 
boundaries of the KDM5C gene.  Due to KDM5C gene structure it was often possible 
to design amplicons encompassing adjacent exons as well as the intervening intron.  
For these reasons only 20 amplicons were required to amplify the entire coding 
region of KDM5C (Appendix 5D).  PCR amplification of all exons was performed in 
a 25µl reaction volume using 100ng of genomic DNA, 10µM of each primer, 2.5µM 
dNTP’s [Bioline], 1× GoTaq buffer [Promega] and 1U GoTaq Polymerase 
[Promega].  The PCR profile consisted of an initial denaturation step at 95ºC for 3 
min, followed by 30 cycles at 95ºC for 30s, 59ºC for 30s, and 72ºC for 30s.  A final 
elongation at 72ºC for 3 min completed the PCR amplification. PCR was conducted 
on a Px2 thermal cycler [Thermo Electron Corporation].  All PCR products were 
checked by electrophoresis on a 1.5% agarose gel and visualised with EtBr. 












5.2.2.3 dHPLC analysis of the 26 KDM5C exons 
Mutation detection in all KDM5C amplicons by dHPLC was performed as described 
previously for the ARX exons (Section 5.2.1.3).  The selected method temperatures 
for each individual exon appear in Table 5.3. 
 
Table 5.3 Temperatures of the various dHPLC methods employed in the screening of 
the 26 KDM5C  exons. 
KDM5C exons Temperature 1 (ºC) Temperature 2 (ºC) Temperature 3 (ºC) 
1 64.1 64.9  
 2 62.3   
3 60.2   
4 59 60.9  
5 60.1  62.5  
6&7  58.8 60.9  
8 61.3 63  
9&10 59.4 61.4  
11&12 59.7 60.5  
13&14 64 66  
15&16 62   
17 61.6  64.5  
18 63.4   
19 63 64.2  
20 61.5 62.5  
21&22 61.7 62.6  
23 62.5 63.1 65.1 
24&25 61 63.1  
26 64 67.5  
 
5.2.2.4 DNA sequencing of KDM5C dHPLC variants  
DNA sequencing was performed as before for ATRX amplicons (Section 4.2.1.4). 
 
5.2.2.5 Screening of KDM5C intronic variations in a control population 
One hundred X chromosomes were screened for KDM5C intronic DNA sequence 
changes to attain an indication of the variants’ allele frequency in the relevant 
population.  Controls were matched for gender and ethnicity.  These control screens 
were performed using restriction enzyme digests and/or amplification refractory 















BbrP1 digest to detect the c.351-38C>T variation 
PCR amplification of exon 4 in 100 control samples was performed as described 
previously (Section 5.2.1.2).  The c.351-38C>T variation destroys a BbrP1 
restriction site within the PCR product of KDM5C exon 4.  PCR products were 
digested with BbrP1 [Roche] according to manufacturer’s instructions [Roche].  
Restriction enzyme digest products were electrophoresed on a 2% agarose gel and 
visualised with EtBr. 
 
ARMS-PCR to detect the c.2517-7_8insTAC variation 
A reverse primer sequence was designed to bind specifically to the wild type 
sequence at position c.2571-7 of the KDM5C transcript (Figure 5.6).  The PCR was 
performed in a final reaction volume of 25µl and consisted of 2.5µM dNTP’s 
[Bioline], 1× GoTaq buffer [Promega] and 1U GoTaq Polymerase [Promega].  
Primer concentrations were as follows: KDM5C exon18 forward (10µM) and reverse 
primer (5 µM) and 10µM of the wildtype specific primer (5' ctgtgggggctatgaagtatc 
3').  The PCR profile consisted of an initial denaturation step at 95ºC for 3 min, 
followed by 30 cycles at 95ºC for 30s, 59ºC for 30s, and 72ºC for 30s and a final 
elongation at 72ºC for 3 min on a Px2 thermal cycler [Thermo Electron Corporation].  
PCR products were electrophoresed on a 3% agarose gel and visualised with EtBr. 
 
Dde1 digest to detect the c.2623-45G>A 
PCR amplification of exon 19 in 100 control samples was performed as described 
previously (Section 5.2.1.2).  The c.2623-45G>A variation destroys a Dde1 
restriction site within the PCR product of KDM5C exon 19.  PCR products were 
digested with Dde1 [New England Biolabs] according to manufacturer’s instructions 
[New England Biolabs].  Restriction enzyme products were separated using a 12% 
polyacrylamide gel electrophoresis. (PAGE)  and visualised by silver staining. 
 
ARMS-PCR to detect the c.2623-45G>A 
An ARMS-PCR was designed so as to screen for the c.2623G>A variant in the 
control population as an alternative to Dde1 digestion which was unsuccessful. In a 
manner similar to that illustrated in Figure 5.6 a reverse primer sequence was 
designed to bind specifically to the wild type sequence at position c.2623-45 of the 












consisted of 2.5µM dNTP’s [Bioline], 1× Go Taq buffer [Promega] and 1U Go Taq 
Polymerase [Promega].  Primer concentrations were as follows: 10µM KDM5C 
exon18 forward and reverse primer as well as 10µM of the wildtype specific primer 
(5' aactcctcagctgggcccac 3').  The PCR profile consisted of an initial denaturation 
step at 95ºC for 3 min, followed by 30 cycles at 95 ºC for 30s, 58 ºC for 30s, and 72 
ºC for 30s.  A final elongation at 72 ºC for 3 min completed the PCR amplification. 
PCR was conducted on a Px2 thermal cycler [Thermo Electron Corporation].  PCR 
products were electrophoresed on a 3% agarose gel and visualised with EtBr. 
 
 
Figure 5.6 ARMS-PCR used to detect the presence of c.2517-7_8insTAC in KDM5C. (a) In the 
presence of the wildtype both reverse primers bind to produce two PCR products of 54 and 190bp. (b) 
The inhibition of PCR amplification due to restriction of reverse primer binding owing to the TAC 
insertion sequence, therefore leading only to the single 190bp product. 
5.2.2.6 Screening for an intronic insertion in a XLMR patient cohort  
Affected males from 76 XLMR families were screened for the c.2517-7_8insTAC 
variation in order to further elucidate the disease-association of this sequence variant.  













5.3.1 MUTATION DETECTION IN ARX  
5.3.1.1 Mutation detection in ARX using dHPLC 
Mutation detection in the five ARX exons in a total of 113 affected males (77 XLMR 
families and 36 sib-pairs) revealed no altered dHPLC profiles in exons 1, 2b, 4 and 5.  
However, three samples (Fx362.1, Fx391.1, Fx446.1) showed deviant dHPLC 
profiles for exon 2a (Figures 5.7). In addition, an altered dHPLC pattern was 
















Figure 5.7 Altered dHPLC profiles in ARX exon 2a. All PCR products were subject to dHPLC under 
semi-denaturing conditions, those samples with a variant formed heteroduplexes with the wild-type 
sample.  These heteroduplexes elute at different times due to variable affinity for the column matrix. 



















































































Figure 5.8 Chromatogram of the ARX exon 3 variant in sample Fx378.1.  PCR products were 
separated under semi-denaturing conditions.  Here, the control (wildtype – blue) sample elutes with 
only a single peak as compared to Fx378.1 (black) which elutes as two time points hence indicating 
the presence of a DNA sequence variation Fx378.  This dHPLC analysis was performed at 64.3°C. 
 
 
5.3.1.2 Sequencing and segregation analysis of samples showing aberrant dHPLC 
profiles 
DNA sequencing of those samples exhibiting altered dHPLC profiles revealed the 
presence of three exonic changes (exon 2a) in samples Fx362.1, Fx391.1 and 
Fx446.1  and one intronic change (intron 3) in Fx378.1. 
 
The c.300G>A variant in family Fx362 
Individual Fx362.1 was shown to carry a c.300G>A transition within the coding 
region of exon 2a which encodes for a synonymous mutation (Figure 5.9).   The 
c.300G>A was not reported in any of the SNP databases and was therefore a novel 
nucleotide change.  While this variation was a silent mutation, it could not be ruled 
out that the variant induced aberrant splicing at a putative ESE site.  Therefore, the 





































Figure 5.9 DNA Sequence analysis results illustrating the c.300G>A in ARX exon 2a in individual 
FX362.1. (a) An electropherogram of FX362.1, the c.300G>A transition is indicated by the black 
arrow.  (b) An exert of the BioEdit alignment of the consensus sequence (top row) to sample Fx362.1 




Family Fx362 consisted of three brothers, the two elder brothers (Fx362.1 and 
Fx362.2) present with NS-XLMR, with MR in the mild-moderate range and 
macrocephaly.  The youngest sib (Fx362.3) exhibited none of the features of his 
elder brothers and there was no further family history of mental handicap.  
Segregation analysis of the c.300G>A mutation in ARX exon 2a by dHPLC analysis 
demonstrated that this change did not segregate with the MR phenotype in this 
family (Figure 5.10).  The c.300G>A was originally identified in the patient Fx362.1, 
but was not detected in either the affected sib (Fx362.2) or the unaffected brother 
(Fx362.3) by dHPLC analysis.  Therefore, the c.300G>A variation was not the 
disease-causing change in this family.    














Figure 5.10 Segregation analysis of the c.300G>A ARX exon 2a mutation in family Fx362. The 
chromatogram generated at a temperature of 71.6°C (a) illustrating the aberrant profile of sample 
FX362.1 (green) as compared to the control (red) indicative of the c.300G>A variation.  (b) The 
chromatogram showing samples Fx362.2 (affected sib) and Fx362.3 (unaffected sib) have the same 
profile as the control sample and not that of Fx362.1.  It was therefore concluded that neither of the 
sibs of Fx362.1 carry the c.300G>A variation. 
 
The c.428_451dup mutation in families Fx391 and Fx446 
Upon DNA sequencing, samples Fx391.1 and Fx446.1 were both shown to be 
positive for the common ARX c.428_451dup mutation (Figure 5.11).  It was therefore 
concluded that the c.428_451dup located in the second polyalanine tract was the 
cause of XLMR in these two families. 
 
Figure 5.11 Sequence analysis results of ARX exon 2a showing the c.428_451dup in individual 
FX391.1 (a) An electropherogram of sample FX391.1, the c.428_451dup mutation is underlined in 
red.  (b) An exert of the BioEdit alignment of the consensus sequence (top row) to sample Fx391.1 
(bottom row) illustrating the conserved sequence (represented by the dots (.) ) as well as the 

































































Family Fx391 exhibited an extensive history of mental handicap (NS-XLMR in the 
mild-moderate range) which segregated in an X-linked fashion (Figure 5.12).  Carrier 
testing for the c.428_451dup mutation using dHPLC in the mother (Fx391.2) of the 
proband (Fx391.1) reflected a positive result (Figure 5.13).  No further family 
members were available for mutation/carrier testing in this family.   
 
 





Figure 5.13 Chromatogram showing the c.428_451dup mutation in carrier (Fx391.2).  Here PCR 
products of ARX exon 2a are separated on the basis of size using dHPLC.  The c.428_451dup 
mutation positive (blue) elutes from the column later than the mutation negative (grey).  The carrier 







































Family Fx446 exhibited an X-linked inheritance of MR (Figure 5.14).  The proband 
presented with mild-moderate NS-XLMR which included hypotonia and mild facial 
dysmorphism.  The mother (Fx446.2) of the proband (Fx446.1) was the only 
individual available for carrier/mutation testing in the family.  DHPLC analysis 




Figure 5.14 Pedigree of family Fx446.  The proband has an affected female maternal cousin (hatched 
circle), however, this individual was not examined by clinicians participating in this study and 





Figure 5.15 Chromatogram showing the c.428_451dup mutation in carrier (Fx446.2).  Here PCR 
products of ARX exon 2a are separated on the basis of size using dHPLC.  The c.428_451dup 
mutation positive (blue) elutes from the column later than the mutation negative (grey).  The carrier 










































The c.1119+79G>A variant in family Fx378 
Fx378.1 was shown to carry an intron 3 variation designated, c.1119+79G>A (Figure 
5.16).  This intronic SNP has been previously reported (rs2074002) and has no 
known disease associations.  While no population or individual data exists for this 
SNP it has been validated by multiple submissions to the NCBI database.  The 




Figure 5.16 Chromatogram showing the c.428_451dup mutation in carrier (Fx446.2) Here PCR 
products of ARX exon 2a are separated on the basis of size using dHPLC.  The c.428_451dup 
mutation positive (blue) elutes from the column later than the mutation negative (grey).  The carrier 
mother (Fx446.2) has two peaks which correspond to the mutant and wild type allele (red).  
 
5.3.1.3 The c.428_451dup and c.304ins(GCG)7 PCR-based screen 
Mutation screening for the c.428_451dup and c.304ins(GCG)7 in 183 isolated male 
MR patients revealed no polyalanine expansions in this group of patients (Figure 
5.17).    












   
 
Figure 5.17 The ARX c.428_451dup and c.304ins(GCG)7 PCR based screen in isolated males with 
MR. PCR products were assessed on a 3% agarose gel and visualised with EtBr.  Lane 1 shows the 
100bp molecular weight marker, Lanes 2 and 13 show samples previously demonstrated as positive 
for the c.428_451dup mutation (501bp), while lanes 3-12 illustrate a subset of the 183 isolated MR 
males in this screen (PCR of the sample in lane 11 failed), Lane 14 shows the no-DNA control.  The 
c.428_451dup and c.304ins(GCG)7 mutations was not detected in any of these individuals or the 
remainder of the cohort of 183 isolated MR males. 
 
 
5.3.2 MUTATION DETECTION IN KDM5C USING DHPLC 
5.3.2.1 dHPLC analysis in the 26 KDM5C exons 
DHPLC analysis of the twenty KDM5C amplicons in the cohort of 25 patients 
identified three DNA sequence variations.  Aberrant dHPLC profiles were identified 
in the samples corresponding to individuals Fx135, Fx361 and Fx277 in exons 4, 18 






















Figure 5.18 Chromatograms of the KDM5C variants. All PCR products were subject to dHPLC under 
semi-denaturing conditions. (a) The exon 4 variant in sample Fx135.1 . Here, Fx135.1 (black) elutes 
before the control (blue) and there is subtle evidence of two peaks indicative of heteroduplex 
formation. (b) The exon 18 variant in sample Fx361.1.  Here, the presence of two peaks in sample 
Fx361.1 (pink) is evident as compared to the homoduplex in the control sample (red). DHPLC was 
performed at a temperature of 63.4°C (c) The exon 19 variant in Fx277.1. The heteroduplex formation 
indicative of an underlying sequence variation is evident by the presence of two peaks in Fx277.1 
(brown) as compared to the homoduplex peak in the wildtype sample (grey) DHPLC was performed 




















































































5.3.2.2 Sequencing analysis of samples showing aberrant dHPLC profiles and 
variant screening in additional cohorts. 
DNA sequencing of samples, Fx135, Fx361, Fx277, showing aberrant dHPLC 
profiles revealed the exact underlying nature of the sequence variation in amplicons 
of exon 4, 18 and 19 respectively. 
 
The c.351-38C>T variant in family Fx135. 
Individual Fx135 was shown to carry an intronic change (intron 3) designated c.351-
38C>T (Figure 5.19).  Due to the variant’s intronic nature, this mutation has no 
direct affect on the amino acid sequence, however, a splicing alteration could not be 
ruled out at this point.  This variation has not been previously described in any of the 
SNP databases. Unfortunately, no additional family members were available for 
segregation analysis, therefore the prevalence of the c.351-38C>T variant was 
assessed in a background population. 
 
 
Figure 5.19 DNA sequence analysis results illustrating the c.351-38C>T in KDM5C intron 3 in 
individual Fx135.1. The sample Fx135.1 represents an affected female therefore the (a) 
electropherogram of Fx135.1illustrating the c.351-38C>T indicated by the black arrow and designated 
N owing to the presence of two alleles at this position.  (b) An exert of the BioEdit alignment of the 
consensus sequence (top row) to sample Fx135.1 (bottom row) illustrating the conserved sequence 

















The presence of c.351-38C>T variation was screened, using a BbrP1 digest, in 100 
unaffected male controls that were matched for ethnicity.  This variation was 
detected in three of the 100 DNA samples from unaffected males (Figure 5.20).  Due 
to the presence of this intronic variation in unaffected individuals it was concluded 
that the c.351-38C>T was a novel SNP and therefore not associated with MR 
pathogenesis in family Fx135. 
 
Figure 5.20 Screening for the KDM5C c.351-38C>T variant in 100 background controls.  The 
presence of the c.351-38C>T variation destroys a BbrPI RE site at nucleotide 39 of the exon 4 PCR 
product.  Therefore only in the presence of the wildtype sequence will cleavage occur (256bp), while 
the mutant sequence remains intact (277bp).  Restriction enzyme digest products were separated on 
the basis of size using gel electrophoresis (2% agarose gel) and visualised with EtBr.  Lane 1: 
molecular weight marker (100bp), Lane 2: male sample from background population positive for the 
c.351-38C>T variation, Lane 3: wildtype sample, Lane 4 sample Fx135.1 affected female 
heterozygous for c.351-38C>T, Lane 5: no-DNA control. 
 
The c.2517-7_8insTAC variant identified in family Fx361 
A c.2517-7_8insTAC in intron 17 was identified in individual Fx361 (Figure 5.21).  
This variant has been reported previously in a male patient with XLMR (Jensen et al. 
2005).  Jensen and colleagues (2005) did not detect the c.2517-7_8insTAC change in 
312 control X-chromosomes screened.  Furthermore, in this study, by ARMs-PCR it 
was demonstrated that this variant was not present in 100 ethnically matched 
unaffected males (Figure 5.22).  Unfortunately, no additional family members were 
available for co-segregation analysis.  However, given that the c.2517-7_8insTAC 
variation has now been identified in two XLMR individuals but not 412 control X 
chromosomes, the presence of this intronic variation was further assessed in the 76 
probands of clear XLMR families by ARMS-PCR in an attempt to identify additional 
XLMR individuals with this intronic variant.  Unfortunately, the c.2517-7_8insTAC 













Figure 5.21 DNA sequence analysis results illustrating the c.2517-7_8insTAC in KDM5C intron 17 in 
individual Fx361.1.  (a) An electropherogram of sample FX361.1, the c.2517-7_8insTAC variation is 
underlined in red.  (b) An exert of the BioEdit alignment of the consensus sequence (top row) to 
sample Fx361.1 (bottom row) illustrating the conserved sequence (represented by the dots (.) ) as well 





Figure 5.22 ARMS-PCR products to detect the c.2517-7_8insTAC variation in control X-
chromosomes. PCR products were separated on the basis of size using gel electrophoresis (3%) and 
visualised with EtBr Lane 1: 100bp molecular weight marker, Lanes 2 and 20: sample Fx361.1 
mutation positive for the c.2517-7_8insTAC variation and hence not producing the smaller 54bp band.  
Lanes 3-19: a subset of the 100 unaffected males screened, this variation was not detected in this 
background population group. 
 
The c.2623-45G>A variant in family Fx277. 
Sequencing in individual Fx277 revealed an intronic c.2623-45G>A change in intron 
18 (Figure 5.23).  This change has no direct consequence on the amino acid sequence 
but an effect on splicing could not be dismissed.  This variation has not been 
previously described in either of the SNP databases (NCBI, Ensembl).  Furthermore, 
no additional family members were available for co-segregation analysis, therefore 















Figure 5.23 DNA sequence analysis results illustrating the c.2623-45G>A in KDM5C intron 18 in 
individual Fx277.1.  (a) An electropherogram of FX277.1, the c.2623-45G>A transition is indicated 
by the black arrow.  (b) An exert of the BioEdit alignment of the consensus sequence (top row) to 
sample Fx277.1 (bottom row) illustrating the conserved sequence (represented by the dots (.)) as well 
as the G>A mismatch. 
 
 
The c.2623-45G>A could not be assessed in control X chromosomes using Dde1 
restriction enzyme (RE) digest analysis.  There are multiple Dde1 cleavage sites 
within this PCR fragment, with the wildtype having 6 sites compared to the five 
present in the c.2623-45G>A variant.  Subsequent to Dde1digestion of the KDM5C 
exon 19 PCR product, it was predicted that the wildtype and mutant would produce 
bands of 16, 34, 66, 73, 93, 248 and 16, 48, 66, 73, 93, 248 respectively.  The 
difference between the two banding patterns (the 34bp and 48bp products) could not 
be discerned by PAGE and therefore the c.2623-45G>A could not be screened in a 
control population using this method.  Therefore, an ARMS-PCR was designed as an 
alternative to RE digestion.  The ARMS-PCR was predicted to produce two PCR 
products (544bp and 57bp) in the wildtype, while only one band (544bp) in the 
presence of the c.2623-45G>A variation.  However, despite several optimisation 
steps, the difference between the wildtype 57bp product and the primer dimer could 
not be discerned and the variant could not be assessed using this method.  Due to the 
deeply intronic nature of this variation and thus the enhanced likelihood of the 
variation not playing a role in disease, this variant was not further assessed using a 














5.4.1 THE ARX GENE 
Mutations in the ARX gene are thought to be one of the leading causes of XLMR 
accounting for up to 9.5% of this disorder (Poirier et al. 2006).  The purported high 
prevalence of mutations makes ARX the second major contributor to XLMR after 
FMR1.  For these reasons, ARX was an excellent candidate for mutation screening in 
affected individuals with X-linked inheritance who are negative for the FMR1 
5’UTR expansion.  In this study, mutation detection of the ARX gene coding region 
(and intron/exon boundaries) in 113 XLMR probands revealed two disease-causing 
c.428_451dup mutations in patients Fx391.1 and Fx446.1.  In addition, a known SNP 
c.1119+79G>A (rs2074002) was identified in intron 3 of patient Fx378.1 and a novel 
SNP (c.300G>A) was detected in exon 2a of individual Fx362.1.  Finally, no 
c.428_451dup or c.304ins(GCG)7 expansions were detected in the 183 individuals 
screened by the allele fragment length-based PCR assay. 
 
The c.428_451dup mutation detected in individuals Fx391.1 and Fx446.1 was 
originally described in 5 XLMR families and 1 sporadic MR case.  The duplication 
segregated in these XLMR families and was not detected in 300 control X 
chromosomes, leading the authors to conclude that this duplication was responsible 
for the MR etiology in these families (Bienvenu et al. 2002).  Since then the 
c.428_451dup has been reported in numerous cohorts and accounts for 45% of all 
mutations reported to date (Appendix 5A).  In both families Fx446 and Fx391 
described here, the c.428_451dup mutation segregated with the disorder and was 
therefore predicted to be the disease-causing mutation in these families. 
 
A diverse range of phenotypes have been associated with this 24bp duplication 
including MRX, Partington syndrome and West syndrome (Bienvenu et al. 2002, 
Gronskov et al. 2004, Stromme et al. 2002a).  However, the majority of 
c.428_451dup patients (32 of 38 cases (84%)) present with NS-XLMR.  
Concomitantly, patients from families Fx446 and Fx391 have a non-syndromic 
presentation of XLMR, with Fx391 presenting with mild facial dysmorphism and 













The c.428_451dup mutation results in the expansion of the second ARX polyalanine 
tract from 12 to 20 alanine residues.  The pathogenic nature of this mutation has not 
been clearly elucidated and its pathogenic role has been the source of conflicting 
results.  Polyalanine expansions in other genes, particularly transcription factors (e.g. 
ZIC2 and HOXD13) have been shown to exert their pathogenic effects by protein 
aggregation and increased apoptosis (Albrecht and Mundlos. 2005).  Based on this 
premise it was hypothesised that the expansion of the second ARX polyalanine tract 
invoked pathogenic effects by a similar apoptosis-induced mechanism.  
Investigations to test this disease mechanism have reached contradictory conclusions.  
Two reports showed that c.428_451dup expansion does not cause nuclear protein 
aggregation (Poirier et al. 2004, Shoubridge et al. 2007), while unpublished results 
referred to in a review by Gecz and colleagues (2006) suggested that nuclear 
aggregates are a feature of this polyA expansion (Gecz, Cloosterman and Partington. 
2006).  Given the compelling experimental evidence that the c.428_451dup 
expansion does not result in aggregation of the mutant protein, compared to the 
unsubstantiated unpublished results, it is likely that nuclear aggregation is not the 
c.428_451dup disease-causing mechanism (Poirier et al. 2004, Shoubridge et al. 
2007).   
 
These data suggest that an alternative disease mechanism to protein aggregation is 
induced by the second polyalanine tract expansion.  Polyalanine tracts have been 
hypothesised to be integral to the maintenance of protein tertiary structure which 
determines protein-protein interactions and/or DNA binding (Amiel et al. 2004).  In 
support of this theory, polyalanine expansions in the transcription factor, ZIC2, affect 
the ability of this protein to bind target DNA sequences, resulting in virtually 
complete abrogation of target gene transcriptional activity (Brown et al. 2005).  In a 
similar fashion, ARX polyalanine expansions may affect DNA-binding to target 
genes with concomitant effects on the proteins transcriptional repression and 
activation activity.  Now that a number of ARX target genes have been identified by 
gene expression analysis in Arx knockout mice (Fulp et al. 2008), it will be possible 
to test this theory.  The mRNA expression profile in c.428_451dup positive patients 
for the subset of identified ARX target genes could be assessed using a quantitative 
method (such as quantitative real-time PCR) in order to test for dysregulation at these 













Given the severe clinical presentation of patients with truncating and complete loss 
of function ARX mutations (i.e. XLAG and ACC) it is not expected that the 
c.428_451dup mutation, with its mild clinical manifestation, to lead to a complete 
loss of function.  It would be interesting to compare target gene expression profiles 
between different ARX mutations so as to give an indication of the function of the 
various ARX conserved domains. 
 
The known SNP (c.1119+79G>A) was idenitifed in intron 3 of individual FX378.1, 
was found to be catalogued in the reference SNP database curated by NCBI 
(accession number rs2074002).   Therefore, this SNP cannot be associated with the 
disorder in family Fx378.1 due to its presence in the general (and unaffected) 
population.    
 
A  c.300G>A transition was detected in individual Fx362.1, this silent mutation has 
not been previously described in the SNP databases of either NCBI or Ensembl.  
Segregation analysis in the family demonstrated that this alteration did not track with 
the disorder in the family, as neither the proband’s affected (Fx362.2) nor unaffected 
(Fx362.3) brother carry this variant.  For these reasons, the c.300G>A alteration was 
not the disease-causing mutation in Family Fx362.  Investigations in the background 
population would determine whether the c.300G>A is a rare variant or a novel SNP.   
 
 Interestingly, the c.300G>A variation was shown to disrupt the ESE site, SRp55, 
using the ESEFinder prediction tool described in Chapter 4 (Cartegni et al. 2003).  
The disruption of this site could lead to aberrant intron splicing which while not the 
disease-causing change in this family could contribute to the disease pathogenesis.  
Similarly Gronskov and colleagues (2004) detected an ARX polymorphism 
c.1347C>T in MR patients as well as unaffected family members.  This 
polymorphism created a novel, strong Srp55 binding site, leading the authors to 
speculate that this change could act as a modifier (Gronskov et al. 2004).  Given the 
low mutation detection rates in XLMR families, particularly in sib-pairs, it has been 
hypothesised that a proportion of familial XLMR recurrence can be accounted for 
using a polygenic model (Mandel and Chelly. 2004, Raymond and Tarpey. 2006, 












predisposition toward learning disability.  It is hypothesised that these two putative 
splicing variants (c.300G>A and c.1347C>T) could act as modifiers, but mRNA 
analysis should be conducted first to test for aberrant splicing. 
 
Furthermore, in support of the ‘X-linked risk allele’ theory, an additional variant was 
detected in the same sib-pair of family Fx362 in a collaborative study between the 
Wellcome Trust Sanger Institute in Hinxton, Cambidge and the Division of Human 
Genetics UCT.  In this study, individual Fx362.2 was shown to carry a truncating 
variant (p.S76fsX7) in ARSF (Tarpey et al. 2009).  This variant did not segregate in 
the family, with the affected brother (Fx362.1) testing negative for this truncating 
mutation.  In addition, ARSF truncating variants were identified in five of 1346 
controls, leading to the conclusion that ARSF was not an XLMR gene.  Furthermore, 
truncating variants in additional X-linked genes were detected in normal controls, 
with these deleterious mutations being present in up to 1% of X-linked genes in the 
general population (Tarpey et al. 2009).  The accumulation of truncating variants in 
X-linked genes (X-linked risk factors) above a certain threshold is an attractive 
inheritance model for the ‘unexplained’ XLMR families, which requires further 
investigation. 
 
While the role of X-linked ‘risk-factors’ in the pathogenesis of MR remains to be 
elucidated, the role of the ARX polyalanine expansions is quite clear.  Cumulatively, 
expansions of the first two polyalanine tracts account for 61% (Appendix 5A) of all 
ARX mutations.  For these reasons the presence of these polyalanine expansions was 
assessed in 183 males with isolated, unexplained MR.  While no mutations were 
detected in this group, this result was in keeping with previous reports suggesting a 
low mutation frequency in certain cohorts, particularly those including sporadic MR 
cases.  Gronskov et al. (2004) screened 682 males with developmental delay for the 
two common polyalanine expansions and identified only two disease-causing 
mutations (~0.3%) (Gronskov et al. 2004).  Also, the EuroMRX consortium reports 
only a 0.1% detection rate in sporadic MR (de Brouwer et al. 2007). 
 
Mutation detection in the ARX gene posed numerous problems, primarily due to the 
excessive GC content of the ARX coding regions.  PCR amplification of exon 2a 












eventually optimised using a specialised buffer and a high fidelity Taq polymerase.  
The difficulties experienced, however, prompted an investigation of the relationship 
between GC content and PCR efficiency in collaboration with Prof H. Viljoen and 
colleagues at the Department of Chemical and Biomedical Engineering, University 
of Nebraska-Lincoln, USA. Through these studies it was established that the PCR 
efficiency of GC-rich templates is strongly dependant on PCR annealing time, with a 
shorter annealing time (3-6 seconds) being optimal (Mamedov et al. 2008). 
 
In this South African study, two c.428_451dup mutations were identified from a total 
of 113 clear or putative XLMR families assessed, resulting in a mutation detection 
frequency of ~1.8% in this cohort.  A figure much lower than previous reports of 
ARX mutations accounting for between 6.6-9.5% of XLMR cases (de Brouwer et al. 
2007, Mandel and Chelly. 2004, Poirier et al. 2006).  However, of the 113 XLMR 
patients assessed here, 36 were part of a sib-pair (29 brother pairs, 7 brother-sister 
pairs), 34 showed putative X-linked inheritance and only 43 were clearly XLMR 
(Appendix 5C).  Therefore, ARX mutations account for 4.6% of clear XLMR cases in 
this South African cohort, a figure much closer to previous reports.  Also, the 
detection rate of 0/29 brother pairs (0%) was similar to that of the EuroMRX 
consortium of 1.5% (de Brouwer et al. 2007). 
 
The two ARX c.428_451dup mutations detected in this South African cohort 
reflected current ARX literature, in terms of both mutation detection rates and clinical 
presentation.  It was therefore concluded that diagnostic testing for the two 
polyalanine expansions using the PCR and gel electrophoresis-based approach 
described here was both necessary and justified in the South African setting.  Patients 
with an X-linked history of NS-XLMR or a known ARX MR ‘epilepsy’ syndrome 
should be investigated for these polyalanine expansions subsequent to 5’UTR FMR1 
expansion testing. 
 
In keeping with these conclusions, diagnostic testing for the first two ARX 
polyalanine expansions (c.428_451dup and c.304ins(GCG)7) has been implemented 
at the Division of Human Genetics, UCT.  Since the test’s inception 12 patients have 
been referred to the Division by local clinicians and to date, one c.304ins(GCG)7 












improved the diagnostic yield of patients with MR and will continue to do so.  This 
enhanced diagnostic yield in turn affords improved genetic management for MR 
families, positively impacting the burden of disease alleviation,particularly important 
in a developing country such as South Africa. 
 
5.4.2 THE KDM5C GENE 
The KDM5C gene is one of the more commonly mutated XLMR genes, with 
reported prevalence of 4.2% and 4.3% in XLMR and sib-pair cohorts respectively 
(de Brouwer et al. 2007).  In general, patients with KDM5C mutations present with 
NS-XLMR, although common additional clinical features speech impairment (45%), 
short stature (40%), hyperreflexia or spasticity (35%), aggressive behaviour (30%), 
epilepsy/seizures (30%) and hand abnormalities (30%) (Abidi et al. 2008, Adegbola 
et al. 2008, Jensen et al. 2005, Rujirabanjerd et al. 2009, Santos et al. 2006, Tzschach 
et al. 2006)  In this study, 25 XLMR patients with one or more of these features were 
screened for mutations in the 26 KDM5C exons but no disease-causing mutations 
were identified. 
 
While no disease-causing KDM5C mutations were identified, three patients were 
shown to carry intronic variants.  The first, in patient Fx135.1, designated c.351-
38C>T and residing in intron 3, was not previously described in the SNP databases.  
This novel change was detected in 3/100 (3%) of the ethnically matched male control 
DNA samples analysed by allele-specific restriction enzyme digest.  It was therefore 
concluded that the c.351-38C>T variant constitutes a novel SNP. 
 
The second alteration (c.2517-7_8insTAC) in intron 17 of KDM5C was identified in 
patient Fx361.1.  The proband presents with MRX and speech delay as does his 
younger brother but there was no further family history.  This insertion (c.2517-
7_8insTAC) has been previously described in an XLMR patient, although the 
pathogenic nature is unknown (Jensen et al. 2005).  In an attempt to elucidate the 
association between this intronic insertion and MR the presence of the alteration was 
assessed in 100 ethnically matched male controls by ARMS-PCR but did not detect 
the change.  Interestingly, Jensen and colleagues (2005) did not detect this variant in 













The c.2517-7_8insTAC is located seven base pairs from the KDM5C intron 17/exon 
18 boundary.  Also, this insertion is located just 2bp upstream of the branch site.  
This branch site is rich in pyrimidines and is the binding site for the U2AF65 
component of the splicesome complex (Cartegni, Chew and Krainer. 2002) (Figure 
5.24).  A disruption to the DNA tertiary structure by the c.2517-7_8insTAC insertion 
could compromise U2AF65 binding with concomitant effects on accurate splicing of 
KDM5C exon 18.  To test this hypothesis it was first necessary to first confirm the 
c.2517-7_8insTAC insertion in the proband’s affected brother, and secondly to 
sequence the patients mRNA to detect putative aberrant splicing.  Unfortunately, 
despite multiple attempts, the family could not be re-contacted and thus it was not 




Figure 5.24 Assembly of the splicesome component, U2AF65, at the pyrimidine-rich branch site.  The 
consensus DNA sequence comprising the branch site is YRYYRY, for JARID1C intron 17 the 
consensus sequence reads TGTGAT.  However, the flanking sequence in the wildtype reads 
TGTGATact (flanking sequence in lowercase) while the c.2517-7_8insTAC mutation alters the 
sequence to TGTGATtacact, this modification in DNA structure may affect the binding of U2AF65 
with subsequent aberrant splicing of intron 17. (Figure from Cartegni, Chew and Krainer. 2002) 
 
By ARMS-PCR, 77 probands from XLMR families were screened in an attempt to 
identify additional XLMR patients with this insertion, however, the c.2517-
7_8insTAC was not detected.  In conclusion, the detection of the c.2517-7_8insTAC 
in two affected individuals but not 412 (cumulative number) control samples, 
together with the insertion’s close proximity to critical splicesome recognition 














The third intronic variant identified in this KDM5C mutation analysis was the 
c.2623-45G>A transition detected in patient Fx277.1.  This intron 18 variant has not 
been described in any of the SNP databases.  The presence of this variant in an 
ethnically matched male control population was not possible, as optimisation of the 
molecular techniques (allele-specific restriction enzyme digestion and ARMS-PCR) 
were unsuccessful.  In addition, re-establishment of contact with this XLMR family 
was not possible, thus co-segregation analysis of the c.2623-45G>A transition could 
not be performed.  While other methods (eg dHPLC and DNA sequencing) are 
available to detect this variant in a background population, they are prohibitively 
expensive.  Given these limitations the exact role of this variant in the pathogenesis 
of MR remains unknown, however, given the variant’s deeply intronic nature it was 
deemed unlikely to cause alterations in splicing of the KDM5C transcript. 
 
To date, two large scale KDM5C mutation detection analyses have been reported in 
XLMR cohorts.  The first was conducted by the European EuroMRX consortium 
which reported mutations in seven (4.2%) of the 166 XLMR families and five (4.3%) 
of the 116 brother-pairs screened (de Brouwer et al. 2007).  The second report, from 
an American study, identified KDM5C mutations in two (8.6%) out of 23 linked 
XLMR families, one (0.6%) of the 172 XLMR families and one (1.1%) of 92 
sporadic MR patients presenting with short stature (Abidi et al. 2008).   By 
comparison, the study described in this dissertation included 25 MR patients, hence 
even though this cohort was enriched based on clinical presentation it was not 
unexpected that no mutations were detected.  However, success in similar small 
cohorts has been reported elsewhere, KDM5C mutation detection in a cohort of 24 
XLMR patients revealed a single disease-causing mutation (Santos et al. 2006).  
Therefore, despite no mutations being detected in this cohort, screening of KDM5C 
in a larger cohort of patients with the characteristic clinical presentation would give a 
better indication as to the prevalence of mutations in this XLMR gene in South 













5.4.3 SUMMARY AND CONCLUSIONS 
The higher mutation detection rates in certain XLMR genes make them excellent 
candidates for molecular screening investigations in clinically stratified cohorts.  The 
450 probands in this study were originally referred to the Division of Human 
Genetics, UCT for molecular testing of the most common XLMR mutation, the 
FMR1 5’UTR expansion.  Of these referrals ~23% of XLMR families are positive 
for this Fragile X syndrome mutation, a prevalence in keeping with international 
reports.   
 
To identify the XLMR etiology in the remaining 77% of families ARX, the next most 
frequently mutated XLMR gene was screened, as well as KDM5C, commonly 
implicated in the disorder.  While the mutation detection frequencies in these studies 
were low, 4.6% and 0% respectively, it should be noted that the cohorts investigated 
were relatively small in comparison to other studies reporting higher frequencies.  
Therefore, extended mutation screening in these XLMR genes would give a more 
accurate reflection of these genes’ mutation frequencies in the South African 
population. 
 
Given the relatively low detection rates and the vast number of XLMR genes, it 
remains difficult to stratify cohorts for screening in XLMR genes despite emerging 
genotype-phenotype correlations aiding clinical stratification.  This is especially true 
in a developing country such as South Africa with fewer resources and a battling 
public health system.  In the future it is envisaged that the cost of microarray and 
high-throughput DNA sequencing will reduce and the screening of all XLMR genes 
will be relatively simple and cost effective.  However, this reality is a long-way off in 
South Africa and in the meantime, additional diagnostic strategies need to be put in 
place. 
 
Despite the low pick-up rates in these XLMR genes, studies such as these are crucial 
in establishing molecular techniques which will extend the repertoire of diagnostic 
genetic testing offered to XLMR patients and their families.  To this end, the 












and c.304ins(GCG)7) has been successfully implemented under the auspices of the 
NHLS.   
 
The central hypothesis of this dissertation was to ascertain the effect of ‘epigenetic’ 
XLMR gene mutations on the DNA methylation pattern of affected individuals.  In 
this chapter, two patients with mutations in the ARX gene have been identified, a 
transcriptional regulator, these affected individuals are thus potential candidates for 















IDENTIFICATION OF DISEASE-CAUSING 
MUTATIONS IN SOUTH AFRICAN XLMR 
PATIENTS  
 
The central aim of this dissertation is to assess the epigenomic profiles of patients 
with known disease-causing XLMR gene mutations.  In order to achieve this aim it 
was necessary to first identify patients with these XLMR gene mutations within the 
450 MR families that comprise the Division of Human Genetics, UCT, DNA bank.  
The complex genetic landscape of MR dictated that several molecular approaches be 
employed in order to achieve this objective.  These included: CNV analysis (Chapter 
2), linkage analysis (Chapter 3), positional candidate gene screening (Chapter 4), and 
finally functional candidate gene screening (Chapter 5). 
 
CNV detection using whole-genome SNP arrays led to the detection of two disease-
causing mutations.  The first, a 17p11.2Del in individual Fx343.1, causes the Smith 
Magenis syndrome in this MR patient.  This heterozygous deletion spans 
approximately 3Mb and encompasses over 30 genes.  While many of the genes in 
this region may potentially play a role in epigenetic regulation it would be difficult to 
delineate the potential effect of each gene in the event that there was a change in the 
epigenomic profile.  Second to this, the heterozygous deletion detected here was 
autosomal, while the focus of this study was primarily concerned with X-
chromosomal genes.  Therefore, the 17p11.2Del was not a good candidate for 
investigation in the epigenetic phase of this dissertation. 
 
The second disease-causing mutation was the de novo 0.8Mb Xq25Dup detected in 
an isolated case (XMR8.1) of MR.  This duplication encompassed four known genes 
(GRIA3, THOC2, XIAP, STAG2) of which GRIA3 has previously been implicated in 












epigenetic regulation.  The remaining genes have not been previously implicated in 
disease; however, STAG2 represents an interesting candidate for contribution to the 
MR phenotype in this patient given the proteins putative functioning as a chromatin 
remodeler.  Second to this, duplications in other chromatin remodelers (ATRX and 
MECP2) have been shown to cause MR.  However, given the uncertain role of 
STAG2 in the pathogenesis of the disorder in this individual, as well as the potential 
confounding effects of the additional duplicated genes, the Xq25Dup was not 
selected for follow-up epigenomic investigations.   
 
By employing the linkage analysis technique in four XLMR families, the disease-
associated X-chromosomal region was refined sufficiently for the selection of 
positional candidate genes in two of these families (Fx67 and XMR2).  Subsequent 
positional candidate gene screening in family Fx67 entailed the mutation screening 
of the XLMR genes ATP6AP2 and TSPAN7.  However, no mutations were identified 
in either of these two XLMR genes.  In addition, given the genetic heterogeneity of 
XLMR it was not possible to effectively prioritise mutation screening of the 
remaining 25 genes located within the disease-associated region in this family.  
Therefore, the disease-causing mutation in family Fx67 remains unknown at this 
stage.  Conversely, linkage analysis and subsequent positional candidate gene 
analysis in family XMR2 led to the detection of a disease-causing mutation 
(c.5987_6011del) in the XLMR gene, ATRX.  Given the proposed role of ATRX as a 
chromatin remodeler, patients with mutations in this gene were good candidates for 
the proposed epigenomic studies and investigation of this dissertation’s central aim 
(Part B). 
 
Notwithstanding this finding, further investigations were pursued in order to identify 
additional XLMR gene mutations for inclusion in the second phase of this study.  
Therefore, the functional candidate genes ARX and KDM5C were selected for 
mutation screening in clinically stratified cohorts on the basis of previously reported 
mutation frequencies.  Screening of the second most commonly-mutated XLMR 
gene, ARX, led to the identification of the common ARX disease-causing mutation, 
c.428_451dup, in individuals Fx446.1 and Fx391.1.  Subsequently, mutation 
screening for the two most common ARX mutations (c.428_451dup and 












patients by the NHLS based at the Division of Human Genetics, UCT.  Since 
implementation of this diagnostic test, an additional patient with the c.304ins(GCG)7 
mutation has been identified.  ARX has been proposed to function as a 
transcriptional regulator and therefore could potentially affect the epigenomic profile 
in mutation positive individuals (Part B).  Mutation screening in KDM5C, also a 
significant contributor to XLMR, revealed no disease-causing mutations in the study 
cohort.  While KDM5C mutation positive patients remain good candidates for 
epigenomic profiling given the protein’s role in histone demethylation, these 
investigations were not possible in this study as no KDM5C mutations were detected. 
 
In summary, the strategic molecular approaches adopted in this study have been 
successfully implemented in the identification of disease-causing mutations in the 
ARX and ATRX genes.  Given the purported function of these genes as a transcription 
activator/repressor (ARX) and chromatin remodeler (ATRX), these genes both posed 













PART B  
INVESTIGATION OF DNA METHYLATION 
PROFILES IN PATIENTS POSITIVE FOR 
MUTATIONS IN XLMR GENES 
 
A large proportion (22%) of XLMR genes are either known or postulated to play a 
role in transcriptional regulation (Figure 1.3).  These ‘epigenetic’ XLMR genes 
include transcription activator/repressors (e.g. ARX) and chromatin remodelers (e.g. 
ATRX).  The functional roles of these protein families overlap in a co-ordinated way 
to control gene expression.  Furthermore, the interaction of these protein families 
with the two primary epigenetic marks, histone modifications and DNA methylation, 
induce a chromatin state which is applicable to the transcriptional state required.  
Thus, it was hypothesised in this study that mutations in XLMR genes involved in 
this transcription regulation pathway would lead to aberrant DNA methylation.  
 
In order to test this hypothesis, first, mutations in the ARX and ATRX genes were 
identified using various molecular approaches in a cohort of South African XLMR 
patients (Part A).  Subsequently, these genes were prioritised for whole-genome 
DNA methylation analyses in mutation positive patients.   
 
The ARX gene has been demonstrated to function as a transcription repressor and 
activator (Chapter 5), therefore this gene was a good candidate for whole-genome 
DNA methylation analysis.  Despite, the identification of three mutation positive 
ARX patients, as well as the suitability of ARX to test this study’s hypothesis, these 
patients were not further assessed for DNA methylation aberrations.  The reasons for 
ARX exclusion were two-fold.  Firstly, the expression profile of the ARX transcript 
suggest that the gene is not expressed (Stromme et al. 2002b), or else it is expressed 
at low levels in peripheral blood leucocytes (PBLs) (Ohira et al. 2002).  Given that 
these cells were the only source of DNA available for this study, at this stage it was a 
concern whether impairment of ARX function would exert its pathogenic effects in 












DNA methylation experiments described in Chapter 6, these quantities of DNA were 
not available and difficulties were experienced in contacting the affected families.  
 
The ATRX gene has been shown to function as a chromatin remodeler (Chapter 4).  
Also, unlike ARX, the ATRX transcript was shown to be expressed in adult PBLs 
(Villard et al. 1997).  In addition, ATR-X patients exhibit α-thalassaemia due to the 
reduced expression of the α-globin gene (Gibbons et al. 1995), suggesting that 
ATRX functions in multiple tissues.  Therefore, while DNA isolated from brain 
tissue would be ideal, it was hypothesised that lymphocytic DNA could be used to 
investigate DNA methylation profiles in these patients given the multitude of tissues 
affected in ATR-X syndrome.   Finally, sufficient DNA from four affected males and 
three unaffected members of family XMR2 was available for whole-genome DNA 
methylation analysis.  The ATRX mutation positive family, XMR2, was therefore 















CHAPTER 6  

















The pathogenic mechanisms by which mutations in XLMR genes lead to cognitive 
deficits in MR patients are poorly understood.  Thus, an understanding of which 
biological pathways are disrupted by mutations, as well as the intricate details of the 
resulting pathophysiology is essential if the ultimate goal of MR therapeutic 
intervention is ever to be realised.  With this in mind, in this study, the role of DNA 
methylation as a pathogenic mechanism by which XLMR gene mutations exert their 
effects was investigated. 
 
The ATRX gene is one of the 22% of XLMR genes which play a role transcriptional 
regulation.  The participation of ATRX in gene regulation is supported by several 
lines of evidence, including: 
 Association with chromatin remodelling complexes by interaction with 
proteins such as: 
 The repressive polycomb group protein, EZH2 (Cardoso et al. 1998). 
EZH2 is a polycomb group (PcG) protein involved in homeotic 
transcriptional repression during development 
 The heterochromatin protein, HP1 (McDowell et al. 1999) 
 Transcription/apoptosis cofactor, DAXX (Ishov, Vladimirova and 
Maul. 2004) 
 The MBD protein, MeCP2 (Nan et al. 2007) 
 DNA hypomethylation at the acrocentric chromosomal regions which 
encompass the rDNA gene arrays in ATRX mutation positive patients.  
Conversely, DNA hypermethylation at Y-specific repeats (DYZ2) is also 
evident in these patients (Gibbons et al. 2000) 
 The protein’s localisation to PML-NBs, sites of transcription regulation (Xue 
et al. 2003) 
 The weak chromatin remodelling ability of ATRX, as demonstrated by 













 Dysregulation of numerous genes involved in neurogenesis and neuronal 
development in conditional Atrx knock-out mice (Levy et al. 2008) 
 The localisation of ATRX to an H3K9me2-hotspot upstream of the Xist locus 
which controls X-inactivation in females (Baumann and De La Fuente. 2009). 
 
Collectively, this evidence strongly motivates for a chromatin remodelling function 
for ATRX.  Also, the aforementioned observations have led to the hypothesis that 
ATRX forms part of a neuronal transcription repression complex which targets 
methylated promoter regions (Figure 6.1) (Kramer and van Bokhoven. 2009).   
 
 
Figure 6.1 A theoretical transcription repression complex functioning in neuronal cells.  The 
formation of this complex involves the targeting of repressive chromatin remodelers (ATRX, Sin3a, 
HDACs, EZH, HP1) to methylated DNA by interaction with MeCP2.  This repressive complex could 
subsequently prevent the formation of the CBP-RSK-CREB1 transcription activation complex, thus 
inducing gene repression (Kramer and van Bokhoven. 2009). 
 
While aberrations in DNA methylation have already been demonstrated in ATR-X 
patients at rDNA gene regions and Y-specific repeats (Gibbons et al. 2000), no 
whole-genome investigations of DNA methylation status in ATR-X patients have 
been conducted to date.  Furthermore, given the substantial evidence for the role of 
ATRX in gene regulation and the concomitant importance of DNA methylation in 
this process, it was hypothesised that aberrant DNA methylation was a pathogenic 
mechanism associated with ATRX mutations.  Therefore, in this study a whole-
genome CpG island and promoter DNA methylation analysis in ATRX mutation 
positive family, XMR2, was conducted so as to assess the extent of DNA 













6.2.1 METHYLATION-DEPENDENT IMMUNOPRECIPITATION (MEDIP)-
CHIP ASSAY 
Methylation dependent immunoprecipitation and array hybridisation (MeDIP-Chip) 
was employed to assess the whole-genome promoter DNA methylation profiles of 
ATRX mutation positive patients, as compared to unaffected family members 
(procedure outlined in Figure 6.2).   
 
 
Figure 6.2 The whole-genome MeDIP-Chip procedure adopted in this study.   DNA samples are 
sonicated to shear the DNA into smaller fragments.  Immunoprecipitation using a 5-methylcytosine 
specific antibody enriches the DNA for methylated portion of the genome (IP).  Subsequently, the IP 
and input (IN) DNA are differentially fluorescently labelled and, in this study, hybridised to a CpG 
island and promoter array in order to generate DNA methylation profiles for each individual. (Figure 
from Wilson et al. 2006). 
 
 
Given the lack of resources and expertise available at UCT, these investigations were 
conducted together with Dr. Andrew Sharp at the Department of Human Genetics 














DNA samples obtained from the four ATRX mutation positive patients 
(XMR2.5/13/25/26) as well as three unaffected male family members 
(XMR2.14/17/21) (pedigree in Appendix 3A) were subject to a MeDIP protocol.  
MeDIP was used in order to enrich DNA samples for the methylated CpG portions of 
the genome.  This was achieved by immunocapture of the methylated fraction of the 
genome using an antibody specific for 5-methyl-Cytosine (Weber et al. 2005).   
 
This MeDIP protocol entailed the sonication of 15µg of each DNA sample to obtain 
fragment sizes of 200-800bp using a Branson 450D sonifier.  Subsequently, 2.5µg of 
sonicated DNA was removed from the solution and set aside for array labelling and 
hybridisation (untreated DNA fraction).  The remainder of the sonicated DNA was 
denatured and subject to immunocapture by incubation with 10µg of 5meth-C 
antibody [Diagenode] at 4°C with rotation overnight.  Protein A sepharose beads 
[Life technologies] were used to bind the DNA-antibody component of the solution.  
After a brief incubation (2 hours at 4°C with rotation), the DNA-antibody-agarose 
complex was washed thrice with IP buffer in order to retain only the DNA-protein 
complex.  The protein A agarose beads-antibody complex was subsequently digested 
using proteinase K [Qiagen] (incubation at 55°C with rotation overnight).   A phenol-
chloroform DNA extraction was performed in order to purify the methylated CpG 
fraction of DNA, which was subsequently precipitated using 100% ethanol, 5M NaCl 
and glycogen, followed by washing with 70% ethanol.  The precipitated DNA was 
hereafter resuspended in TE buffer and quantified on a Nanodrop 
[ThermoScientific]. 
 
6.2.1.2 Array preparation, labelling and hybridisation 
In order to obtain a genome-wide promoter DNA methylation pattern, DNA 
(untreated and methylation-enriched fractions) from all patients and controls were 
analysed by array hybridisation using the HD2 deluxe CpG island and promoter 
array [NimbleGen].  This commercially-available array platform consists of 2.1 
million 50-75mer probes which encompass all annotated promoters, CpG islands and 
miRNA promoters, as well as manually selected ENCODE regions.  These regions 












The array hybridisation procedure entailed DNA labelling by random priming using 
Cy3 (methylated DNA fraction) and Cy5 (sonicated, untreated DNA)-conjugated 
random nonamers, as per manufacturer’s instructions [Nimblegen].  Equal quantities 
(35µg) of Cy3 and Cy5 labelled DNA were combined and added to the reagents of 
the NimbleGen Hybridisation kit (according to manufacturer’s specifications).  
Samples were then hybridised to the HD2 deluxe CpG island and promoter array 
[NimbleGen] by incubation in a MAUI hybridisation station [BioMicro systems] for 
two days.  Subsequent to DNA sample-array hybridisation, the arrays were washed 
using the Nimblegen Wash Buffer kit according to manufacturer’s instructions.   
 
All arrays were scanned on the G2565 Agilent scanner [Agilent Tecnologies] at a 
5µm resolution according to manufacturer’s recommendations.  The NimbleScan 
Version 2.5 [NimbleGen] software was used to analyse raw data and generate 
independent probe log2 fold changes. The SignalMap V.1.9 [NimbleGen] software 
was used to visualise log2 fold changes according to genomic location of the probes.  
Duplicate array-hybridisations and analyses were performed for each DNA sample.  
 
6.2.1.3 Statistical analysis for differentially methylated region (DMR) detection 
In order to identify potential DMRs, statistical analyses were performed to establish 
which loci harboured differential methylation ratios between the ATR-X patients 
(XMR2.5/13/25/26) and controls (unaffected family members) (XMR2.14/17/21).  
All statistical analyses were performed by Dr. Eugenia Migliavacca (Department of 
Human Genetics and Development, University of Geneva Medical School, Geneva, 
Switzerland) using software form the Bioconductor project (Gentleman et al. 2004). 
 
Prior to statistical analyses a quantile normalisation was performed for each array, 
this normalisation accounts for systematic bias incurred when comparing different 
arrays (e.g. DNA-labelling, MeDIP enrichment) (Bolstad et al. 2003). Also, a novel 
approach to outlier replacement was implemented (A. Sharp, unpublished data) and a 














Subsequent to these normalisation and filtering steps, a moderated t-score test was 
performed (as employed in the LIMMA software package Smyth. 2004) in order to 
detect significantly different methylation values between the ATR-X mutation 
positive (XMR2.5/13/25/26) and control individual (XMR2.14/17/21) groups.  In 
order to account for multiple testing, a false discovery rate (FDR) correction was 
applied (Benjamini and Hochberg. 1995).  Potential DMRs were identified by 
clusters of probes with significantly differential methylation fold changes at a 
relatively low stringency threshold.  These clusters were defined as regions which 
encompassed a single probe with a FDR adjusted p-value ≤0.01 that were flanked by 
at least two additional probes with nominal p-values ≤0.01.  These clusters were 
subject to further computational analyses and filtering methods. 
 
6.2.1.4 Computational analysis of potential DMRs 
All overlapping potential DMRs were merged in order to form a non-redundant set of 
genomic loci using the online software tool, Galaxy (http://main.g2.bx.psu.edu/).   In 
addition, chromosomal regions harbouring CNVs and segmental duplications (SDs) 
are prone to alterations in copy number which can produce false positives in array 
data (A. Sharp, unpublished data, Vega et al. 2009).  Thus, Galaxy was used to 
remove all potential DMRs that overlapped with known CNVs (Conrad et al. 2009) 
and segmental duplications (dataset from the UCSC genome browser, 
http://genome.ucsc.edu/).  Finally, subsequent to these filtering techniques, Galaxy 
was used to retrieve the genomic DNA sequence of putative DMRs. 
 
6.2.1.5 Prioritisation of potential DMRs for validation 
In order to validate the results of the MeDIP-Chip experiments, a number of DMRs 
were selected for bisulphite DNA sequencing, these included putative DMRs with: 
 the highest absolute value t-score statistic (four loci) 
 the highest average (for all differentially methylated probes in that region) 













6.2.2. VALIDATION OF PUTATIVE DMRs BY BISULPHITE-DNA 
SEQUENCING  
In order to validate the potential DMRs identified by this MeDIP-Chip assay, Sanger 
DNA sequencing was utilised, subsequent to the treatment of genomic DNA with 
sodium bisulphite.  Treatment of genomic DNA with sodium bisulphite results in the 
conversion of unmethylated cytosine residues to uracil by deamination, while 
methylated cytosines are protected from this conversion by the 5-methyl-C 
modification.  Target DMRs were then amplified using the bisulphite-treated DNA 
as a template and amplicons were subject to DNA sequencing.  Subsequently, 
unmethylated cytosine residues appear as thymine nucleotides on the resulting 
electropherogram, which were clearly distinguishable from the cytosine residues 
(which correspond to methylated Cs). 
 
6.2.2.1 Bisulphite treatment of DNA 
In order to convert unmethylated cytosine residues to uracil nucleotides, patient and 
control DNA was treated with the Epitect® bisulfite kit [Qiagen] according to 
manufacturer’s instructions. 
 
6.2.2.2. PCR of putative DMRs 
PCR primers were designed to amplify each of the potential DMRs using the Methyl 
Primer Express software V1.0 [Applied Biosystems] (Appendix 6A).  PCR 
amplification was performed in a 25µl reaction containing 100ng of bisulphite-
treated DNA, 10µM of each forward and reverse primer, 2.5µM dNTP’s [Bioline], 
1× JumpStart REDtaq buffer [Sigma-Aldrich] and 1U JumpStart REDtaq DNA 
polymerase [Sigma-Aldrich].  A ‘touchdown’ PCR profile was employed, entailing 
an initial denaturation step at 95ºC for 5 min, followed by 10 cycles of 95ºC for 10s, 
66ºC for 10s (with 1ºC decrements/cycle) and 72ºC for 30s.  Subsequently, 30 cycles 
of 95ºC for 10s, 55ºC for 10s and 72ºC for 30s were performed and a final elongation 
at 72ºC for 5 min completed the PCR amplification. PCR was conducted on a Px2 
thermal cycler [Thermo Electron Corporation] and PCR success was assessed by 












6.2.2.3 DNA sequencing of putative DMRs 
Subsequent to PCR amplification, each putative DMR was subject to DNA 
sequencing.  Each PCR product was incubated with 5U Exonuclease 1 [Fermentas] 
and 1U Shrimp Alkaline Phosphotase [Fermentas] (ExoSAP treatment) per 10µl of 
PCR product to remove unincorporated dNTPS and primers from the PCR reaction. 
The PCR product and enzymes were incubated at 37ºC for 30min and was followed 
by enzyme inactivation at 80ºC for 15min.  The purified PCR products were then 
subject to DNA sequencing as described before (Section 4.2.1.5). 
 
6.2.3 QUANTIFICATION OF DNA METHYLATION AT DMRS 
Those loci which were found to harbour true positive DMRs by bisulphite DNA 
sequencing (Section 6.2.2.3), were cloned and individual colonies sequenced in order 
to obtain a semi-quantitative measure of DNA methylation across the region in both 
the ATR-X patients and unaffected controls. 
 
6.2.3.1. Cloning of DMR PCR product 
PCR was performed for each of the validated DMRs as above (Section 6.2.2.2) in the 
four affected males (XMR2.5/13/25/26) and the three unaffected family members 
(XMR2.14/17/21).   PCR products were purified using the Qiagen Gel Extraction Kit 
as per manufacturer’s instructions [Qiagen].  Purified PCR products were cloned by 
T/A cloning using the pGEM®-T Easy Vector System [Promega].  This cloning 
protocol involved the insertion of the purified DMR PCR product into the pGEM®-T 
Easy Vector [Promega] at the synthesised T/A cloning region within the multiple 
cloning site (Figure 6.3) according to manufacturer’s instructions [Promega].  
Subsequently, the vector-insert recombinant DNA molecules were transformed into 
chemically competent JM109 E.coli cells using a heat-shock protocol [Promega]. 
Cells were incubated in 950µl 2× YT broth at 37°C with shaking (~150rpm) for 90 
min.  Thereafter, 200µl of cells were spread onto plates containing 2× YT agar 
supplemented with 100µg/ml ampicillin [Sigma-Aldrich], 100µg/ml of bromo-
chloro-indolyl-galactopyranoside (X-gal) [Roche] and 200µg/ml Isopropyl β-D-1-













The pGEM-T Easy vector carries the lacZ gene, which encodes the α fragment of β-
gal, while JM109 cells contain the β fragment of β-gal, association of the two 
fragments results in the formation of a functional β-gal enzyme. This active β-gal 
enzyme hydrolyses X-gal to produce a blue dye resulting in blue colonies, in the 
presence of IPTG.  Thus, upon ligation of the insert into pGEM-T Easy, the α 
fragment of β-gal is disrupted and thus β-gal is not produced, resulting in the 
formation of white colonies. Therefore, blue colonies contain only vector, whilst 
white colonies contain vector plus the DMR PCR product.   Hence, white colonies 




Figure 6.3 The pGEM®-T Easy Vector [Promega] circle map.  DMR bisulphite-treated DNA PCR 
products were inserted at the T/A cloning site (red arrow).  PCR was performed using the pUC/M13 
forward (F) and reverse primers (R) (blue arrows). DNA sequencing was performed using the 

















 6.2.3.2 PCR and DNA sequencing of cloned DMR products 
Twenty positive (white) colonies generated by T/A cloning in each patient and 
control individual of family XMR2 were selected for DNA sequencing.  These 
colonies were picked and placed in 10µl distilled water, incubated at 95°C for five 
minutes and centrifuged briefly at 13000rpm for 45s.  Thereafter, 2µl of this solution 
was used as the template for the PCR reaction.  In addition to this plasmid DNA, the 
PCR reaction was performed using 10µM of the plasmid-specific [pGEM®-T Easy 
Vector] forward (5’ gttttcccagtcacgac 3’) and reverse primers (5’caggaaacagctatgac 
3’), 2.5µM dNTP’s [Bioline], 1.5µM MgCl2 [Applied Biosystems], 1× AmpliTaq 
Gold® PCR buffer [Applied Biosystems] and AmpliTaq Gold® DNA polymerase 
[Applied Biosystems] in a final reaction volume of 25µl.  The PCR cycling 
conditions and gel electrophoresis were performed as above (Section 6.2.2.2.).  DNA 
sequencing was performed after ExoSAP treatment (Section 6.2.2.3) as described 
previously (Section 4.2.1.5) using the aforementioned plasmid-specific forward 
primer (Figure 6.3).   The software programme BiQ Analyzer was used to analyse 
the DNA sequencing and generate ‘lollipop’ diagrams (Bock et al. 2005). 
 
6.3 RESULTS 
6.3.1 WHOLE-GENOME CPG ISLAND AND PROMOTER DNA 
METHYLATION ARRAY ANALYSIS 
Comparison of whole-genome promoter DNA methylation profiles between four 
affected and three unaffected individuals of family XMR2, led to the identification of 
112 unique putative DMRs (Appendix 6B).  These putative DMRs were selected on 
the basis of one probe exhibiting a FDR-adjusted p-value ≤0.01, combined with at 
least two additional flanking probes with a nominal p-value ≤0.01.  Subsequent to the 
removal of all DMRs containing overlapping regions with known CNVs and SDs, a 
total of 107 unique putative DMRs were identified.   
 
From these 107 putative DMRs, a total of eight loci were selected for validation.  
These candidate DMRs (Table 6.1) were selected as they possessed the highest 
absolute t-score value (rows 1-5, Table 6.1) or the highest absolute value average t-












score values for all probes exhibiting significantly differentially methylation values.  
Interestingly, the chromosomal region encompassing probe, CHR16FS010387819 
(row 4, Table 6.1 and Figure 6.4/5), scored highest at both a single probe, as well as 
for the average across the DMR.   
 
Table 6.1 The eight DMRs selected for validation by bisulphite DNA sequencing 
 












1. CHR16FS010387819 9.1126 2.49E-18 2.66E-12 5.367544 5.08E-02 
2. CHR11FS126375528 -8.1971 2.47E-15 4.77E-10 -4.34842 2.38E-01 
3. CHR17FS034606720 -8.1907 2.59E-15 4.77E-10 -4.43846 1.51E-01 
4. CHR05FS001853381 7.8763 2.45E-14 1.87E-09 4.940175 6.36E-02 
5. CHR02FS065138632 6.8146 2.98E-11 5.03E-07 4.176412 9.56E-02 
6. CHR19FS015436362 -6.8001 3.26E-11 5.43E-07 -5.30631 5.53E-03 
7. CHR18FS031177845 -7.0706 5.77E-12 1.58E-07 -4.98466 3.93E-02 
8. CHR05FS074359693 5.8915 7.40E-09 2.91E-05 4.8544 3.32E-03 
Highlighted in red, the criterion upon which selection for validation was based  
 
Figure 6.4 The DMR encompassing the probe CHR16FS010387819; a DMR identified by whole-
genome promoter DNA methylation analysis in ATRX mutation positive patients.  The signalMap 
[Nimblegen] output illustrating the hypermethylation at the chromosome 16 (~10.387Mb – 
10,388Mb) region in ATRX mutation positive patients (red) as compared to the unaffected sibs (green) 














Figure 6.5 The DMR encompassing the probe CHR16FS010387819; a DMR identified by whole-
genome promoter DNA methylation analysis in ATRX mutation positive patients and subsequent 
statistical analyses.  The output generated by statistical analysis also showing the hypermethylation of 
this 16p region in the ATR-X patients (red) as compared to the unaffected sibs (blue). 
 
 
6.3.2 VALIDATION OF PUTATIVE DMRS  
Bisulphite DNA sequence analysis of the eight putative DMRs prioritised for 
validation revealed one true positive DMR, encompassing the central probe 
CHR16FS010387819 (Figure 6.6a, b).  The DMR corresponds to an approximately 
1kb interval on chromosome 16 (16p13.2) (Figure 6.6c).  This chromosomal interval 
encompasses a CpG island which corresponds to the promoter region of the 
Activating Transcription Factor 7 Interacting Protein 2 (ATF7IP2).  While the 
electropherogram generated from these DNA sequencing investigations validated the 
hypermethylation at this locus, this technique did not allow the quantification of the 
proportion of cells with methylation.  Therefore, a semi-quantitative DMR PCR 















Figure 6.6 The 16p13.2 DMR verified by bisulphite DNA sequencing in affected individuals of 
family XMR2.  (a) An electropherogram of the bisulphite sequencing results of the ATF7IP2 promoter 
region in an unaffected individual XMR2.14.  The red arrows indicate the location of the CpG sites, 
which in this individual correspond to thymine (T) residues, illustrating the complete conversion of 
unmethylated cytosine residues by the bisulphite treatment. (b) An electropherogram of the same 
16p13.2 locus in affected individual (XMR2.25), here the red arrows indicate the presence of 
unmethylated cytosine residues (T) as well as the methylated cytosine residues (C) at the CpG sites.  
This electropherogram indicates ATF7IP2 hypermethylation in this patient and confirms the results of 
the DNA methylation array results.  (c) A UCSC exert of the hypermethylated ATF7IP2 locus in the 
ATR-X patients, this hypermethylation occurs in the CpG island upstream of ATF7IP2.  No segmental 
duplications or CNVs are present in this region. 
 
 
The remaining seven putative DMRs prioritised for validation by bisulphite DNA 
sequencing showed no discernable difference between patients and controls at the 
CpG sites investigated (Figure 6.7).  Therefore, it was concluded that these seven 















Figure 6.7 The DMR encompassing the CHR17FS034606720 probe, an example of a DMR identified 
by the DNA methylation whole-genome promoter array that was not confirmed by bisulphite DNA 
sequencing. (a) The electropherogram generated by bisulphite DNA sequencing in the unaffected 
individual (XMR2.17).  Red arrows correspond to the CpG sites; all sites contain only thymine 
residues, illustrating a complete lack of cytosine methylation at this methylation sensitive locus. (b) 
The corresponding electropherogram from affected individual (XMR2.25) illustrates the same 
unmethylated cytosine residues (T nucleotides) at all CpG sites.  Thus there is no differential DNA 
methylation at this particular locus in affected individuals of ATR-X family XMR2. 
 
6.2.3 QUANTIFICATION OF DNA METHYLATION AT THE ATF7IP2 
PROMOTER REGION 
The semi-quantitative DMR PCR cloning investigations showed variable 
methylation ratios across 23 CpG sites of between 8-34% in the ATR-X patients 
(XMR2.5/13/25/26) and 0-7% in the unaffected family members (XMR2.14/17/21) 
(Figure 6.8).  Also, the distribution of methylated cytosine residues demonstrated 
intercellular and inter-individual variability (Figure 6.9/10/11).  These results show 
that ATRX mutation positive individuals have significantly increased levels of DNA 
methylation at the ATF7IP2 promoter region as compared to the unaffected members 



















Figure 6.8The semi-quantitative DNA methylation analysis of the ATF7IP2 promoter region in ATRX 
mutation positive patients of family XMR2 as well as the unaffected family members.  For each of the 
23 CpG sites located within this promoter region (x-axis) the corresponding proportion of cells with 
ATF7IP2 methylation (y-axis) for the affected (red) and unaffected (black) family members is shown.  
At all CpG sites the level of methylation was substantially higher (up to 34%) in ATRX mutation 
positive individuals, indicating hypermethylation of this ATF7IP2 promoter region. 
 
 
Figure 6.9 ‘Lollipop’ diagrams exemplifying the methylation levels at the ATF7IP2 promoter region 
in (a) ATR-X patient  (XMR2.13) and (b) unaffected individual (XMR2.14).  Each ‘lollipop’ 
corresponds to a CpG site within the ATF7IP2 region, with clear ‘lollipops’ indicated unmethylated 
cytosine residues and black ‘lollipops’ indicating methylation at these sites.  It is evident from these 
DNA methylation representations that the proportion of cells with methylation at this locus in the 
ATR-X patient supercede those in the unaffected individual at each of these five DNA sequences and 

























































































































Figure 6.10 The semi-quantitative analysis illustrating the methylation level distribution in the three 
unaffected family members of XMR2. For each of the 23 CpG sites located within this promoter region 
(x-axis) the corresponding proportion of cells with ATF7IP2 methylation (y-axis).  Intra and inter-

























































































































































































































































































































Figure 6.11 The semi-quantitative analysis illustrating the methylation level distribution in the four 
affected sibs of family XMR2. For each of the 23 CpG sites located within this promoter region (x-axis) 
the corresponding proportion of cells with ATF7IP2 methylation (y-axis).  Intra and inter-individual 


















































































































































































































































































































































































































The comparative whole-genome DNA methylation analysis conducted between the four 
ATR-X patients and the three unaffected XMR2 family members identified a total of 
112 putative DMRs.  Subseqeunt to exclusion of those regions overlapping with know 
CNVs or SDs, 107 putative DMRs remained of which eight were subject to validation 
by bisulphite DNA sequencing.  These validation experiments demonstrated ATF7IP2 
promoter hypermethylation in ATR-X patients as compared to the unaffected family 
members of XMR2. 
 
From the total of 112 potential DMRs, five regions (~4%) were excluded on the basis of 
the DNA sequence overlapping with known copy number variations (CNVs) or SDs.  
These genomic regions are prone to rearrangements and/or are repetitive in nature; this 
makes sequence variation at these loci between individuals common.  Furthermore, 
changes in copy number are indistinguishable from methylation enrichment peaks in 
MeDIP-Chip experiments (A.Sharp, unpublished data).  Therefore, it was likely that the 
observed locus-specific changes in DNA methylation were due to variation in DNA 
sequence rather than an epigenetic modification thereof (i.e. cytosine methylation).  
Thus in order to reduce the number of false positive results, these regions were excluded 
from any further analyses. 
 
From the remaining 107 potential DMRs, the eight DMRs with the highest (nominal 
and average) absolute t-score values were selected for validation.  Of these eight 
candidate DMRs, one locus, encompassing the ATF7IP2 promoter region, was 
confirmed by bisulphite-modified DNA sequencing.  The bisulphite DNA sequencing 
electropherograms generated from each of the four affected individuals demonstrated 
the presence of both unmethylated (T residues) and methylated cytosines (C residues) at 
each of the 23 promoter CpG sites investigated.  In contrast, for each of the three 
unaffected family members there was no evidence of methylation at any of these 23 
CpG sites as indicated by the occurrence of only thymine residues (unmethylated 
cytosines).  These results illustrated an increase in methylation at the ATF7IP2 promoter 














Not surprisingly, the true positive ATF7IP2 locus had the highest t-score statistic 
(9.1126, adjusted FDR p-value 2.49E-18) at a single probe, as well as the highest 
average t-score value (5.367544, adjusted FDR p-value 2.66E-12) across the region.  
The values of the remaining seven candidate regions had markedly lower t-score 
statistics (Table 6.1).  Also, these results suggest that a significantly high t-score value 
at a single probe should be accompanied by significantly high t-scores at flanking 
probes (therefore generating a high average t-score).  While an attempt was made to 
account for the effects of a single deviant probe by selecting DMRs with at least two 
flanking probes with nominal p-values ≥0.01, these results suggest that future studies of 
this nature should employ stricter DMR selection criteria.  In addition, the number of 
potential DMRs could be reduced by basing DMR selection criteria on a relatively high 
t-score as well p-value (as appose to just the p-value).  However, in defence of the 
strategy employed here, DNA methylation studies of this nature have not been 
performed before and therefore a relatively liberal statistical approach was originally 
employed in attempt to reduce false negative rates.  Finally, as with the CNV SNP array 
analysis (Chapter 2), the importance of validating array results has once again been 
highlighted. 
 
It was not possible to accurately quantify the proportion of cells with methylation at the 
ATF7IP2 locus from the electropherograms generated by bisulphite DNA sequencing.  
Therefore, a PCR cloning technique was adopted in order to obtain a semi-quantitative 
measure of methylation ratios in these ATR-X patients. The semi-quantitative analysis 
of the ATF7IP2 promoter region using a cloning and colony-PCR technique showed 
variable methylation levels across the 23 CpG sites of this region.  In ATR-X patients 
the proportion of CpG sites methylated was on average between 8 and 34%, conversely 
in unaffected family members this averaged methylation level was between 0 and 7%.  
This result clearly demonstrated the significant degree of ATF7IP2 hypermethylation as 
a result of the ATRX mutation in family XMR2.  Furthermore, this semi-quantitative 
technique demonstrated the intrafamilial variability of methylation levels at this locus.  
For instance, there was a small level of methylation of CpG sites in the unaffected 
family members.  Unaffected individual (XMR2.14) exhibited methylation at several 
CpG sites in up to 8% of cells, conversely individual (XMR2.17) did not demonstrate 
DNA methylation at any CpG sites for each of the 20 positive clones sequenced.  These 
results suggested that there may be a low level of variable DNA methylation is present 












this intrafamilial variability of methylation ratios at this locus was also apparent in the 
ATRX mutation positive patients, it is likely that this variability is merely similar to the 
variability observed in unaffected family members.  However, it would be pertinent to 
explore the possibility that residual levels of ATRX transcript correlated with the degree 
if DNA methylation at the ATF7IP2 promoter region in each affected individual. 
 
Given that hypermethylation at promoter regions leads to a reduction in transcription at 
the corresponding locus, it is likely that the DNA mehtlyation alteration described in 
this study leads to a reduction in ATF7IP2 transcript levels.  This deduction could not 
be tested at this stage due to a lack of mRNA sample availability from XMR2 family 
members.  Also, verification of ATF7IP2 hypermethylation (and investigation of 
corresponding transcript levels) in additional ATR-X patients should be performed in 
order to substantiate the findings described here. 
 
The ATF7IP2 gene, also known as MBD1-containing chromatin-associated factor2 
(MCAF2), is located at 16p13.2.  ATF7IP2 transcribes a 2046bp mRNA that encodes a 
681 amino acid protein of approximately 100 kDa (Ichimura et al. 2005) that is known 
to be expressed in the brain.  ATF7IP2 is known to bind to the transcription repression 
domain of the methylated-cytosine binding protein, MBD1 (Ichimura et al. 2005).  
Furthermore, ATF7IP2 has also been shown to interact with the transcription activator 
Sp1 and to a lesser extent (in the cell line investigated i.e. K562), the histone H3K9 
methyltransferase, SETDB1 (Ichimura et al. 2005).  The overlapping protein 
interactions of ATRX and ATF7IP2 suggest that these two proteins may form part of 
the same protein complex or repressive chromatin assembly pathway.  This hypothesis 
is supported by several lines of empirical evidence (Figure 6.12).  Firstly, ATF7IP2 
forms a complex with SETDB1, responsible for the methylation of H3K9 (Ichimura et 
al. 2005).  In turn, this H3K9me3 mark has been shown to elicit ATRX localisation at Y-
specific repeats and pericentric heterochromatin as well as to the Xist locus during X-
inactivation (Baumann et al. 2008, Baumann and De La Fuente. 2009).  Also, ATR-X 
patients exhibit marked hypermethylation at Y-specific repeats (Gibbons et al. 2000).  
In addition, H3K9me3 serves as a mark for HP1, this protein localises with ATRX at 
heterochromatic regions (McDowell et al. 1999).  These data suggest that ATRX 
targeting to these heterochromatic regions, which is dependent on H3K9me3, may be 
reliant on the histone methyltransferase activity of SETDB1 through co-operation with 














Figure 6.12 The theoretical complex involving ATRX and ATF7IP2.  ATF7IP2 controls the histone 
methyltransferase activity of SETDB1.  H3K9me3 at specific loci leads to the recruitment of ATRX and 
subsequent chromatin silencing 
 
ATF7IP2 has also been shown to bind MBD1 (Ichimura et al. 2005), moreover, 
methylated cytosine residues and the subsequent recruitment of MBD proteins is a mark 
of repressive chromatin.  Interestingly, ATRX also interacts with another MBD protein, 
MeCP2 (Nan et al. 2007), further suggesting a similar repressive chromatin remodelling 
function for ATRX and ATF7IP2.  It would therefore be interesting to assess the 
ATF7IP2 promoter DNA methylation status in MECP2 mutation positive patients, in 
order to test the extent of a putative overlapping function between ATRX and ATF7IP2, 
as well as the respective associated MBD proteins. 
 
There is also evidence that ATF7IP2 may have a transcription activating role in addition 
to the aforementioned repressive function.  ATF7IP2 associates with the transcription 
activator Sp1 (Ichimura et al. 2005), known to localise to the PML-NBs, sites of active 
transcription (Vallian, Chin and Chang. 1998).  Furthermore, ATRX has been shown to 
interact the with transcription co-activator DAXX at the PML-NBs (Xue et al. 2003).  
Once again these overlapping transcriptional regulatory roles of ATRX and ATF7IP2 
suggest these proteins may participate in similar gene regulation pathways.  While the 
aforementioned empirical data provides evidence suggesting ATF7IP2 and ATRX have 
similar repressive/activating chromatin remodelling properties and potentially function 
in the same protein complex, this hypothesis requires further experimental validation.  
Such experiments could take the form of yeast two-hybrid assays or 












It remains to be established whether the ATF7IP2 promoter hypermethylation in ATR-
X patients is due to direct targeting by ATRX.  Alternatively, assuming 
hypermethylation leads to reduced ATF7IP2 transcript levels, it is tempting to speculate 
that these proteins form part of a transcription remodelling complex which requires 
proportional levels of ATRX and ATF7IP2.  It has been previously suggested that 
ATRX is required in precise stoichiometric amounts for protein function (Berube et al. 
2002, Picketts et al. 1996).  Hence, in the presence of reduced ATRX levels, ATF7IP2 
production would be concomitantly reduced by DNA methylation of the ATF7IP2 
promoter region.  It would therefore be interesting to assess whether residual levels of 
ATRX transcripts correlated with a putative reduced ATF7IP2 mRNA levels in ATR-X 
patients.   
 
Alterations to the ATF7IP2 transcript have not been previously associated with any 
disease phenotype.  Furthermore, no MR chromosomal aberrations or MR candidate 
loci have been reportedly linked to this region.  However, the overlapping function of 
ATF7IP2 and ATRX suggests that ATF7IP2 is a good candidate MR gene.  With the 
expected increase in CNV testing in MR patients, as well as homozygosity mapping in 
autosomal recessive families, it is expected that the number of autosomal MR loci will 
concomitantly increase.  In such instances, ATF7IP2 would be a mutation screening 
candidate in patients linked to this locus.  Therefore, in this study a novel strategy for 
the identification of MR candidate genes has been presented.  Furthermore, using this 
novel research approach it has been shown that alterations to the DNA methylation 
profile is evident in MR patients.  Application of this technique to mutation negative 
MR patients may provide novel insights into the role of this epigenetic mechanism in 
MR pathogenesis and furthermore identify new candidate MR genes. 
 
The results presented here show that ATRX aberrations do not lead to wide-spread 
changes at CpG promoter regions.  The array design selected for this study (Whole-
Genome CpG island and promoter array) targets only the genomic regions which are 
associated with CpG sites at promoter regions.  Therefore, it does not cover intragenic 
and intergenic regions which can also be subject to cytosine methylation, though 
modification of these regions is less well-studied.  Previously it was shown that ATRX 
mutation positive patients have DNA methylation aberrations at specific loci which do 
not correspond to promoter regions.  These loci included the rDNA gene arrays which 












22).  These regions were largely unmethylated in patients as compared to normal 
individuals (up to 20% of rDNA CpG sites were methylated) (Gibbons et al. 2000).  The 
whole-genome CpG promoter HD2 array (Nimblegen) used in this study does not have 
probe coverage at these acrocentric regions, most likely due to the repetitive nature of 
the satellite tandem repeats which comprise these regions.  Similarly, the 
hypermethylation of Y-specific repeats (DYZ2) in ATR-X patients observed by 
Gibbons and colleagues (2000) was not replicated in this study due to a lack of probe 
coverage in these repetitive regions (Gibbons et al. 2000).  However, given that no 
genome-wide DNA methylation studies in ATR-X patients have been conducted to date 
and that DNA methylation is most well-studied at CpG promoter regions, this array 
platform was selected for these investigations.   
 
The DNA samples selected for these investigations were isolated from lymphocytes; 
this approach may also account for the lack of multiple aberrantly DNA methylated 
sites in ATR-X patients.  Therefore, these experiments would ideally be performed in 
the primary affected organ, the brain.  However, this tissue is difficult to obtain and 
requires the acquisition of post-mortem patient samples.  Alternatively, similar DNA 
methylation investigations could be performed in the conditional ATRX knock-out 
models such as those generated by Berube and colleagues (2005) (Berube et al. 2005), 
or using siRNA ATRX knockdown in human neuronal cell lines. 
 
The whole-genome promoter DNA methylation approach adopted in this study has been 
successfully employed for the detection of an aberrantly methylated gene, ATF7IP2.  
The results of these investigations have therefore provided a novel research direction for 
further investigations of a potential repressive chromatin complex including ATRX and 
ATF7IP2.  These future studies will contribute to the understanding of the pathogenesis 
of ATR-X and related syndromes.  Furthermore, ATF7IP2 would present a good 
candidate for mutation screening in autosomal MR patient cohorts that, by future 
homozygosity mapping studies, or CNV studies, are shown to be linked to the 16p13.2 
locus.  Finally, while the effects of ATRX ablation on promoter DNA methylation are 
not widespread, these investigations show that changes to cytosine methylation are a 
molecular feature of MR in at least one XLMR gene.  Employing the methodology 
presented in this study for DNA methylation aberration investigations in additional 
XLMR ‘epigenetic’ genes, will establish the extent of the role of this epigenetic 













CHAPTER 7  
FINAL DISCUSSION AND CONCLUSIONS 
 
MR is a debilitating condition affecting a significant proportion of the population.  
While the causes of MR are extremely heterogeneous and include both genetic and 
environmental factors, recent years have seen major advances in defining the genetic 
basis of this disorder.  These advances can primarily be attributed to the rapid expansion 
of molecular genetic techniques, in particular high-throughput DNA sequencing and 
microarray technologies.  By implementation of these techniques, a total of 87 XLMR 
genes have been identified to date.  Of these genes, 45 (52%) have been discovered in 
the last five years, with the remainder being identified in the preceding 13 years 
(Chiurazzi et al. 2008, Cho et al. 2008, Molinari et al. 2008, Tarpey et al. 2009). 
However, despite this exponential growth in the number of XLMR genes, up to 50% of 
XLMR remains unexplained (de Brouwer et al. 2007, Gecz, Shoubridge and Corbett. 
2009).   
 
It is reasonable to conclude that the remaining unexplained XLMR cases can be 
attributed to novel XLMR genes.  Also, while the role of chromosomal aberrations in 
MR has been well-established, the more recent application of microarrays to detect even 
smaller CNVs has led to an increase in the number of disease-causing copy-number 
changes.  It is expected that as the use of microarrays for CNV detection becomes more 
widespread, a significant proportion of unexplained MR cases will be resolved by CNV 
identification.  However, it is also expected that novel disease mechanisms, including 
mutations in non-coding regions or epigenetic changes, will be discovered.  In lieu of 
this supposition, the role of DNA methylation in XLMR pathogenesis has been alluded 
to (Froyen et al. 2006), but not investigated.  Furthermore, existing molecular 
techniques need to be adapted to detect changes in the DNA methylation profiles in 
affected individuals.  To this end, this study tested the hypothesis that specific XLMR 
genes exert their pathogenic effects by altering the DNA methylation profile of mutation 













The research strategy adopted in this study comprised of two main components.  Firstly, 
in Part A, a variety of molecular techniques were employed to detect mutations in 
XLMR ‘epigenetic’ genes.  This aspect of the study included: CNV analysis, linkage 
analysis and positional candidate gene mutation screening, as well as functional 
candidate gene mutation screening.  From these analyses, those individuals whose 
etiology was defined by a disease-causing mutation were prioritised for DNA 
methylation profiling in the secondary phase of this dissertation.  Ultimately, in Part B, 
the ATR-X family identified in this study was selected for whole-genome DNA 
methylation profiling.  The elucidation of DNA methylation alterations in these patients 
illustrate that changes to this epigenetic mechanism are indeed apparent in XLMR 
patients, if only on a limited scale, for at least one XLMR gene.  However, collectively 
these molecular investigations address XLMR pathogenesis on a much wider scale.  In 
the sections that follow, the findings of this study are discussed in relation to three main 
themes: XLMR gene identification, unravelling the pathogenic role of epigenetic 
molecular mechanisms, and finally a brief look towards the future therapeutics which 
may ultimately be developed for patients that suffer from this debilitating condition.  
 
7.1 XLMR: IDENTIFYING A GENETIC CAUSE 
7.1.1. CONTRIBUTION OF DISEASE-CAUSING CNVS 
Since the application of microarray technologies to the identification of MR-causing 
CNVs numerous studies have reported high detection rates of up to 24% (Aston et al. 
2008) (Table5.1).  Therefore, in collaboration with colleagues at the Department of 
Human Genetics, Nijmegen, The Netherlands, 30 South African MR patients presenting 
with MR and additional clinical manifestations were assessed for disease-causing CNVs 
using a 250K SNP array.  These investigations led to the detection of three disease-
causing alterations, 17p11.2Del, Xq25Dup and lastly the Xq26.3-27.3Del which 
exhibits low penetrance. In addition, two CNVs of indeterminate disease-causing 
nature, 6q24.3 and 4p16.3Del, were detected. 
 
The approximately 3Mb 17p11.2Del was detected in individual Fx343.1.  This CNV 
was shown to overlap with the known Smith Magenis microdeletion syndrome 
chromosomal region.  Therefore, the MR and associated phenotype in this individual 












mutation.  Furthermore, a retrospective review of the patient’s clinical records (which 
were not available to us prior to this study) indeed revealed that this patient had been 
previously diagnosed with Smith Magenis syndrome by FISH. 
 
The second disease-causing CNV detected in this study was the de novo Xq25Dup 
detected in individual XMR8.1.  The Xq25Dup encompasses 4 known genes (GRIA3, 
THOC2, XIAP, and STAG2) of which, GRIA3 is a known XLMR gene (Wu et al. 2007).  
Duplications in this chromosomal region have been previously reported (Bonnet et al. 
2009, Chiyonobu et al. 2007). The duplications described in these previous reports 
encompass GRIA3 (Chiyonobu et al. 2007) and the GRIA3, XIAP, STAG2 genes 
(Bonnet et al. 2009).  Thus, in contrast to the duplication described in this study, neither 
of these previously reported duplications encompassed the THOC2 gene.  Given the 
more severe presentation of individual XMR8.1 as compared to the patients described in 
previous reports, it is hypothesised here that THOC2 may play a role in the pathogenesis 
of MR in this individual.  These results highlight the potential that CNV detection holds 
for the identification of novel MR genes.  The delineation of the dosage-sensitive genes 
within disease-causing CNVs presents a novel way to identify candidate genes for 
mutation detection in XLMR/MR cohorts.   
 
The 10Mb Xq26.3-27.3Del detected in family Fx444 exhibited variable phenotypic 
expression.  Family Fx444 presented with a typical X-linked inheritance; the proband 
presented with severe MR, haemophilia B, Lennox Gestault epilepsy syndrome and 
multiple dysmorphic features.  The proband’s deceased maternal cousin presented with 
a similar phenotype, while his half-brother presents only with Haemophillia B and mild 
learning disability.  The half-brothers and the carrier mother were all positive for the 
Xq26.3-27.3Del.  The region encompasses 21 genes, including F9 (mutations in which 
cause Haemophillia B) and SOX3, previously shown to be mutated in MR patients.  The 
remaining 19 genes encode for proteins whose function do not make them candidates 
for pathogenesis of this disorder, or else they constitute part of proteins which may have 
redundant function.  Therefore, due to the phenotypic variability observed between 
patients with SOX3 mutations (Solomon et al. 2004, Woods et al. 2005), as well as Sox3 
knock-out mice (Rizzoti et al. 2004), it was concluded that the Xq26.3-27.3Del causes 
the syndromic MR presentation in family Fx444, but that this deletion exhibits low 













The detection of this low penetrance Xq26.3-27.3Del in family Fx444 also highlights 
the care that should be exercised when interpreting the disease-causing nature of 
detected CNVs.  In this instance, it is particularly difficult to anticipate the phenotypic 
outcome of males carrying this deletion, complicating genetic counselling and future 
management of family Fx444.  Furthermore, similar CNVs with variable penetrance 
have been reported.  A 16p11.2Del encompassing an exact genomic interval was 
identified in individuals with autism, MR with/without MCA, speech and learning 
problems, as well as normal cognitive function (Bijlsma et al. 2009).  Similarly, the 
15q13 microdeletion/duplication has been associated with inter and intra-individual 
variability resulting in a spectrum of phenotypes, from severe MR with additional 
features, to complete lack of a recognisable disease phenotype (van Bon et al. 2009).  
As the use of whole-genome arrays becomes more wide-spread it is anticipated that 
additional cases of low penetrance and phenotypic variability, such as those 
aforementioned, will be reported.  It will be important to develop international, as well 
as institutional guidelines for the delivery of such reports and subsequent genetic 
counselling of families. 
 
In the CNV analysis described in this study, the pathogenic nature of two variants, 
6q24.3 in Fx151.1 and 4p16.3Del in XMR14.1, could not be determined due to the 
unavailability of parent DNA to assess the segregation of these variants in the families.  
As in previous studies, these results highlight the importance of the availability of 
parents for testing in order to attribute a CNV molecular MR diagnosis.  Thus, taken 
together, parent availability will be an important consideration during the development 
of protocols and procedures for the implementation of CNV testing in molecular 
diagnostics in South Africa. 
 
As CNV studies become more widespread and as this technology is increasingly 
incorporated as a first-line diagnostic tool, it is concomitantly expected that the number 
of microdeletion/duplication syndromes will increase.  In order to facilitate molecular 
diagnosis of these syndromes it is critical that these disorders are catalogued in freely 
available, web-based databases.  The database of chromosomal imbalance and 
phenotype using Ensembl resources (DECIPHER) 
(https://decipher.sanger.ac.uk/application/) is an example of such a database (Firth et al. 
2009).  DECIPHER, based at the Wellcome Trust Sanger Institute, Cambridge, UK, 












participating centres world-wide.  In addition, the CNP compilation allows easier 
dissection of CNVs detected in array analyses.  With the accumulation of information 
pertaining to genomic architecture, and its role in MR, databases such as these will be 
critical in MR diagnosis due to CNVs. 
 
The CNV detection rate in this study was 1/17 (6%) in XLMR families (assuming the 
Xq26.3-27.3Del in family Fx444 was indeed the disease-causing mutation).  However, 
this detection rate should be interpreted with caution given the small sample size, even 
though the rate was consistent with that reported in previous studies (Lugtenberg et al. 
2006, Madrigal et al. 2007). Despite, the numerous reports of X-chromosomal CNVs 
accounting for XLMR, to date only two studies have analysed copy number in XLMR 
cohorts exclusively.  Lugtenberg et al. (2006) screened 40 NS-XLMR families using a 
whole X-chromosome screen and identified three disease-causing mutations, hence 
resolving 7.5% of XLMR cases studied (Lugtenberg et al. 2006).  Madrigal and 
colleagues (2007) screened 52 XLMR patients using an X-specific BAC array and 
detected five disease-causing mutations (pick-up rate 9.5%) (Madrigal et al. 2007).  
Together with the results of this dissertation, these studies strongly motivate for 
systematic screening of XLMR families using commercially available whole X-
chromosome specific arrays, or alternatively, X-chromosome specific Multiplex 
Amplifiable Probe Hybridisation (MAPH) (Kousoulidou et al. 2007), or exon-specific 
X-chromosome arrays (Bashiardes et al. 2009). 
 
In addition to the Xq26.3-27.3Del identified in XLMR family Fx444, this study led to 
the detection of two additional disease-causing mutations, (Xq25Dup in XMR8, and 
17p11.2 in Fx343) in the total of thirty MR patients assessed (10% pick-up rate).  
Furthermore, CNVs have been demonstrated to account for up to 24% of MR in some 
cohorts (Aston et al. 2008) (Table 5.1). Collectively this evidence suggests that CNV 
analysis using whole-genome arrays in isolated/autosomal dominant MR cases as well 
as X-specific arrays in XLMR families would be a critical addition to the repertoire of 
MR diagnostic tests offered by the NHLS.  However, at present, the department lacks 
the technologies required to perform microarray experiments (hence this study was 
conducted at the Department of Human Genetics, Nijmegen Medical Centre, The 
Netherlands).  Therefore, until the necessary infrastructure is available (funding 












microdeletion syndromes and subtelomeric regions using MLPA techniques, under the 
auspices of the NHLS. 
 
The establishment of a genomics platform at UCT for CNV detection is critical not only 
for MR diagnostics but also for the advancement of medical genomics research on a 
broader scale.  The importance of CNVs in the pathogenesis of several disorders 
including schizophrenia (Walsh et al. 2008), autism (Miller et al. 2009), HIV 
susceptibility (Gonzalez et al. 2005) and Crohn disease (Fellermann et al. 2006), have 
been demonstrated recently.  It is expected that in the future numerous additional 
disorders will found to be explained, at least in part, by mutations that affect copy 
number of the human genome. 
 
7.1.2. XLMR MUTATIONS IN CODING REGIONS  
7.1.2.1 Linkage analysis and positional candidate gene screening 
Linkage analysis and subsequent positional candidate gene screening has been 
successfully implemented in the identification of numerous genes for both XLMR and a 
multitude of additional disorders.  In this study, this research strategy was successfully 
adopted to identify the ATRX disease-causing mutation in family XMR2.  Initial whole-
X chromosomal linkage analysis in 12 individuals of family XMR2 showed linkage of 
XLMR to a 38Mb critical interval.   Additional fine-mapping in the region, as well as 
genotyping of four additional family members led to a reduction of the critical 
chromosomal interval to a 10Mb region at Xq13.1-q21.1.  Encompassed within this 
linked interval were nine known XLMR genes.  Based on phenotypic expression of 
known ATRX mutation positive patients, this gene was selected as the primary candidate 
gene in family XMR2.  These results illustrate the importance of good clinical 
characterisation of affected family members in order to prioritise candidate genes.   
 
By mutation screening of the three ATRX mutation hotspots in family XMR2 a 
c.5987_6011del mutation was detected in exon 26.  This 24bp deletion was predicted in 
silico to give rise to a truncating mutation (p.1987fsX56).  However, aberrant splicing, 
due to disruption of an ESE site, results in the deletion of 66bp from the mRNA 
(r.5957_6022del) and ultimately an interrupted protein (p.1987_2008del).  These results 












mechanism and secondly, the importance of phenotypic rescue observed for ATRX 
mutations. 
 
There are now numerous reports of ESE site disruption resulting in aberrant splicing of 
pre-mRNA transcripts and ultimately human disease (Boichard et al. 2008, Collin et al. 
2008, Ramser et al. 2005).  Of particular importance are the reports of synonymous 
(Collin et al. 2008) and silent (Boichard et al. 2008, Ramser et al. 2005) mutations 
leading to aberrant splicing, these examples exemplify the necessity to characterise 
genomic mutations on a mRNA transcript level.  There are most-likely a number of 
variants identified by XLMR gene screening projects which are classified as benign 
which in actual fact affect splicing.  Investigation of these ‘benign’ variants could be 
assisted by the use of prediction programmes including ESEFinder used in this study 
and others as reviewed by Houdayer and colleagues (Houdayer et al. 2008). 
 
The ATR-X patients in family XMR2 exhibit phenotypic rescue by alternative splicing 
of the ATRX transcript.  The genomic deletion in this family was predicted to give rise 
to a truncated protein, however, an alternative splicing event, putatively due to 
alternative ESE site usage, allows skipping of the truncating event and generates an 
interrupted full-length protein.  This nonsense-associated alternative splicing (NAS) has 
been described in several other disorders including Duchenne Muscular Dystrophy 
(DMD) (Nishiyama et al. 2008), pyruvate dehydrogenase (PDH) deficiency (Ridout et 
al. 2008) and cystic fibrosis (Aznarez et al. 2007).  NAS can be induced by a number of 
either intronic or exonic factors including enhancers or silencers.  However, the extent 
of this phenotypic NAS rescue mechanism in the pathogenesis of XLMR is not known.  
To date, to the author’s knowledge, only two XLMR genes have been shown to make 
use of this mechanism.  Firstly, the ATRX mutation as described in this study, as well as 
all patients with truncating mutations downstream of the ATRX ADD domain, exhibit 
similar NAS events (Gibbons et al. 2008). Secondly, more recently, mutations in the 
XLMR gene, PQBP1, were shown to elicit NAS by enhanced skipping of the mutated 
exon 4 in a mutation-specific manner (Musante et al. 2010).  Similar investigations in 
XLMR gene mutation positive individuals will enhance our understanding of NAS in 
the pathogenesis of XLMR and perhaps provide novel insights for putative therapeutic 














The clinical presentation of family XMR2 was consistent with phenotypes described in 
previous ATRX mutation positive patients.  Importantly, an affected individual in this 
family do not present with α-thalassaemia.  Therefore, this observation supports the 
suggestion that this clinical feature should not be a defining criterion for ATRX mutation 
screening (Villard et al. 1999). 
 
In this study, a mutation protocol technique was developed to detect mutations in the 
three ATRX mutation hotspots which account for 76% of all known mutations in this 
gene.  This mutation detection protocol entailed isolation of mRNA from the affected 
individual, after a cDNA synthesis step, PCR and subsequent DNA sequencing were 
performed for the three mutation hotspots.  The amplification and analysis of just three 
regions greatly reduced the cost associated with mutation detection within this gene.  
This protocol has been incorporated into the diagnostic protocols of the NHLS.  Given 
the rarity of the condition, to date, only a single individual has been referred to the 
Division for diagnostic testing.  However, it is envisaged that, in the future, the 
implementation of this diagnostic test will still have a positive influence on the 
alleviation of the unexplained MR cases for a small number of families in South Africa. 
 
Linkage analysis in a smaller family, Fx56, resulted in the definition of a much larger 
chromosomal region (Xp11.4-Xq21.1) spanning 76Mb and encompassing 
approximately 397 genes.  Genotyping of additional markers did not result in reduction 
of the disease-associated region.  Also, no additional family members could be recruited 
to this study, due to problems re-establishing contact with the family.  Therefore, this 
critical interval could not be refined and it was not possible to prioritise positional 
candidate genes for mutation screening.   
 
The problems encountered with re-establishing contact with families not only in the 
linkage phase of this dissertation, but also throughout the course of this study was a 
limiting factor, which needs to be addressed in future studies.  These problems are a 
reflection of capacity problems that Divisional clinicians experience as well as the 
overloading of the public health system, both matters need to be addressed on a national 
level.  At a divisional level, some of these deficits could be ameliorated by storage of 
bloods/plasma at -80°C, or preferably cyropreserved (Louie and King. 1991), thus 
preserving the integrity of the cells so that patient cell lines (EBV-transformed 












that future XLMR/MR studies are conducted prospectively rather than retrospectively 
so as to avoid problems with contacting family members.  
 
Family Fx67 consisted of three affected brothers and their unaffected mother, due to the 
family’s small size, linkage analysis could not be conducted, as a meaningful LOD 
score could not be generated.  However, allele segregation analysis spanning the X 
chromosome, showed co-segregation of six microsatellite markers with the disorder in 
this family.  No additional family members were available for genotyping and the co-
segregating region could not be further reduced in this family.  The six microsatellite 
markers spanned 11Mb of a relatively gene poor region (Xp21.1-Xp11.4) which 
consists of 27 known genes, of which two (ATP6AP2 and TSPAN7) have been 
previously implicated in XLMR.  
 
Patients previously reported with mutations in ATP6AP2 and TSPAN7 present with NS-
XLMR.  Concomitantly, patients in family Fx67 also exhibit NS-XLMR; therefore, 
ATP6AP2 and TSPAN7 were subject to mutation screening in the three affected 
individuals, but no disease-causing mutations were identified.  While, it could not be 
ruled out that the MR presentation in this family was not X-linked, these results are 
suggestive of Fx67 harbouring a novel XLMR gene mutation.  Unfortunately, at this 
stage, the remaining 25 genes within the putative disease-associated chromosomal 
interval were not subject to mutation detection in family Fx67.  The reasons for this 
were two-fold; firstly, a significant LOD score could not be generated for this family.  
Secondly, given the genetic heterogeneity of MR, it was difficult to prioritise candidate 
gene screening within this interval especially given the NS-XLMR presentation of 
affected individuals in Fx67.   
 
The difficulty experienced in prioritising candidate genes was evident not only in this 
study, but has also been well documented though-out the years of XLMR research.  
Bioinformatics approaches, such as those discussed by Oti and Brunner (2007) cannot 
be applied in the context of MR research given the vast number of functional pathways 
in which XLMR genes participate (Oti and Brunner. 2007).  In order to circumvent this 
problem, it is envisaged that mutation screening of multiple candidate genes will 














These linkage analyses and positional candidate gene screens demonstrate that as 
medical and genetic infrastructure becomes more apparent in less developed countries, 
it will be possible to conduct molecular investigations in additional XLMR families. 
Using relatively cost-effective techniques such as those described here, it is likely that 
mutations will be found in these families in both novel and known XLMR genes.  Thus, 
it was demonstrated here, that studies such as these are important in elucidating novel 
causes of XLMR, this is particularly important in context of XLMR given the high 
percentage (˃50%) of unexplained MR cases. 
 
7.1.2.2 Screening functional candidate genes 
The ARX gene 
After the CGG expansion mutation in the FMR1 gene promoter region, ARX mutations 
are the second biggest contributor to XLMR.  In this study, 113 clear (43) or putative 
(70) XLMR families were assessed for mutations in the five ARX exons using dHPLC.  
DNA sequencing of samples with deviant dHPLC profiles revealed two c.428_451dup 
mutations in Fx391.1 and Fx446.1, the carrier mothers of these individuals were also 
found to be positive for this mutation.  Also, a c.300G>A was identified in Fx362.1; 
however, this variant did not segregate with the disorder in this male sib-pair.  
Furthermore, screening for the two common polyalanine ARX expansion mutations 
(c.428_451dup and c.304ins(GCG)7) in 183 isolated male MR patients revealed no 
alterations in these patients.  
 
The c.428_451dup is the most common disease-causing ARX mutation and accounts for 
39/84 (46%) of all reported cases (Appendix 5A).  The identification of the two 
c.428_451dup expansions in this study increase the preponderance of this second 
polyalanine tract expansion in ARX mutation positive patients to 48%.  The second most 
common ARX mutation is an expansion of the first polyalanine tract, mainly the 
c.304ins(GCG)7, which accounts for an additional 15% of all mutations described to 
date.  Therefore, collectively, the polyalanine expansion mutations account for 63% of 
all known ARX mutations.   
 
In individual Fx362.1 a c.300G>A mutation was detected, this mutation did not 
segregate with the disorder in the family as it was not detected in this individual’s 












mutation in this family.  However, it was interesting to note that the c.300G>A mutation 
was predicted to alter an ESE site, Srp55; similar ESE site disruptions have been 
reported in ARX.  Gronskov and colleagues (2004) described an ARX c.1347C>T 
variant, that similarly affected a Srp55 ESE site, in un/affected XLMR patients and 
speculated that this variant could act as a modifier (Gronskov et al. 2004).  Second to 
this, through a collaborative study, an ARSF truncating variant (p.S76fsX7) was 
identified in individual Fx362.2 but not Fx362.1 (Tarpey et al. 2009).  Thus, while 
neither of these variants are the disease-causing mutation in this brother-pair it is 
speculated here that an accumulation of similar protein truncating or modifying variants 
could lead to XLMR in family Fx362 in the mould of a multifactorial of “x-linked risk 
factor’ hypothesis.  In support of this hypothesis, in the study by Tarpey et al. (2009), 
truncating variants were present in up to 1% of X-linked genes in the general population 
(Tarpey et al. 2009), suggesting that there may be a threshold above which the 
accumulation of these variants manifests in XLMR, specifically non-syndromic, mild 
MR.   
 
The pick-up rate for ARX mutations in this study was 2/43 (4.5%) among clear XLMR 
families.  Despite this low mutation rate (4.5%) as compared to previous international 
reports of detection rates spanning 6.6-9.5% (de Brouwer et al. 2007, Mandel and 
Chelly. 2004, Poirier et al. 2006), this figure was significant enough to warrant the 
development of an ARX diagnostic test.  Given the cost-effectiveness of the PCR-based 
approach, the screening of the common ARX mutations (c.428_451dup and 
c.304ins(GCG)7) for XLMR families was implemented as part of the diagnostic testing 
protocols of the NHLS in late 2007.  Since its inception a patient with a c.304ins(GCG)7 
polyalanine ARX expansion has been identified from a total of 19 referred patients.  
Thus, the incorporation of this diagnostic test has already had a positive impact on 
alleviating the burden of unexplained MR in the Western Cape region of South Africa 
and will continue to do so in the future.   
 
The screening of 183 isolated male MR cases for the two most common ARX 
polyalanine expansion mutations revealed no mutations in this group of patients.  This 
zero detection rate for isolated male MR cases was in keeping with previous 
international reports; Gronskov et al. (2004) reported a 0.3% detection rate while de 












Gronskov et al. 2004).  Collectively, these detection rates indicate that ARX polyalanine 
expansion diagnostic testing is not advised in isolated cases of MR. 
 
The KDM5C gene 
After, FMR1 and ARX, KDM5C is one of the more commonly mutated XLMR genes.  
Thus, in this study 25 patients presenting with clinical features found to be predominant 
in KDM5C mutation positive patients were assessed for mutations in the 26 KDM5C 
exons using dHPLC.  Three alterations, c.351-38C>T in Fx135.1, c.2623-45G>A in 
Fx277.1 and c.2517-7_8insTAC in Fx361.1, were detected by DNA sequencing of these 
samples which exhibited altered dHPLC profiles. 
 
The c.351-38C>T, originally detected in individual Fx135.1, was detected in three out 
of 100 ethnically matched controls using a PCR and RE digest approach.  Therefore, 
given that this variant was not previously reported in web-based databases (dbSNP at 
NCBI or Ensembl), it was concluded that the c.351-38C>T variant constitutes a novel 
SNP.  Thus, this variant was not the disease-causing variant in family Fx135. 
The c.2623-45G>A was originally identified in Fx277.1; this variant had not been 
previously described.  It was not possible to screen for this variant using either RE 
digest or ARMS-PCR in the background population as neither of these techniques was 
successfully optimised.  While more expensive technologies are available to screen for 
this variant, these techniques were not implemented due to the deeply intronic nature of 
this alteration and thus the minimal likelihood that it contributes to disease in this 
family.   
 
The c.2517-7_8insTAC was detected in Fx361.1. in this study.  This variant has been 
previously described in a family with XLMR, but was not detected in 312 control X 
chromosomes screened (Jensen et al. 2005).  In concordance with these previously 
published results, the c.2517-7_8insTAC was not detected in 100 unaffected males 
using an ARMs-PCR screening technique in this study. Thus, cumulatively, this variant 
has been detected in two XLMR patients to date, but not 412 control X chromosomes.  
In addition, the c.2517-7_8insTAC lies directly adjacent to the pyrimidine-rich branch 
site which is essential to correct pre-mRNA splicing.  Collectively, this evidence 
suggests that this alteration is the disease-causing mutation in these XLMR families, but 
verification by mRNA sequencing in either of these patients is required to definitely 













Of the total of 501 XLMR families and sib-pairs investigated in large cohorts 
internationally, a total of 18 (3.2%) KDM5C disease-causing mutations have been 
described (de Brouwer et al. 2007, Santos et al. 2006).  Thus it was not unexpected that 
no KDM5C mutations were detected in this study, despite the fact that this South 
African study cohort was enriched based on a clinical presentation previously described 
in mutation positive patients.  An investigation in even larger, clinically relevant South 
African patient cohorts will give a better approximation of the incidence of KDM5C 
mutations in this population group.  It is anticipated that these studies will be aided by 
future developments in next generation DNA sequencing technologies, both in terms of 
cost and accessibility. 
 
Future functional candidate gene screening studies 
Additional mutation screening investigations in XLMR genes with high mutation 
frequencies, such as the ARX and KDM5C investigations described here, will guide the 
development of additional MR diagnostic tests in South Africa.  Amongst the more 
commonly mutated genes, MECP2 duplications are one of the most prevalent.  To this 
end, the incidence of MECP2 duplications are being investigated within this research 
group at the Division.  Preliminary results suggest successful mutation detection, which 
further substantiates the feasibility of diagnostic MECP2 duplication testing for XLMR 
patients in the future.   
 
With regards to future mutation screening in functional candidate genes it is critical that 
detailed clinical information is obtained from clinicians referring MR patients to the 
Division of Human Genetics, UCT in order to stratify patient cohorts according to 
clinical presentation.  With this in mind, together with the Divisional clinicians, a 
clinical manifestations datasheet is in the developmental stages.   Furthermore it is 
envisaged that as the cost of array technology is reduced and more information on 
common XLMR gene mutations are collected that ‘first-line’ mutation detection will be 
performed on commercially available microarrays.  Such technologies have been 
successfully employed in our Division for the group of retinal degenerative disorders 













7.1.3 ACCOUNTING FOR UNEXPLAINED XLMR: FUTURE DIRECTIONS 
Despite the nearly thirty years of research and the identification of 87 XLMR genes, the 
disease XLMR etiology remains unexplained in most families.  The most 
comprehensively studied group of XLMR families are those of the EuroMRX 
consortium, comprising approximately 600 families. Mutation screening of 90 known or 
candidate XLMR genes in this cohort identified the molecular etiology in 42% of 
XLMR families (at least one obligate female carrier) and 17% of brother-pairs (2-5 sibs) 
(de Brouwer et al. 2007).  More, recently a substantially more comprehensive study 
screened 718 Vega (Vertebrate Gene Annotation)-annotated X-chromosomal genes (at a 
coverage of 75%) in 208 XLMR family probands (Tarpey et al. 2009).  A genetic cause 
of XLMR was attributed in a total of 25% of these XLMR families. 
 
It is conceivable that additional mutations lie in the 25% of the Vega-annotated genes 
not screened in the large re-sequencing project (Tarpey et al. 2009).  Also, additional 
gene mutations may lie in genic regions which have not yet been curated by the Vega 
project.  Finally, given the number of NS-XLMR genes which have been implicated in 
single or minimal numbers of families, a substantial proportion of XLMR may be 
attributed to mutations in single genes making them difficult to detect.  Future ‘next-
generation’ DNA sequencing projects will most likely identify numerous monogenic 
causes of XLMR.   
 
Despite the number of XLMR families hypothesised to be resolved by gene mutations 
in coding regions, it is also expected that a significant proportion of XLMR will be 
attributed to additional molecular mechanisms (Figure 7.1), including: Copy number 
Variations (CNVs) which have not yet been systematically investigated in XLMR 
cohorts, mutations in regulatory and noncoding RNA (ncRNA) regions, epimutations, 













Figure 7.1 A hierarchal depiction of the putative regions or disease-mechanisms outside of the coding 
regions which may account for the pathogenesis of unexplained XLMR  
 
7.1.3.1 Mutations in non-coding regions 
 Disease-causing variants in regulatory or mRNA splicing regions 
The coding regions of X-chromosomal genes have been extensively investigated in 
XLMR patients in various studies.  By comparison, relatively few have addressed the 
role of non-protein-coding X-chromosomal loci in the pathogenesis of XLMR.  For 
instance functional chromosomal regions which encompass XLMR gene enhancers, 
promoters and consensus sequences critical for correct transcript splicing have not been 
strategically investigated. 
 
The ARX gene may present a good candidate gene for investigation of regulatory region 
mutations.  ARX is flanked by 11 UCEs which have been to hypothesised to function as 
enhancers (Bejerano et al. 2004), indeed to date one of these UCEs (uc.467) has been 
shown to function as an ARX enhancer (Colasante et al. 2008).  In this research group at 
the Division four UCE elements downstream of ARX (including uc.467) were subjected 
to dHPLC for mutation detection in a small cohort of eight FMR1/ARX mutation 
negative patients, but no mutations were detected (M. Fish, submitted for BSc (Med) 












however, now that techniques have been optimised for mutation detection, larger 
FMR1/ARX mutation negative cohorts can be screened for these mutations in these 
elements.  It is also essential that future patient cohorts consist of XLMR patients with 
whom good communications exist, as, in the event of an UCE alteration being detected, 
a functional effect will need to be tested by assessment of ARX mRNA levels in the 
patient.  
 
The encyclopaedia of DNA elements (ENCODE) project is a multicentre collaborative 
project which aims to identify all functional elements in the human genome 
(www.genome.gov/10005107) (ENCODE Project Consortium. 2004).  The pilot phase 
of this project has been completed and future outcomes will provide valuable 
information for the sequencing of these regulatory variants (ENCODE Project 
Consortium et al. 2007). Furthermore, with the advent and application of technologies 
such as ‘next generation’ sequencing, especially being used in combination with 
microarrays for target sequence enrichment, the ability to perform these sorts of 
investigations are becoming possible.   
 
Disease-causing variants in noncoding RNAs 
Mutations of other non-coding regions may also affect gene regulation; these include 
the group of noncoding RNAs which include microRNAs (miRNAs), long noncoding 
(ncRNAs) (e.g. antisense transcripts) and a multitude of other small RNAs.  To date, no 
ncRNA sequence mutations have been directly implicated in MR.  However, 
dysregulation of miRNAs have been seen in a number of MR disorders including 
DiGeorge/22q11Del syndrome (Stark et al. 2008), Down syndrome (Kuhn et al. 2008, 
Kuhn et al. 2010), and Rett syndrome (Nomura et al. 2008), suggesting aberrations in 
this pathway may be important in MR pathogenesis.  Only a single study by Chen and 
colleagues (2006) has attempted to test whether miRNA mutations are causative for 
XLMR (Chen et al. 2006).  The group screened 13 brain-expressed miRNAs in 464 
individuals with NS-XLMR and detected four sequence variants (in three miRNAs).  
These variants were determined to be functionally neutral and the authors conclude that 
mutations in these elements may be under strong selection pressure (Chen et al. 2006).  
However, as the location and sequence of novel miRNAs become known from the 












findings by Chen et al (2006) can be validated and thus determine the pathogenic role of 
miRNAs in XLMR.   
 
Mutations within long ncRNAs such as antisense transcripts have not been identified in 
MR patients.  However, as is the case for miRNAs, there is empirical evidence to 
suggest these transcripts are dysregulated in patients with known MR syndromes.  For 
example, the Antisense Fragile X Mental Retardation Protein (ASFMR1 or FMR4) 
transcript is silenced in individuals with Fragile X syndrome (full mutation) and 
upregulated in premutation carriers (Ladd et al. 2007).  However, siRNA-mediated 
silencing of ASFMR1 did not affect FMR1 expression, but rather, resulted in cell-cycle 
alterations and increased apoptosis (Khalil et al. 2008).  It remains unclear though, 
whether this antisense transcript plays a role in the pathogenesis of FXS and requires 
further experimentation.  A second antisense ncRNA transcript, the UBE3 antisense 
transcript, has been shown to be upregulated in human and mouse MeCP2 deficient 
brains, with a concomitant reduction in UBE3 expression.  As UBE3 deficiency results 
in Angelman syndrome (AS) and given the phenotypic overlap between AS and Rett 
syndrome, it is proposed that dysregulation of the UBE3 antisense transcript contributes 
to the clinical presentation of patients with MecP2 loss-of-function (Makedonski et al. 
2005).  While mutations in these ncRNAs have not been found to be causative for MR, 
their role in the pathogenesis of the disorder makes them good candidates for XLMR 
cohort screening, particularly in families where a linkage interval has already been 
defined.  In addition, it is envisaged that projects such as ENCODE will determine the 
location and sequence of such antisense transcripts and enable researchers to identify 
putative disease-associations.  
 
7.1.3.2 Polygenic models of inheritance 
A hypothetical molecular mechanism which may account for the surplus of unidentified 
XLMR involves the adoption of a different mode of inheritance.  It has been proposed 
that various gene polymorphisms on the X chromosome predispose males to MR, rather 
than cause the condition (Mandel and Chelly. 2004).  This X-linked ‘risk factors’ 
hypothesis has recently been expanded to include autosomal polymorphisms (Raymond 
and Tarpey. 2006).  Certainly the alterations identified in family Fx362 would seem to 
support this supposition; however, to date no significant empirical evidence has been 













7.1.3.3 The role of epimutations 
A significant proportion of XLMR may, in theory, be accounted for by the presence of 
epimutations in affected individuals.  Epimutations are defined as epigenetic alterations 
that are not dependant on the primary DNA code, and that cause transcriptional 
silencing of a gene that is normally active, or conversely, activation of a silent gene 
(Holliday. 1987, Holliday. 2006).  De novo epimutations have been reported in two 
patients with 14q32.2 hypomethylation who present with phenotypic presentation which 
mimics maternal uniparental disomy (UPD) of chromosome 14 (upd(14)mat) (Hosoki et 
al. 2008, Zechner et al. 2009).  These reports suggest that DNA methylation errors may 
be a disease mechanism in sporadic cases of MR.   
 
The biggest caveat to a trans-generational inheritance model for epimutations is that 
epigenetic marks are erased and reset in the germline at each successive generation.  
There are some challenges to this view. Evidence for the constitutional (germline) 
inheritance of epimutations has been demonstrated in plants (Chandler and Stam. 2004) 
and mice (Morgan et al. 1999).  However, the only instance of constitutional 
epimutations in humans have been seen where the epigenetic alteration is dependent on 
the nucleotide sequence (Hitchins et al. 2007, Ligtenberg et al. 2009, Sutcliffe et al. 
1992).  Given that these alterations are essentially dependent on the primary DNA code, 
they do not strictly speaking constitute epimutations according to the accepted 
definition by Holliday (Holliday. 2006).  However, there appears to be some ambiguity 
in current literature as the aforementioned reports refer to the changes in DNA 
methylation (that are based on the primary DNA code) as constitutional epimutations.  , 
These alterations are referred to as epimutations herein, in keeping with current 
literature trends. 
 
These constitutional epimutations include hypermethylation of the MLH1 locus which 
occurs in the presence of a G>A SNP in hereditary non-polyopsis colorectal cancer 
(HNPCC) patients (Hitchins et al. 2007).  Similarly MSH2 promoter hypermethylation 
has been reported in HNPCC patients with TACSTD1 3’ deletions (Ligtenberg et al. 
2009). Finally, expansion of the FMR1 CGG repeat causes promoter hypermethylation 
(Sutcliffe et al. 1992).  However, to date, there is no evidence for a trans-generational 













The lack of identification of constitutional epimutations may also reflect the necessity 
for two ‘hits’ at biallelically expressed loci for disease manifestation. Indeed, those 
instances where epimutations have been associated with disease occur at imprinted loci 
(e.g. Angelman/ PraderWilli Syndrome) or in autosomal dominant disorders (e.g. 
HNPCC).  However, given the hemizygosity of the X chromosome in males it may be 
expected that constitutional epimutations of X chromosomal gene regulatory regions 
may be more common.  In order to test this hypothesis, clear, unexplained XLMR 
families should be investigated for DNA methylation aberrations across the X 
chromosome.  Furthermore, these investigations could be guided by previously linked 
chromosomal regions in these families, e.g. of the EuroMRX consortium.  It should be 
noted that while X-chromosomal changes to DNA methylation may be identified in 
such prospective studies, it is likely that these alterations will act in cis with an 
underlying change to the primary DNA code.  However, these putative constitutive 
epimutations are probably more easily identifiable by DNA methylation alterations, 
with the putative genomic cause identified subsequently.  
 
Finally, the ATF7IP2 hypermethylation observed in the ATR-X patients described in 
this study, as well as previous studies showing DNA methylation alterations in these 
patients (Gibbons et al. 2000), add further credence to the role of epimutations such as 
DNA methylation in the pathogenesis of XLMR.  
 
 
7.2 THE ROLE OF EPIGENETICS AS AN XLMR DISEASE 
MECHANISM 
In this study, the hypothesis that DNA methylation alterations are a feature of MR in 
patients positive for XLMR gene mutations was tested.  In order to fulfil this aim, DNA 
methylation profiles in an ATRX mutation positive family (XMR2) were investigated.  
This was achieved by conducting whole genome CpG island and promoter DNA 
methylation profiling using a MeDIP-Chip method.  Subsequently, DMRs between 
affected and unaffected family members of family XMR2 were identified using a novel 
statistical pipeline. From the total of 113 putative DMRs identified, a single promoter 
region, encompassing ATF7IP2, was verified using bisulphite DNA sequencing.   A 












bisulphite DNA sequencing technique, established that ATF7IP2 promoter DNA 
methylation ratios in affected individuals vary between 8-34% as compared to 
unaffected sibs who have only 0-7% of sites methylated at the CpG sites within this 
locus.  These results demonstrate that hypermethylation of ATF7IP2 promoter region 
was apparent in ATRX mutation positive patients of this family. 
 
The ATF7IP2 hypermethylation observed in this study is hypothesised to lead to 
reduced levels of transcript and concomitantly, ATF7IP2 protein.  The reduction in 
protein levels is likely to have an effect on the chromatin remodelling complexes in 
which ATF7IP2 functions.  ATF7IP2 is known to bind MBD1 as well as the histone 
methyltransferase, SETDB1 and the transcription activator SP1 (Ichimura et al. 2005).  
This suggests that ATRX and ATF7IP2 may form part of the same transcription 
regulation complex and opens up new avenues of investigation for elucidating the 
pathogenesis induced by ATRX mutations.  It can only be assumed that extended DNA 
methylation profiling in ‘epigenetic’ XLMR gene mutation positive patients will yield 
similar results.  Elucidation of novel XLMR gene interacting proteins and subsequent 
investigation thereof will contribute to the understanding of XLMR disease mechanisms 
as well as indirectly enhance knowledge of the normal functioning of epigenetic 
mechanisms.  
 
The altered DNA methylation profiles observed in ATRX mutation positive patients in 
this study therefore supports a role for dysregulation of this epigenetic mechanism in the 
pathogenesis of XLMR.  The adoption of the whole-genome DNA methylation profiling 
methodology described in this dissertation to investigate the epigenetic profile of 
additional XLMR genes will elucidate the extent of this epigenetic disease mechanism.  
Those XLMR genes encoding proteins which interact with ATRX on a molecular level, 
for instance MeCP2 (Nan et al. 2007), would be good candidates for DNA methylation 
profiling in mutation positive patients.  MECP2 is also a particularly good candidate 
given its methylated DNA binding ability.  However, evidence suggests that MeCP2 
does not regulate target genes at promoter regions but rather through distal interactions 
(Yasui et al. 2007), therefore requiring a different array  platform to that described in 
this dissertation.  
 
While ATRX is expressed in the lymphocytes, the expression of a number of additional 












methylation studies such as those described in this dissertation as well as follow-up 
immunoprecipitation studies.  The advent of induced pluripotent stem cell (iPS) 
technology (Dimos et al. 2008) will allow researchers to develop neuronal cell models 
which can circumvent this problem.  Furthermore, generation of patient-specific 
neuronal cell lines, provide good cellular model systems for the testing of potential 
therapeutics. 
 
An in depth knowledge of the disease mechanism governing the XLMR condition is the 
ultimate goal on the path to exploration of novel therapeutic targets and treatments for 
the disorder.  For example, in the approximately thirty years since its first implication in 
XLMR, the FMR1 gene has been extensively studied and the defective molecular 
mechanisms causing the FXS unravelled.  These molecular mechanisms are discussed 
in detail elsewhere (D'Hulst and Kooy. 2009, Hagerman et al. 2009), but briefly 
summarised here.  FMR1 is an RNA-binding protein which regulates long term 
depression (LTD) of synapses through the glutamate receptor (mGluR) pathway.  In the 
absence of FMR1, this mGluR pathway lacks the negative feedback loop induced by 
FMR1 and is hence over-stimulated.  The resulting exasperated neuronal LTD 
eventually leads to weakened synaptic connection in FXS patients.  Intricate knowledge 
of functioning of this system can be exploited in the quest to identify therapeutic targets.   
 
7.3 TREATMENT OF XLMR: THE ULTIMATE GOAL 
The development of the aforementioned mGluR theory has led to the suggestion that 
antagonists of this pathway may be utilised in the treatment of FXS.  Indeed, already 
significant phenotypic rescue has been seen in mouse, fly and zerbrafish models of FXS 
(McBride et al. 2005, Tucker, Richards and Lardelli. 2006, Yan et al. 2005).  Given the 
successes of this pharmacological intervention in animal models, in 2008 the first 
clinical trial in FXS patients using an mGluR antagnostic (Fenobam) was established 
(Hagerman et al. 2009).  Also, in a recent study a small group of FXS patients treated 
with Lithium showed improvement in verbal memory and behaviour, possibly due to a 
correction of the mGluR pathway functioning (Berry-Kravis et al. 2008).  Finally, other 
studies have suggested that GABAergic antagonists may also be effective treatment in 
FXS (Chang et al. 2008).  Clinical trials testing amelioration of some of the symptoms 













The aforementioned studies suggest the therapeutic correction of these 
neurotransmission signalling pathways is a promising treatment protocol for FXS 
patients.  However, given the dynamicity of epigenetic mechanisms, therapeutic 
interventions which could target erroneous or pathogenic marks of this mechanism 
could provide novel targets for treatments.  For instance, an individual with a full FMR1 
expansion mutation was recently identified with normal intelligence (Pietrobono et al. 
2005).  It was shown that the absence of both FMR1 hypermethylation and H3K4 
methylation resulted in the production of normal transcript levels.  However, reduced 
translation was observed due to the CGG expansion with protein levels reduced in the 
individual by 30% as compared to normal controls.  Concomitantly, a separate study 
demonstrated that 5-aza-deoxycytidine treatment of FXS full mutation cell lines 
reversed FMR1 hypermethylation as well as the associated repressive histone marks 
(Pietrobono et al. 2002, Tabolacci et al. 2005).  Collectively these results suggest that 
treatment with similar DNA demethylation targeting drugs may also be useful 
therapeutic treatment in FXS patients, though of course off target effects would need to 
be assessed.  
 
MECP2 is a well-studied XLMR gene, second only to FMR1; however, to date no 
therapies have been established for either loss-of-function mutations in Rett Syndrome 
patients, or overexpression mutations in XLMR patients.  MeCP2 function is thought to 
be particularly complex with this protein being involved in both activating and 
repressive chromatin complexes (Chahrour et al. 2008, Nan et al. 1998, Yasui et al. 
2007).  Given that the Rett Syndrome phenotype was partially rescued after onset of the 
disease in mouse models suggests that this disorder may be amenable to therapy 
(Giacometti et al. 2007, Guy et al. 2007, Jugloff et al. 2008).  To this end, Rett 
syndrome gene therapy is being developed using MECP2 specific self-inactivating 
retroviral vectors and has shown success in neural stem cells (NSC) (Rastegar et al. 
2009).  However, given MECP2’s reported epigenetic function as well as the 
dynamicity of epigenetic mechanisms, therapies which target this pathway may be 
explored.  Possible avenues of investigation may include drugs such as Trichostatin A 
(TCA) which inhibit HDACs (class I and II) (known to interact with MeCP2).  A recent 
report showed that cocaine self-administration in mice resulted in the up-regulation of 
several genes including MECP2, HDAC2 and HDAC11, this up-regulation was 
corrected by treatment with TCA (Host et al. 2009).  These results suggest that TCA 












approach in patients with MECP2 overexpression mutations (male MECP2 duplication 
carriers).   
 
The molecular mechanisms underlying the two aforementioned XLMR genes, FMR1 
and MECP2 are perhaps the most thoroughly investigated.  Hence, particularly in the 
case of FMR1 potential therapies are being actively pursued.  Concomitantly, a 
thorough understanding of the molecular mechanisms of other XLMR genes will pivotal 
in the pursuit of potential targeted therapies.  This is especially true for the ‘epigenetic’ 
XLMR genes such as ATRX, patients with mutations in these chromatin remodelers may 
be good candidates for therapy given the dynamic nature of epigenetic mechanisms.  
 
7.4 CONCLUDING SUMMARY  
The principal findings of this dissertation were: 
 The identification of three disease-causing CNVs: Xq26.3-27.3Del in family 
Fx444, Xq25Dup in XMR8 and 17p11.2 in Fx343 (Chapter 2) 
 Definition of a disease-associated interval in family Fx67, which putatively 
harbours a mutation in a novel XLMR gene (Chapter 3, 4) 
 Definition of a linked critical interval in family XMR2 and subsequent detection 
of a disease-causing mutation (c.5987_6011del) in positional candidate gene, 
ATRX (Chapter 3, 4) 
 The identification of two ARX disease-causing mutations (c.428_451dup) in 
families Fx391 and Fx444 (Chapter 5) 
 The identification of a putative KDM5C mutation (c.2517-7_8insTAC) in 
individual Fx361.1 (Chapter 5) 
 The identification of hypermethylation at the ATF7IP2 promoter region in ATRX 
mutation positive family, XMR2 (Chapter 6). 
 
The principal findings of this study contribute to numerous facets of the XLMR/MR 
research field.  Firstly, the identification of six (putatively seven) disease-causing 
mutations allows further delineation of the molecular causes of MR/XLMR.  Secondly, 
the elucidation of a genetic cause of MR in these families enhances clinical 
management of this disorder in these patients as well as genetic management of the 












substantiated and thus provides the foundation for future research directions concerned 
with understanding disease pathogenesis. 
 
The identification of a low penetrant Xq26.3-27.3Del mutation in family Fx444 
highlights the importance of developing guidelines for the genetic counselling and 
molecular diagnosis of patients carrying similar variably penetrant CNVs.  The 
Xq25Dup identified in XMR8 has led to the detection of novel XLMR candidate genes 
(THOC2 and STAG2).  These results illustrate the importance of CNV analysis in both 
the molecular diagnosis of MR as well as novel XLMR/MR gene detection. 
 
The identification of a disease-associated interval in family Fx67 and the absence of 
mutations in the two known XLMR genes suggested that this family harbours a 
mutation in a novel XLMR gene.  These results illustrate the importance of molecular 
investigations in new XLMR families and exemplify the contribution to the delineation 
of unexplained MR that research in developing countries will make in the future. 
 
The elucidation of a disease-causing mutation in ATRX, as well as two ARX mutations 
now affords enhanced clinical management of these patients as well as genetic 
counselling, carrier testing and prenatal diagnosis for these families.  Also, there is now 
compelling evidence that the KDM5C mutation (c.2517-7_8insTAC) described in this 
study is a disease-causing mutation.  
 
As a result of these investigations, two diagnostic tests (for the two common ARX 
mutations and the ATRX mutation hotspots) have been incorporated into the diagnostic 
protocols offered by the NHLS, based at UCT Medical School.  In addition, the logistics 
and feasibility of including CNV detection using microarray analysis into the diagnostic 
procedures of the NHLS is in the planning stages.  The expansion of the repertoire of 
diagnostic tests offered to MR patients will aid clinicians in South Africa to attribute a 
molecular diagnosis to an increased number of MR patients.  In turn, a molecular 
diagnosis will facilitate clinical management of the disorder, as well as genetic 
counselling, carrier testing and prenatal diagnosis in these families. 
 
While the DNA methylation alterations in family XMR2 were not widespread, the 
detection of hypermethylation at ATF7IP2 suggest that these aberrations are a molecular 












identified as a novel potential interacting protein of ATRX.  Given the role for ATF7IP2 
in chromatin remodelling further investigation of the relationship between ATRX and 
ATF7IP2 could provide important clues to understanding the pathogenesis of ATR-X 
syndrome.  This dissertation has therefore laid the foundation for future research 
directions in understanding ATRX mutation pathogenesis.  Furthermore, these 
investigations suggest ATF7IP2 may be a good candidate gene for mutation screening 
in patients with chromosomal rearrangements in this region, as well as potential future 
autosomal recessive families linked to the region by homozygosity mapping.  Finally, 
hypermethylation at the ATF7IP2 promoter region may hold promise as a future 
molecular diagnostic test for the presence of an ATRX mutation. 
 
In conclusion, the DNA methylation methodology described in this study can be applied 
to additional lymphocyte-expressed ‘epigenetic’ XLMR genes.  These future 
investigations will elucidate the extent of the DNA methylation alterations in MR 
patients, identify novel interacting proteins or protein targets and finally, lead to the 
discovery of novel MR candidate genes.  The acquisition of intricate knowledge of 
epigenetic defects in MR patients, will ultimately contribute to understanding the role 















APPENDIX 2A: DNA CONSENT FORM 
 
 
REQUEST FOR MOLECULAR STUDIES (DNA) 
 
Molecular Laboratory  
Division of Human Genetics Blood should be drawn in 2 plastic EDTA Tubes 
IIDMM, LEVEL 3 (Purple top) +/- 10ml each using a yellow barrel. 
UCT Medical School, Observatory 7925 Each tube should be inverted to mix and should be  
 clearly labelled with the patient's name and DOB 
Tel: (021) 406 6425        Fax: (021) 406 6826 Keep blood in fridge at 4°C until able to send to laboratory 
  
 Please DO NOT send specimens on ice or frozen. 
Please fill in all the information requested:  
 
Surname:____________________________________________First Name(s):_________________________________________ 
New Family:  Yes    No    (If no, please fill in family name)  Family name: ________________________________________ 
Medical Aid: ________________________________________________Medical Aid No: ________________________________ 
Sex:     M        F    Date of Birth:  Year:_____________  Month:_____________________  Day: ______________________ 
Number  of children: ______________________________________ 
Ethnic Origin : ( please indicate ancestry of both your mother and father )_______________________________________________ 
        Fax: 
Contact Address:  ____________________________________ Town: _______________________ Tel: ___________________ 
        Fax: 
Referring Doctor/Sister: ______________________________ Town:  ______________________ Tel: ___________________ 
        Fax: 
Hospital or Address:  _________________________________ Town:  ______________________ Tel: ___________________ 
 
 
Reason for Referral  (Clinical diagnosis): 
Affected                At Risk                 Carrier                 Spouse                 Query                 Unaffected   
Becker Muscular Dys.  Duchenne Muscular Dys   Colonic Carcinoma   
Fragile-X Syndrome   Bipolar Disorder  Huntington Disease  
Retinitis Pigmentosa   Spinocerebellar Ataxia   Waardenberg Syndrome   
 
Additional disorders (apparent or previously treated):  ______________________________________________________________ 
Additional family history                               _______________________________________________________________ 
Clinical Details: 
Physical disability           Mental retardation             Deafness             Impaired vision            Night blindness       
Other:  _________________________________________________________________________________________________ 
Have samples from this patient been sent to a DNA lab before? (DELETE WHERE NOT APPLICABLE)  YES / NO / Don't Know 
If Yes, where: ___________________________________________________________________________________________ 
 
For Laboratory use only: 
 
DNA number: _____________________________________  Vol.Blood: ________________(ml)     Other: _________________ 
 


















I, ____________________________________________________________________  , request that an attempt 
be made using genetic material to assess the probability that:  I /  my child  /  my  unborn child  (DELETE 
WHERE NOT APPLICABLE) might have inherited a disease-causing mutation in the gene 
for:______________________________________________________________________________________ 
  
2. I understand that the genetic material for analysis is to be obtained from:  blood cells/skin sample/other (specify) 
(DELETE WHERE NOT APPLICABLE) :     
  
3. I request that no portion of the sample be stored for later use.   (MARK IF APPLICABLE ) 
  Or 
I request that a portion of the sample be stored indefinitely for (DELETE WHERE NOT APPLICABLE): 
 ( a )  possible re-analysis 
 ( b )  analysis for the benefit of members of my immediate family 
 ( c )  research purposes,  subject to the approval of the University of Cape Town Research Ethics 
         Committee, provided that any information from such research will remain confidential. 
  
4. The results of the analysis carried out on this sample of stored biological material will be made known to me,  
via my doctor, in accordance with the relevant protocol,  if and when  available.  
In addition, I authorise that they may be made known to:  (DELETE WHERE NOT APPLICABLE) : 
 other doctors involved in my care 
 the following family members:   ___________________________________________________________ 
 other: _______________________________________________________________________________ 
  
5. I authorise / do not authorise my doctor(s) (DELETE WHERE NOT APPLICABLE) to provide relevant clinical 
details to the Division of Human Genetics, UCT. 
  
6. I have been informed that:  
( a ) there are risks and benefits associated with genetic analysis and storage of biological material and 
these have been explained to me.  
( b ) the analysis procedure is specific to the genetic condition mentioned above and cannot determine 
the complete genetic makeup of an individual. 
( c ) the genetics laboratory is under an obligation to respect medical confidentiality . 
( d ) genetic analysis may not be informative for some families or family members. 
( e ) even under the best conditions, current technology of this type is not perfect and could lead to 
incorrect results. 
( f ) where biological material is used for research purposes, there may be no direct benefit to me. 
  
7. I understand that I may withdraw my consent for any aspect of the above at any time without this affecting my 
future medical care. 
  
8. ALL OF THE ABOVE HAS BEEN EXPLAINED TO ME IN A LANGUAGE THAT I UNDERSTAND 
AND MY QUESTIONS ANSWERED BY: 
  
    ____________________________    DATE:     __________________                              
 
 
Patient signature _____________________   Witnessed consent    ___________________________ 
 
 













APPENDIX 2B: CLINICAL FEAUTURES OF PATIENTS SELECTED FOR WHOLE-GENOME CNV ANALYSIS 





XLMR  M 
AFFECTED MALE 1(FX76.2): Severe MR, Global developmental delay, Delayed speech, Asymmetrical hearing loss, 
Epileptic seizures, Ataxia, Small stature, Wheelchair bound 
Gross gastric reflux and delayed gastric emptying, Chronic URTI 
Splenomegaly (may relate to respiratory infection), hepatomegaly, Ear infections – grommets 
Behavior: Poor eye contact, Aggressive, Limited social interaction, Autism spectrum  
AFFECTED MALE 2 (XMR3): Severe MR, Unable to speak, Coarse facial features 
MOTOR: Epilepsy, Jerking eye movements, Hypotonic bilaterally, Hyporeflexia, “intractable” seizures, “floppy” no 
spontaneous movement, Contractures, Reflexes appear to be decreased on left side, 5yrs relatively fit-free period during which 
he was on a small dose of Valproate, Twitching, Todd’s paralysis in left side, Pyrexial fits 
INFECTIONS: Pneumonia, Hepatitis, severe prolonged encephalopathic illness, Prolonged chest infections 
Hyperactive 
Metabolic encephalopathy 
EEG left temporal abnormality 
2.  FX131 XLMR M 
Severe MR 
Mild hearing loss 
Large depigmented area on abdomen 
No eye contact 
Autism 
Possibility of hypopituatarism 
Bone of wrist in left hand appear amorphic 
Very poor speech development 








Dysmorphic features: Big ears, Simple ears 
“shawl scrotum” 

















 FAMILY  INHERITANCE EHTNICITY PHENOTYPE 







6.  FX181 XLMR M 




7.  FX233 XLMR M 




Dysmorphic features – large ears, Low set ears, Epicanthic folds 
8.  FX256 XLMR C 
Premature at 36 weeks 
Suspected patent ductus arteriosis after birth 
Tall stature 
Single seizure episode 
Dypsmorphic features -prominent forehead, Prominent metopic ridge, Up-slanting palpebral fissures, Down turned corners of 
mouth, Small nose with anteverted nares, Long philtrum, Heterochromia of iris, Low set ears, Simple ears 
Undescended testes 
9.  FX295 XLMR M 
Dysmorphic features - epicanthic folds, Long face, Arched brows, Prominent lips, Prominent ears 
Large hands 
Macro-orchidism 
10.  FX317 XLMR  


















 FAMILY  INHERITANCE EHTNICITY PHENOTYPE 
11.  FX338 XLMR  
Speech delay 
Microcephaly 
Dysmorphic features – simian crease, Bat ears, squint 
Café au lait spot 
No behavioural problems 




high pain tolerance 
13.  FX361 XLMR SIB PAIRS M 
History of diarrhoea and vomiting 
Myoclonic jerks 
Speech delay - expressive 
Cerebral interdigitations present in anterior interhemisphere area 
Seizures 
Dysmorphic features: Epicanthic folds, Palatine malformation: deep with a ridge in the middle, Hypotelorism 
14.  FX382 XLMR  




High arched palate 
Dysmorphic features – frontal bossing, Coarse facies, Malar hypoplasia, Bulbous nose, Micrognathia. Ptosis, Microcephalic, 
Squint 
Marfenoid habitus – tall, Long fingers, Cubitus valgus 





Hypothyroidism – subclinical 













 FAMILY  INHERITANCE EHTNICITY PHENOTYPE 
16.  FX403 XLMR  C 
Delayed walking 
Speech delay 
Recurrent ear infections and URTI 
Mild obesity 
Generalized hypotone 
Developmental coordination disorder 
17.  FX444 Isolated male  
profound mental retardation 
Growth retardation: height, weight head circumference all in 3rd centile 
Seizures (Lennox Gestualt epilepsy syndrome) 




No speech or ambulation 
18.  FX497 Isolated male M Dyplexia Machroorchidism 
19.  FX509 Isolated male M  
dysmorphism – fairly prominent ears and prominent incisor teeth 
absence of speech 
Unsteady gait and increased limb tone 
tonic-clonic seizures 
20.  FX512 XLMR  Dysmorphic features - tented upper lip, large tongue, Prominent lower lip, Protruding ears, Hypotonia 
21.  FX516 XLMR  SIB PAIRS C 
Facial dysmorphism 
CT: Dandy walker cysts? Posterior fossa malformation: megacisterna magna or posterior fossa arachnoid cyst 




Dysmorphic – large ears, Prominent jaw, Anti-mongoloid eyes, Deep-set eyes, Broad nasal bridge, Short neck, squint, 
“widows peak” 
Mild brachydactyly 
Height, weight and head circumference all normal 
Delayed bone age 
23.  FX520 Isolated male M 
behavioural problems: ADHD,  
aggressive 













*M= Mixed ancestry, C=Caucasian, B=Black 
 FAMILY  INHERITANCE EHTNICITY PHENOTYPE 






25.  XMR8 isolated M 
Severe mental handicap  
SKULL: microcephaly, Abnormal skull bones, Metopic suture open, 3rd fontanelle, Trigonocephaly 
BRAIN: Large ventricles anterior, posterior positive, bilateral ependymal cysts,  
FACIAL DYSMORPHISM: coup shaped mouth, flattened nasal bridge, hockey stick palmar crease, 3 hair ‘crowns’, 
Anterior sagittal cleft deep to root of nose, Narrow forehead, Narrow palate, Micrognathia, Flattened malar area, squint 
GENITOURINARY: Undescended testes, Both testes intra-abdominal, microgenitalia, disconnected vas, Umbilical hernia 
MOTOR: GOR, Vomiting, problems swallowing, Delayed brisk reflexes, Increased tone in arms, Hyperreflexia, Slight 
muscle hypotone, Not walking, Tremendous sensory aversion of feet, Reciprocal crawling, Triplegic, no definite spasticity 
SKELETAL: Right arms tends to be retracted at shoulder 
BEHAVIOUR: Aggressive and hysterical, irritable, frustrated. 
OTHER: Chest infections, Heart murmurs, Speech delay (no speech), Seizures 





Dysmorphism:  Broad forehead, brachycephaly, impression of mild hypertelorism, broad nasal root and tip 
CT brain: “classic lissencephaly”. Thick agyric cortical mantle posteriorly. Low white matter but normal myelination. 





Dysmorphic facies reminiscent of Noonan Syndrome 
ventricular septal defect 
Recurrent hypoglycaemia 
Septicaemia 






















APPENDIX 2C: ALL PRIMER PAIRS USED TO VALIDATE PUTATIVE CNVS  
Sample location primer name sequence Sample location primer name sequence 
Fx151 6q24.2-3 dup 
UTRN_E54_F agggagctatggatgacctg 
Fx277 Xp11.22-21 dup 
JARID1C_EX1_F tatacgaggctcggaaggac 
UTRN_E54_R tgcagcgagtcaatgagtaag JARID1C_EX1_R tcttggtttgtcagcgtctc 
EPM2A_E2_F aaacaacttggtggatggtg WNK3_E2_gF tctcctagtggcagattcctg 
EPM2A_E2_R gcttcatttcattggtgtgc WNK3_E2_gR cctcaacccatgtttcagtg 
SHPRH1_E9_F cacctctgattaccgctttg FGD1_5'upstream_F gaatagttttccccagcaatg 
SHPRH1_E9_R gttgccacaggtgacacttc FGD1_5'upstream_R accctcagttccctgatttg 
GRM1_E2_F tctgtatcgcccattctgac GNL3L_3'UTR F gtattcaggggcaaccaaag 
GRM1_E2_R gaagcctctctcggagtttg GNL3L_3'UTR R agggttaacggtggtaatgg 
STXBP5_E23_F ctccgctcttcatttctgtg USP51_g3'downstream_F catgcctagttccctgaacc 
STXBP5_E23_R gcaatgacaagcactgttcc USP51_g3downstream_R ggaggagtaaaagccaccag 
Fx233 14q32.12 dup 
BTBD7_E9_F tgcttgcagaccttctactcc 
Fx343 17p11.2 del 
NCOR1_gE30_F caccaccatcaaagaaatgg 
BTBD7_E9_R ttggtgatgccttattgtgg NCOR1_gE30_R ctggagttttccgactttcc 
ATXN3_E8_F tggttgcagttattaccagtgc FLCN_gE14_F cgacccaaagaggacacac 
ATXN3_E8_R gcaaatcctcctcatcttcg FLCN_gE14_R tccagaacttcagcagcttg 
NDUFB1_E1_F gtatgatttgctggcgtcac SMCR7_gE1_F gctccgattggagttaggg 
NDUFB1_E1_R cgagaccaagggcaacag SMCR7_gE1_R ctgggaatggaacgtgaag 
CPSF2_E15_F cttcaagcaagttctcttacgg SLC5A10_gE7_F gaccagatcggtggttacg 
CPSF2_E15_R cggactgctacttgattgttg SLC5A10_gE7_F caggtggtgttggcaatg 
RPS6KA5_E16_F ggcttgaggtacaatgaatgg MAP2K3_gE10_F atcctgcggttcccttac 





















Fx512 Xp11.3 dup 
CASK_E15_F attgagggtcacacctcctc 
ARHGEF6_E22 _R actggactcgcctcgaatac CASK_E15_R tgaaactgtaccagccgaac 
FGF13_E6_ F tccatgagccacaatgaatc EFHC2_5'UTR_F actgttggcgacaagaattg 
FGF13_E6 _R acttttgggtgaaggactgc EFHC2_5'UTR_R tgcacacacaaagattgactg 
F9_5'UTR_F cgaccttaccactttcacaatc FUNDC1_3'downstream F cagggctggtatcatacttcc 
F9_5'UTR_R tgatgaggcctggtgattc FUNDC1_3'downstream R gcttttcccaattccaacc 
SOX3_E1_F gcaatgtacagccttctggag UTX_3'UTR_F gcaccactggtttttgtagc 
SOX3_E1_R ctgcgttcgcactactcttg UTX_3'UTR_R cgtccagttggttgacactc 
LDOC1_E1_F gaaccgattctgcaacgac SLC9A7_E17_F tgtttcccctggaagataatg 
LDOC1_E1_R ggatggggctatccatctc SLC9A7_E17_R aacaacactagggcttgcag 
SPANXN4_E2_F cgtttacctgctgctcctg 
Fx512 Xp22.11 Dup 
MBTPS2_E7 _F cctttttgtgggagaccttg 
SPANXN4_E2_R tgctgtgcatctacccagtc MBTPS2_E7 _R aaccaatttggggctcatag 
UBE2NL_3'end_F cagtcagcataggcaaagagtc ACOT9_E17_ F acccacagtgacgtggtatc 
UBE2NL_3'end_R catcttttgacgccagtcc ACOT9_E17_ R gctgaatacatcctcctcctg 
SLITRK2_E2_F tttgccccttcctatgaatc KLHL15_E3_ F gtggtgaagttctgctgctc 
SLITRK2_E2_R gtggttgggttttgactgc KLHL15_E3_ R tgactccctcgatgtttacg 
Xq27.3_1_ F acctgactttgatctgtcactacc POLA_E9_ F gcaatggagtttgaagatgg 
Xq27.3_1_ R ccctccttggctcttacttg POLA_E9_ R ctgctggctcactctctttg 
Xq27.3_2_ F catttgccaacggagtaatg MAGEB6_5 upstream _F aggaccagccaggtttagag 
























ZDHHC9_E11_gR tgtcagagtggatgggagac THOC2_Ex23_R tcgttcatagctggtgtgtg 
AIFM1_5'upstream_F aggtcagggattcaaacagc STAG_Ex20_F ggatgccttattgcgacag 
AIFM1_5'upstream_R ctcagcagaaatggatttgg STAG_Ex20_R actcttcattacagagtgcatgg 
SUHW3_3' upstream_F aaagaacagggaaatctgcac STAG2_Ex34_gF cccctctctctctctcattagg 
SUHW3_3' upstream_R tgcacattcgtcacaacatc STAG2_Ex34_gR ccacttagaaaatgacttcaccac 
SUHW3_5'UTR_F caccaaatagagcacaacttcc ODZ1_Ex3_F ggaagaaaaccaagacagtcatac 
SUHW3_5'UTR_R tgaagcactgatctcatggac ODZ1_Ex3_R ggctattgtaattcatcctcagc 
GPR119_3’'downstream_F aatgacaaggttggcagatg 
XMR12 4p16.2Del 
RGS12_Ex2 _F gggctacttaggctccattg 
GPR119_3'downstream_R gaaaggcagagagtggttcc RGS12_Ex2 _R cgagtggattttctgctctg 
XMR8 Xq28Dup 
CUL4B_gE3_F cctttacaacccagggattc BC042381_Ex1 _F gaacctggagagagccagag 
CUL4B_gE3_R acgcagcttcttctgtatcg BC042381_Ex1 _R gttgaccttttcccaacgtc 
GRIA3_gE11_F cccctggcttatgaaatctg ADRA2C_Ex3 _F ttagagagcagtggcagagg 
GRIA3_gE11_R ttgtcttccaagtgccattc ADRA2C_ Ex3_R ccgactaggtcctggagaag 
GRIA3_Ex12_F aatctcgctgctttcctgac TMEM128_Int2 _F gcctagaatgagctgttggag 
GRIA3_Ex12_R ttcttttgttgaaccggagtc TMEM128_Int2_R tggaggctgagatgtgtttg 


















APPENDIX 2D: PRIMER PAIRS USED FOR MICROSATELLITE 
MARKER ANALYSIS IN FAMILY FX444 
 
Table 2C Details of the X-chromosomal microsatellite markers used for haplotype 





Heterozygosity Size (bp) 
Fluorescent tag (i.e. 
M13 forward primer 
used) 
DXS1071 1.7 - 110-130 Fam 
DXS1223 8.3 0.75 150-160 Fam 
DXS8022 13.7 0.81 190-210 Fam 
DXS1202 26.2 0.81 240-260 Hex 
DXS8090 36.7 0.81 260-270 Ned 
DXS1003 46.3 0.80 160-180 Ned 
DXS1199 53.6 0.72 340-360 Hex 
DXS8092 73.9 0.87 140-160 Rox 
DXS990 92.8 0.77 160-180 Hex 
DXS1220 114.4 0.71 190-210 Fam 
DXS1212 122.2 0.73 320-340 Rox 
DXS1192 138.1 0.84 190-210 Rox 
















APPENDIX 2E: ALL CNVS DETECTED IN 30 MR PATIENTS USING THE 250K NSP AFFYMETRIX ARRAY 
PATIENT DUP/ DEL chromosome BAND 
SIZE 
(Mb) 
START  END  
ACTION 
SNP id Chromosomal position SNP Id 
Chromosomal 
position 
1.  FX76 DUP 14 q11.2 0.16 rs4412905 19,336,854 rs10141075 19,489,991 CNP 
2.  FX76 DUP 15 q11.2 0.98 rs4931862 18,427,103 rs1346662 19,407,629 CNP 
3.  FX76 DEL 18 q12.1 0.007 rs6507033 29 277 562 rs6507040 29 285 278 No genes in region 
4.  FX131 DUP 7 q11.22 0.58 rs517781 70,638,772 rs17147106 75,859,448 Not CNP, XLMR family 
5.  FX131 DEL 8 q24.23 0.17 rs894089 137,861,009 rs7842167 137,931,617 CNP 
6.  FX131 DEL 14 q11.2 0.15 rs1782195 19,336,854 rs8022497 19,489,991 CNP 
7.  FX131 DUP 15 q13.3 0.42 rs7174213 29,806,023 rs4238560 30,231,488 CNP 
8.  FX141 DUP 4 q28.2 0.7 rs2391537 131 081 327 rs9917861 131 775 687 CNP 
9.  FX141 DEL 5 p13.1 0.06 rs1363883 41,293,670 rs399760 41,300,320 CNP 
10.  FX141 DEL 14 q11.2 0.15 rs1782195 19,336,854 rs8022497 19,489,991 CNP 
11.  FX141 DUP 17 q21.31 0.2 rs17659881 41,518,102 rs2732615 41,719,833 CNP 
12.  FX143 DUP 11 q23.3 0.94 rs1624049 115 542 441 rs12271161 116 485 121 Not CNP, XLMR family 
13.  FX151 DEL 2 q37.3 0.08 rs7600642 242,636,531 rs6759916 242,717,659 CNP 
14.  FX151 DUP 6 q24.3 1.07 rs581234 145 649 820 rs9403788 146 827 677 Verify by gQPCR 
15.  FX151 DEL 14 q11.2 0.15 rs1782195 19,336,854 rs8022497 19,489,991 CNP 
16.  FX181 DEL 1 q31.3 0.15 rs424535 193,462,805 rs4915559 193,614,160 CNP 
17.  FX181 DUP 11 p15.1 0.34 rs1384649 18,896,898 rs7104587 18,930,870 CNP 
18.  FX181 DUP 15 q11.2 0.68 rs4931862 18427103 rs8040821 19112164 CNP 
19.  FX233 DUP 14 q32.12 0.3 rs4900092 91 499 257 rs2402130 91 870 956 Verify by gQPCR 
20.  FX233 DEL 14 q11.2 0.15 rs1782195 19,336,854 rs8022497 19,489,991 CNP 












PATIENT DUP/ DEL chromosome BAND 
SIZE 
(Mb) 
START  END  
ACTION 
SNP id Chromosomal position SNP Id 
Chromosomal 
position 
22.  FX256 DUP 11 p15.1 0.34 rs1384649 18,896,898 rs7104587 18,930,870 Not CNP, XLMR family 
23.  FX277 DEL 5 q23.3 0.01 rs7719223 127,852,880 rs6595831 127,863,541 Not CNP, XLMR family 
24.  FX277 DUP 6 q21 0.53 rs17065302 105,336,339 rs1211490 105,864,431 CNP 
25.  FX277 DEL 14 q11.2 0.15 rs1782195 19,336,854 rs8022497 19,489,991 CNP 
26.  FX277 DUP 17 q21.31 0.2 rs17659881 41,518,102 rs2732615 41,719,833 CNP 
27.  FX277 DUP X p11.22 0.7 rs2495782 54,081,339 rs5960365 54,787,066 Verify by gQPCR 
28.  FX295 DUP 2 q14.3 0.11 rs4662794 128,748,055 rs4662808 128,861,934 Not CNP, XLMR family 
29.  FX295 DEL 10 q11.22 0.05 rs10906958 47030119 rs7088096 47079558 CNP 
30.  FX295 DEL 12 p12.1 0.05 rs16926687 23778139 rs11047098 23835465 Not CNP, XLMR family 
31.  FX295 DUP 17 q12 0.5 rs1614133 31,429,427 rs2277662 31,923,810 CNP 
32.  FX317 DEL 9 p24.1 0.09 rs1658957 6,662,097 rs7861740 6,759,429 CNP 
33.  FX317 DUP 11 p15.1 0.03 rs1384649 18,896,898 rs7104587 18,930,870 CNP 
34.  FX317 DUP 14 q11.2 0.16 rs4412905 19,336,854 rs10141075 19,489,991 CNP 
35.  FX317 DUP 22 q11.21 0.4 rs2252257 17,014,854 rs10854539 17,412,288 CNP 
36.  FX338 DUP 9 q33.3 0.11 rs3850586 126,566,536 rs6478760 126,682,300 Not CNP, XLMR family 
37.  FX338 DUP 14 q31.3 0.1 rs17730574 83,607,255 rs7151936 83,704,489 Not CNP, XLMR family 
38.  FX343 DEL 17 p11.2 3.2 rs9910842 16,486,774 rs188138 19,689,696 Verify by gQPCR 
39.  FX361 DEL 11 q11 0.14 rs2868510 55,217,364 rs7114700 55,364,837 CNP 
40.  FX361 DUP 14 q11.2 0.16 rs4412905 19,336,854 rs10141075 19,489,991 CNP 
41.  FX361 DUP 15 q11.2 0.68 rs4931862 18427103 rs8040821 19112164 CNP 
42.  FX361 DUP 17 q21.31 0.12 rs17659881 41 521 621 rs2732615 41 719 833 CNP 
43.  FX382 DUP 8 q11.22 0.54 rs7012121 48,124,531 rs6988862 48,669,181 CNP 
44.  FX398 DEL 14 q11.2 0.15 rs1782195 19,336,854 rs8022497 19,489,991 CNP 












PATIENT DUP/ DEL chromosome BAND 
SIZE 
(Mb) 
START  END  
ACTION 
SNP id Chromosomal position SNP Id 
Chromosomal 
position 
46.  FX398 DUP X p22.31 0.36 rs2732615 8,218,944 rs2018496 8,576,027 CNP 
47.  FX403 DUP 22 q11.23 0.28 rs3912046 23,967,181 rs4822638 24,249,632 CNP 
48.  FX444 DEL 14 q11.2 0.15 rs1782195 19,336,854 rs8022497 19,489,991 CNP 
49.  FX444 DUP 22 q11.23 0.28 rs3912046 23,967,181 rs4822638 24,249,632 CNP 
50.  FX444 DEL X q26.3 2.3 rs2071718 137,664,347 rs10521805 139,947,192 Verify by gQPCR 
51.  FX444 DEL X q27.2 2 rs7877128 140,649,041 rs5908815 142,651,304 Verify by gQPCR 
52.  FX444 DEL X q27.3 1.5 rs2815669 143,463,144 rs5965692 144,985,690 Verify by gQPCR 
53.  FX497 DUP 14 q11.2 0.16 rs4412905 19,336,854 rs10141075 19,489,991 CNP 
54.  FX497 DEL 15 q11.2 0.98 rs4931862 18,427,103 rs1346662 19,407,629 CNP 
55.  FX497 DUP 15 q26.3 0.15 rs7182422 98,752,615 rs8024825 98,905,734 CNP 
56.  FX497 DEL 20 p11.21 0.03 rs3746726 22,936,426 rs2424503 22,969,778 CNP 
57.  FX509 DEL 11 q11 0.14 rs11823507 55,217,364 rs7951100 55,364,837 CNP 
58.  FX509 DUP 14 q11.2 0.15 rs1782195 19,336,854 rs8022497 19,489,991 CNP 
59.  FX509 DEL 14 q31.3 0.07 rs1088638 86,533,539 rs2301487 86,603,364 No genes in region 
60.  FX509 DUP 16 p11.21 0.45 rs1088638 31,010 rs2301487 487,298 CNP 
61.  FX509 DEL 20 p11.21 0.03 rs3746726 22,936,426 rs2424503 22,969,778 CNP 
62.  FX512 DUP 17 p13.1 0.5 rs1614133 31,429,427 rs2277662 31,923,810 CNP 
63.  FX512 DUP 19 p12 0.17 rs8100262 20,613,342 rs587212 20,789,636 Not CNP, XLMR family 
64.  FX512 DUP X p22.11 1.71 rs17332633 23,174,529 rs5944738 24,937,819 Verify by gQPCR 
65.  FX512 DUP X p11.3 1.47 rs5952991 43,582,574 45054364 45,054,364 Verify by gQPCR 
66.  FX516 DEL 2 q37.3 0.08 rs12623542 242,636,531 rs6759916 242,717,659 CNP 
67.  FX516 DEL 15 q11.2 0.27 rs1346662 19,821,421 rs4300610 20,089,383 CNP 
68.  FX517 DEL 8 p23.2 0.08 rs1217655 4,293,738 rs7004990 4,376,431 CNP 












PATIENT DUP/ DEL chromosome BAND 
SIZE 
(Mb) 
START  END  
ACTION 
SNP id Chromosomal position SNP Id 
Chromosomal 
position 
70.  FX520 DEL 5 q25 0.01 rs1428419 123,563,404 rs922555 123,573,747 No genes in region 
71.  FX520 DUP 11 p15.1 0.03 rs1384649 18,896,898 rs7104587 18,930,870 CNP 
72.  FX520 DEL 14 q11.2 0.15 rs1782195 19,336,854 rs8022497 19,489,991 CNP 
73.  FX523 DEL 14 q11.2 0.15 rs1782195 19,336,854 rs8022497 19,489,991 CNP 
74.  XMR8 DUP 11 q21 0.04 rs12271216 96,191,471 rs17129651 96,195,684 No genes in region 
75.  XMR8 DUP 14 q11.2 0.15 rs1782195 19,336,854 rs8022497 19,489,991 CNP 
76.  XMR8 DUP X q25 0.95 rs12396914 122,318,959 rs5958482 123,271,569 Verify by gQPCR 
77.  XMR12 DEL 1 q21.1 1.09 rs7544630 144,607,366 rs0 145,700,996 CNP 
78.  XMR12 DEL 4 p16.3 0.18 rs10937909 4,102,877 rs17629551 4,283,407 Verify by gQPCR 
79.  XMR12 DUP 7 q11.23 0.58 rs1019096 75,788,276 rs17722395 76,367,046 CNP 
80.  XMR12 DEL 9 q21.1 0.02 rs4745105 71,476,355 rs2131039 71,491,754 No genes in region 
81.  XMR12 DEL 20 p11.21 0.03 rs3746726 22,936,426 rs2424503 22,969,778 CNP 
82.  XMR13 DEL 9 q24.1 0.02 rs10815203 5,374,069 rs1535454 5,400,723 CNP 
83.  XMR13 DUP 14 q11.2 0.39 rs2075497 21,634,087 rs17118670 22,029,666 CNP 
84.  XMR13 DUP 17 q12 0.05 rs1614133 31,429,427 rs2277662 31,923,810 CNP 
85.  XMR14 DEL 3 q25.32 0.25 rs9840667 159,349,247 rs9876322 159,601,940 CNP 
86.  XMR14 DEL 8 q24.23 0.17 rs894089 137,757,412 rs7842167 137,931,617 CNP 
87.  XMR14 DUP 11 p15.1 0.03 rs1384649 18,896,898 rs7104587 18,930,870 CNP 
88.  XMR14 DEL 14 q11.2 0.15 rs1782195 19,336,854 rs8022497 19,489,991 CNP 
89.  XMR14 DUP 17 p13.1 0.5 rs1614133 31,429,427 rs2277662 31,923,810 CNP 
90.  XMR14 DEL 20 p11.21 0.03 rs3746726 22,936,426 rs2424503 22,969,778 CNP 
91.  XMR14 DEL X q25 0.14 rs488876 129,100,777 rs5932743 129,238,278 Verify by gQPCR 













APPENDIX3A: PEDIGREES OF FAMILIES FOR X-






Figure 3A1 Pedigree of family Fx56 
Figure 3A2 Pedigree of family Fx36 
 





















Figure 3A4 Pedigree of family XMR2  
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APPENDIX3B: MICROSATELLITE MARKERS USED FOR XLMR 
LINKAGE ANALYSIS. 
 







DXS1060 4.8   FX67  0.8 134-150 Ned  
DXS987 15.7   FX67  0.83 256 Fam 
DXS1226 22.8   FX67  0.89 199-223 Ned 
DXS1048 26.8   FX67  0.74 109 Unlabelled 
DXS1218 29.2   FX67  0.67 255-275 Unlabelled 
DXS9896 29.5   FX67  0.82 192-232 Fam 
DXS1214 31  FX56 FX67 XMR2 0.79 285-298 Hex 
DXS1235 31.7   FX67   233 Fam 
DXS1237 31.8   FX67   156 Hex 
DXS1068 38  FX56 FX67 XMR2 0.79 244-264 Hex 
DXS8042 39.7   FX67  0.72 145-173 Unlabelled 
DXS993 40 FX36 FX56 FX67 XMR2 0.79 267-293 Fam 
DXS6810 42 FX36 FX56 FX67 XMR2 0.69 208-223 Fam 
G10578 44.7 FX36 FX56 FX67 XMR2 0.79 218-261 Fam 
DXS1199 53.7 FX36 FX56 FX67 XMR2 0.76 277-295 Fam 
DXS991 55 FX36 FX56 FX67 XMR2 0.8 313-341 Ned 
DXS1190 55.5 FX36 FX56 FX67 XMR2 0.68 260 Hex 
DXS6785 64.4 FX36 FX56 FX67 XMR2 0.77 143-163 Fam 
DXS8111 68.3    XMR2 0.72 161-171 Hex 
DXS8052 69.6    XMR2 0.78 90-110 Fam 
DXS559 70.8 FX36 FX56 FX67 XMR2 0.74 230-242 Unlabelled 
DXS441 75.2    XMR2 0.75 173-183 Fam 
DXS56 76.8    XMR2 0.75 260-290 Hex 
DXS986 79 FX36 FX56 FX67 XMR2 0.77 151-181 Fam 
DXS990 93  FX56 FX67 XMR2 0.74 122-132 Fam 
DXS6789 95.3   FX67  0.78 118-150  
DXS1106 102  FX56 FX67 XMR2 0.67 126-140 Hex 
DXS8055 114  FX56 FX67 XMR2 0.65 312-324 Hex 
DXS1001 119  FX56 FX67 XMR2 0.82 191-211 Hex 
DXS1047 128  FX56 FX67 XMR2 0.81 156-172 Hex 
DXS1227 140  FX56 FX67 XMR2 0.73 79-99 Fam 
DXS8043 143  FX56  XMR2 0.8 146-180 Ned 
DXS8091 147  FX56  XMR2 0.78 80-102 Hex 
Microsatellite markers of the ABI® Prism Linkage Mapping Set V2 Panel 28 [Applied Biosystems] 
appear in bold  































APPENDIX3D: DETAILS OF PCR AMPLIFICATION OF ALL 
FINE-MAPPING MICROSATELLITE MARKERS USED IN 
GENOTYPING ANALYSIS FOR XLMR FAMILIES 
 
Table 3D1 PCR reagents used for amplification of the fine mapping microsatellite 








DXS1190/  DXS6785/ DXS411/ DXS8111/ DXS8052/ 
DXS56/ DXS6789/DXS1235/ DXS1237/DXS1048/ 
DXS1218/ DXS8042/ DXS9896 
Forward Primer 
(20µM) 
8µM 8µM 10µM 10µM 
Reverse Primer 
(20µM) 
8µM 8µM 10µM 10µM 
dNTP’s (5µM) 
(Bioline) 
5µM - - 5µM 
Buffer (5X)  
(Promega) 
1× - - 1× 
Failsafe buffer J (2X) 
(Epicentre 
Technologies) 
- 1× 1× - 
Go Taq Polymerase 
(5U/µl) 
 (Promega) 
0.5U 0.5U 0.5U 0.5U 
DNA 50ng 50ng 50ng 50ng 
FINAL REACTION 
VOLUME 
10µl 10µl 10µl 10µl 
 
Table 3D2 PCR conditions for amplification of the fine mapping microsatellite markers 
used in the genotyping analysis of XLMR families. 
Condition MICROSATELLITE MARKERS 
 DXS6810 G10578/  DXS1199/ DXS1190/ DXS6785 
DXS559/ DXS411/ DXS8111/ 
DXS8052/ DXS56/  DXS1235/ 
DXS1237/ DXS1048/ 
DXS1218/ DXS8042/ DXS9896 
Initial denaturation 94ºC (3 min)  94ºC (3 min) 95ºC (5 min) 
Cycling conditions 







55 ºC (75 sec) 
72 ºC (15 sec) 
 
 
94 ºC (1min) 
55 ºC (1min) 
72 ºC (1min) 
 
 
95 ºC (30 sec) 
56 ºC (30 sec) 
68 ºC (30 sec) 














APPENDIX4A: PCR PRIMERS USED IN THE AMPLIFICATION 
OF ALL POSITIONAL CANDIDATE GENES 
Table 4A1 Primer pairs used to amplify the ATRX mutation hotspots 
Primer set Primer Tm (‘c) Gc (%) Mer (bp) Product(bp) Sequence (5’-3’) 
PHD domain 
Exon 5 Fwd 50 45 20  attactatgcagagcttgcc 
Exon 9 Rev 53 45 22 691, 581, 467 * gtgcggaataagagtaggttac 
Helicase domain 
hotspot 1 
Exon 17 Fwd 54 55 20 626 tgtgggattgctgctgtgag 
Exon 21 Rev 52 39 23  tctattcctgaactccttaatgg 
Helicase domain 
hotpot 2 
Exon 25 Fwd 50 43 21 687 gttgaagtgattaaggtctgg 
Exon 30 Rev 50 45 20  tgcttagttacttgccgatc 
* There are three isoforms of the ATRX mRNA transcript, the three product sizes (691bp, 581bp, 467bp) correlate 
with the un-spliced, spliced (exon 7 removed) and a second spliced (exons 6 and 7 removed) isoform respectively. 
 
Table 4A2 PCR primer details for amplification of the nine ATP6AP2 exons 
Primer Tm (‘C) Gc (%) Mer (bp) Product Size (bp) Sequence (5’-3’) 
Exon 1 Fwd 53 58 19 360 ctgtcgcttcccaggttac 
Exon 1 Rev 52 50 20  atccagagaagatgctgacg 
Exon 2 Fwd 54 52 21 333 cgctaagtcagtggtgaatgg 
Exon 2 Rev 52 48 21  gtacctacgttcgtttgatgc 
Exon 3 Fwd 52 50 20 433 gtcagtgtcatctcagaacc 
Exon 3 Rev 53 58 19  gagaacagccaagcctcag 
Exon 4 Fwd 50 43 21 402 tgtttaatcttctgtgccctc 
Exon 4 Rev 52 50 20  ccaatacccagaggtatgac 
Exon 5 Fwd 52 50 20 402 gtcatacctctgggtattgg 
Exon 5 Rev 53 43 23  caagtagtataaggaatgggagg 
Exon 6 Fwd 54 52 21 248 gtgccttgcttggtaaatggc 
Exon 6 Rev 51 41 22  ggatcataaatctagggcatac 
Exon 7 Fwd 52 50 20 372 ggctgtgtttgacgtctttc 
Exon 7 Rev 52 50 20  ttgaccctactccatccttg 
Exon 8 Fwd 52 50 21 364 gtggacttaagccattccac 
Exon 8 Rev 51 53 19  ctgctcattcatgtcaccc 
Exon 9 Fwd 52 48 21 486 gaatcacagtcactagactgg 
Exon 9 Rev 53 58 19  ccacagtgggattcacgtc 
 
Table 4A3 PCR primer details for amplification of the seven TM4SF2 exons 
Primer Tm (‘C) GC (%) Mer (bp) ProductSize  (bp) Sequence (5’-3’) 
Exon 1 Fwd 59 78 18 428 cccgtgtcgcctcgcctg 
Exon 1 Rev 58 65 20  atggacagcgactcggccac 
Exon 2 Fwd 55 50 22 350 ccacattgctctgtgctgattc 
Exon 2 Rev 54 62 21  tgtgacctcaagacgaaccac 
Exon 3 Fwd 55 50 22 199 ccgctgattgaaagtaacctac 
Exon 3 Rev 54 52 21  caccccttaactgagttctgc 
Exon 4 Fwd 54 55 20 227 tggagtcagtttgggctgtg 
Exon 4 Rev 55 50 22  caacctacaggcagtccataag 
Exon 5 Fwd 52 50 20 273 acaaggcagtgattgaggag 
Exon 5 Rev 52 50 20  ccaaacattcaccactggtc 
Exon 6 Fwd 54 55 20 197 tcgagtacacatagcccagc 
Exon 6 Rev 54 52 21  cagaggaaaggttagaccagg 
Exon 7 Fwd 54 55 20 234 gtgtggttcggtgacttgag 













APPENDIX 5A: ALL ARX MUTATIONS REPORTED TO DATE 





Mutation Protein change Disorder # cases Reference 
Patients Families  





(16  25 ALA) 




(16  23 ALA) 
ISSX/West syndrome 10 2 (Stromme et al. 2002b) 
West syndrome and dystonia 3 1 (Wohlrab et al. 2005) 
ISSX with severe dyskinetic quadriparesis 6 4 (Guerrini et al. 2007) 
MR and Lennox-Gastaut epilepsy syndrome 1  1 (Wallerstein et al. 2008) 
MRX (including tonic seizures and dystonia but not infantile 
spasms) 1  1 (Shinozaki et al. 2009) 
MRX (non-epileptic seizures, movement disorder) 1 1 (Poirier et al. 2008) 
  Ohtahara syndrome with complex movement disorder 1 1 (Absoud et al. 2009) 
c.304ins(GCG)2 
A102_A111insAA 
(16  18 ALA) MRX (moderate MR, no seizures) 2  1 
(Bienvenu et al. 2002) 
c.333ins(GCG)3 
A102_A111insAAA 
(16  19 ALA) MRX (hypotonia, autism spectrum disorder) 1 1 
(Gronskov et al. 2004) 













Mutation Protein change Disorder # cases Reference 
Patients Families  










MRX( moderate, no seizures, speech deficit, sporadic-seizures) 14 5families 1 sporadic (Bienvenu et al. 2002) 
MRX 11  2 (Stromme et al. 2002b) 
Partingtons syndrome 13  2 (Stromme et al. 2002b) 
ISSX/ West syndrome 7 1 (Stromme et al. 2002b) 
MRX  30  4 (Stepp et al. 2005) 
West syndrome Sporadic (Kato et al. 2003) 
MRX (including seizures and dystonia) 8 3 (Partington et al. 2004) 
MRX (including Partington sign and hypotonia) 1 1 (Gronskov et al. 2004) 
MRX (including speech difficulties, macroorchidism, lower limb 
spasticity or foot dystonia and facial telangiectasia) 18  5 (Szczaluba et al. 2006) 
MRX (mild-severe MR, focal hand dystonia, spasticity, seizures, 
autism, brain cysts,  macroorchidism,  facial telangiectasia) 
21  5 (Nawara et al. 2006) 
Partingtons syndrome, MRX (mild-severe,speech delay, hypotonia) 9  4 (Poirier et al. 2006) 
MRX (moderate – profound and minor congenital anomalies) 5  1 (Laperuta et al. 2007) 
MRX 3  1 (Rujirabanjerd et al. 2007) 
Partingtons syndrome 1  1 (Rujirabanjerd et al. 2007) 





MRX (profound  MR, including infantile-onset seizures) 3 1 (Reish et al. 2009) 














Table 5A2: ARX mutations associated with a malformation clinical presentation 
Mutation Protein change Disorder # cases Reference 
Patients Families  
c.196+2T>C Exon1 skipping XLAG sporadic (Kato et al. 2004) 
c.232G>T p.E78X XLAG (ACC in females) 5 (3 females)  2 (Kato et al. 2004) 
c.335_368del p.A112_G123del&fs XLAG Sporadic (Kato et al. 2004) 
c.392_452del p.P131_A151del&fs XLAG Sporadic (Kato et al. 2004) 
Mutation Protein change Disorder # cases Reference 
Patients Families  
c.81C>G 
p.Y27X 
alternate AUG usage 
p.M41_C562 
Ohtahara syndrome/ West Syndrome 2 1 (Fullston et al. 2010) 
c.98T>C p.L33P MRX (moderate to profound, sei(Stromme et al. 2002a)(Stromme et al. 2002a)zures) 7 1 (Bienvenu et al. 2002) 
c.112C>T p.P38S MRX (including speech delay, truncular obesity, autism) 2 1 (Poirier et al. 2006) 
c.490A>G p.Q163R MRX (moderate to profound MR,  includes cerebellar symptoms, seizures) 6  1 (Bienvenu et al. 2002) 
c.856G>A p.G286S MRX (moderate MR, includes macrocephaly, scoliosis, hypertelorism, seizures) 4  1 (Bienvenu et al. 2002) 
c.1058C>T p.P353L XMESID 6  1 (Scheffer et al. 2002, Stromme et al. 2002b) 
c.1465delG Fs491X MRX (affected female, seizures) 1  1 (Wallerstein et al. 2008) 
IVS4-816_EX5701 
Del (1517bp) 
p.R484fs ISSX/ West syndrome 2  1 (Scheffer et al. 2002) 












c.420_451del  Fs140X XLAG 1 confirmed (familial) (Kitamura et al. 2002) 
Mutation Protein change Disorder # cases Reference 
Patients Families  
c.428-451dup p.A155_W156insAAAAAAAA (1220Ala) Transsphenoidal encephalocele and hypopituitarism 2 1 (Van Esch et al. 2004) 
c.617delG p.G206fs XLAG 1 confirmed (familial) (Kato et al. 2004) 
c.619_647del p.V207_A216del&fs XLAG 1 confirmed (familial) (Kato et al. 2004) 
c.790delC p.R264fsX324 XLAG with ACC (Proud syndrome) 
sporadic  (Uyanik et al. 2003) 
XLAG 1 confirmed (familial) (Kitamura et al. 2002) 
c.994C>T p.R332H XLAG with ACC (Proud syndrome) sporadic  (Uyanik et al. 2003) 
c.995 G>A p.R332H XLAG sporadic (Kitamura et al. 2002) 
c.995G>C p.R332P XLAG sporadic (Kato et al. 2004) 
c.998C>A p.T333N Proud/ACC 3  1 (Kato et al. 2004) 
c.1028T>A p.L343Q XLAG 2  1 (Kitamura et al. 2002) 
c.1058C>G p.P353R XLAG 1 confirmed (familial) (Kato et al. 2004) 
c.1105G>T p.E369X hydraencephaly, abnomal genetalia sporadic (Kato et al. 2004) 
c.1117C>T p.Q373X XLAG sporadic (Kitamura et al. 2002) 
c.1119+1G>C Skipping of exon 3 XLAG 1 confirmed (familial) (Kato et al. 2004) 
c.1188insC Fs396X XLAG sporadic (Kitamura et al. 2002) 
c.1372delG Fs457X XLAG 
sporadic (Kitamura et al. 2002) 
XLAG sporadic (Kato et al. 2004) 
c.1561G>A p.A521T XLAG/LCH sporadic (Kato et al. 2004) 
EX1_2Del No protein XLAG 1 confirmed (familial) (Kitamura et al. 2002) 
EX2_5Del G66_C562Del XLAG (ACC in females) 2  1 (Kato et al. 2004) 
Total of malformation ARX mutation positives 34 26  
ACC:  Ageneis of Corpus Callosum 













APPENDIX5B: ALL PUBLISHED MUTATIONS IN KDM5C 








2 c. 202_203insC Arg68fsX7 
Severe MR 




Aggressive behaviour  
(Jensen et al. 2005) 
3 c.229G>A Ala77Thr 
Severe MR 
Broad hands  with 
brachydactyly 
Delayed speech 




Affected females (mild MR) 
(Abidi et al. 2008) 
3 c.260A>G Asp87Gly Mild MR No speech 
(Tzschach et al. 
2006) 
8 c.994C>T Arg332X 
Severe MR 
No speech 
Mother- mild MR  
(Tzschach et al. 
2006) 
9 c.1162G>C Ala388Pro 
Mild MR  
 Microcephaly 
Mild dysmorphic facial 
features 
(Jensen et al. 2005) 
9 c.1204G>T Asp402Tyr 




(Jensen et al. 2005) 
10 c. 1353C>G Ser451Arg 
Severe MR 
Mild dysmorphism – large 
ears 
Overfriendly, anxious. 
(Santos et al. 2006) 
11 c.1510G>A Val504Met 





(Abidi et al. 2008) 
Intron 
11 c.1583+5>A Glu468fsX2 




Mild asymmetry of legs and 
arms 
Hypertonia 
 brisk plantar reflexes 
(Abidi et al. 2008) 





High/prominent nasal bridge 
Females- learning disabilities/ 
mild MR  
(Rujirabanjerd et al. 
2009) 
14 c.1924T>C Phe642Leu 
Severe MR  
No speech 
Seizures 
Aggressive behaviour  

























(Jensen et al. 2005) 
15 c.2092G>A Glu698Lys Severe MR (Jensen et al. 2005) 
15 c.2191C>T Leu731Phe 
Severe MR 






(Jensen et al. 2005) 
15 c.2248C>T Arg750Trp Severe MR No speech 
(Tzschach et al. 
2006) 
16 c.2252A>G Tyr751Cys Moderate MR (Tzschach et al. 2006) 
16 c.2296C>T Arg766Trp Autism (Adegbola et al. 2008) 
21 c.3258_3259insC Lys1087fsX43 
Severe MR 
Speech delay 
Short stature  
Epilepsy 
Prominent ears, nose, 
eyebrows 
Abnormal skin pigmentation  
Hyperreflexia, spasticity 
Flexion contractor 
Broad feet, bulbous fingertips 
Female-learning disability 
(Rujirabanjerd et al. 
2009) 
23 c.3864G>A Trp1288X 
Severe MR  
Spasiticity 
 Epileptic seizures 
Short stature  
Microcephaly 
Hypermetropia 
Affected female with mood 
disorder 
(Jensen et al. 2005) 
26 c.4441_4442delAG Arg1481fsX9 





















APPENDIX 5C: PATIENT COHORTS FOR MUTATION DETECTION IN FUNCTIONAL CANDIDATE GENES. 
Table 5C1 XLMR families and sib-pairs selected for ARX mutation screening 
# FAM# INHERITANCE PHENOTYPE # FAM# INHERITANCE PHENOTYPE 
1.  FX 2 Sib-pair* Female affected 26.  FX89 XLMR?  
2.  FX4 Sib-pair* Female (twins) affected 27.  FX91 Sib-pair  
3.  FX11 XLMR Female affected 28.  FX95 Sib-pair* Long face, large ears 
4.  FX15 Sib-pair* Female affected 29.  FX98 XLMR Large ears 
5.  FX22 XLMR  30.  FX100 XLMR Large ears 
6.  FX25 Sib-pair  31.  
FX102 Sib-pair Large ears, forehead testicles; tall narrow 
face, prominent chin 7.  FX36 Sib-pair  
8.  FX38 XLMR?  32.  FX105 XLMR  
9.  FX42 XLMR?  33.  FX116 XLMR Hyperactive, dysmorphic faces 
10.  FX45 Sib-pair  34.  FX124 Sib-pair Large ears 
11.  FX46 Sib-pair Severe MR 35.  FX126 XLMR Almond shaped ears, epicanthic folds 
12.  FX48 Sib-pair  36.  FX128 XLMR Behavioural difficulties 
13.  FX55 XLMR?  37.  FX130 Sib-pairs Long face and ears, large testicles 
14.  FX58 XLMR?  38.  
FX131 XLMR 
Severe MR, autistic features, poor speech 
development 15.  FX62 XLMR   
16.  FX67 Sib-pair  39.  FX135 Sib-pair* Low set ears, hypoplastic third face 
17.  FX71 Sib-pair*  40.  
FX137 XLMR Female affected previously diagnosed with 
Soto’s syndrome 18.  FX75 XLMR?  
19.  FX76 XLMR Epilepsy 41.  FX141 XLMR N genetalia, high forehead 
20.  FX78 XLMR?  42.  FX143 XLMR Large ears 
21.  FX79 XLMR  43.  FX147 Sib-pair* Affected female, mild MR  
22.  FX80 XLMR  44.  FX151 Sib-pair  
23.  FX84 Sib-pair  45.  FX157 XLMR Moderate MR, mild Dysmorphism 
24.  FX87 Sib-pair  46.  FX160 XLMR  












# FAM# INHERITANCE PHENOTYPE # FAM# INHERITANCE PHENOTYPE 
48.  FX165 XLMR  
73. FX293 Sib-pairs 
large ears, macrocephaly, severe language 
delay 49.  FX166 XLMR  
50.  FX167 XLMR  
51.  FX177 XLMR 
Mild delay, epicanthic folds, mid face 
hypoplasia, large ears 
 
74. FX295 XLMR  
52.  FX181 XLMR  75. FX299 XLMR? Affected female 
53.  FX188 XLMR Long face, large ears, clinodactyly 76. FX300 XLMR? Affected female 
54.  FX196 XLMR?  77. FX302 XLMR? Affected female 
55.  FX198 Sib-pairs  78. FX312 XLMR  
56.  FX210 Sib-pairs  79. FX313 XLMR?  
57.  FX217 XLMR?  80. FX315 XLMR Macrocephaly, large ears 
58.  FX218 XLMR? Seizures, cocne facial features, mildly 
dysmorphic, strabismus 
81. FX317 XLMR Autistic features 
59.  FX219 XLMR? 
Affected females, large ears, Macrocephaly, 
seizures, soft dysmorphic 
82. 
FX338 XLMR?  
60.  FX220 XLMR?  83. FX346 Sib-pairs Hyperactive 
61.  FX225 XLMR?  84. FX348 XLMR  
62.  FX228 Sib-pairs  85. FX353 XLMR? Affected female 
63.  FX231 XLMR Mild MR 86. FX360 Sib-pairs  
64.  FX233 Sib-pairs 
Dysmorphic, dev delay, large ears, 
microcephaly 
87. 
FX361 Sib-pairs Speech delay 
65.  FX234 Sib-pairs ADHD, epilepsy 88. FX362 Sib-pairs  
66.  FX239 Sib-pairs  89. FX366 XLMR? Epilepsy 
67.  FX243 XLMR  90. FX376 XLMR  
68.  FX244 XLMR? Dysmorphic ears 91 FX378 XLMR?  
69.  FX256 XLMR Dysmorphic 92. FX382 XLMR?  
70.  FX265 XLMR? Mother mild mental handicap 93. FX384 XLMR?  
71.  FX277 XLMR Dev delay, long face, normal ears and testis 94. FX391 XLMR  













# FAM# INHERITANCE PHENOTYPE 
96.  FX402 Sib-pairs  
97.  FX403 XLMR 
Index: mild global delay, FAM: muscle 
dystrophy, clumsy 
98.  FX413 Sib-pairs  
99.  FX415 XLMR?  
100. FX417 Sib-pairs  
101. FX420 XLMR?  
102. FX421 XLMR?  
103. FX425 XLMR? Mild Dysmorphism, behavioural deterioration 
104. FX428 XLMR  
105. FX430 XLMR?  
106. FX431 XLMR?  
107. FX434 Sib-pairs  
108. FX442 XLMR  
109. FX443 XLMR?  
110. FX446 XLMR Global dev delay, hypotonia, mild 
dysmorphism 
111. FX449 XLMR?  
112. FX452 XLMR?  
113. XMR3.1 XLMR  
 














Table 5C2 Isolated male MR cases selected for screening of the c. c.428_451dup mutation 
# FAM # PHENOTYPE # FAM # PHENOTYPE 
1.  FX8  24. FX97 Severe MR 
2.  FX12  
25. FX99 anti-mongolian slant, low set ears, preaxial polydactyly – big toes, 
3.  FX14  
4.  FX16  26. FX101  
5.  FX17  27. FX103  
6.  FX18  28. FX106 Strabismus 
7.  FX19 maternal uncle aggressive 29. FX107 NF, epilepsy, facial features of FX 
8.  FX23  30. FX108  
9.  FX24 Autism 31. FX109  
10.  FX26  32. FX110  
11.  FX28  33. FX112 epilepsy, macro-orchidism at birth, epicanthic folds 
12.  FX29  34. FX113 mild MR, large jaw and head 
13.  FX33 Epilepsy, diplegia,birth asphyxia 35. FX114 large ears and penis 
14.  FX52 
tall, long narrow facies, crowded teeth, narrow, high arched 
palate, long neck, chest wide and narrow, mild webbing of 
fingers, large testes 
36. 
FX115  
15.  FX57 
socialisation and speech delay, long face, long low set ears, 




16.  FX59 
course features, long faceand thick supraorbital ridge and 
synophris, large testicles, forceps delivery 
38. 
FX118  
17.  FX70  39. FX119  
18.  FX72  40. FX121  
19.  FX73  41. FX123  
20.  FX82  42. FX129 behaviour disorder, epilepsy, hyperactivity 
21.  FX85 large ears, hyperactive, Prominent forehead, big hand and feet 43. FX132  
22.  FX90 Epilepsy 44. FX133 large ears, 












# FAM # PHENOTYPE # FAM # PHENOTYPE 
46.  FX138  75. FX211 FX type dysmorphology 
47.  FX139 severe MR, autism, dysmorphic, large ears 76. FX212 dysmorphology: long face, large ears, chin and testis 
48.  FX140  77. FX213  
49.  FX142  78. FX214 moderate MR, tall, occasional aggression 
50.  FX144 epilepsy 79. FX216  
51.  FX145 mild MR, large ears 80. FX221 dysmorphic features of FX 
52.  FX146 behavioural problems, long face, ears and large testis 81. FX222 deafness 
53.  FX150 large testicles 82. FX223 large testicles 
54.  FX152  83. FX224 adopted, autistic, severe anxiety 
55.  FX159  84. 
FX227 
moderate to mild MR, unusual facies with hyperteliarism, back slanting 
ears, high arched palate, slightly small head circum 56.  FX161 v large ears, microcephalic, tall, deafness, impaired vision 
57.  FX168  85. FX229 severe MR, arthrogryposis, greying hair 
58.  FX169 aggressive outbursts 86. FX230  
59.  FX172 behaviour disorder, long face, testis 87. 
FX236 
progressive neurodevelopment delay from 2 yrs, ataxia, global speech 
delay, N MRI   60.  FX174 brilliant blue eyes 
61.  FX175 dev and speech delay, prominent lips, maxillars hypoplasia 88. FX237  
62.  FX176 macroplasia 89. FX238  
63.  FX178  90. FX241  
64.  FX180 big ears and genetalia 91. FX245  
65.  FX182 large ears, short stature, aggressive behaviour 92. FX247 dev delay, dysmorphic 
66.  FX185  93. FX248  
67.  FX187  94. FX249  
68.  FX189  95. FX250  
69.  FX191 mild dysmorphic features, thin face, min communication 96. FX252 Hyperactive,seizures 
70.  FX197 pervasive developmental disorder (autism spectrum) 97. FX254 ADHD 
71.  FX200 developmental delay, social problems, corneal opacity 98. FX255  
72.  FX206  99. FX263  
73.  FX207 speech delay 100. FX271 behavioural problems, mild dysmorphology 












# FAM # PHENOTYPE # FAM # PHENOTYPE 
102. FX274  131. FX343 small penis, behaviour, hyperplegia, high pain tolerance, dev delay 
103. FX275 large ears 132. FX345  
104. FX276 learning disability 133. FX349 dysmorphic dev delay 
105. FX279 dysmorphic 134. FX356  
106. FX282  135. FX357  
107. FX289 severe MR, 136. FX358 global dev delay 
108. FX290 global delay, autism, profoundly deaf, large ears 137. FX359  
109. FX291  138. FX363 severe MR, autistic features 
110. FX292 dysmorphic, autistic behaviour 139. FX367  
111. FX297  140. FX369 severe global delay, autistic features 
112. FX298 Soto’s syndrome? 141. FX370 dev delay 
113. FX305  142. FX371  
114. FX306  143. FX372 global dev delay 
115. FX307 macro-orchidism, prominent jaw 144. FX381  
116. FX308  145. FX386  
117. FX309  146. FX387  
118. FX310  147. FX389  
119. FX311  148. FX390  
120. FX316  149. FX395 global delay 
121. FX322  150. FX396 twins 
122. FX323  151. FX397  
123. FX324 short attention span, big ears 152. FX400 global delay 
124. FX327 pervasive dev disorder,mild dysmorphism 153. FX401  
125. FX328 Speech problems, enuresis 154. FX404 macrocrania, bat ears 
126. FX330 dev delay, behaviour problems, hyperphagia 155. FX405  
127. FX331 physical disability 156. FX406 global delay 
128. FX332 large ears 157. FX407 marphanoid habitus 
129. FX341 large ears 158. FX410  













# FAM # PHENOTYPE 
160. FX416 autistic features 
161. FX422 Hydrocephalus, epilepsy, large ears, speech 
162. FX423  
163. FX427  
164. FX429 global delay 
165. FX432  
166. FX439  
167. FX440  
168. FX441  
169. FX445 behavioural difficulties 
170. FX451  
171. FX453  
172. FX454  
173. FX455 physical disability 
174. FX458  
175. FX459  
176. FX461  
177. FX462 Global dev delay 
178. FX463  
179. FX472  
180. FX477 Prognathism, big ears, macrocephaly 
181. FX478 Schizophrenic 
182. FX482  



















# FAM # PHENOTYPE 
1.  FX46 severe MR 
2.  FX76 epilepsy 
3.  FX98 Large ears 
4.  FX100 Moderate MR, large ears 
5.  FX102 large ears, forehead and testicles, tall narrow face, prominent chin(SIB PAIRS) 
6.  FX116 hyperactivity, dysmorphic facies 
7.  FX124 large ears (SIB PAIRS) 
8.  FX128 behavioural difficulties 
9.  FX131 severe MR, autistic features, poor speech development 
10.  FX135 low set ears and hypoplastic central third face (SIB PAIRS) 
11.  FX143 Large ears 
12.  FX148 Moderate MR 
13.  FX157 moderate MR, mild dysmorphism 
14.  FX177 mild delay, epicanthic folds, mid face hypoplasia, large ears 
15.  FX188 long face, large ears, webbing of fingers, clinodactyly 
16.  FX233 dysmorphic, dev delay, large ears, microcephaly 
17.  FX256 dysmorphism 
18.  FX277 dev delay, long face, normal ears and testis, epilepsy 
19.  FX293 large ears, macrocephaly, severe language delay (SIB PAIRS) 
20.  FX317  autistic features 
21.  FX361 speech delay 
22.  FX373 global delay, behaviour problems 
23.  FX56 Linkage 
24.  FX36 Linkage 











APPENDIX 5D: PCR PRIMERS USED IN THE AMPLIFCATION 
OF ALL FUNCTIONAL CANDIDATE GENES. 
Table 5D.1 Primer sets used to amplify the five ARX exons for downstream mutation 
detection.  
 
Table 5D.2 Primer sets used to amplify the 26 JARID1C exons for downstream 
mutation detection 
Exon Primer amplicon size (bp) Mer(bp) GC Tm( °C) Sequence (5’ – 3’) 
1 Fwd 475 20 45 58 tccgttataacccgctatct 
1 Rev 475 19 53 58 acagccctggctagatgtt 
2A Fwd 658 18 61 58 ccaaggcgtcgaagtctg 
2A Rev 658 20 50 60 tcatcttcttcgtcctccag 
2B Fwd 528 18 72 62 accggcaccgaggacgac 
2B Rev 528 20 65 64 gagtccaggagccaagcgtc 
3 fwd 262 19 58 60 agtaggcctgccatagagg 
3 Rev 262 20 45 58 tgatcctgcttctcttggtt 
4 Fwd 777 20 45 58 ttgaagttgcggctcctatt 
4 Rev 777 20 50 60 ggttgtcacggttgtcgtta 
5 Fwd 573 18 61 58 caggaaagccctctctgc 
5 Rev 573 20 55 54 gcatccagactgctgtgaag 
Exon Primer amplicon size (bp) Mer(bp) GC Tm( °C) Sequence (5’ – 3’) 
1 Fwd 526 54 52 21 gacgctgacaaaccaagatgg 
1 Rev 526 54 52 21 cctactgcttcattccgtctc 
2 Fwd 175 56 44 25 cactatgctgagataactcaagtcc 
2 Rev 175 55 48 23 ctcaggtatacattctcccaacc 
3 Fwd 288 52 50 20 ccaaagatagtggtcagtgg 
3 Rev 288 52 48 21 ccttccattgcagcctaaaga 
4 fwd 294 51 53 19 ctttctacaggcctactcc 
4 Rev 294 52 48 21 atctgtgctgaagggtaaagc 
5 Fwd 249 56 60 20 ctggagtccatgtcctgacc 
5 Rev 249 54 55 20 agccttagccagaaggaagg 
6 and 7 Fwd 533 56 60 20 gtctgccccagatagcagtc 
6 and 7 Rev 533 56 60 20 cgaactggtccagtgccatg 
8 Fwd 349 55 48 23 gacctagcatgactagcctatac 
8 Rev 349 57 55 22 gactatggctgagctaagaggc 
9 and 10 Fwd 601 54 52 21 cagttccacttgggaggattc 
9 and 10 Rev 601 55 50 22 ctcatggctacataagacaggc 
11 and 12 Fwd 530 54 52 21 cttagcataaccctcatgccc 
11 and 12 Rev 530 54 55 20 aatcactcctgccgcttgtc 
13 and 14 fwd 594 52 50 20 gtctgggattctgttgtcag 
13 and 14 Rev 594 54 55 20 ccaccagaatagggtgcttg 
15 and 16 Fwd 533 55 50 22 gaatctaaagtaggggtcggtg 
15 and 16 Rev 533 54 52 21 gggaatagaacttgcctgtgg 
17 Fwd 296 54 52 21 ccacaggcaagttctattccc 
17 Rev 296 54 52 21 ctggatcctcagcaccttatg 
18 Fwd 190 54 55 20 aggcactgagtttggacctg 
18 Rev 190 53 58 19 gtccccttgatccctcatc 
19 Fwd 544 56 57 21 ggtgggacaaggttccatctg 
19 Rev 544 56 57 21 gagcgtgatacctaaggccac 
20 Fwd 277 56 57 21 gcagaccacatcagactgagc 
20 Rev 277 55 63 19 ccaacccatcccagcaacc 
21 and 22 fwd 565 52 50 20 tggcaagttgaactgagctg 
21 and 22 Rev 565 52 48 21 tatcatcaccaagcccttctc 
23 Fwd 716 56 57 21 gtaggctgctgacccactttg 
23 Rev 716 55 63 19 cagggccgagcctaaactg 
24 and 25 Fwd 503 54 52 21 cttcacttcagttgcccctac 
24 and 25 Rev 503 55 63 19 tactcggcctgacctcctg 
26 Fwd 527 55 63 19 aggaggtcaggccgagtag 












APPENDIX 5E: PCR CONDITIONS FOR ARX AMPLIFCATION.  





1 2A 2B 3 4 5 
Forward Primer (20µM) 15µM 10µM 40µM 15µM 15µM 10µM 
Reverse Primer (15µM) 15µM 10µM 40µM 15µM 15µM 10µM 
dNTP’s (5µM)[Bioline] 5µM - 20µM 5µM 5µM - 
Buffer (10X) [Invitrogen] 1× - 1× 1× 1× - 
Failsafe buffer J (2X) 
[Epicentre Technologies] 1× 1× 1× 1× 1× 1× 
Taq Polymerase (5U/µl)  
[Invitrogen] 1U - 2U 1U 1U - 
ELT polymerase (5U/µl) 
[Roche] 
- 2,5U - - - 1,5U 
MgCl2 [Invitrogen] 75µM - 150µM 75µM 75µM - 
DNA 100ng 100ng 400ng 100ng 100ng 100ng 
DMSO [Merck] - - 8% - 2,5% - 
FINAL REACTION 
VOLUME 50µl 25µl 100µl 50µl 50µl 25µl 
 
Table 5E2 Optimised cycling conditions for PCR amplification of 6 ARX amplicons  
Condition Exon 
 1 2a 2b 3 4 5 
Thermal cycler * A.B A.B PX2 A.B A.B PX2 










59–54 ºC (30s) 
72 ºC(30s) 










59–55 ºC (30s) 





















95 ºC (1min) 






55 ºC (1min) 




95 ºC (1min) 
57 ºC (1min) 




95 ºC (1min) 
55 ºC (1min) 















*Thermal cyclers: A.B: GeneAmp® PCR system 9700 [Applied Biosystems] 


















 Probe ID Primer Forward (5’ – 3’) Reverse (5’ – 3’) 
 CHR16FS010387819 Chr16_ATF71P2_Ex1_BSP ttagttggttgtgtttgattggt aacttttacttacccctcaaaac 
 CHR11FS126375528 CHR11_KIRREL_EX1_BSP tattttgattgaagaggaagaagta aacacaaccttttcccccactatc 
 CHR17FS034606720 CHR17_CACNB1_EX1_BSP gaaggtttgttggtatttggta cccatccttacaaattataattaa 
 CHR05FS001853381 CHR5_MRPL36_5’UTR_BSP agtggataggagaaatgtaaataggtt cccaaaaatatcccaacaaa 
 CHR02FS065138632 CHR2_CEP68_INT1_BSP tggaaagatggagattagtgatg aaacccaaaacaaactaaccc 
 CHR19FS015436362 CHR19_ZIM_PEG_BSP gatggtatttaatgggtggg acaccaatactatccctattaccac 
 CHR18FS031177845 CHR18_ZNF24_EX1_BSP gtgggaaatggagggaagg aaactctctaaccccctatatcc 













APPENDIX 6B: THE 112 UNIQUE DMRS IDENTIFIED BY 
MEDIP-CHIP AND STATISITCAL ANALYSES 
  
chromosome Start position End position Chromosome Start position End position 
X 16713584 16715711 5 131624135 131626245 
X 128942083 128944357 5 137700566 137702661 
1 25127455 25129575 5 150516390 150518478 
1 28112640 28114750 5 174082407 174084517 
1 44643249 44645350 5 175156626 175158726 
1 54726407 54728517 5 176784401 176787011 
1 70592010 70594090 6 31740492 31742702 
1 93417417 93419632 6 89846345 89848425 
1 109557476 109559581 6 134315526 134318204 
1 144183679 144186069 6 139735765 139737840 
1 151500233 151502418 7 74825442 74827788 
1 152437180 152439156 8 38972194 38974279 
1 152442735 152444350 8 97575058 97577188 
1 153242508 153244618 8 109163371 109165476 
1 153374591 153377005 9 101900242 101902337 
1 154964148 154966253 9 129717966 129720151 
1 181870746 181872941 10 22649207 22651531 
1 204009878 204012050 10 102810609 102813194 
2 11804805 11807716 10 119123054 119125254 
2 28469900 28472413 11 13941342 13943542 
2 44441092 44443200 11 34030116 34032226 
2 65137130 65139632 11 57120910 57123428 
2 172674115 172676449 11 57883019 57885535 
2 175740043 175742263 11 59334117 59336807 
2 220083073 220085143 11 62069543 62071728 
2 232279156 232281456 11 118393757 118395857 
3 49881048 49883447 11 118476701 118478796 
3 99797733 99799857 11 126374716 126377220 
3 168935011 168937116 12 26169141 26171531 
4 30330137 30332543 12 37585584 37587710 
4 38481135 38483735 12 52179951 52182039 
4 103967233 103969433 12 54995331 54998056 
4 115738669 115740854 12 70342897 70345267 
5 1852571 1854881 12 78851846 78853956 
5 74233023 74234523 12 84197019 84199146 
5 74359003 74360988 14 51603918 51606023 












chromosome Start position End position Chromosome Start position End position 
14 68328161 68330437 17 35389589 35391689 
14 99016701 99018911 17 35508602 35510829 
15 41871192 41873507 17 45139582 45141812 
15 64780655 64783027 18 31176844 31179350 
15 80123746 80125831 18 72336489 72338668 
16 10387119 10389529 19 9111291 9113789 
16 19802650 19804846 19 11391713 11393834 
16 29982732 29984839 19 13086497 13089317 
16 30576341 30578526 19 15435262 15437667 
16 33869722 33871932 19 38806836 38808336 
16 49138052 49140542 19 38859806 38861781 
16 56983125 56985295 19 51081155 51083264 
16 66677187 66679500 19 53585545 53587610 
17 7699038 7701328 19 62041555 62044363 
17 27617519 27619810 20 41250092 41252389 
17 30593413 30595608 20 43995825 43997940 
17 32366016 32368346 22 19113293 19115393 
17 33971876 33973972 22 22683333 22684833 
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